<SEC-DOCUMENT>0001213900-17-011671.txt : 20171109
<SEC-HEADER>0001213900-17-011671.hdr.sgml : 20171109
<ACCEPTANCE-DATETIME>20171109160652
ACCESSION NUMBER:		0001213900-17-011671
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20170930
FILED AS OF DATE:		20171109
DATE AS OF CHANGE:		20171109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38247
		FILM NUMBER:		171190819

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0917_aytubioscience.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>
<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>UNITED
STATES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>FORM 10-Q</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#9746; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Quarterly Period Ended: September 30, 2017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>or
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File No.&nbsp;001-38247 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>AYTU
BIOSCIENCE, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>47-0883144</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
                                         or other jurisdiction of</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>incorporation
        or organization)</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(IRS
                                         Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>373
Inverness Parkway, Suite 206 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Englewood,
Colorado 80112 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
of principal executive offices, including zip code) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(720)
437-6580 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Registrant&rsquo;s
telephone number, including area code) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation S-T during the preceding 12 months (or for
such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See definition of &ldquo;accelerated filer&rdquo;, &ldquo;large accelerated filer&rdquo; and &ldquo;smaller
reporting company&rdquo; in Rule&nbsp;12B-2 of the Exchange Act. (Check one):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9746;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    Growth Company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of November 1, 2017, there were 4,402,638 shares of Common Stock outstanding.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AYTU
BIOSCIENCE, INC. AND SUBSIDIARY </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE QUARTER ENDED SEPTEMBER 30, 2017 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART&nbsp;I&mdash;FINANCIAL
INFORMATION</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;1.&#9;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Financial Statements&#9;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Balance Sheets as of September 30, 2017 (unaudited) and June 30, 2017&#9;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Operations for the three months ended September 30, 2017 (unaudited) and the three months ended September 30,
    2016 (unaudited)&#9;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statement of Stockholders&rsquo; Equity (unaudited)&#9;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Cash Flows for the three months ended September 30, 2017 (unaudited) and the three months ended September 30,
    2016 (unaudited)&#9;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Consolidated Financial Statements (unaudited)&#9;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;2.&#9;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations&#9;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;3.&#9;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative
    and Qualitative Disclosures About Market Risk&#9;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;4.&#9;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls
    and Procedures&#9;</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART&nbsp;II&mdash;OTHER
    INFORMATION</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;1.&#9;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    Proceeding</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;1A.&#9;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;2.&#9;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered
    Sales of Equity Securities and Use of Proceeds</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;3.&#9;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults
    Upon Senior Securities</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;4.&#9;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine
    Safety Disclosures</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;5.&#9;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Information</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;6.&#9;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act
of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than
statements of historical facts contained in this Quarterly Report, including statements regarding our anticipated future clinical
and regulatory events, future financial position, business strategy and plans and objectives of management for future operations,
are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words
such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;forecast,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo;
&ldquo;suggest,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo;
&ldquo;plan,&rdquo; or similar words, or the negatives of such terms or other variations on such terms or comparable terminology.
Such forward-looking statements include, without limitation: the planned expanded commercialization of our products and the potential
future commercialization of our product candidates, our anticipated future cash position; the assimilation into our operations
of acquired assets and entities; our plan to acquire additional assets; the anticipated start dates, durations and completion
dates, as well as the potential future results, of our ongoing and future clinical trials; the anticipated designs of our future
clinical trials; anticipated future regulatory submissions and events; and future events under our current and potential future
collaborations. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including without
limitation the risks described in &ldquo;Risk Factors&rdquo; in Part&nbsp;I, Item&nbsp;1A of our most recent Annual Report on
Form 10-K, and in the reports we filed with the Securities and Exchange Commission. These risks are not exhaustive. Moreover,
we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible
for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which
any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking
statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the
events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements. We assume no obligation to update or supplement forward-looking
statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Quarterly Report on Form 10-Q includes trademarks, such as Aytu, Natesto, ProstaScint, MiOXSYS, RedoxSYS, and Fiera, which are
protected under applicable intellectual property laws and we own or have the rights to. Solely for convenience, our trademarks
and trade names referred to in this Quarterly Report on Form 10-Q may appear without the <SUP>&reg;</SUP> or <SUP>TM</SUP> symbols,
but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law,
our rights to these trademarks and trade names. &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I&mdash;FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 48.95pt"><B>Item&nbsp;1.</B></TD><TD><B>Consolidated Financial Statements </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AYTU BIOSCIENCE,
INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">September 30,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">June 30,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="font-weight: bold; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Current assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,021,527</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">802,328</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,371</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,214</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,211,845</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">528,039</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Inventory, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,171,260</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,312,221</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt">Prepaid expenses and other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">262,057</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">310,760</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Total current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,742,060</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,028,562</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Fixed assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">566,913</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">647,254</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Developed technology, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,294,306</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,337,333</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Customer contracts, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Trade names, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">158,238</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">164,037</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Natesto asset, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,901,391</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,231,072</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,426</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,426</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Patents, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">264,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">271,278</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 10pt">Deposits</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,888</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,888</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Total long-term assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,503,773</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,969,955</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">21,245,833</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">14,998,517</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">Liabilities and Stockholders' Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Accounts payable and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,660,764</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,220,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">903,386</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">782,536</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Accrued compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">680,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">339,704</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Deferred rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,455</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,673</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt">Current contingent consideration</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">257,036</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">261,155</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,508,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,610,468</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Long-term contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,566,443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,386,782</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Deferred rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,451</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt">Warrant derivative liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,818,263</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,892,892</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,998,701</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Commitments and contingencies (Note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Preferred Stock, par value $.0001; 50,000,000 shares authorized; shares issued and outstanding 2,250 (unaudited) and 0, respectively as of September 30, 2017 and June 30, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 4,224,840 (unaudited) and 824,831, respectively as of September 30, 2017 and June 30, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">422</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,667,289</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,069,463</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(73,314,771</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(69,069,729</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Total stockholders' equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,352,941</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,999,816</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total liabilities and stockholders' equity</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">21,245,833</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">14,998,517</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AYTU BIOSCIENCE, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<BR>
September 30,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 1.5pt">Product revenue</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,076,368</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">697,980</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total revenue</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,076,368</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">697,980</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Cost of sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">287,201</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191,924</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,954</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">232,022</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Research and development - related party (Note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,998</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Sales, general and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,618,403</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,704,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Sales, general and administrative - related party (Note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,772</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt">Amortization and impairment of intangible assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">385,841</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">437,014</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,432,399</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,664,480</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Loss from operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,356,031</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,966,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt">Interest (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(188,745</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(415,381</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt">Derivative income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">299,734</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(70,609</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt">Unrealized gain on investment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">728,100</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt">Total other (expense) income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">110,989</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">242,110</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,245,042</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,724,390</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: 0; padding-left: 0">Weighted average number of Aytu common shares
    outstanding</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,415,402</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">244,937</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0">Basic and diluted Aytu net loss &nbsp;&nbsp;per common share</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1.76</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(23.37</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying
notes are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AYTU BIOSCIENCE, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statement of Stockholders&rsquo;
Equity </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Preferred Stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Additional<BR>
paid-in</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Total Stockholders'</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">capital</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; padding-left: 10pt; text-indent: -10pt">Balance - June 30, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">824,831</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">82</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">73,069,463</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">(69,069,729</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">3,999,816</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Stock-based compensation (unaudited)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195,105</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195,105</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Issuance of restricted stock (unaudited)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,306</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Earn-out payment to Nuelle shareholders (unaudited)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,589</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,589</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Issuance of preferred and common stock, net of $1,402,831 in cash issuance costs
    (unaudited)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,196,665</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,318,846</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,319,167</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Adjustment for rounding of shares due to stock split
    (unaudited)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">326</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt">Net loss (unaudited)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(4,245,042</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(4,245,042</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Balance - September 30, 2017 (unaudited)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,250</TD><TD STYLE="padding-bottom: 4pt; text-align: left"></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1</TD><TD STYLE="padding-bottom: 4pt; text-align: left"></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,224,840</TD><TD STYLE="padding-bottom: 4pt; text-align: left"></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">422</TD><TD STYLE="padding-bottom: 4pt; text-align: left"></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">79,667,289</TD><TD STYLE="padding-bottom: 4pt; text-align: left"></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(73,314,771</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,352,941</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying
notes are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AYTU BIOSCIENCE, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Cash Flows
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; padding-right: 0; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<BR>
September 30,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; padding-right: 0; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; padding-right: 0; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0; padding-left: 10pt; text-indent: -10pt">Cash flows from operating activities</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 20pt; padding-right: 0; text-indent: -10pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(4,245,042</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(5,724,390</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 10pt; text-indent: -10pt">Adjustments to reconcile net loss to cash provided by (used in) operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-right: 0; text-indent: -10pt">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195,105</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,043,712</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-right: 0; text-indent: -10pt">Issuance of restricted stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,306</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,466</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-right: 0; text-indent: -10pt">Depreciation, amortization and accretion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">653,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">822,161</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-right: 0; text-indent: -10pt">Derivative (income) expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(299,734</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,609</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-right: 0; text-indent: -10pt">Amortization of prepaid research and development - related party (Note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,496</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-right: 0; text-indent: -10pt">Unrealized (gain) on investment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(728,100</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-right: 0; text-indent: -10pt">Compensation through issuance of stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">509,996</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-right: 0; text-indent: -10pt">Issuance of warrants to initial investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">589,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 30pt; text-indent: -10pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 40pt; padding-right: 0; text-indent: -10pt">(Increase) in accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(683,806</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(347,013</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 40pt; padding-right: 0; text-indent: -10pt">Decrease (increase) in inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(60,650</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 40pt; padding-right: 0; text-indent: -10pt">Decrease (increase) in prepaid expenses and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,703</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(337,525</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 40pt; padding-right: 0; text-indent: -10pt">(Decrease) in accounts payable and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(559,636</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(109,365</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 40pt; padding-right: 0; text-indent: -10pt">Increase (decrease) in accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(498,516</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 40pt; padding-right: 0; text-indent: -10pt">Increase (decrease) in accrued compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">340,841</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(668,792</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 40pt; padding-right: 0; text-indent: -10pt">(Decrease) increase in deferred rent</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,669</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">75</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-right: 0">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,217,808</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,332,459</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; padding-right: 0; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 10pt; text-indent: -10pt">Cash flows used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; padding-right: 0; text-indent: -10pt">Purchases of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,721</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt; padding-right: 0; text-indent: -10pt">Installment payment for Primsol asset</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-right: 0">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(504,721</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-right: 0; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 10pt; text-indent: -10pt">Cash flows from financing activities</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 30pt; padding-right: 0; text-indent: -10pt">Issuance of preferred, common stock and warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,839,995</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt; padding-right: 0; text-indent: -10pt">Issuance costs related to preferred, common stock and warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,402,831</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 30pt; padding-right: 0; text-indent: -10pt">Issuance of common stock to Lincoln Park Capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">631,481</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt; padding-right: 0; text-indent: -10pt">Costs related to sale of common stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,247</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-right: 0; padding-left: 10pt; text-indent: -10pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,437,164</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">607,234</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 10pt; text-indent: -10pt">Net change in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,219,356</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,229,946</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-right: 0; padding-left: 10pt; text-indent: -10pt">Cash and cash equivalents at beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">877,542</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,054,190</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-right: 0; padding-left: 10pt; text-indent: -10pt">Cash and cash equivalents at end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,096,898</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,824,244</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; padding-right: 0; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 10pt; text-indent: -10pt">Non-cash transactions:</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: right">&nbsp;</TD><TD STYLE="font-family: Arial, Helvetica, Sans-Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: right; padding-right: 0; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 10pt; text-indent: -10pt">Warrants issued to investors and underwriters (see Note 5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,117,997</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 10pt; text-indent: -10pt">Earn-out payment to Nuelle Shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,589</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 10pt; text-indent: -10pt">Primsol accretion included in accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,126</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 10pt; text-indent: -10pt">Fixed assets included in accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95,866</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an internal
part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AYTU BIOSCIENCE,
INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Notes to Consolidated
Financial Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 1 - Business, Basis of Presentation, Business Combinations,
Divestitures, License/supply agreement and Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu BioScience, Inc. (&ldquo;Aytu&rdquo;, the &ldquo;Company&rdquo;
or &ldquo;we&rdquo;) was incorporated as Rosewind Corporation on August&nbsp;9, 2002 in the State of Colorado. Aytu was re-incorporated
in the state of Delaware on June&nbsp;8, 2015. Aytu is a commercial-stage specialty life sciences company concentrating on developing
and commercializing products with an initial focus on urological diseases and conditions. Aytu is currently focused on addressing
significant medical needs in the areas of hypogonadism, urological cancers, male infertility, and sexual wellness and vitality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis of Presentation </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These unaudited consolidated financial statements represent
the financial statements of Aytu and its subsidiary, Aytu Women&rsquo;s Health. These unaudited consolidated financial statements
should be read in conjunction with Aytu&rsquo;s Annual Report on Form 10-K for the year ended June 30, 2017, which included all
disclosures required by generally accepted accounting principles (&ldquo;GAAP&rdquo;). In the opinion of management, these unaudited
consolidated financial statements contain all adjustments necessary to present fairly the financial position of Aytu for the balance
sheet, the results of operations and cash flows for the interim periods presented. The results of operations for the period ended
September 30, 2017 are not necessarily indicative of expected operating results for the full year. The information presented throughout
this report as of and for the period ended September 30, 2017 and 2016 is unaudited.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Through a multi-step reverse triangular merger, on April 16,
2015, Vyrix Pharmaceuticals, Inc. (&rsquo;&lsquo;Vyrix&rsquo;&rsquo;) and Luoxis Diagnostics, Inc. (&rsquo;&lsquo;Luoxis&rsquo;&rsquo;)
merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue
the specialty healthcare market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS
and Zertane products. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law
and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common
stockholder received one share of common stock for every 12.174 shares held. On June 30, 2016, Aytu effected another reverse stock
split in which each common stockholder received one share of common stock for every 12 shares held. On August 25, 2017, Aytu effected
a third reverse stock split in which each common stockholder received one share of common stock for every 20 shares held (herein
referred to collectively as the &ldquo;Reverse Stock Splits&rdquo;). All share and per share amounts in this report have been
adjusted to reflect the effect of these Reverse Stock Splits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Combination&mdash;ProstaScint </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2015, Aytu entered into and closed on an asset purchase
agreement with Jazz Pharmaceuticals, Inc. (&ldquo;Jazz Pharmaceuticals&rdquo;). Pursuant to the agreement, Aytu purchased assets
related to the Jazz Pharmaceuticals&rsquo; product known as ProstaScint<SUP>&reg;</SUP> (capromab pendetide), including certain
intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &rsquo;&lsquo;ProstaScint
Business&rsquo;&rsquo;), and assumed certain of Jazz Pharmaceuticals&rsquo; liabilities, including those related to product approvals
and the sale and marketing of ProstaScint. The purchase price consisted of an upfront payment of $1.0 million. We also agreed
to pay an additional $500,000, which was paid after the transfer of the ProstaScint-related product inventory, and $227,000 which
was paid September 30, 2015 (which represents a portion of certain FDA fees). We will also pay 8% on net sales made after October
31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was initially
valued at $664,000 and was revalued as of June 30, 2017 at $54,000 using a discounted cash flow. The total fair value consideration
for the purchase was $2.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s allocation of consideration transferred
for ProstaScint as of the purchase date of May&nbsp;20, 2015 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Fair
    Value</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Tangible assets</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">727,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Intangible assets</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">1,590,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">Goodwill</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid">74,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt; padding-left: 0; text-indent: 0">Total assets acquired</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">2,391,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Included in the intangible assets is developed technology of
$790,000, customer contracts of $720,000 and trade names of $80,000, each of which will be amortized over a ten-year period. At
June 30, 2017, the ProstaScint asset was impaired based upon sales projections that we intend to only sell this product through
mid-fiscal 2019, when this product expires. The value for the intangible assets were adjusted to $54,000 for developed technology,
$7,000 for trade names and $0 for customer contracts. The amortization expense was $12,000 and $40,000 for the three months ended
September 30, 2017 and 2016, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of September 30, 2017, the contingent consideration increased
by $6,000 due to accretion.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Combination&mdash;Primsol</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2015, Aytu entered into and closed on an Asset Purchase
Agreement with FSC Laboratories, Inc. (&ldquo;FSC&rdquo;). Pursuant to the agreement, Aytu purchased assets related to FSC&rsquo;s
product known as Primsol&reg; (trimethoprim solution), including certain intellectual property and contracts, inventory, work
in progress and all marketing and sales assets and materials related solely to Primsol (together, the &ldquo;Primsol Business&rdquo;),
and assumed certain of FSC&rsquo;s liabilities, including those related to the sale and marketing of Primsol arising after the
closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu paid $500,000 at closing for the purchase of the Primsol
Business, and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the
transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 which was paid on April 1,
2016, (b) $500,000 which was paid on July 1, 2016, and (c) $250,000 which was paid in November 2016 (together, the &ldquo;Installment
Payments&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s allocation on consideration transferred
for Primsol as of the purchase date of October 5, 2015 was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Fair
    Value</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Tangible assets</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">182,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Intangible assets</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">1,470,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">Goodwill</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid">147,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt; padding-left: 0; text-indent: 0">Total assets acquired</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">1,799,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Included in tangible assets was $102,000 of inventory and $80,000
of work-in-process inventory. Included in the intangible assets was developed technology of $520,000, customer contracts of $810,000
and trade names of $140,000, each of which was being amortized over a six-year period. Amortization expense of $0 and $61,000
was recognized in the three months ended September 30, 2017 and 2016, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Divestiture &ndash; Primsol</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 31, 2017, we entered into and closed on an Asset Purchase
Agreement with Allegis Holdings, LLC (the &ldquo;Purchaser&rdquo;). Pursuant to the agreement, we sold to the Purchaser all of
our assets related to our product known as Primsol, including certain intellectual property and contracts, inventory, work in
process and all marketing assets and materials related solely to Primsol (together, the &ldquo;Primsol Asset&rdquo;). We retain
any liability associated with the Primsol Asset that occurred prior to the closing. The Purchaser paid us $1,750,000 at the closing
for the Primsol Asset. We recognized a gain of approximately $428,000 on the sale which is included in sales, general and administrative
expense on our statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have evaluated this transaction and concluded that it is
not significant to our business and therefore the results are included in continuing operations, as the criteria to be presented
as discontinued operations was not satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>License and Supply Agreement&mdash;Natesto</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2016, Aytu entered into and closed a license and supply
agreement to acquire the exclusive U.S. rights to Natesto&reg; (testosterone) nasal gel from Acerus Pharmaceuticals Corporation,
or Acerus, which rights we acquired effective upon the expiration of the former licensee&rsquo;s rights, which occurred on June
30, 2016. The license&rsquo;s term runs for the greater of eight years or until the expiry of the latest to expire patent including
claims covering Natesto and until the entry on the market of at least one AB-rated generic product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu paid Acerus an upfront fee of $2.0 million upon execution
of the agreement. In October 2016, we paid an additional $2.0 million, and in January 2017, Aytu paid the final upfront payment
of $4.0 million. Aytu also purchased, on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2.5
million (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately US $0.16 per share.
These shares were a held for sale trading security and were valued at fair market value. Aytu could not dispose of these shares
until after August 29, 2016. During the second half of fiscal 2017, Aytu sold all of these shares. The gross proceeds from the
sales totaled $1.1 million, the cost of the sales totaled $92,000, and we recognized a loss on investment of $1.0 million. In
the quarter ended September 30, 2016, we had an unrealized gain on this investment of $728,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the upfront payments, we must make the following
one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following events (provided that, the maximum
aggregate amount payable under such milestone payments will be $37.5 million):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 92%; font-size: 10pt"><FONT STYLE="font-size: 10pt">$2.5 million if net sales during any four consecutive
    calendar quarter period equal or exceed $25.0 million (the &ldquo;First Milestone&rdquo;); the First Milestone payment is
    required to be paid even if the threshold is not met in the event that the agreement is terminated for any reason other than
    material breach by Acerus, bankruptcy of either party, or termination by Acerus because it believes the amounts payable to
    Aytu for agreed upon trial work would no longer make the agreement economically viable for Acerus;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">$5.0 million if net sales during any four consecutive calendar quarter
    period equal or exceed $50.0 million;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">$7.5 million if net sales during any four consecutive calendar quarter
    period equal or exceed $75.0 million;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">$10.0 million if net sales during any four consecutive calendar
    quarter period equal or exceed $100.0 million; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">$12.5 million if net sales during any four consecutive calendar
    quarter period equal or exceed $125.0 million.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of the net identifiable asset acquired totaled
$10.5 million which is being amortized over eight years. The amortization expense for each of the three months ended September
30, 2017 and 2016 were $330,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The contingent consideration was valued at $3.2 million using
a Monte Carlo simulation, as of June 30, 2016. As of June 30, 2017, the contingent consideration was revalued and increased to
$5.7 million based on increased future estimated sales performance of Natesto using a Monte Carlo simulation. The contingent consideration
accretion expenses for the three months ended September 30, 2017 was $161,000, resulting in the contingent consideration value
of $5.8 million. The contingent consideration accretion expense for the three months ended September 30, 2016 was $46,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Merger/Subsidiary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2017, Aytu Women&rsquo;s Health, LLC., a wholly-owned
subsidiary of Aytu, acquired Nuelle, Inc., or Nuelle, a women&rsquo;s sexual health company. This transaction expanded our product
portfolio with the addition of the Fiera<SUP>&reg;</SUP> personal care device for women.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the Merger, (i) each share of Nuelle common stock and each
option or warrant to purchase Nuelle stock was cancelled, and (ii) each share of Nuelle preferred stock was converted into the
right to receive shares of our common stock. We issued to the Nuelle preferred stockholders an aggregate of 125,000 shares of
our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, Nuelle preferred stockholders will be entitled
to revenue earn-out payments equal to a designated percentage of net sales on tiers of net sales up to $100.0 million, with an
average rate for all tiers in the mid-single digit range and a maximum aggregate payout of $6.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nuelle stockholders additionally will be entitled to milestone
earn-out payments of up to a potential aggregate of $24.0 million, upon the attainment by us of designated net sales thresholds
over any sequential four calendar quarter period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The first $1.0 million of earn-out payments will be paid in
shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock. The
stock portion of any earn-out will be calculated by dividing each Nuelle stockholder&rsquo;s portion of the earn-out by the average
closing price of our common stock for the 10 trading days prior to the earlier of the date we deliver notice to the Nuelle stockholders
of the earn-out or any public disclosure by us of the earn-out being due and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event that we do not make all of the required earn-out
payments to the Nuelle stockholders before May 3, 2022, and we also close a divestiture before May 3, 2022 of any of the products
acquired in the transaction, we will pay the Nuelle stockholders a combination of (i) cash in an amount equal to 10% of the value
of all cash, securities and other property paid to us in the divestiture (cash is to be 60% of the total consideration), and (ii)
shares of our common stock equal to the Nuelle stockholders&rsquo; portion of the divestiture payment divided by the average closing
price of our common stock for the 10 trading days prior to the earlier of the closing date of the divestiture or the public disclosure
of the divestiture (shares of common stock are to be 40% of the total consideration).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the upfront issuance of common stock, we must
make the following one-time payments to the Nuelle stockholders within 90 days of the occurrence of the following events (provided
that, the maximum aggregate amount payable under such milestone payments will be $24.0 million):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 92%; font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Upon achieving the first
    occurrence of Net Sales of $10.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment
    to the Nuelle security holders of an amount equal to $1.0 million;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Upon achieving
    the first occurrence of Net Sales of $17.5 million over any sequential four calendar quarter period, Aytu will make a one-time
    payment to the Nuelle security holders of an amount equal to $1.8 million;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Upon achieving
    the first occurrence of Net Sales of $25.0 million over any sequential four calendar quarter period, Aytu will make a one-time
    payment to the Nuelle security holders of an amount equal to $2.5 million;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Upon achieving the first occurrence
    of Net Sales of $37.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle
    security holders of an amount equal to $3.8 million;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Upon achieving the first occurrence
    of Net Sales of $50.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle
    security holders of an amount equal to $5.0 million; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Upon achieving the first occurrence
    of Net Sales of $100.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the
    Nuelle security holders of an amount equal to $10.0 million.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s allocation on consideration transferred
for Nuelle as of the purchase date May&nbsp;5, 2017 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Fair
    Value</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Tangible assets</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">2,061,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Intangible assets</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">1,540,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">Goodwill</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid">238,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt; padding-left: 0; text-indent: 0">Total assets acquired</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">3,839,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Included in the intangible assets is developed technology of
$1.3 million, customer contracts of $80,000 and trade names of $160,000, each of which will be amortized over a nine to twelve-year
period. Amortization expense of $38,000 and $0 was recognized for the three months ended September 30, 2017 and September 30,
2016, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The contingent consideration was valued at $1.9 million using
a Monte Carlo simulation, as of May 2017. The contingent consideration accretion expense for the three months ended September
30, 2017 and September 30, 2016 was $20,000, and $0 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the quarter ended September 30, 2017, we paid the first
earn-out payment to Nuelle shareholders of $12,000 issued in Aytu common stock, which was 25% of the Aytu Women&rsquo;s Health
net revenue for fiscal 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, upon the closing of the merger, we assumed liabilities
of $47,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recently Issued Accounting Pronouncements, Not Adopted as
of September 30, 2017 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2017, the FASB issued ASU No. 2017-09,&nbsp;&ldquo;Compensation-Stock
Compensation (Topic 718) Scope of Modification Accounting&nbsp;(ASU 2017-09).&rdquo; ASU 2017-09 clarifies which changes to the
terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard
is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company
is currently evaluating the impact of its adoption of this standard on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2017, the FASB issued ASU 2017-04, &ldquo;Intangibles
- Goodwill and Other (Topic 350).&rdquo; The amendment simplifies the subsequent measurement of goodwill by removing the second
step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test
by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount
by which the carrying amount exceeds the reporting unit&rsquo;s fair value; however, the loss recognized should not exceed the
total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment
for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective
basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal
years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1,
2017. The Company does not believe that adoption of this amendment will have a material impact on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2017, the FASB issued ASU 2017-01, &ldquo;Business
Combinations (Topic 805) Clarifying the Definition of a Business.&rdquo; The amendment clarifies the definition of a business,
which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets
or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance
is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively
for public business entities for annual periods beginning after December 15, 2017, including interim periods within those periods.
Early adoption is permitted. The Company does not expect an immediate impact from this codification however, if Aytu seeks to
purchase additional assets in the future it could have an impact if that purchase is accounted for as a business combination or
an asset purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">In June 2016, the FASB issued
ASU 2016-13, &ldquo;Financial Instruments &ndash; Credit Losses&rdquo; to require the measurement of expected credit losses for
financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The
main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit
losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. This
ASU is effective for private companies and emerging growth companies beginning after December 15, 2020; the ASU allows for early
adoption as of the beginning of an interim or annual reporting period beginning after December 15, 2018. The Company is currently
assessing the impact that ASU 2016-13 will have on its consolidated financial statements but does not anticipate there to be a
material impact.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2016, the FASB issued ASU 2016-02, &ldquo;Leases
(Topic 842).&rdquo; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a
lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance
or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective
for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective
transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning
of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company
is currently evaluating the impact of its adoption of this standard on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2016, the FASB issued ASU 2016-01, &ldquo;Financial
Instruments &ndash; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,&rdquo;
which requires that all equity investments be measured at fair value with changes in the fair value recognized through net income
(other than those accounted for under the equity method of accounting or those that result in consolidation of the investee).
The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total
change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected
to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments
in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities
that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate
the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for
public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December
15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2014, the FASB issued ASU 2014-09, Topic 606, Revenue
from Contracts with Customers (the &ldquo;New Revenue Standard&rdquo;). The amendments in this ASU provide a single model for use
in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including
industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized to depict the transfer
of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled
in exchange for those goods and services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash
flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14 which deferred the
effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12 to
clarify, among other things, the implementation guidance related to principal versus agent considerations, identifying performance
obligations, and accounting for licenses of intellectual property. The New Revenue Standard is effective for fiscal years beginning
after December 15, 2017, including interim periods within those fiscal years. Early application is not permitted. The amendments
in this update are to be applied on a retrospective basis, either to each prior reporting period presented or by presenting the
cumulative effect of applying the update recognized at the date of initial application. The New Revenue Standard will be effective
for the Company in fiscal 2019. The Company is evaluating the adoption methodology and the impact of this ASU on its consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash; Fixed Assets </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fixed assets are recorded at cost and, once placed in service,
are depreciated on the straight-line method over the estimated useful lives. Fixed assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Estimated<BR>
    Useful Lives in</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">As of<BR>
    September 30,</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">As of<BR>
    June 30,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">years</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 65%; font-size: 10pt; text-align: left; padding: 0; text-indent: 0">Manufacturing equipment</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 9%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2 - 5</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">405,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">405,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">Leasehold improvements</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">3</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">111,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">111,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">Office equipment, furniture and other</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">2 - 5</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">287,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">287,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">Lab equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">3 - 5</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">90,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">90,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 1.5pt; text-indent: 0">Less accumulated depreciation and amortization</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1.5pt solid">(326,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1.5pt solid">(246,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 10pt; text-indent: 0">Fixed assets, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">567,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">647,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The depreciation expense was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">Three
    Months Ended<BR>
September 30,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">2016</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Depreciation expense</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">80,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">19,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 3 &ndash; Patents </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Costs of establishing patents, consisting of legal and filing
fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third-party
appraisal, was $500,000. The Zertane patents were acquired in connection with the 2011 acquisition of DMI BioSciences by Ampio,
the former parent company of Aytu, and were being amortized over the remaining U.S. patent lives of approximately 11 years, which
were to expire in March 2022. In fiscal 2016, we redirected our resources towards our commercial-stage products and the Company
determined that this asset had no further value as the Company did not have the resources to complete the necessary clinical trials
and bring it to market before the patents expired. The remaining fair value of the Zertane patents were expensed as of June 30,
2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The cost of the Luoxis patents were $380,000 when they were
acquired in connection with the 2013 formation of Luoxis and are being amortized over the remaining U.S. patent lives of approximately
15 years, which expires in March 2028. Patents consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; padding-left: 0; text-indent: 0">As of<BR>
September 30,</TD><TD STYLE="font-size: 10pt; text-align: center; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; padding-left: 0; text-indent: 0">As of <BR>
June 30,</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; padding-left: 0; text-indent: 0">Patents</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">880,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">880,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">Less accumulated amortization</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid">(615,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">)</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid">(609,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: 0">Patents, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">265,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">271,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amortization expense was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0"><FONT STYLE="font-weight: normal; font-style: normal">Three
    Months Ended<BR>
September 30,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">2016</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;Amortization expense</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">6,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">7,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 4 &ndash; Revenue Recognition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The $1,076,000 and $698,000 of product revenue recognized during
the three months ended September 30, 2017 and 2016, respectively, represent sales of the Company&rsquo;s products, Natesto, ProstaScint,
and Primsol, and the MiOXSYS and RedoxSYS Systems, as well as products in the Fiera line.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 5 &ndash; Fair Value Considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu&rsquo;s financial instruments include cash and cash equivalents,
restricted cash, accounts receivable, accounts payable and accrued liabilities, and warrant derivative liability. The carrying
amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable,
and other current assets and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related
contingent consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of
potential future events. The valuation policies are determined by the Chief Financial Officer and approved by the Company&rsquo;s
Board of Directors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Authoritative guidance defines fair value as the price that
would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants
at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of
observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data
obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu&rsquo;s assumptions of what market
participants would use in pricing the asset or liability developed based on the best information available in the circumstances.
The hierarchy is broken down into three levels based on reliability of the inputs as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 8%"><FONT STYLE="font-size: 10pt">Level&nbsp;1:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; width: 92%"><FONT STYLE="font-size: 10pt">Inputs that reflect unadjusted
    quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;</FONT></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Level&nbsp;2:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">Inputs that include quoted prices for similar
    assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or
    indirectly; and</FONT></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Level&nbsp;3:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">Unobservable inputs that are supported by
    little or no market activity.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu&rsquo;s assets and liabilities which are measured at fair
value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement.
Aytu&rsquo;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change
in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents Aytu&rsquo;s financial liabilities
that were accounted for at fair value on a recurring basis as of September 30, 2017, by level within the fair value hierarchy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Fair
    Value Measurements Using</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Level
    1</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Level
    2</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Level
    3</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><U>September 30, 2017</U></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">LIABILITIES</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Warrant derivative liability</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">3,818,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">3,818,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Contingent consideration</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">7,823,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">7,823,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-decoration: underline; padding-left: 0; text-indent: 0">June 30, 2017</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">LIABILITIES</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Warrant derivative liability</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Contingent consideration</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">7,648,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">7,648,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrant derivative liability was valued using the lattice
valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments.
The warrants related to the warrant derivative liability are not actively traded and therefore classified as Level 3. Significant
assumptions in valuing the warrant derivative liability, based on estimates of the value of Aytu common stock and various factors
regarding the warrants, were as follows as of issuance and as of September 30, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">September 30, 2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">At Issuance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Warrants:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 10pt">Volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">183.0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">188.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Equivalent term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.90</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.83</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth a reconciliation of changes
in the fair value of the derivative financial liabilities classified as Level 3 in the fair value hierarchy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Derivative
    Instruments</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">Balance as of June 30, 2017</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%; font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: 0">Warrant issuances</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">4,118,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 10pt">Change in fair value
    included in earnings</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">(300,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">Balance as of September 30, 2017</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">3,818,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We classify our contingent consideration liability in connection
with the acquisition of ProstaScint, Natesto and Fiera within Level 3 as factors used to develop the estimated fair value are
unobservable inputs that are not supported by market activity. We estimate the fair value of our contingent consideration liability
based on projected payment dates, discount rates, probabilities of payment, and projected revenues. Projected contingent payment
amounts are discounted back to the current period using a discounted cash flow model. There was no change in the fair value of
the contingent consideration during the period ended September 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt inherit,serif; margin: 0">The following table sets forth a summary of changes in the contingent consideration
for the period ended September 30, 2017:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Contingent Consideration</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%">Balance as of June 30, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,648,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Increase due to accretion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">187,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Decrease due to contractual payment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(12,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Balance as of September 30, 2017</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,823,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6 &ndash; Commitments and Contingencies </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Commitments and contingencies are described below and summarized
by the following table for the designated fiscal years ending June 30, as of September 30, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; padding-left: 0; text-indent: 0">Remaining</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Thereafter</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 16%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Prescription Database</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">1,220,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">647,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">573,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">Natesto</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">15,000,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">2,500,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">5,000,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">7,500,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt; text-indent: -10pt">Manufacturing/commercial supply agreement</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">Office Lease</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">138,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">108,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">30,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">16,358,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">755,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">603,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">2,500,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">5,000,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">7,500,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Prescription Database</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2016, Aytu entered into an agreement with a company
that will provide Aytu with prescription database information. Aytu agreed to pay approximately $1.9 million over three years
for access to the database of prescriptions written for Natesto. The payments have been broken down into quarterly payments, the
first of which was made in November 2016, the second payment was made in January 2017, the third payment was made in April 2017,
and the fourth payment was made in August 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Natesto</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2016, the Company entered into an agreement with Acerus
whereby Aytu agreed to pay $8.0 million for the exclusive U.S. rights to Natesto (see Note 1). The first payment totaling $2.0
million was paid in April 2016, the second installment payment was paid in October 2016. The final payment totaling $4.0 million
was paid in January 2017. Additionally, Aytu is required to make the first milestone payment of $2.5 million even if the milestone
is not reached, and anticipates making the second milestone payment of $5.0 million along with the third milestone payment of
$7.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Manufacturing/Commercial Supply Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2015, Aytu entered into a Master Services Agreement
with Biovest International, Inc. (&ldquo;Biovest&rdquo;). The agreement provides that Aytu may engage Biovest from time to time
to provide services in accordance with mutually agreed upon project addendums and purchase orders. Aytu expects to use the agreement
from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing,
release or storage of its products for the ProstaScint product. In September 2016, Aytu entered into a Commercial Supply Agreement
with Grand River Aseptic Manufacturing, Inc. (&ldquo;GRAM&rdquo;). The agreement provides that Aytu may engage GRAM from time
to time to provide services in accordance with mutually agreed upon work orders. As of September, 30, 2017, both contracts were
still on hold as the Company evaluates its strategic options for the ProstaScint product. If the contracts are not restarted,
Aytu does not anticipate any future liability related to either contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Office Lease </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2015, Aytu entered into a 37-month operating lease
for a space in Raleigh, North Carolina. This lease has initial base rent of $3,000 a month, with total base rent over the term
of the lease of approximately $112,000. In September 2015, the Company entered into a 37-month operating lease in Englewood, Colorado.
This lease has an initial base rent of $9,000 a month with a total base rent over the term of the lease of approximately $318,000.
The Company recognizes rental expense of the facilities on a straight-line basis over the term of the lease. Differences between
the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred
rent. Rent expense for the respective periods is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid">Three Months Ended<BR>
September
    30,</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;Rent expense</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">35,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">35,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7 &ndash; Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Capital Stock / Restricted Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At September 30, 2017 and June 30, 2017, Aytu had 4,224,840
and 824,831 common shares outstanding, respectively, and 2,250 and 0 preferred shares outstanding, respectively. The Company has
100.0&nbsp;million shares of common stock authorized with a par value of $0.0001&nbsp;per share and 50.0&nbsp;million shares of
preferred stock authorized with a par value of $0.0001 per share, of which 10,000 were designated Series A Convertible Preferred
Stock. Included in the common stock outstanding are 243,000 shares of restricted stock issued to employees and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 11, 2017, we entered into a Securities Purchase Agreement
with various investors pursuant to which we agreed to sell Class A and Class B equity units for gross proceeds of approximately
$11.8 million. Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares
of common stock and were sold at a negotiated price of $3.00 per unit. Class B units consist of one (1) share of our newly created
Series A Convertible Preferred Stock (the &ldquo;Series A Preferred Stock&rdquo;) and warrants to purchase one and one-half (1.5)
shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at
a negotiated price of $1,000.00 per unit to those purchasers who, together with their affiliates and certain related parties,
would beneficially own more than 9.99% of our outstanding common stock following the offering. These Series A Preferred stock
converts into common shares at $3.00 per common share, which when fully exercised will increase the common shares outstanding
by 750,000 shares. The offering closed on August 15, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the offering, we issued an aggregate of 3,196,665 shares
of our common stock, 2,250 shares of Series A Preferred Stock and warrants to purchase up to an aggregate of 6,314,671 shares
of our common stock, which included 394,669 warrants issued to the underwriters as compensation for the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We incurred certain expenses related to this transaction to
attorneys and underwriters inclusive of a 9% cash fee and warrants to purchase 10% of the aggregate number of shares issued in
the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the closing of the financing, we terminated
the Purchase Agreement, dated as of July 27, 2016, by and between us and Lincoln Park Capital Fund, LLC. The termination was effective
on August 16, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2017, Aytu issued 200,000 shares of restricted
stock to employees, which vest in September 2027. This expense is included in sales, general and administrative. For the three
months ended September 30, 2017, the expense was $2,000. The fair value of the restricted stock was $404,000. The unrecognized
expense of $402,000 will be recognized over the next ten years.</P>

<P STYLE="font: 10pt Times-Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times-Roman,serif; margin: 0">Aytu also has 43,000 shares of restricted stock outstanding and unvested which
were not issued out of the 2015 Stock Option and Inventive Plan. These shares vest in July 2026 and the unrecognized expense of
$2,435,000 will be recognized over the next ten years. During the quarter ended September 30, 2017, the expense related to these
awards was $70,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2017, Aytu issued 3,018 shares of common stocks
as the earn-out payment to Nuelle Shareholders for fiscal 2017. (See Note 1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 8 &ndash; Equity Instruments </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Options </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June&nbsp;1, 2015, Aytu&rsquo;s stockholders approved the
2015 Stock Option and Incentive Plan (the &ldquo;2015 Plan&rdquo;), which, as amended in July 2017, provides for the award of
stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 3.0 million shares
of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting,
satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will
be added back to the shares of common stock available for issuance under the 2015 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the 2015 Stock Plan, 3.0 million shares of the
Company&rsquo;s common stock, are reserved for issuance. The fair value of options granted was calculated using the Black-Scholes
option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of
the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend
yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the
expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is
based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Stock option activity is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Number
    of Options</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Weighted
    Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Weighted
    Average Remaining Contractual Life in Years</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-indent: 0; padding-left: 0">Outstanding June 30, 2017</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">38,263</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">16.31</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">8.40</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 10pt">Granted</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 10pt">Exercised</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; text-indent: 0; padding-left: 10pt">Forfeited/Cancelled</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">(139</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">16.40</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt; text-indent: 0; padding-left: 0">Outstanding September 30, 2017</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">38,124</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">16.31</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">8.13</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt; text-indent: 0; padding-left: 0">Exercisable at September 30, 2017</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">23,385</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">16.40</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">7.85</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt; text-indent: 0; padding-left: 0">Available for grant at
    September 30, 2017</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">2,761,876</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock-based compensation expense related to the fair value
of stock options was included in the statements of operations as research and development expenses and selling, general and administrative
expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option
pricing model and expenses the fair value ratably over the vesting period<FONT STYLE="font-family: Times New Roman, Times, Serif">.
</FONT>The following table summarizes stock-based compensation expense for the stock option issuances for the three months ended
September 30, 2017 and 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid">Three Months Ended<BR>
September
    30,</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">Selling, general and administrative:</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 10pt">Stock options</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">195,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">1,044,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 10pt">Restricted Stock</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">72,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">75,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt; padding-left: 0; text-indent: 0">Total share-based compensation
    expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">267,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">1,119,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">As of&nbsp;September 30, 2017, there
was&nbsp;$571,000 of total unrecognized share-based compensation expense related to non-vested stock options. The Company expects
to recognize this expense over a weighted-average period of 1.60&nbsp;years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrants </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of all warrants is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Number
    of Warrants</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Weighted
    Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Weighted
    Average Remaining Contractual Life in Years</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-indent: 0; padding-left: 0">Outstanding June 30, 2017</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">286,049</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">50.29</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">4.23</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Warrants issued to investors in connection
    with the private offering</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">5,920,002</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">3.60</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Warrants issued to underwritters
    for the private offering</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">394,669</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">3.60</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt; text-indent: 0; padding-left: 0">Outstanding September 30, 2017</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">6,600,720</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">5.62</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">4.86</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times-Roman,serif">In connection
with our August 2017 private offering, </FONT>we issued to investors and underwriters warrants to purchase an aggregate of 6,314,671
shares of common stock <FONT STYLE="font-family: Times-Roman,serif">at an exercise price of $3.60 with a term of five years from
August 25, 2017. These warrants are accounted for under derivative liability treatment. </FONT>(see Note 5).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All warrants issued in fiscal 2018 were valued using the lattice
option pricing model. In order to calculate the fair value of the warrants, certain assumptions were made regarding components
of the model, including the selling price or fair market value of the underlying common stock, risk-free interest rate, volatility,
expected dividend yield, and contractual life. Changes to the assumptions could cause significant adjustments to valuation. The
Company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. The
risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar
maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Significant assumptions in valuing the warrants issued during
the September 30, 2017 quarter are included in Note 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 9 &ndash; Related Party Transactions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Executive Stock Purchases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When Aytu completed the August 2017 offering, our executive
officers Joshua Disbrow and Jarrett Disbrow participated in this offering, purchasing 83,333, units each.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Services Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2015, Aytu entered into an agreement with Ampio, whereby
Aytu agreed to pay Ampio a set amount per month for shared overhead, which includes costs related to the shared corporate staff
and other miscellaneous overhead expenses. This agreement as amended in November 2015, April 2016, July 2016, and again in January
2017 required a monthly payment of $12,000. This agreement was terminated in June 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sponsored Research Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2013, Luoxis entered into a sponsored research agreement
with TRLLC, an entity controlled by Ampio&rsquo;s director and Chief Scientific Officer, Dr.&nbsp;Bar-Or. The agreement was amended
in January 2015 and provided for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration for services related to research
and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $615,000 which
was being amortized over the contractual term of 60.5 months and was divided between current and long-term on the balance sheet;
as of September 2014, this amount had been paid in full. This agreement was terminated in March 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 10 &ndash; Segment Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu manages our Company and aggregates our operational and
financial information in accordance with two reportable segments: Aytu and Aytu Women&rsquo;s Health. The Aytu segment consists
of our core male urology products. The Aytu Women&rsquo;s Health segment contains our women&rsquo;s health products. Select financial
information for these segments is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Three
    months ended<BR>
September 30,</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">2016</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">Consolidated Revenue:</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: 0">Aytu</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0">972,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0">698,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; padding-bottom: 1.5pt; text-indent: 0">Aytu
    Women&rsquo;s Health</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">104,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; padding-bottom: 4pt; text-indent: 0">Consolidated
    revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0">1,076,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0">698,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">Consolidated net loss:</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: 0">Aytu</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0">(3,725,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0">(5,724,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; padding-bottom: 1.5pt; text-indent: 0">Aytu
    Women&rsquo;s Health</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">(520,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; padding-bottom: 4pt; text-indent: 0">Consolidated
    net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0">(4,245,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 0; text-indent: 0">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0">(5,724,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 0; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">Total consolidated
    assets:</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: 0">Aytu</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0">18,115,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0; text-indent: 0">14,999,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt; padding-bottom: 1.5pt; text-indent: 0">Aytu
    Women&rsquo;s Health</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">3,131,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; padding-bottom: 4pt; text-indent: 0">Total
    consolidated assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0">21,246,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0">14,999,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 11 &ndash; Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 20, 2017, the Company was approved for listing and
began trading on The NASDAQ Capital Market under the company&rsquo;s current ticker symbol, AYTU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 24, 2017, Aytu entered into a 24-month extension
of our operating lease for the Englewood, Colorado office space. The base rent will remain at $9,000 per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 25, 350 of our preferred shares outstanding converted
into 116,666 shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 25, Aytu issued 61,000 shares to Nuelle shareholders
as a prepayment for the fiscal 2018 earn-out payment that will be due to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 7, 2017, Aytu issued 495,000 restricted shares
to executives, directors and consultants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;2. Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This discussion should be read in conjunction with Aytu
BioScience, Inc.&rsquo;s Annual Report on Form 10-K for the year ended June 30, 2017, filed on August 31, 2017. The following
discussion and analysis contains forward-looking statements that involve risks and uncertainties. Actual results could differ
materially from those projected in the forward-looking statements. For additional information regarding these risks and uncertainties,
please see the risk factors included in Aytu&rsquo;s Form 10-K filed with the Securities and Exchange Commission on August 31,
2017. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview/recent events </B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a commercial-stage specialty life science company concentrating
on developing and commercializing products with an initial focus on urological diseases and conditions. We are currently focused
on addressing significant medical needs in the areas of hypogonadism, male infertility, urological cancers and female personal
care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 11, 2017, we entered into a Securities Purchase Agreement
with various investors pursuant to which we agreed to sell Class A and Class B equity units for gross proceeds of approximately
$11.8 million. Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares
of common stock and were sold at a negotiated price of $3.00 per unit. Class B units consist of one (1) share of our newly created
Series A Convertible Preferred Stock (the &ldquo;Series A Preferred Stock&rdquo;) and warrants to purchase one and one-half (1.5)
shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at
a negotiated price of $1,000 per unit to those purchasers who, together with their affiliates and certain related parties, would
beneficially own more than 9.99% of our outstanding common stock following the offering. The offering closed on August 15, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the offering, we issued an aggregate of 3,196,665 shares
of our common stock, 2,250 shares of Series A Preferred Stock and warrants to purchase up to an aggregate of 6,314,671 shares
of our common stock, which included 394,669 warrants issued to the underwriters as compensation for the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of the date of this Report, we have financed operations
through a combination of private and public debt and equity financings including net proceeds from the private placements of stock
and convertible notes. Although it is difficult to predict our liquidity requirements, based upon our current operating plan,
as of the date of this Report, we believe we will have sufficient cash to meet our projected operating requirements into the first
half of fiscal 2019, at which point we anticipate nearing or reaching cash-flow breakeven. See &ldquo;Liquidity and Capital Resources.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have only begun to generate material revenues from the commercialization
of our product candidates in the last fiscal year. We recognized approximately $1.1 million in revenue from Natesto, ProstaScint,
MiOXSYS and Fiera sales during the three months ended September 30, 2017. We have incurred accumulated net losses since our inception,
and at September 30, 2017, we had an accumulated deficit of $73.3 million. Our net loss was $4.2 million for the three months
ended September 30, 2017 and we used $4.2 million in cash from operations during the three months ended September 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Significant Accounting Policies and Estimates </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our consolidated financial statements have been prepared in
accordance with accounting principles generally accepted in the United States of America. The preparation of the consolidated
financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. On an
on-going basis, management evaluates its estimates and judgments, including those related to recoverability and useful lives of&nbsp;long-lived
assets, stock compensation, valuation of derivative instruments, allowances and contingencies. Management bases its estimates
and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily
apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The methods,
estimates, and judgments used by us in applying these critical accounting policies have a significant impact on the results we
report in our consolidated financial statements. Our significant accounting policies and estimates are included in our Annual
Report on Form 10-K for the fiscal year ended June 30, 2017, filed with the SEC on August 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information regarding our accounting policies and estimates
can be found in the Notes to the consolidated Financial Statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Newly Issued Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information regarding the recently issued accounting standards
(adopted and pending adoption as of September 30, 2017) is combined in Note 1 to the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations &ndash; September 30, 2017 Compared
to September 30, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Results of operations for the three months ended September
30, 2017 and the three months ended September 30, 2016 reflected losses of approximately $4.2 million and $5.7 million, respectively.
These losses include, in part, non-cash charges related to stock-based compensation, depreciation, amortization and accretion,
in the amount of $621,000 for the three months ended September 30, 2017 and $2.4 million for the three months ended September
30, 2016, respectively. The non-cash charges decreased in the three months ended 2017 primarily due to the decrease in stock-compensation
expense, the amortization of intangible assets, derivative expense, compensation through issuance of common stock and issuance
of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><I>Product revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recognized $1,076,000 and $698,000 for the three months
ended September 30, 2017 and 2016, respectively, related to the sale of our products Natesto, ProstaScint, Primsol, and Fiera
as well as the MiOXSYS and RedoxSYS Systems. Our revenues grew from the launch of our Natesto product, which has increased 193%
compared to the same quarter in 2016 and due to our acquisitions and ensuing sales of the Fiera products, which occurred late
in fiscal 2017 and expanded marketing of our commercial products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As is customary in the pharmaceutical industry, our gross product
sales are subject to a variety of deductions in arriving at reported net product sales. Provisions for these deductions are recorded
concurrently with the recognition of gross product sales revenue and include discounts, chargebacks, distributor fees, processing
fees, as well as allowances for returns and Medicaid rebates. Provision balances relating to estimated amounts payable to direct
customers are netted against accounts receivable and balances relating to indirect customers are included in accounts payable
and accrued liabilities. The provisions recorded to reduce gross product sales and net product sales are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">Three
    Months Ended<BR>
September 30,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">2016</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Gross product</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">2,243,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">925,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Provisions to reduce
    gross product sales to net product sales</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">(1,167,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">(227,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 4pt; text-indent: 0; padding-left: 0">Net product revenue</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">1,076,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">698,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Percentage of gross sales to net sales</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">48.0</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">%</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">75.5</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cost of Sales</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The cost of sales of $287,000 and $192,000 recognized for the
three months ended September 30, 2017 and 2016, respectively, are related to the Natesto, ProstaScint, and Primsol products and
the MiOXSYS and RedoxSYS Systems, as well as products in the Fiera line. We expect to see cost of sales continue to increase in
the fiscal year 2018 as we expect our sales of our current products to continue to grow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.2pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs consist of clinical trials and
sponsored research, manufacturing transfer expense, sponsored research &ndash; related party and consultants and other. These
costs relate solely to research and development without an allocation of general and administrative expenses and are summarized
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">Three
    Months Ended<BR>
September 30,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">2016</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Manufacturing tech transfer</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">75,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Clinical trials and sponsored research</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">140,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">156,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Sponsored research - related party</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">48,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Consultants and other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">1,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">1,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">141,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">280,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Comparison of Three Ended September 30, 2017 and 2016 </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses decreased $139,000, or 49.6%,
for the three months ended September 30, 2017 compared to the three months ended September 30, 2016. This was due primarily to
switching our focus towards our commercial products. We anticipate research and development expense will decrease in fiscal 2018
as compared to fiscal 2017 due to that fact that we will continue to focus on our existing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Selling, General and Administrative</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative expenses consist of labor costs,
including personnel costs for employees in executive, commercial, business development and operational functions; stock-based
compensation; patents and intellectual property; professional fees including legal, auditing, accounting, investor relations,
shareholder expense and printing and filing of SEC reports; occupancy, travel and other including rent, governmental and regulatory
compliance, insurance, and professional subscriptions; directors fees; and management fee &ndash; related party. These costs are
summarized as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">Three
    Months Ended<BR>
September 30,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><FONT STYLE="font-weight: normal; font-style: normal">2016</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; text-indent: 0; padding-left: 0">Labor</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">2,400,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">2,255,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Stock-based compensation</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">267,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">1,119,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Patent costs</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">128,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">26,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Professional fees</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">419,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">262,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Occupancy, travel and other</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">1,364,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">2,003,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Directors Fees</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">40,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">40,000</TD><TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Management fee - related
    party</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">51,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">4,618,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right; padding-left: 0; text-indent: 0">5,756,000</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Comparison of Three Months Ended September 30, 2017 and
2016</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative costs decreased $1,138,000, or 19.8%,
for the three months ended September 30, 2017, compared to the three months ended September 30, 2016. The primary decrease was
in stock-based compensation, and occupancy, travel and other which was related to decreased costs from the stock options that
were vested and immediately exercisable in July 2016, as well as the initial sales training for our Natesto product which occurred
in July 2016. We expect general and administrative expenses to be approximately flat for the remainder of fiscal 2018 as compared
to the three months ended September 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Amortization of Intangible Assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amortization of intangible assets was $386,000 and $437,000
for the three months ended September 30, 2017, compared to the three months ended September 30, 2016. This expense decreased due
to the impairment of the ProstaScint assets in fiscal 2017, and the corresponding amortization of its finite-lived intangible
assets. We expect this expense to remain flat for the remainder of 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Cash Used in Operating Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2017, our operating
activities used $4.2 million in cash, which was approximately the same as the net loss of $4.2 million, primarily as a result
of the non-cash depreciation, amortization and accretion, derivative income and stock-based compensation offset by a decrease
in accounts payable and an increase in accounts receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2016, our operating
activities used $5.3 million in cash, which was less than the net loss of $5.7 million primarily as a result of the non-cash depreciation,
amortization and accretion, and stock-based compensation offset by the unrealized gain on investment, accounts payable, accrued
liabilities, and accrued compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Cash Used in Investing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2017, we used zero
cash in investing activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended September 30, 2016, we used cash
in investing activities of $505,000, $5,000 of which was used to purchase fixed assets, and $500,000 of which was paid as the
second installment towards the Primsol asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Cash from Financing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Net cash provided by financing activities in the three months ended September
30, 2017 of $10.4 million was primarily related to the private offering of $11.8 million, offset by the cash offering cost of
$1.4 million.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash provided by financing activities in the three months
ended September 30, 2016 of $607,000 was primarily related to the common stock issuance of $631,000 offset by the issuance costs
of $24,000 to Lincoln Park.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Liquidity and Capital Resources</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a relatively young company with substantial revenue
growth goals, demonstrated by the nearly 55% revenue growth year over year for the three months ended September 30, 2017. Our
primary activities are focused on commercializing our approved products, acquiring products and developing our product candidates,
and raising capital. As of September 30, 2017, we had cash and cash equivalents totaling $7.1 million available to fund our operations
offset by an aggregate of $2.6 million in accounts payable and accrued liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With the additional capital that we raised in August 2017 of
$11.8 million, we believe we have sufficient resources to fund our operations through fiscal 2018 and into the middle of fiscal
2019. We believe, if our sales continue to grow while being able to maintain research and development and selling, general and
administrative costs, that will continue to decrease our net losses and cash burn during the remainder of fiscal 2018. With these
assumptions, we believe that we have sufficient cash on hand to reach cash-flow breakeven and potentially profitability. If necessary,
in the future we will evaluate the capital markets from time to time to determine when to raise additional capital in the form
of equity, convertible debt or other financing instruments, depending on market conditions relative to our need for funds at such
time. We will seek to raise additional capital at such time as we conclude that such capital is available on terms that we consider
to be in the best interests of our Company and our stockholders. Over the last three years, including recently, volatility in
the financial markets has adversely affected the market capitalizations of many bioscience companies and generally made equity
and debt financing more difficult to obtain. This volatility, coupled with other factors, may limit our access to additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At this time, we expect to satisfy our future cash needs through
private or public sales of our securities or debt financings. We cannot be certain that financing will be available to us on acceptable
terms, or at all. Over the last three years, including recently, volatility in the financial markets has adversely affected the
market capitalizations of many bioscience companies and generally made equity and debt financing more difficult to obtain. This
volatility, coupled with other factors, may limit our access to additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we cannot raise adequate additional capital in the future
when we require it, we could be required to delay, reduce the scope of, or eliminate one or more of our commercialization efforts
or our research and development programs. We also may be required to relinquish greater or all rights to product candidates at
less favorable terms than we would otherwise choose. This may lead to impairment or other charges, which could materially affect
our balance sheet and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Off Balance Sheet Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not have off-balance sheet arrangements, financings,
or other relationships with unconsolidated entities or other persons, also known as &ldquo;variable interest entities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 48.95pt"><B>Item&nbsp;3.</B></TD><TD><B>Quantitative and Qualitative Disclosures About
                                         Market Risk. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are not currently exposed to material market risk arising
from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. We have not
identified a need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 48.95pt"><B>Item&nbsp;4.</B></TD><TD><B>Controls and Procedures. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of the end of the period covered by this Quarterly Report
on Form 10-Q, an evaluation was carried out by our management, with the participation of the Chief Executive Officer and Chief
Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e)
under the Securities Exchange Act of 1934, as amended, or the Exchange Act.&nbsp;Based on such evaluation, the Chief Executive
Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective to ensure that information
required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in the SEC&rsquo;s rules and forms, and are operating in an effective manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Changes in Internal Control over Financial Reporting </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no changes in our internal controls over financial
reporting that occurred during the last fiscal quarter that has materially affected, or is reasonably likely to materially affect,
our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II. OTHER INFORMATION </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 48.95pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;
                                         1.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
                                         Proceedings. </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently not a party to any material pending legal proceedings, whether routine or non-routine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 48.95pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;1A.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
                                         Factors. </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth below, there have been no material changes to the discussion of risk factors included in our most recent Annual Report
on Form 10-K, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 48.95pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;2.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unregistered
                                         Sales of Securities and Use of Proceeds. </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 48.95pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Defaults
                                         Upon Senior Securities. </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 48.95pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;
                                         4.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mine
                                         Safety Disclosures. </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 48.95pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;5.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
                                         Information. </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">On
November 7, 2017, the Company&rsquo;s Compensation Committee approved an increase in the Base Salary of Joshua R. Disbrow, the
Company&rsquo;s Chief Executive Officer, to $330,000 effective as of November 1, 2017. The approval effectively amends the Employment
Agreement between the Company and Mr. Disbrow to provide for a new base salary of $330,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 48.95pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;
                                         6.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits.
                                         </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; padding-right: 0; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
</TD>
    <TD STYLE="width: 1%; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; width: 90%; border-bottom: Black 1.5pt solid; padding-right: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; padding-right: 0; text-indent: 0"><A HREF="f10q0917ex31-1_aytubio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; padding-right: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; padding-right: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; padding-right: 0; text-indent: 0"><A HREF="f10q0917ex31-2_aytubio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; padding-right: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; padding-right: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0; text-indent: 0"><A HREF="f10q0917ex32-1_aytubio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of&nbsp;2002*.</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD NOWRAP STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; padding-right: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; font: 10pt Times New Roman, Times, Serif; padding-right: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101&#9;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
                                         (eXtensible Business Reporting Language). The following materials from Aytu BioScience,
                                         Inc.&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 formatted
                                         in XBRL: (i) the Consolidated Balance Sheet, (ii) the Consolidated Statement of Operations,
                                         (iii) the Consolidated Statement of Stockholders&rsquo; Equity (Deficit), (iv) the Consolidated
                                         Statement of Cash Flows, and (v) the Consolidated Notes to the Financial Statements.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0; text-indent: 0; width: 4%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-left: 0; text-indent: 0; text-align: left; width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    certification attached as Exhibit&nbsp;32.1 accompanying this Quarterly Report on Form&nbsp;10-Q pursuant to 18 U.S.C. Section&nbsp;1350,
    as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, shall not be deemed &ldquo;filed&rdquo; by the
    Registrant for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AYTU
    BIOSCIENCE, INC.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;Joshua
                                         R. Disbrow</FONT></P>
</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Joshua
    R. Disbrow</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
    Executive Officer</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date:
    November 9, 2017</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;Gregory
                                         A. Gould</FONT></P>
</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gregory
    A. Gould</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
    Financial Officer</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 0.1in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date:
    November 9, 2017</B></FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">25</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10q0917ex31-1_aytubio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Certification by Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section&nbsp;302 of the Sarbanes-Oxley
Act of 2002 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Joshua R. Disbrow, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">1.</TD><TD>I have reviewed this report on Form 10-Q of Aytu BioScience, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules&nbsp;13a&mdash;15(e) and 15d&mdash;15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules&nbsp;13a&mdash;15(f) and 15d&mdash;15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that
has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or
persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top; padding: 0; width: 60%"><FONT STYLE="font-size: 10pt">Date: November 9, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; width: 5%">By:</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; padding: 0; width: 35%; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">/s/ Joshua R. Disbrow</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0"></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; padding: 0"><FONT STYLE="font-size: 10pt"><B>Joshua R. Disbrow</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; padding: 0"><FONT STYLE="font-size: 10pt"><B>Chief Executive Officer</B></FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>f10q0917ex31-2_aytubio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Certification by Chief Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;302 of the
Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Gregory A Gould, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">1.</TD><TD>I have reviewed this report on Form 10-Q of Aytu BioScience, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules&nbsp;13a&mdash;15(e) and 15d&mdash;15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules&nbsp;13a&mdash;15(f) and 15d&mdash;15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that
has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or
persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies or material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; width: 60%"><FONT STYLE="font-size: 10pt">Date:&nbsp;November 9, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0; text-align: left; width: 35%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">/s/ Gregory A. Gould&nbsp;</P>
</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Gregory A. Gould</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Chief Financial Officer</B></FONT></TD></TR>
</TABLE>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10q0917ex32-1_aytubio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification Pursuant to 18 U.S.C.
Section&nbsp;1350, as Adopted</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the filing of the quarterly report on Form
10-Q for the quarter ended September 30, 2017 (the &ldquo;Report&rdquo;) by Aytu BioScience, Inc. (the &ldquo;Company&rdquo;),
each of the undersigned hereby certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">1.</TD><TD>The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended,
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; width: 60%"><FONT STYLE="font-size: 10pt">Dated: November 9, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 40%; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">/s/ Joshua R. Disbrow</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt"><B>Joshua R. Disbrow</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt"><B>Chief Executive Officer</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Dated: November 9, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">/s/ Gregory A. Gould</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt"><B>Gregory A. Gould</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-size: 10pt"><B>Chief Financial Officer</B></FONT></TD></TR>
</TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>aytu-20170930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated using Ez-XBRL version 8.0.1.0 [11/08/2017 11:00:53 PM] -->
<!-- Based on XBRL 2.1 -->

<xbrli:xbrl xmlns:aytu="http://www.aytubio.com/20170930"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31"
 xmlns:us-types="http://fasb.org/us-types/2017-01-31"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:utr="http://www.xbrl.org/2009/utr"
>
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="aytu-20170930.xsd" />
<!-- Context Section  -->
<xbrli:context id="Context_As_Of_31_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_AgreementAxis_SponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="aytu:AgreementAxis">aytu:SponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-03-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_AgreementAxis_SponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="aytu:AgreementAxis">aytu:SponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-03-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00_AgreementAxis_SponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="aytu:AgreementAxis">aytu:SponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-02
</xbrli:startDate>
<xbrli:endDate>
2015-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_May_2015T00_00_00_TO_20_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-05-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_May_2015T00_00_00_TO_20_May_2015T00_00_00_ProductOrServiceAxis_ProstaScintMember_FiniteLivedIntangibleAssetsByMajorClassAxis_DevelopedTechnologyRightsMember_BusinessAcquisitionAxis_JazzPharmaceuticalsIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">aytu:ProstaScintMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:JazzPharmaceuticalsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-05-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_May_2015T00_00_00_TO_20_May_2015T00_00_00_BusinessAcquisitionAxis_JazzPharmaceuticalsIncMember_ProductOrServiceAxis_ProstaScintMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:JazzPharmaceuticalsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">aytu:ProstaScintMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-05-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_May_2015T00_00_00_TO_20_May_2015T00_00_00_BusinessAcquisitionAxis_JazzPharmaceuticalsIncMember_ProductOrServiceAxis_ProstaScintMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:JazzPharmaceuticalsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">aytu:ProstaScintMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-05-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-05-01
</xbrli:startDate>
<xbrli:endDate>
2015-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-06-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-09-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_05_Oct_2015T00_00_00_TO_05_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-10-05
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_21_Sep_2015T00_00_00_TO_05_Oct_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_DevelopedTechnologyRightsMember_BusinessAcquisitionAxis_PrimsolBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-09-21
</xbrli:startDate>
<xbrli:endDate>
2015-10-05
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_DevelopedTechnologyRightsMember_BusinessAcquisitionAxis_PrimsolBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-02
</xbrli:startDate>
<xbrli:endDate>
2015-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember_StatementScenarioAxis_PaidOnApril12016Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">aytu:PaidOnApril12016Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-02
</xbrli:startDate>
<xbrli:endDate>
2015-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember_StatementScenarioAxis_NoLaterThanSeptember302016Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">aytu:NoLaterThanSeptember302016Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-02
</xbrli:startDate>
<xbrli:endDate>
2015-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember_StatementScenarioAxis_NoLaterThanJuly012016Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">aytu:NoLaterThanJuly012016Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-02
</xbrli:startDate>
<xbrli:endDate>
2015-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-04-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_BusinessCombinationSeparatelyRecognizedTransactionsAxis_SecondUpfrontMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">aytu:SecondUpfrontMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-04-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-04-01
</xbrli:startDate>
<xbrli:endDate>
2016-04-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_FirstMilestoneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:FirstMilestoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-04-01
</xbrli:startDate>
<xbrli:endDate>
2016-04-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_SecondMilestoneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SecondMilestoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-04-01
</xbrli:startDate>
<xbrli:endDate>
2016-04-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_ThirdMilestoneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:ThirdMilestoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-04-01
</xbrli:startDate>
<xbrli:endDate>
2016-04-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_ForthMilestoneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:ForthMilestoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-04-01
</xbrli:startDate>
<xbrli:endDate>
2016-04-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_FifthMilestoneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:FifthMilestoneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-04-01
</xbrli:startDate>
<xbrli:endDate>
2016-04-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_30_Apr_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-04-01
</xbrli:startDate>
<xbrli:endDate>
2016-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_30_Apr_2016T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:NatestoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-04-01
</xbrli:startDate>
<xbrli:endDate>
2016-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:PrescriptionDatabaseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-05-01
</xbrli:startDate>
<xbrli:endDate>
2016-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jul_2015T00_00_00_TO_30_Jun_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2016T00_00_00_TO_30_Jun_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2016T00_00_00_TO_31_Jul_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_BusinessAcquisitionAxis_NuelleIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_RestrictedStockMember_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_AytuBioscienceIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuWomensHealthMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_AytuBioscienceIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuWomensHealthMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:NatestoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:NatestoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_BusinessCombinationSeparatelyRecognizedTransactionsAxis_ThirdUpfrontMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">aytu:ThirdUpfrontMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_AgreementAxis_ServicesAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="aytu:AgreementAxis">aytu:ServicesAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-03-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-03-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_05_May_2017T00_00_00_TO_05_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-05-05
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_05_May_2017T00_00_00_TO_05_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-05-05
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_DevelopedTechnologyRightsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-05-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-05-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-05-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-05-01
</xbrli:startDate>
<xbrli:endDate>
2017-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_FirstMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:FirstMilestoneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-05-01
</xbrli:startDate>
<xbrli:endDate>
2017-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_SecondMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SecondMilestoneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-05-01
</xbrli:startDate>
<xbrli:endDate>
2017-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_ThirdMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:ThirdMilestoneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-05-01
</xbrli:startDate>
<xbrli:endDate>
2017-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_ForthMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:ForthMilestoneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-05-01
</xbrli:startDate>
<xbrli:endDate>
2017-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_FifthMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:FifthMilestoneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-05-01
</xbrli:startDate>
<xbrli:endDate>
2017-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-05-01
</xbrli:startDate>
<xbrli:endDate>
2017-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_RangeAxis_MaximumMember_BusinessAcquisitionAxis_NuelleIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-05-01
</xbrli:startDate>
<xbrli:endDate>
2017-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_SixthMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SixthMilestoneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-05-01
</xbrli:startDate>
<xbrli:endDate>
2017-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jul_2016T00_00_00_TO_30_Jun_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jul_2016T00_00_00_TO_30_Jun_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jul_2016T00_00_00_TO_30_Jun_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aytu:ContingentConsiderationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_11_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-08-11
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_11_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-08-11
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-08-01
</xbrli:startDate>
<xbrli:endDate>
2017-08-11
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-08-01
</xbrli:startDate>
<xbrli:endDate>
2017-08-11
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-08-01
</xbrli:startDate>
<xbrli:endDate>
2017-08-11
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_ClassUnitsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:ClassUnitsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-08-01
</xbrli:startDate>
<xbrli:endDate>
2017-08-11
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_ClassBUnitsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:ClassBUnitsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-08-01
</xbrli:startDate>
<xbrli:endDate>
2017-08-11
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_25_Aug_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-08-01
</xbrli:startDate>
<xbrli:endDate>
2017-08-25
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-08-01
</xbrli:startDate>
<xbrli:endDate>
2017-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_AwardTypeAxis_RestrictedStockMember_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementBusinessSegmentsAxis_AytuBioscienceIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuWomensHealthMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NuelleMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FinancialInstrumentAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember_FiniteLivedIntangibleAssetsByMajorClassAxis_DevelopedTechnologyRightsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_BusinessAcquisitionAxis_ProstascintBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_ZertanePatentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ZertanePatentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LuoxisPatentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:LuoxisPatentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FinancialInstrumentAxis_WarrantMember_SubsidiarySaleOfStockAxis_NoteWarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aytu:ContingentConsiderationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_AwardTypeAxis_StockCompensationPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:NatestoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:PrescriptionDatabaseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementBusinessSegmentsAxis_AytuBioscienceIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuWomensHealthMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_ZertanePatentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ZertanePatentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LuoxisPatentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:LuoxisPatentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aytu:ContingentConsiderationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_ManufacturingAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:ManufacturingAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_JazzPharmaceuticalsIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:JazzPharmaceuticalsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2017T00_00_00_TO_24_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-10-01
</xbrli:startDate>
<xbrli:endDate>
2017-10-24
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_25_Oct_2017T00_00_00_TO_25_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-10-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_25_Oct_2017T00_00_00_TO_25_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_BusinessAcquisitionAxis_NuelleMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-10-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_05_Oct_2017T00_00_00_TO_25_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-10-05
</xbrli:startDate>
<xbrli:endDate>
2017-10-25
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Nov_2017T00_00_00_TO_01_Nov_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-11-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Nov_2017T00_00_00_TO_07_Nov_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-11-02
</xbrli:startDate>
<xbrli:endDate>
2017-11-07
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw;:cV5c444c555cT{h>EFJJF9FI1JGEF18JH<1=6H<18F7F4EIEE:H7 -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id='CAD'><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit>
<xbrli:unit id='CAD_per_Share'><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">AYTU BIOSCIENCE, INC</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">0001385818</dei:EntityCentralIndexKey>
<dei:TradingSymbol contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">AYTU</dei:TradingSymbol>
<dei:AmendmentFlag contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">false</dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">--06-30</dei:CurrentFiscalYearEndDate>
<dei:DocumentType contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">2017-09-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">2018</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">Q1</dei:DocumentFiscalPeriodFocus>
<dei:EntityFilerCategory contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_01_Nov_2017T00_00_00_TO_01_Nov_2017T00_00_00" unitRef="shares" decimals="INF">4402638</dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">802328</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">7021527</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">75214</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">75371</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">528039</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1211845</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:InventoryNet contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">1312221</us-gaap:InventoryNet>
<us-gaap:InventoryNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1171260</us-gaap:InventoryNet>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">310760</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">262057</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">3028562</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">9742060</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">647254</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">566913</us-gaap:PropertyPlantAndEquipmentNet>
<aytu:CoreAndDevelopedTechnologyNet contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">1337333</aytu:CoreAndDevelopedTechnologyNet>
<aytu:CoreAndDevelopedTechnologyNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1294306</aytu:CoreAndDevelopedTechnologyNet>
<us-gaap:IndefiniteLivedContractualRights contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">77667</us-gaap:IndefiniteLivedContractualRights>
<us-gaap:IndefiniteLivedContractualRights contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">76667</us-gaap:IndefiniteLivedContractualRights>
<us-gaap:IndefiniteLivedTradeNames contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">164037</us-gaap:IndefiniteLivedTradeNames>
<us-gaap:IndefiniteLivedTradeNames contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">158238</us-gaap:IndefiniteLivedTradeNames>
<us-gaap:OtherAssetsNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">9231072</us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">8901391</us-gaap:OtherAssetsNoncurrent>
<us-gaap:Goodwill contextRef="Context_As_Of_20_May_2015T00_00_00_TO_20_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">74000</us-gaap:Goodwill>
<us-gaap:Goodwill contextRef="Context_As_Of_05_Oct_2015T00_00_00_TO_05_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">147000</us-gaap:Goodwill>
<us-gaap:Goodwill contextRef="Context_As_Of_05_May_2017T00_00_00_TO_05_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleMember" unitRef="USD" decimals="0">238000</us-gaap:Goodwill>
<us-gaap:Goodwill contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">238426</us-gaap:Goodwill>
<us-gaap:Goodwill contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">238426</us-gaap:Goodwill>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">271278</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">271000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">264944</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">265000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:DepositsAssetsNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">2888</us-gaap:DepositsAssetsNoncurrent>
<us-gaap:DepositsAssetsNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2888</us-gaap:DepositsAssetsNoncurrent>
<us-gaap:AssetsNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">11969955</us-gaap:AssetsNoncurrent>
<us-gaap:AssetsNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">11503773</us-gaap:AssetsNoncurrent>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">14999000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_AytuBioscienceIncMember" unitRef="USD" decimals="0">14999000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:Assets contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">14998517</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">21245833</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementBusinessSegmentsAxis_AytuBioscienceIncMember" unitRef="USD" decimals="0">18115000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember" unitRef="USD" decimals="0">3131000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">2220400</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1660764</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">782536</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">903386</us-gaap:AccruedLiabilitiesCurrent>
<aytu:AccruedCompensationCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">339704</aytu:AccruedCompensationCurrent>
<aytu:AccruedCompensationCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">680545</aytu:AccruedCompensationCurrent>
<us-gaap:DeferredRentCreditCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">6673</us-gaap:DeferredRentCreditCurrent>
<us-gaap:DeferredRentCreditCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">6455</us-gaap:DeferredRentCreditCurrent>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">261155</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">257036</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">3610468</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">3508186</us-gaap:LiabilitiesCurrent>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">227000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_28_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_BusinessCombinationSeparatelyRecognizedTransactionsAxis_SecondUpfrontMember" unitRef="USD" decimals="-5">2000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">7386782</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">7648000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">7648000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">7566443</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">6000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">7823000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">7823000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
<us-gaap:DeferredRentCreditNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">1451</us-gaap:DeferredRentCreditNoncurrent>
<us-gaap:DeferredRentCreditNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">3818263</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">3818000</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">3818000</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">10998701</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">14892892</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1</us-gaap:PreferredStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">82</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">422</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">73069463</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">79667289</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">-69069729</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-73314771</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">3999816</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">82</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">73069463</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-69069729</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">6352941</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">422</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">79667289</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-73314771</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="0">1</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">14998517</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">21245833</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">2250</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">10000</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">2250</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_25_Oct_2017T00_00_00_TO_25_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">350</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" decimals="INF">824831</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">4224840</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" decimals="INF">824831</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">4224840</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">243000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:SalesRevenueNet contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">697980</us-gaap:SalesRevenueNet>
<us-gaap:SalesRevenueNet contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1076368</us-gaap:SalesRevenueNet>
<us-gaap:Revenues contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">697980</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_AytuBioscienceIncMember" unitRef="USD" decimals="0">698000</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:Revenues contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1076368</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementBusinessSegmentsAxis_AytuBioscienceIncMember" unitRef="USD" decimals="0">972000</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember" unitRef="USD" decimals="0">104000</us-gaap:Revenues>
<us-gaap:CostOfRevenue contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">191924</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">287201</us-gaap:CostOfRevenue>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">232022</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">140954</us-gaap:ResearchAndDevelopmentExpense>
<aytu:ResearchAndDevelopmentRelatedParty contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">47998</aytu:ResearchAndDevelopmentRelatedParty>
<aytu:ResearchAndDevelopmentRelatedParty contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">5704750</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">4618403</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:CostsAndExpensesRelatedParty contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">50772</us-gaap:CostsAndExpensesRelatedParty>
<us-gaap:CostsAndExpensesRelatedParty contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<aytu:AmortizationAndImpairmentOfIntangibleAssets contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">437014</aytu:AmortizationAndImpairmentOfIntangibleAssets>
<aytu:AmortizationAndImpairmentOfIntangibleAssets contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">385841</aytu:AmortizationAndImpairmentOfIntangibleAssets>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">6664480</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">5432399</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-5966500</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-4356031</us-gaap:OperatingIncomeLoss>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">415381</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">188745</us-gaap:InterestExpense>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-70609</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">299734</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:GainLossOnInvestments contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">728100</us-gaap:GainLossOnInvestments>
<us-gaap:GainLossOnInvestments contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">242110</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">110989</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-5724390</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_AytuBioscienceIncMember" unitRef="USD" decimals="0">-5724000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-4245042</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementBusinessSegmentsAxis_AytuBioscienceIncMember" unitRef="USD" decimals="0">-3725000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember" unitRef="USD" decimals="0">-520000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-4245042</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="0">244937</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="0">2415402</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="2">-23.37</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="2">-1.76</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">824831</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">4224840</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="INF">2250</us-gaap:SharesOutstanding>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">195105</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">195105</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">72306</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">20</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">72286</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Context_Custom_01_Jul_2016T00_00_00_TO_31_Jul_2016T00_00_00" unitRef="shares" decimals="INF">50000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">200000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">11589</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">12000</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">11589</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">3018</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" xsi:nil="true"/>
<aytu:IssuanceOfPreferredAndCommonStockNetCost contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">6319167</aytu:IssuanceOfPreferredAndCommonStockNetCost>
<aytu:IssuanceOfPreferredAndCommonStockNetCost contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">320</aytu:IssuanceOfPreferredAndCommonStockNetCost>
<aytu:IssuanceOfPreferredAndCommonStockNetCost contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6318846</aytu:IssuanceOfPreferredAndCommonStockNetCost>
<aytu:IssuanceOfPreferredAndCommonStockNetCost contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<aytu:IssuanceOfPreferredAndCommonStockNetCost contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="0">1</aytu:IssuanceOfPreferredAndCommonStockNetCost>
<aytu:IssuanceOfPreferredAndCommonStockNetShare contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">3196665</aytu:IssuanceOfPreferredAndCommonStockNetShare>
<aytu:IssuanceOfPreferredAndCommonStockNetShare contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="INF">2250</aytu:IssuanceOfPreferredAndCommonStockNetShare>
<aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<aytu:AdjustmentForRoundingOfSharesDueToConversion contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">326</aytu:AdjustmentForRoundingOfSharesDueToConversion>
<aytu:AdjustmentForRoundingOfSharesDueToConversion contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1402831</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1043712</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">195105</us-gaap:ShareBasedCompensation>
<us-gaap:RestrictedStockExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">75466</us-gaap:RestrictedStockExpense>
<us-gaap:RestrictedStockExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">72306</us-gaap:RestrictedStockExpense>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">822161</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">653313</us-gaap:DepreciationDepletionAndAmortization>
<aytu:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">30496</aytu:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties>
<aytu:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">728100</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
<us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">509996</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">589377</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">347013</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">683806</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInInventories contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">60650</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-140961</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">337525</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-48703</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-109365</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-559636</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-498516</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">120850</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<aytu:IncreaseDecreaseInAccruedCompensation contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-668792</aytu:IncreaseDecreaseInAccruedCompensation>
<aytu:IncreaseDecreaseInAccruedCompensation contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">340841</aytu:IncreaseDecreaseInAccruedCompensation>
<us-gaap:IncreaseDecreaseInPrepaidRent contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-75</us-gaap:IncreaseDecreaseInPrepaidRent>
<us-gaap:IncreaseDecreaseInPrepaidRent contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1669</us-gaap:IncreaseDecreaseInPrepaidRent>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-5332459</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-4217808</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">4721</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">500000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-504721</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">11839995</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<aytu:PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<aytu:PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1402831</aytu:PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">631481</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">24247</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">607234</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">10437164</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-5229946</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">6219356</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="Context_As_Of_30_Jun_2016T00_00_00_TO_30_Jun_2016T00_00_00" unitRef="USD" decimals="0">8054190</us-gaap:CashCashEquivalentsAndShortTermInvestments>
<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">2824244</us-gaap:CashCashEquivalentsAndShortTermInvestments>
<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">877542</us-gaap:CashCashEquivalentsAndShortTermInvestments>
<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">7096898</us-gaap:CashCashEquivalentsAndShortTermInvestments>
<aytu:WarrantsIssuedToInvestorsAndUnderwriters contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<aytu:WarrantsIssuedToInvestorsAndUnderwriters contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">4117997</aytu:WarrantsIssuedToInvestorsAndUnderwriters>
<aytu:EarnOutPaymentToOtherShareholders contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<aytu:EarnOutPaymentToOtherShareholders contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">11589</aytu:EarnOutPaymentToOtherShareholders>
<aytu:PrimsolBusinessPurchaseIncludedInPrimsolPayable contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">49126</aytu:PrimsolBusinessPurchaseIncludedInPrimsolPayable>
<aytu:PrimsolBusinessPurchaseIncludedInPrimsolPayable contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<aytu:FixedAssetsIncludedInAccountsPayable contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">95866</aytu:FixedAssetsIncludedInAccountsPayable>
<aytu:FixedAssetsIncludedInAccountsPayable contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Note 1 - Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Aytu BioScience, Inc. (&amp;#8220;Aytu&amp;#8221;, the &amp;#8220;Company&amp;#8221; or &amp;#8220;we&amp;#8221;) was incorporated as Rosewind Corporation on August&amp;#160;9, 2002 in the State of Colorado. Aytu was re-incorporated in the state of Delaware on June&amp;#160;8, 2015. Aytu is a commercial-stage specialty life sciences company concentrating on developing and commercializing products with an initial focus on urological diseases and conditions. Aytu is currently focused on addressing significant medical needs in the areas of hypogonadism, urological cancers, male infertility, and sexual wellness and vitality.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;These unaudited consolidated financial statements represent the financial statements of Aytu and its subsidiary, Aytu Women&amp;#8217;s Health. These unaudited consolidated financial statements should be read in conjunction with Aytu&amp;#8217;s Annual Report on Form 10-K for the year ended June 30, 2017, which included all disclosures required by generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;). In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position of Aytu for the balance sheet, the results of operations and cash flows for the interim periods presented. The results of operations for the period ended September 30, 2017 are not necessarily indicative of expected operating results for the full year. The information presented throughout this report as of and for the period ended September 30, 2017 and 2016 is unaudited.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Through a multi-step reverse triangular merger, on April 16, 2015, Vyrix Pharmaceuticals, Inc. (&amp;#8217;&amp;#8216;Vyrix&amp;#8217;&amp;#8217;) and Luoxis Diagnostics, Inc. (&amp;#8217;&amp;#8216;Luoxis&amp;#8217;&amp;#8217;) merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue the specialty healthcare market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS and Zertane products. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares held. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares held. On August 25, 2017, Aytu effected a third reverse stock split in which each common stockholder received one share of common stock for every 20
 shares held
 (herein referred to collectively as the &amp;#8220;Reverse Stock Splits&amp;#8221;). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Business Combination&amp;#8212;ProstaScint&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (&amp;#8220;Jazz Pharmaceuticals&amp;#8221;). Pursuant to the agreement, Aytu purchased assets related to the Jazz Pharmaceuticals&amp;#8217; product known as ProstaScint&lt;sup&gt;&amp;#174;&lt;/sup&gt;&amp;#160;(capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &amp;#8217;&amp;#8216;ProstaScint Business&amp;#8217;&amp;#8217;), and assumed certain of Jazz Pharmaceuticals&amp;#8217; liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consisted of an upfront payment of $1.0 million. We also agreed to pay an additional $500,000, which was paid after the transfer of the ProstaScint-related product inventory, and $227,000 which was paid September 30, 2015 (which represents a portion of certain FDA fees). We will also pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was initially valued at $664,000 and was revalued as of June 30, 2017 at $54,000 using a discounted cash flow. The total fair value consideration for the purchase was $2.4 million.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s allocation of consideration transferred for ProstaScint as of the purchase date of May&amp;#160;20, 2015 is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Tangible assets&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;727,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Intangible assets&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;1,590,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Goodwill&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px;
 font-size: 10pt; border-bottom-color: black;
 border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;74,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Total assets acquired&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,391,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Included in the intangible assets is developed technology of $790,000, customer contracts of $720,000 and trade names of $80,000, each of which will be amortized over a ten-year period. At June 30, 2017, the ProstaScint asset was impaired based upon sales projections that we intend to only sell this product through mid-fiscal 2019, when this product expires. The value for the intangible assets were adjusted to $54,000 for developed technology, $7,000 for trade names and $0 for customer contracts. The amortization expense was $12,000 and $40,000 for the three months ended September 30, 2017 and 2016, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of September 30, 2017, the contingent consideration increased by $6,000 due to accretion.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Business Combination&amp;#8212;Primsol&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (&amp;#8220;FSC&amp;#8221;). Pursuant to the agreement, Aytu purchased assets related to FSC&amp;#8217;s product known as Primsol&amp;#174; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the &amp;#8220;Primsol Business&amp;#8221;), and assumed certain of FSC&amp;#8217;s liabilities, including those related to the sale and marketing of Primsol arising after the closing.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Aytu paid $500,000 at closing for the purchase of the Primsol Business, and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 which was paid on April 1, 2016, (b) $500,000 which was paid on July 1, 2016, and (c) $250,000 which was paid in November 2016 (together, the &amp;#8220;Installment Payments&amp;#8221;).&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial;
 text-decoration-color: initial;"&gt;The Company&amp;#8217;s allocation on
 consideration transferred for Primsol as of the purchase date of October 5, 2015 was as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Tangible assets&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;182,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Intangible assets&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;1,470,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Goodwill&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;147,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Total assets acquired&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,799,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Included in tangible assets was $102,000 of inventory and $80,000 of work-in-process inventory. Included in the intangible assets was developed technology of $520,000, customer contracts of $810,000 and trade names of $140,000, each of which was being amortized over a six-year period. Amortization expense of $0 and $61,000 was recognized in the three months ended September 30, 2017 and 2016, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Divestiture &amp;#8211; Primsol&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On March 31,
 2017, we entered into and closed on an Asset Purchase Agreement with Allegis Holdings, LLC (the
 &amp;#8220;Purchaser&amp;#8221;). Pursuant to the agreement, we sold to the Purchaser all of our assets related to our product known as Primsol, including certain intellectual property and contracts, inventory, work in process and all marketing assets and materials related solely to Primsol (together, the &amp;#8220;Primsol Asset&amp;#8221;). We retain any liability associated with the Primsol Asset that occurred prior to the closing. The Purchaser paid us $1,750,000 at the closing for the Primsol Asset. We recognized a gain of approximately $428,000 on the sale which is included in sales, general and administrative expense on our statement of operations.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We have evaluated this transaction and concluded that it is not significant to our business and therefore the results are included in continuing operations, as the criteria to be presented as discontinued operations was not satisfied.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;License and Supply Agreement&amp;#8212;Natesto&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In April 2016, Aytu entered into and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto&amp;#174; (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we acquired effective upon the expiration of the former licensee&amp;#8217;s rights, which occurred on June 30, 2016. The license&amp;#8217;s term runs for the greater of eight years or until the expiry of the latest to expire patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic product.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Aytu paid Acerus an upfront fee of $2.0 million upon execution of the agreement. In October 2016, we paid an additional $2.0 million, and in January 2017, Aytu paid the final upfront payment of $4.0 million. Aytu also purchased, on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2.5 million (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately US $0.16 per share. These shares were a held for sale trading security and were valued at fair market value. Aytu could not dispose of these shares until after August 29, 2016. During the second half of fiscal 2017, Aytu sold all of these shares. The gross proceeds from the sales totaled $1.1 million, the cost of the sales totaled $92,000, and we recognized a loss on investment of $1.0 million. In the quarter ended September 30, 2016, we had an unrealized gain on this investment of $728,000.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In addition to the upfront payments, we must make the following one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $37.5 million):&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align:
 top;"&gt;&lt;td style="width: 63px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 63px; font-size: 10pt;"&gt;&lt;font
 style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1441px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;$2.5 million if net sales during any four consecutive calendar quarter period equal or exceed $25.0 million (the &amp;#8220;First Milestone&amp;#8221;); the First Milestone payment is required to be paid even if the threshold is not met in the event that the agreement is terminated for any reason other than material breach by Acerus, bankruptcy of either party, or termination by Acerus because it believes the amounts payable to Aytu for agreed upon trial work would no longer make the agreement economically viable for Acerus;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;$5.0 million if net sales during any four consecutive calendar quarter period equal or exceed $50.0 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;$7.5 million if net sales during any four consecutive calendar quarter period equal or exceed $75.0 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;$10.0 million if net sales during any four consecutive calendar quarter period equal or exceed $100.0 million; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;$12.5 million if net sales during any four consecutive calendar quarter period equal or exceed $125.0 million.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of the net identifiable asset acquired totaled $10.5 million which is being amortized over eight years. The amortization expense for each of the three months ended September 30, 2017 and 2016 were $330,000.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The contingent consideration was valued at $3.2 million using a Monte Carlo simulation, as of June 30, 2016. As of June 30, 2017, the contingent consideration was revalued and increased to $5.7 million based on increased future estimated sales performance of Natesto using a Monte Carlo simulation. The contingent consideration accretion expenses for the three months ended September 30, 2017 was $161,000, resulting in the contingent consideration value of $5.8 million. The contingent consideration accretion expense for the three months ended September 30, 2016 was $46,000.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Merger/Subsidiary&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2017, Aytu Women&amp;#8217;s Health, LLC., a wholly-owned subsidiary of Aytu, acquired Nuelle, Inc., or Nuelle, a women&amp;#8217;s sexual health company. This transaction expanded our product portfolio with the addition of the Fiera&lt;sup&gt;&amp;#174;&lt;/sup&gt;&amp;#160;personal care device for women.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;
 text-decoration-style: initial; text-decoration-color: initial;"&gt;In the Merger, (i) each share of Nuelle common stock and each option or warrant to purchase Nuelle stock was cancelled, and (ii) each share of Nuelle preferred stock was converted into the right to receive shares of our common stock. We issued to the Nuelle preferred stockholders an aggregate of 125,000 shares of our common stock.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In addition, Nuelle preferred stockholders will be entitled to revenue earn-out payments equal to a designated percentage of net sales on tiers of net sales up to $100.0 million, with an average rate for all tiers in the mid-single digit range and a maximum aggregate payout of $6.9 million.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Nuelle stockholders additionally will be entitled to milestone earn-out payments of up to a potential aggregate of $24.0 million, upon the attainment by us of designated net sales thresholds over any sequential four calendar quarter period.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The first $1.0 million of earn-out payments will be paid in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock. The stock portion of any earn-out will be calculated by dividing each Nuelle stockholder&amp;#8217;s portion of the earn-out by the average closing price of our common stock for the 10 trading days prior to the earlier of the date we deliver notice to the Nuelle stockholders of the earn-out or any public disclosure by us of the earn-out being due and payable.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In the event that we do not make all of the required earn-out payments to the Nuelle stockholders before May 3, 2022, and we also close a divestiture before May 3, 2022 of any of the products acquired in the transaction, we will pay the Nuelle stockholders a combination of (i) cash in an amount equal to 10% of the value of all cash, securities and other property paid to us in the divestiture (cash is to be 60% of the total consideration), and (ii) shares of our common stock equal to the Nuelle stockholders&amp;#8217; portion of the divestiture payment divided by the average closing price of our common stock for the 10 trading days prior to the earlier of the closing date of the divestiture or the public disclosure of the divestiture (shares of common stock are to be 40% of the total consideration).&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In addition to the upfront issuance of common stock, we must make the following one-time payments to the Nuelle stockholders within 90 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $24.0 million):&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; width: 63px; text-indent: 0px; font-size:
 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; width: 63px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td
 style="padding: 0px; width: 1441px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon achieving the first occurrence of Net Sales of $10.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.0 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: justify; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon achieving the first occurrence of Net Sales of $17.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.8 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-align: justify; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: justify; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon achieving the first occurrence of Net Sales of $25.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $2.5 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon achieving the first occurrence of Net Sales of $37.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $3.8 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon achieving the first occurrence of Net Sales of $50.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $5.0 million; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; font-stretch: normal;"&gt;&amp;#9679;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon achieving the first occurrence of Net Sales of $100.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $10.0 million.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;The Company&amp;#8217;s allocation on consideration transferred for Nuelle as of the purchase date May&amp;#160;5, 2017 is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Tangible assets&lt;/td&gt;&lt;td
 style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px;
 text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;2,061,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Intangible assets&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;1,540,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Goodwill&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;238,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Total assets acquired&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,839,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Included in the intangible assets is developed technology of $1.3 million, customer contracts of $80,000 and trade names of $160,000, each of which will be amortized over a nine to twelve-year period. Amortization expense of $38,000 and $0 was recognized for the three months ended September 30, 2017 and September 30, 2016, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The contingent consideration was valued at $1.9 million using a Monte Carlo simulation, as of May 2017. The contingent consideration accretion expense for the three months ended September 30, 2017 and September 30, 2016 was $20,000, and $0 respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;During the quarter ended September 30, 2017, we paid the first earn-out payment to Nuelle shareholders of $12,000 issued in Aytu common stock, which was 25% of the Aytu Women&amp;#8217;s Health net revenue for fiscal 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Additionally, upon the closing of the merger, we assumed liabilities of $47,000.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements, Not Adopted as of September 30, 2017&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal
 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;
 text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2017, the FASB issued ASU No. 2017-09,&amp;#160;&amp;#8220;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&amp;#160;(ASU 2017-09).&amp;#8221; ASU 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of its adoption of this standard on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2017, the FASB issued ASU 2017-04, &amp;#8220;Intangibles - Goodwill and Other (Topic 350).&amp;#8221; The amendment simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe that adoption of this amendment will have a material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2017, the FASB issued ASU 2017-01, &amp;#8220;Business Combinations (Topic 805) Clarifying the Definition of a Business.&amp;#8221; The amendment clarifies the definition of a business, which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively for public business entities for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect an immediate impact from this codification however, if Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business combination or an asset purchase.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="background-color: white;"&gt;In June 2016, the FASB issued ASU 2016-13, &amp;#8220;Financial Instruments &amp;#8211; Credit Losses&amp;#8221; to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. This ASU is effective for private companies and emerging growth companies beginning after December 15, 2020; the ASU allows for early adoption as of the beginning of an interim or annual reporting period beginning after December 15, 2018. The Company is currently assessing the impact that ASU 2016-13 will have on its consolidated financial statements but does not anticipate there to be a material impact.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform:
 none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In February 2016, the FASB issued ASU 2016-02, &amp;#8220;Leases (Topic 842).&amp;#8221; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its adoption of this standard on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2016, the FASB issued ASU 2016-01, &amp;#8220;Financial Instruments &amp;#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,&amp;#8221; which requires that all equity investments be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2014, the FASB issued ASU 2014-09, Topic 606, Revenue from Contracts with Customers (the &amp;#8220;New Revenue Standard&amp;#8221;). The amendments in this ASU provide a single model for use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14 which deferred the effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12 to clarify, among other things, the implementation guidance related to principal versus agent considerations, identifying performance obligations, and accounting for licenses of intellectual property. The New Revenue Standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is not permitted. The amendments in this update are to be applied on a retrospective basis, either to each prior reporting period presented or by presenting the cumulative effect of applying the update recognized at the date of initial application. The New Revenue Standard will be effective for the Company in fiscal 2019. The Company is evaluating the adoption methodology and the impact of this ASU on its consolidated financial statements.&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Note 2 &amp;#8211; Fixed Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over the estimated useful lives. Fixed assets consist of the following:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 24.5pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;Estimated&lt;br /&gt;Useful Lives in&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;As of&lt;br /&gt;September 30,&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;As of&lt;br /&gt;June 30,&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; width: 1019px; text-align: left; text-indent: 0px; font-size: 10pt;"&gt;Manufacturing equipment&lt;/td&gt;&lt;td style="width: 16px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;2 - 5&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-size: 10pt;"&gt;405,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-size: 10pt;"&gt;405,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-size: 10pt;"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;3&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;111,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;111,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-size: 10pt;"&gt;Office equipment, furniture and other&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;2 - 5&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;287,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;287,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-size: 10pt;"&gt;Lab equipment&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;3 - 5&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:
 left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 1.5pt; text-align: left; text-indent: 0px; font-size: 10pt;"&gt;Less accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(326,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(246,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px; font-size: 10pt;"&gt;Fixed assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;567,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;647,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The depreciation expense was as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px;
 font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Depreciation expense&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;80,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;19,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 3 &amp;#8211; Patents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third-party appraisal, was $500,000. The Zertane patents were acquired in connection with the 2011 acquisition of DMI BioSciences by Ampio, the former parent company of Aytu, and were being amortized over the remaining U.S. patent lives of approximately 11 years, which were to expire in March 2022. In fiscal 2016, we redirected our resources towards our commercial-stage products and the Company determined that this asset had no further value as the Company did not have the resources to complete the necessary clinical trials and bring it to market before the patents expired. The remaining fair value of the Zertane patents were expensed as of June 30, 2016.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The cost of the Luoxis patents were $380,000 when they were acquired in connection with the 2013 formation of Luoxis and are being amortized over the remaining U.S. patent lives of approximately 15 years, which expires in March 2028. Patents consist of the following:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;As of&lt;br /&gt;September 30,&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;As of&amp;#160;&lt;br /&gt;June 30,&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Patents&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;880,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;880,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(615,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px;
 font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(609,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;"&gt;Patents, net&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;265,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;271,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The amortization expense was as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;Amortization expense&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;6,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;7,000&lt;/td&gt;&lt;td style="text-align: left;
 text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
<aytu:RevenueRecognitionDisclosureTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Note 4 &amp;#8211; Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The $1,076,000 and $698,000 of product revenue recognized during the three months ended September 30, 2017 and 2016, respectively, represent sales of the Company&amp;#8217;s products, Natesto, ProstaScint, and Primsol, and the MiOXSYS and RedoxSYS Systems, as well as products in the Fiera line.&lt;/p&gt;&lt;/div&gt;</aytu:RevenueRecognitionDisclosureTextBlock>
<us-gaap:FairValueDisclosuresTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Note 5 &amp;#8211; Fair Value Considerations&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Aytu&amp;#8217;s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities, and warrant derivative liability. The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential future events. The valuation policies are determined by the Chief Financial Officer and approved by the Company&amp;#8217;s Board of Directors.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu&amp;#8217;s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td style="width: 126px; font-size: 10pt; vertical-align: top;"&gt;&lt;font style="font-size: 10pt;"&gt;Level&amp;#160;1:&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1441px; font-size: 10pt; vertical-align: bottom;"&gt;&lt;font style="font-size: 10pt;"&gt;Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; vertical-align: top;"&gt;&lt;font style="font-size: 10pt;"&gt;Level&amp;#160;2:&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; vertical-align: bottom;"&gt;&lt;font style="font-size: 10pt;"&gt;Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="font-size: 10pt; vertical-align: top;"&gt;&lt;font style="font-size: 10pt;"&gt;Level&amp;#160;3:&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; vertical-align: bottom;"&gt;&lt;font style="font-size: 10pt;"&gt;Unobservable inputs that are supported by little or no market activity.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Aytu&amp;#8217;s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Aytu&amp;#8217;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif;
 margin: 0pt 0px; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following table presents Aytu&amp;#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of September 30, 2017, by level within the fair value hierarchy.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;Fair Value Measurements Using&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 1&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 2&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 3&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&lt;u&gt;September 30, 2017&lt;/u&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;LIABILITIES&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Warrant derivative liability&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;
 text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align:
 left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;3,818,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;3,818,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Contingent consideration&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;7,823,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;7,823,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt; text-decoration: underline;"&gt;June 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;LIABILITIES&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size:
 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Warrant derivative liability&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Contingent consideration&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;7,648,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;7,648,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The warrant derivative liability was valued using the lattice valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. The warrants related to the warrant derivative liability are not actively traded and therefore classified as Level 3. Significant assumptions in valuing the warrant derivative liability, based on estimates of the value of Aytu common stock and various factors regarding the warrants, were as follows as of issuance and as of September 30, 2017:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 24.5pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 24.5pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;September 30, 2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;At Issuance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Warrants:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1177.67px; text-align: left;
 padding-left: 10pt;"&gt;Volatility&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;183.0&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;188.0&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Equivalent term (years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.88&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.90&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.83&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 24.5pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following table sets forth a reconciliation of changes in the fair value of the derivative financial liabilities classified as Level 3 in the fair value hierarchy:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Derivative Instruments&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Balance as of June 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1365.67px; text-align: left; text-indent: 0px; padding-left: 10pt; font-size: 10pt;"&gt;Warrant issuances&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;4,118,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;"&gt;Change in fair value included in earnings&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(300,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Balance as of September 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width:
 4pt; border-bottom-style: double;"&gt;3,818,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We classify our contingent consideration liability in connection with the acquisition of ProstaScint, Natesto and Fiera within Level 3 as factors used to develop the estimated fair value are unobservable inputs that are not supported by market activity. We estimate the fair value of our contingent consideration liability based on projected payment dates, discount rates, probabilities of payment, and projected revenues. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. There was no change in the fair value of the contingent consideration during the period ended September 30, 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;"&gt;The following table sets forth a summary of changes in the contingent consideration for the period ended September 30, 2017:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Contingent Consideration&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px;"&gt;Balance as of June 30, 2017&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;7,648,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Increase due to accretion&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;187,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Decrease due to contractual payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(12,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Balance as of September 30, 2017&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;7,823,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 6 &amp;#8211; Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Commitments and contingencies are described below and summarized by the following table for the designated fiscal years ending June 30, as of September 30, 2017:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;Remaining&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2019&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2020&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2021&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2022&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Thereafter&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 251px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Prescription Database&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;1,220,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;
 text-indent:
 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;647,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;573,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Natesto&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;15,000,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;7,500,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt; font-size: 10pt;"&gt;Manufacturing/commercial supply agreement&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size:
 10pt;"&gt;-&lt;/td&gt;&lt;td
 style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Office Lease&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;138,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;108,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;16,358,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;755,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;603,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size:
 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;7,500,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Prescription Database&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In May 2016, Aytu entered into an agreement with a company that will provide Aytu with prescription database information. Aytu agreed to pay approximately $1.9 million over three years for access to the database of prescriptions written for Natesto. The payments have been broken down into quarterly payments, the first of which was made in November 2016, the second payment was made in January 2017, the third payment was made in April 2017, and the fourth payment was made in August 2017&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Natesto&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In April 2016, the Company entered into an agreement with Acerus whereby Aytu agreed to pay $8.0 million for the exclusive U.S. rights to Natesto (see Note 1). The first payment totaling $2.0 million was paid in April 2016, the second installment payment was paid in October 2016. The final payment totaling $4.0 million was paid in January 2017. Additionally, Aytu is required to make the first milestone payment of $2.5 million even if the milestone is not reached, and anticipates making the second milestone payment of $5.0 million along with the third milestone payment of $7.5 million.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Manufacturing/Commercial Supply Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif;
 margin: 0pt 0px; color:
 #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In October 2015, Aytu entered into a Master Services Agreement with Biovest International, Inc. (&amp;#8220;Biovest&amp;#8221;). The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. Aytu expects to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of its products for the ProstaScint product. In September 2016, Aytu entered into a Commercial Supply Agreement with Grand River Aseptic Manufacturing, Inc. (&amp;#8220;GRAM&amp;#8221;). The agreement provides that Aytu may engage GRAM from time to time to provide services in accordance with mutually agreed upon work orders. As of September, 30, 2017, both contracts were still on hold as the Company evaluates its strategic options for the ProstaScint product. If the contracts are not restarted, Aytu does not anticipate any future liability related to either contract.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Office Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In June 2015, Aytu entered into a 37-month operating lease for a space in Raleigh, North Carolina. This lease has initial base rent of $3,000 a month, with total base rent over the term of the lease of approximately $112,000. In September 2015, the Company entered into a 37-month operating lease in Englewood, Colorado. This lease has an initial base rent of $9,000 a month with a total base rent over the term of the lease of approximately $318,000. The Company recognizes rental expense of the facilities on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;Rent expense&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td
 style="text-align: right; text-indent:
 0px; padding-left: 0px; font-size: 10pt;"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<aytu:CommonStockTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Note 7 &amp;#8211; Common Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Capital Stock / Restricted Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;At September 30, 2017 and June 30, 2017, Aytu had 4,224,840 and 824,831 common shares outstanding, respectively, and 2,250 and 0 preferred shares outstanding, respectively. The Company has 100.0&amp;#160;million shares of common stock authorized with a par value of $0.0001&amp;#160;per share and 50.0&amp;#160;million shares of preferred stock authorized with a par value of $0.0001 per share, of which 10,000 were designated Series A Convertible Preferred Stock. Included in the common stock outstanding are 243,000 shares of restricted stock issued to employees and directors.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On August 11, 2017, we entered into a Securities Purchase Agreement with various investors pursuant to which we agreed to sell Class A and Class B equity units for gross proceeds of approximately $11.8 million. Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares of common stock and were sold at a negotiated price of $3.00 per unit. Class B units consist of one (1) share of our newly created Series A Convertible Preferred Stock (the &amp;#8220;Series A Preferred Stock&amp;#8221;) and warrants to purchase one and one-half (1.5) shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at a negotiated price of $1,000.00 per unit to those purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding common stock following the offering. These Series A Preferred stock converts into common shares at $3.00 per common share, which when fully exercised will increase the common shares outstanding by 750,000 shares. The offering closed on August 15, 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In the offering, we issued an aggregate of 3,196,665 shares of our common stock, 2,250 shares of Series A Preferred Stock and warrants to purchase up to an aggregate of 6,314,671 shares of our common stock, which included 394,669 warrants issued to the underwriters as compensation for the transaction.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We incurred certain expenses related to this transaction to attorneys and underwriters inclusive of a 9% cash fee and warrants to purchase 10% of the aggregate number of shares issued in the transaction.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In connection with the closing of the financing, we terminated the Purchase Agreement, dated as of July 27, 2016, by and between us and Lincoln Park Capital Fund, LLC. The
 termination was
 effective on August 16, 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In September 2017, Aytu issued 200,000 shares of restricted stock to employees, which vest in September 2027. This expense is included in sales, general and administrative. For the three months ended September 30, 2017, the expense was $2,000. The fair value of the restricted stock was $404,000. The unrecognized expense of $402,000 will be recognized over the next ten years.&lt;/p&gt;&lt;p style="font: 10pt/normal times-roman, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times-roman, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Aytu also has 43,000 shares of restricted stock outstanding and unvested which were not issued out of the 2015 Stock Option and Inventive Plan. These shares vest in July 2026 and the unrecognized expense of $2,435,000 will be recognized over the next ten years. During the quarter ended September 30, 2017, the expense related to these awards was $70,000.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In September 2017, Aytu issued 3,018 shares of common stocks as the earn-out payment to Nuelle Shareholders for fiscal 2017. (See Note 1).&lt;/p&gt;&lt;/div&gt;</aytu:CommonStockTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Note 8 &amp;#8211; Equity Instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On June&amp;#160;1, 2015, Aytu&amp;#8217;s stockholders approved the 2015 Stock Option and Incentive Plan (the &amp;#8220;2015 Plan&amp;#8221;), which, as amended in July 2017, provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 3.0 million shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Pursuant to the 2015 Stock Plan, 3.0 million shares of the Company&amp;#8217;s common stock, are reserved for issuance. The fair value of options granted was calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Stock option activity is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of Options&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Remaining Contractual Life in Years&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Outstanding June 30, 2017&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;38,263&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;16.31&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size:
 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;8.40&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-left: 10pt; font-size: 10pt;"&gt;Granted&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 10pt; font-size: 10pt;"&gt;Exercised&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;"&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(139&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;16.40&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Outstanding September 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;38,124&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;16.31&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;8.13&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Exercisable at September 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;23,385&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt;
 padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;16.40&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;7.85&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Available for grant at September 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,761,876&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and selling, general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period&lt;font style="font-family: 'times new roman', times, serif;"&gt;.&amp;#160;&lt;/font&gt;The following table summarizes stock-based compensation expense for the stock option issuances for the three months ended September 30, 2017 and 2016:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Selling, general and administrative:&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1177.67px; text-align: left; text-indent: 0px; padding-left: 10pt; font-size: 10pt;"&gt;Stock options&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;195,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;
 text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;1,044,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;"&gt;Restricted Stock&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;72,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;75,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Total share-based compensation expense&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;267,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,119,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;As of&amp;#160;September 30, 2017, there was&amp;#160;$571,000 of total unrecognized share-based compensation expense related to non-vested stock options. The Company expects to recognize this expense over a weighted-average period of 1.60&amp;#160;years.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;A summary of all warrants is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of Warrants&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Remaining Contractual Life in Years&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Outstanding June 30, 2017&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;286,049&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;50.29&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;4.23&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Warrants issued to investors in connection with the private offering&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;5,920,002&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;3.60&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Warrants issued to underwritters for the private offering&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;394,669&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;3.60&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Outstanding September 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style:
 double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;6,600,720&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;5.62&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;4.86&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;In connection with our August 2017 private offering,&amp;#160;&lt;/font&gt;we issued to investors and underwriters warrants to purchase an aggregate of 6, 314,671 shares of common stock&amp;#160;&lt;font style="font-family: 'times new roman', times, serif;"&gt;at an exercise price of $3.60 with a term of five years from August 25, 2017. These warrants are accounted for under derivative liability treatment.&amp;#160;&lt;/font&gt;(see Note 5).&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;All warrants issued in fiscal 2018 were valued using the lattice option pricing model. In order to calculate the fair value of the warrants, certain assumptions were made regarding components of the model, including the selling price or fair market value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and contractual life. Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Significant assumptions in valuing the warrants issued during the September 30, 2017 quarter are included in Note 5.&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Note 9 &amp;#8211; Related Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Executive Stock Purchases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;When Aytu completed the August 2017 offering, our executive officers Joshua Disbrow and Jarrett Disbrow participated in this offering, purchasing 83,333, units each.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Services Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In July 2015, Aytu entered into an agreement with Ampio, whereby Aytu agreed to pay Ampio a set amount per month for shared overhead, which includes costs related to the shared corporate staff and other miscellaneous overhead expenses. This agreement as amended in November 2015, April 2016, July 2016, and again in January 2017 required a monthly payment of $12,000. This agreement was terminated in June 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Sponsored Research Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&amp;#8217;s director and Chief Scientific Officer, Dr.&amp;#160;Bar-Or. The agreement was amended in January 2015 and provided for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration for services related to research and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $615,000 which was being amortized over the contractual term of 60.5 months and was divided between current and long-term on the balance sheet; as of September 2014, this amount had been paid in full. This agreement was terminated in March 2017.&lt;/p&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:SegmentReportingDisclosureTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Note 10 &amp;#8211; Segment Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Aytu manages our Company and aggregates our operational and financial information in accordance with two reportable segments: Aytu and Aytu Women&amp;#8217;s Health. The Aytu segment consists of our core male urology products. The Aytu Women&amp;#8217;s Health segment contains our women&amp;#8217;s health products. Select financial information for these segments is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6"&gt;Three months ended&lt;br /&gt;September 30,&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;Consolidated Revenue:&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 1177.67px; text-indent: 0px; padding-left: 10pt; font-stretch: normal;"&gt;Aytu&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 18px; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;972,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;698,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;
 background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"&gt;Aytu Women&amp;#8217;s Health&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;104,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;Consolidated revenue&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;1,076,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;698,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;Consolidated net loss:&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 10pt; font-stretch: normal;"&gt;Aytu&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;(3,725,000&lt;/td&gt;&lt;td
 style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;)&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;(5,724,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"&gt;Aytu Women&amp;#8217;s Health&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(520,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;)&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;Consolidated net loss&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;(4,245,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;)&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;(5,724,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;Total consolidated assets:&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px;
 font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 10pt; font-stretch: normal;"&gt;Aytu&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;18,115,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;14,999,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"&gt;Aytu Women&amp;#8217;s Health&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;3,131,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;Total consolidated assets&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;21,246,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;14,999,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Note 11 &amp;#8211; Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;October 20, 2017, the Company was approved for listing and began trading on The NASDAQ Capital Market under the company&amp;#8217;s current ticker symbol, AYTU.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On October 24, 2017, Aytu entered into a 24-month extension of our operating lease for the Englewood, Colorado office space. The base rent will remain at $9,000 per month.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On October 25, 350 of our preferred shares outstanding converted into 116,666 shares of our common stock.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On October 25, Aytu issued 61,000 shares to Nuelle shareholders as a prepayment for the fiscal 2018 earn-out payment that will be due to them.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On November 7, 2017, Aytu issued 495,000 restricted shares to executives, directors and consultants.&lt;/p&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;These unaudited consolidated financial statements represent the financial statements of Aytu and its subsidiary, Aytu Women&amp;#8217;s Health. These unaudited consolidated financial statements should be read in conjunction with Aytu&amp;#8217;s Annual Report on Form 10-K for the year ended June 30, 2017, which included all disclosures required by generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;). In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position of Aytu for the balance sheet, the results of operations and cash flows for the interim periods presented. The results of operations for the period ended September 30, 2017 are not necessarily indicative of expected operating results for the full year. The information presented throughout this report as of and for the period ended September 30, 2017 and 2016 is unaudited.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Through a multi-step reverse triangular merger, on April 16, 2015, Vyrix Pharmaceuticals, Inc. (&amp;#8217;&amp;#8216;Vyrix&amp;#8217;&amp;#8217;) and Luoxis Diagnostics, Inc. (&amp;#8217;&amp;#8216;Luoxis&amp;#8217;&amp;#8217;) merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue the specialty healthcare market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS and Zertane products. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares held. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares held. On August 25, 2017, Aytu effected a third reverse stock split in which each common stockholder received one share of common stock for every 20 shares held (herein referred to collectively as the &amp;#8220;Reverse Stock Splits&amp;#8221;). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:BusinessCombinationsPolicy contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Business Combination&amp;#8212;ProstaScint&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (&amp;#8220;Jazz Pharmaceuticals&amp;#8221;). Pursuant to the agreement, Aytu purchased assets related to the Jazz Pharmaceuticals&amp;#8217; product known as ProstaScint&lt;sup&gt;&amp;#174;&lt;/sup&gt;&amp;#160;(capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &amp;#8217;&amp;#8216;ProstaScint Business&amp;#8217;&amp;#8217;), and assumed certain of Jazz Pharmaceuticals&amp;#8217; liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consisted of an upfront payment of $1.0 million. We also agreed to pay an additional $500,000, which was paid after the transfer of the ProstaScint-related product inventory, and $227,000 which was paid September 30, 2015 (which represents a portion of certain FDA fees). We will also pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was initially valued at $664,000 and was revalued as of June 30, 2017 at $54,000 using a discounted cash flow. The total fair value consideration for the purchase was $2.4 million.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s allocation of consideration transferred for ProstaScint as of the purchase date of May&amp;#160;20, 2015 is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Tangible assets&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;727,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Intangible assets&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;1,590,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Goodwill&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;74,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Total assets acquired&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:
 left; text-indent: 0px; padding-left: 0px;
 font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,391,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Included in the intangible assets is developed technology of $790,000, customer contracts of $720,000 and trade names of $80,000, each of which will be amortized over a ten-year period. At June 30, 2017, the ProstaScint asset was impaired based upon sales projections that we intend to only sell this product through mid-fiscal 2019, when this product expires. The value for the intangible assets were adjusted to $54,000 for developed technology, $7,000 for trade names and $0 for customer contracts. The amortization expense was $12,000 and $40,000 for the three months ended September 30, 2017 and 2016, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of September 30, 2017, the contingent consideration increased by $6,000 due to accretion.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Business Combination&amp;#8212;Primsol&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (&amp;#8220;FSC&amp;#8221;). Pursuant to the agreement, Aytu purchased assets related to FSC&amp;#8217;s product known as Primsol&amp;#174; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the &amp;#8220;Primsol Business&amp;#8221;), and assumed certain of FSC&amp;#8217;s liabilities, including those related to the sale and marketing of Primsol arising after the closing.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Aytu paid $500,000 at closing for the purchase of the Primsol Business, and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 which was paid on April 1, 2016, (b) $500,000 which was paid on July 1, 2016, and (c) $250,000 which was paid in November 2016 (together, the &amp;#8220;Installment Payments&amp;#8221;).&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 was as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px;
 text-transform: none; text-indent: 0px; letter-spacing: normal;
 font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Tangible assets&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;182,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Intangible assets&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;1,470,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Goodwill&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;147,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Total assets acquired&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,799,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Included in tangible assets was $102,000 of inventory and $80,000 of work-in-process inventory. Included in the intangible assets was developed technology of $520,000, customer contracts of $810,000 and trade names of $140,000, each of which was being amortized over a six-year period. Amortization expense of $0 and $61,000 was recognized in the three months ended September 30, 2017 and 2016, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Divestiture &amp;#8211; Primsol&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On March 31, 2017, we entered into and closed on an Asset Purchase Agreement with Allegis Holdings, LLC (the &amp;#8220;Purchaser&amp;#8221;). Pursuant to the agreement, we sold to the Purchaser all of our assets related to our product known as Primsol, including certain intellectual property and contracts, inventory, work in process and all marketing assets and materials related solely to Primsol (together, the &amp;#8220;Primsol Asset&amp;#8221;). We retain any liability associated with the Primsol Asset that occurred prior to the closing. The Purchaser paid us
 $1,750,000 at the closing for the Primsol Asset. We recognized a gain of approximately $428,000 on the sale which is
 included in sales, general and administrative expense on our statement of operations.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We have evaluated this transaction and concluded that it is not significant to our business and therefore the results are included in continuing operations, as the criteria to be presented as discontinued operations was not satisfied.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;License and Supply Agreement&amp;#8212;Natesto&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In April 2016, Aytu entered into and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto&amp;#174; (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we acquired effective upon the expiration of the former licensee&amp;#8217;s rights, which occurred on June 30, 2016. The license&amp;#8217;s term runs for the greater of eight years or until the expiry of the latest to expire patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic product.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Aytu paid Acerus an upfront fee of $2.0 million upon execution of the agreement. In October 2016, we paid an additional $2.0 million, and in January 2017, Aytu paid the final upfront payment of $4.0 million. Aytu also purchased, on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2.5 million (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately US $0.16 per share. These shares were a held for sale trading security and were valued at fair market value. Aytu could not dispose of these shares until after August 29, 2016. During the second half of fiscal 2017, Aytu sold all of these shares. The gross proceeds from the sales totaled $1.1 million, the cost of the sales totaled $92,000, and we recognized a loss on investment of $1.0 million. In the quarter ended September 30, 2016, we had an unrealized gain on this investment of $728,000.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In addition to the upfront payments, we must make the following one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $37.5 million):&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 63px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 63px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1441px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;$2.5 million if net sales during any four consecutive calendar quarter period equal or exceed $25.0 million (the &amp;#8220;First Milestone&amp;#8221;); the First Milestone payment is required to be paid even if the threshold is not met in the event that the agreement is terminated for any reason other than material
 breach by Acerus, bankruptcy of either party, or termination by Acerus because it believes the amounts payable to Aytu for agreed upon
 trial work would no longer make the agreement economically viable for Acerus;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;$5.0 million if net sales during any four consecutive calendar quarter period equal or exceed $50.0 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;$7.5 million if net sales during any four consecutive calendar quarter period equal or exceed $75.0 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;$10.0 million if net sales during any four consecutive calendar quarter period equal or exceed $100.0 million; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;$12.5 million if net sales during any four consecutive calendar quarter period equal or exceed $125.0 million.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of the net identifiable asset acquired totaled $10.5 million which is being amortized over eight years. The amortization expense for each of the three months ended September 30, 2017 and 2016 were $330,000.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The contingent consideration was valued at $3.2 million using a Monte Carlo simulation, as of June 30, 2016. As of June 30, 2017, the contingent consideration was revalued and increased to $5.7 million based on increased future estimated sales performance of Natesto using a Monte Carlo simulation. The contingent consideration accretion expenses for the three months ended September 30, 2017 was $161,000, resulting in the contingent consideration value of $5.8 million. The contingent consideration accretion expense for the three months ended September 30, 2016 was $46,000.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Merger/Subsidiary&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2017, Aytu Women&amp;#8217;s Health, LLC., a wholly-owned subsidiary of Aytu, acquired Nuelle, Inc., or Nuelle, a women&amp;#8217;s sexual health company. This transaction expanded our product portfolio with the addition of the Fiera&lt;sup&gt;&amp;#174;&lt;/sup&gt;&amp;#160;personal care device for women.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In the Merger, (i) each share of Nuelle common stock and each option or warrant to purchase Nuelle stock was cancelled, and (ii) each share of Nuelle preferred stock was converted into the right to receive shares of our common stock. We issued to the Nuelle preferred stockholders an aggregate of 125,000 shares of our common
 stock.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px;
 white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In addition, Nuelle preferred stockholders will be entitled to revenue earn-out payments equal to a designated percentage of net sales on tiers of net sales up to $100.0 million, with an average rate for all tiers in the mid-single digit range and a maximum aggregate payout of $6.9 million.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Nuelle stockholders additionally will be entitled to milestone earn-out payments of up to a potential aggregate of $24.0 million, upon the attainment by us of designated net sales thresholds over any sequential four calendar quarter period.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The first $1.0 million of earn-out payments will be paid in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock. The stock portion of any earn-out will be calculated by dividing each Nuelle stockholder&amp;#8217;s portion of the earn-out by the average closing price of our common stock for the 10 trading days prior to the earlier of the date we deliver notice to the Nuelle stockholders of the earn-out or any public disclosure by us of the earn-out being due and payable.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In the event that we do not make all of the required earn-out payments to the Nuelle stockholders before May 3, 2022, and we also close a divestiture before May 3, 2022 of any of the products acquired in the transaction, we will pay the Nuelle stockholders a combination of (i) cash in an amount equal to 10% of the value of all cash, securities and other property paid to us in the divestiture (cash is to be 60% of the total consideration), and (ii) shares of our common stock equal to the Nuelle stockholders&amp;#8217; portion of the divestiture payment divided by the average closing price of our common stock for the 10 trading days prior to the earlier of the closing date of the divestiture or the public disclosure of the divestiture (shares of common stock are to be 40% of the total consideration).&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In addition to the upfront issuance of common stock, we must make the following one-time payments to the Nuelle stockholders within 90 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $24.0 million):&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; width: 63px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; width: 63px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 1441px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon achieving the first occurrence of Net Sales of $10.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.0 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td
 style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size:
 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: justify; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon achieving the first occurrence of Net Sales of $17.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.8 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-align: justify; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: justify; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon achieving the first occurrence of Net Sales of $25.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $2.5 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon achieving the first occurrence of Net Sales of $37.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $3.8 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon achieving the first occurrence of Net Sales of $50.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $5.0 million; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px;"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; font-stretch: normal;"&gt;&amp;#9679;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon achieving the first occurrence of Net Sales of $100.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $10.0 million.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s allocation on consideration transferred for Nuelle as of the purchase date May&amp;#160;5, 2017 is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Tangible assets&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;2,061,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px;
 padding-left: 0px; font-size: 10pt;"&gt;Intangible assets&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent:
 0px; padding-left: 0px; font-size: 10pt;"&gt;1,540,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Goodwill&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;238,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Total assets acquired&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,839,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Included in the intangible assets is developed technology of $1.3 million, customer contracts of $80,000 and trade names of $160,000, each of which will be amortized over a nine to twelve-year period. Amortization expense of $38,000 and $0 was recognized for the three months ended September 30, 2017 and September 30, 2016, respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The contingent consideration was valued at $1.9 million using a Monte Carlo simulation, as of May 2017. The contingent consideration accretion expense for the three months ended September 30, 2017 and September 30, 2016 was $20,000, and $0 respectively.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;During the quarter ended September 30, 2017, we paid the first earn-out payment to Nuelle shareholders of $12,000 issued in Aytu common stock, which was 25% of the Aytu Women&amp;#8217;s Health net revenue for fiscal 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Additionally, upon the closing of the merger, we assumed liabilities of $47,000.&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements, Not Adopted as of September 30, 2017&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2017, the FASB issued ASU No. 2017-09,&amp;#160;&amp;#8220;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&amp;#160;(ASU 2017-09).&amp;#8221; ASU 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of its adoption of this standard on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2017, the FASB issued ASU 2017-04, &amp;#8220;Intangibles - Goodwill and Other (Topic 350).&amp;#8221; The amendment simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe that adoption of this amendment will have a material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2017, the FASB issued ASU 2017-01, &amp;#8220;Business Combinations (Topic 805) Clarifying the Definition of a Business.&amp;#8221; The amendment clarifies the definition of a business, which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively for public business entities for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect an immediate impact from this codification however, if Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business combination or an asset purchase.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="background-color: white;"&gt;In June 2016, the FASB issued ASU 2016-13, &amp;#8220;Financial Instruments &amp;#8211; Credit Losses&amp;#8221; to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. This ASU is effective for private companies and emerging growth
 companies
 beginning after December 15, 2020; the ASU allows for early adoption as of the beginning of an interim or annual reporting period beginning after December 15, 2018. The Company is currently assessing the impact that ASU 2016-13 will have on its consolidated financial statements but does not anticipate there to be a material impact.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In February 2016, the FASB issued ASU 2016-02, &amp;#8220;Leases (Topic 842).&amp;#8221; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its adoption of this standard on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2016, the FASB issued ASU 2016-01, &amp;#8220;Financial Instruments &amp;#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,&amp;#8221; which requires that all equity investments be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May 2014, the FASB issued ASU 2014-09, Topic 606, Revenue from Contracts with Customers (the &amp;#8220;New Revenue Standard&amp;#8221;). The amendments in this ASU provide a single model for use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14 which deferred the effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12 to clarify, among other things, the implementation guidance related to principal versus agent considerations, identifying performance obligations, and accounting for licenses of intellectual property. The New Revenue Standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is not permitted. The amendments in this update are to be applied on a retrospective basis, either to each prior reporting period presented or by presenting the cumulative effect of applying the update recognized at the date of initial application. The New Revenue Standard will be effective for the Company in fiscal 2019. The Company is evaluating the adoption methodology and the impact of this ASU on its consolidated financial statements.&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember">&lt;div&gt;&lt;table style="width: 1422.73px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1252.73px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Tangible assets&lt;/td&gt;&lt;td style="width: 14.54px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 14.54px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 127.27px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;727,000&lt;/td&gt;&lt;td style="width: 13.63px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Intangible assets&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;1,590,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Goodwill&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;74,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Total assets acquired&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,391,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
<us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember">&lt;div&gt;&lt;table style="width: 1422.73px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1252.73px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Tangible assets&lt;/td&gt;&lt;td style="width: 14.54px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 14.54px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 127.27px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;182,000&lt;/td&gt;&lt;td style="width: 13.63px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Intangible assets&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;1,470,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Goodwill&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;147,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Total assets acquired&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,799,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
<us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NuelleMember">&lt;div&gt;&lt;table style="width: 1422.73px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Fair Value&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1252.73px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Tangible assets&lt;/td&gt;&lt;td style="width: 14.54px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 14.54px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 127.27px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;2,061,000&lt;/td&gt;&lt;td style="width: 13.63px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Intangible assets&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;1,540,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Goodwill&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;238,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Total assets acquired&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,839,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;Estimated&lt;br /&gt;Useful Lives in&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;As of&lt;br /&gt;September 30,&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;As of&lt;br /&gt;June 30,&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; width: 1019px; text-align: left; text-indent: 0px; font-size: 10pt;"&gt;Manufacturing equipment&lt;/td&gt;&lt;td style="width: 16px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;2 - 5&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-size: 10pt;"&gt;405,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-size: 10pt;"&gt;405,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-size: 10pt;"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;3&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;111,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;111,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-size: 10pt;"&gt;Office equipment, furniture and other&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;2 - 5&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;287,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;287,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-size: 10pt;"&gt;Lab equipment&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;3 - 5&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 1.5pt; text-align: left; text-indent: 0px; font-size: 10pt;"&gt;Less accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(326,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(246,000&lt;/td&gt;&lt;td style="text-align:
 left; padding-bottom: 1.5pt; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px; font-size: 10pt;"&gt;Fixed assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;567,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;647,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Depreciation expense&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;80,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;19,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;As of&lt;br /&gt;September 30,&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;As of&amp;#160;&lt;br /&gt;June 30,&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Patents&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;880,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;880,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(615,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(609,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;"&gt;Patents, net&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;265,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;271,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-style: normal; font-weight: normal;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;Amortization expense&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;6,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;7,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;Fair Value Measurements Using&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 1&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 2&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level 3&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&lt;u&gt;September 30, 2017&lt;/u&gt;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;LIABILITIES&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Warrant derivative liability&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;3,818,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;3,818,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Contingent consideration&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;7,823,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;7,823,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt; text-decoration: underline;"&gt;June 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;LIABILITIES&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Warrant derivative liability&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size:
 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Contingent consideration&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;7,648,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;7,648,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;September 30, 2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;At Issuance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Warrants:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1177.67px; text-align: left; padding-left: 10pt;"&gt;Volatility&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;183.0&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;188.0&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Equivalent term (years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.88&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.90&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.83&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Derivative Instruments&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Balance as of June 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1365.67px; text-align: left; text-indent: 0px; padding-left: 10pt; font-size: 10pt;"&gt;Warrant issuances&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;4,118,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;"&gt;Change in fair value included in earnings&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(300,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Balance as of September 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,818,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
<us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Contingent Consideration&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px;"&gt;Balance as of June 30, 2017&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;7,648,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 10pt;"&gt;Increase due to accretion&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;187,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;Decrease due to contractual payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(12,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Balance as of September 30, 2017&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;7,823,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
<aytu:CommitmentsAndContingenciesDisclosureTableTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;Remaining&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2018&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2019&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2020&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2021&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2022&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Thereafter&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 251px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Prescription Database&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;1,220,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;647,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;573,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td
 style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Natesto&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;15,000,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;7,500,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt; font-size: 10pt;"&gt;Manufacturing/commercial supply agreement&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Office Lease&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black;
 border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;138,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;108,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;16,358,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;755,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;603,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;5,000,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;
 border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;7,500,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</aytu:CommitmentsAndContingenciesDisclosureTableTextBlock>
<us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;Rent expense&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRentExpenseTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of Options&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Remaining Contractual Life in Years&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Outstanding June 30, 2017&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;38,263&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;16.31&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;8.40&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-left: 10pt; font-size: 10pt;"&gt;Granted&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 10pt; font-size: 10pt;"&gt;Exercised&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;"&gt;Forfeited/Cancelled&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(139&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;16.40&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px;
 padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Outstanding September 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;38,124&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;16.31&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;8.13&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Exercisable at September 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;23,385&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;16.40&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;7.85&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Available for grant at September 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,761,876&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Three Months Ended&lt;br /&gt;September 30,&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Selling, general and administrative:&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1177.67px; text-align: left; text-indent: 0px; padding-left: 10pt; font-size: 10pt;"&gt;Stock options&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;195,000&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;1,044,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;"&gt;Restricted Stock&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;72,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;75,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Total share-based compensation expense&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;267,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,119,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of Warrants&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Remaining Contractual Life in Years&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Outstanding June 30, 2017&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;286,049&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;50.29&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;4.23&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;Warrants issued to investors in connection with the private offering&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;5,920,002&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;3.60&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;Warrants issued to underwritters for the private offering&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;394,669&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;3.60&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;
 text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;Outstanding September 30, 2017&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;6,600,720&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;5.62&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;4.86&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
<us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6"&gt;Three months ended&lt;br /&gt;September 30,&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;Consolidated Revenue:&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 1177.67px; text-indent: 0px; padding-left: 10pt; font-stretch: normal;"&gt;Aytu&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 18px; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;972,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;698,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"&gt;Aytu Women&amp;#8217;s Health&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;104,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent:
 0px;
 padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;Consolidated revenue&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;1,076,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;698,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;Consolidated net loss:&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 10pt; font-stretch: normal;"&gt;Aytu&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;(3,725,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;)&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;(5,724,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"&gt;Aytu Women&amp;#8217;s Health&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(520,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;)&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;Consolidated net loss&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;(4,245,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;)&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;(5,724,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;Total consolidated assets:&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 10pt; font-stretch: normal;"&gt;Aytu&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;18,115,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;14,999,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"&gt;Aytu Women&amp;#8217;s Health&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times
 new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;3,131,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;Total consolidated assets&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;21,246,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;14,999,000&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
<aytu:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets contextRef="Context_As_Of_20_May_2015T00_00_00_TO_20_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">727000</aytu:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
<aytu:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets contextRef="Context_As_Of_05_Oct_2015T00_00_00_TO_05_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">182000</aytu:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
<aytu:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets contextRef="Context_As_Of_05_May_2017T00_00_00_TO_05_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleMember" unitRef="USD" decimals="0">2061000</aytu:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="Context_As_Of_20_May_2015T00_00_00_TO_20_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">1590000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="Context_As_Of_05_Oct_2015T00_00_00_TO_05_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">1470000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="Context_As_Of_05_May_2017T00_00_00_TO_05_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">1540000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="Context_As_Of_05_May_2017T00_00_00_TO_05_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleMember" unitRef="USD" decimals="0">1540000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="Context_As_Of_31_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_DevelopedTechnologyRightsMember" unitRef="USD" decimals="-5">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="Context_As_Of_31_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="USD" decimals="0">80000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="Context_As_Of_31_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="USD" decimals="0">160000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="Context_As_Of_20_May_2015T00_00_00_TO_20_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">2391000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="Context_As_Of_05_Oct_2015T00_00_00_TO_05_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">1799000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="Context_As_Of_05_May_2017T00_00_00_TO_05_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">3839000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="Context_As_Of_05_May_2017T00_00_00_TO_05_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleMember" unitRef="USD" decimals="0">3839000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="-5">10500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_JazzPharmaceuticalsIncMember" unitRef="USD" decimals="-5">2400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
<us-gaap:StockholdersEquityReverseStockSplit contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares held. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares held. On August 25, 2017, Aytu effected a third reverse stock split in which each common stockholder received one share of common stock for every 20 shares held (herein referred to collectively as the "Reverse Stock Splits"). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.</us-gaap:StockholdersEquityReverseStockSplit>
<us-gaap:PaymentsToAcquireBusinessesGross contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="-5">1000000</us-gaap:PaymentsToAcquireBusinessesGross>
<us-gaap:PaymentsToAcquireBusinessesGross contextRef="Context_Custom_02_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">500000</us-gaap:PaymentsToAcquireBusinessesGross>
<us-gaap:PaymentsToAcquireBusinessesGross contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="-5">2000000</us-gaap:PaymentsToAcquireBusinessesGross>
<us-gaap:PaymentsToAcquireBusinessesGross contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="-5">2000000</us-gaap:PaymentsToAcquireBusinessesGross>
<us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="Context_Custom_02_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">142000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
<us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="Context_Custom_02_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember_StatementScenarioAxis_PaidOnApril12016Member" unitRef="USD" decimals="0">500000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
<us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="Context_Custom_02_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember_StatementScenarioAxis_NoLaterThanSeptember302016Member" unitRef="USD" decimals="0">250000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
<us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="Context_Custom_02_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember_StatementScenarioAxis_NoLaterThanJuly012016Member" unitRef="USD" decimals="0">500000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
<us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_BusinessCombinationSeparatelyRecognizedTransactionsAxis_ThirdUpfrontMember" unitRef="USD" decimals="-5">4000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="-5">2500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">6900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember" unitRef="USD" decimals="0">187000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
<aytu:BusinessCombinationContingentConsiderationPercentage contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="pure" decimals="2">0.08</aytu:BusinessCombinationContingentConsiderationPercentage>
<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">664000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="Context_FYE_01_Jul_2015T00_00_00_TO_30_Jun_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="-5">3200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">1900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="Context_FYE_01_Jul_2016T00_00_00_TO_30_Jun_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="-5">5700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="-5">5800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_20_May_2015T00_00_00_TO_20_May_2015T00_00_00_ProductOrServiceAxis_ProstaScintMember_FiniteLivedIntangibleAssetsByMajorClassAxis_DevelopedTechnologyRightsMember_BusinessAcquisitionAxis_JazzPharmaceuticalsIncMember" unitRef="USD" decimals="0">790000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_20_May_2015T00_00_00_TO_20_May_2015T00_00_00_BusinessAcquisitionAxis_JazzPharmaceuticalsIncMember_ProductOrServiceAxis_ProstaScintMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="USD" decimals="0">720000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_20_May_2015T00_00_00_TO_20_May_2015T00_00_00_BusinessAcquisitionAxis_JazzPharmaceuticalsIncMember_ProductOrServiceAxis_ProstaScintMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="USD" decimals="0">80000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_DevelopedTechnologyRightsMember_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">520000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="USD" decimals="0">810000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">880000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">380000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">880000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_Custom_21_Sep_2015T00_00_00_TO_05_Oct_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_DevelopedTechnologyRightsMember_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">140000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">40000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">61000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">330000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">7000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">12000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">330000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">38000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">6000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember_FiniteLivedIntangibleAssetsByMajorClassAxis_DevelopedTechnologyRightsMember" unitRef="USD" decimals="0">54000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">7000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerContractsMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfIntangibleAssets>
<aytu:BusinessCombinationConsiderationTransferredInventory contextRef="Context_Custom_02_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">102000</aytu:BusinessCombinationConsiderationTransferredInventory>
<aytu:BusinessCombinationConsiderationTransferredInventory contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">102000</aytu:BusinessCombinationConsiderationTransferredInventory>
<aytu:BusinessCombinationConsiderationTransferredProductInventory contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">500000</aytu:BusinessCombinationConsiderationTransferredProductInventory>
<aytu:BusinessCombinationConsiderationTransferredProductInventory contextRef="Context_Custom_02_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">40000</aytu:BusinessCombinationConsiderationTransferredProductInventory>
<aytu:BusinessCombinationConsiderationTransferredWorkInProcessInventory contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">80000</aytu:BusinessCombinationConsiderationTransferredWorkInProcessInventory>
<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="shares" decimals="INF">12245411</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="shares" decimals="INF">125000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="Context_As_Of_28_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="-5">2000000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="Context_As_Of_28_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="CAD" decimals="-5">2500000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
<us-gaap:BusinessAcquisitionSharePrice contextRef="Context_As_Of_28_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD_per_Share" decimals="2">0.16</us-gaap:BusinessAcquisitionSharePrice>
<us-gaap:BusinessAcquisitionSharePrice contextRef="Context_As_Of_28_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="CAD_per_Share" decimals="3">0.207</us-gaap:BusinessAcquisitionSharePrice>
<aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_FirstMilestoneMember" unitRef="USD" decimals="-5">2500000</aytu:OneTimeNonRefundablePayments>
<aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_SecondMilestoneMember" unitRef="USD" decimals="-5">5000000</aytu:OneTimeNonRefundablePayments>
<aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_ThirdMilestoneMember" unitRef="USD" decimals="-5">7500000</aytu:OneTimeNonRefundablePayments>
<aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_ForthMilestoneMember" unitRef="USD" decimals="-5">10000000</aytu:OneTimeNonRefundablePayments>
<aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_FifthMilestoneMember" unitRef="USD" decimals="-5">12500000</aytu:OneTimeNonRefundablePayments>
<aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-6">10000000</aytu:OneTimeNonRefundablePayments>
<aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_FirstMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">1000000</aytu:OneTimeNonRefundablePayments>
<aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_SecondMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">1800000</aytu:OneTimeNonRefundablePayments>
<aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_ThirdMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">2500000</aytu:OneTimeNonRefundablePayments>
<aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_ForthMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">3800000</aytu:OneTimeNonRefundablePayments>
<aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_FifthMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">5000000</aytu:OneTimeNonRefundablePayments>
<aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_SixthMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">10000000</aytu:OneTimeNonRefundablePayments>
<aytu:SalesRevenueTarget contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_FirstMilestoneMember" unitRef="USD" decimals="-5">25000000</aytu:SalesRevenueTarget>
<aytu:SalesRevenueTarget contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_SecondMilestoneMember" unitRef="USD" decimals="-5">50000000</aytu:SalesRevenueTarget>
<aytu:SalesRevenueTarget contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_ThirdMilestoneMember" unitRef="USD" decimals="-5">75000000</aytu:SalesRevenueTarget>
<aytu:SalesRevenueTarget contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_ForthMilestoneMember" unitRef="USD" decimals="-5">100000000</aytu:SalesRevenueTarget>
<aytu:SalesRevenueTarget contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_FifthMilestoneMember" unitRef="USD" decimals="-5">125000000</aytu:SalesRevenueTarget>
<aytu:SalesRevenueTarget contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">100000000</aytu:SalesRevenueTarget>
<aytu:SalesRevenueTarget contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_FirstMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">10000000</aytu:SalesRevenueTarget>
<aytu:SalesRevenueTarget contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_SecondMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">17500000</aytu:SalesRevenueTarget>
<aytu:SalesRevenueTarget contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_ThirdMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">25000000</aytu:SalesRevenueTarget>
<aytu:SalesRevenueTarget contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_ForthMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">37500000</aytu:SalesRevenueTarget>
<aytu:SalesRevenueTarget contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_FifthMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">50000000</aytu:SalesRevenueTarget>
<aytu:SalesRevenueTarget contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_TypeOfArrangementAxis_SixthMilestoneMember_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">100000000</aytu:SalesRevenueTarget>
<us-gaap:PaymentsForPurchaseOfOtherAssets1 contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">1750000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
<us-gaap:GainLossOnSaleOfBusiness contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="0">428000</us-gaap:GainLossOnSaleOfBusiness>
<aytu:CostOfSaleForInvestment contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember" unitRef="USD" decimals="0">92000</aytu:CostOfSaleForInvestment>
<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00" unitRef="USD" decimals="-5">11800000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
<us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember" unitRef="USD" decimals="-5">1100000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
<us-gaap:UnrealizedGainLossOnInvestments contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember" unitRef="USD" decimals="0">728000</us-gaap:UnrealizedGainLossOnInvestments>
<us-gaap:UnrealizedGainLossOnInvestments contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember" unitRef="USD" decimals="-5">1000000</us-gaap:UnrealizedGainLossOnInvestments>
<us-gaap:AccretionExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">46000</us-gaap:AccretionExpense>
<us-gaap:AccretionExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">0</us-gaap:AccretionExpense>
<us-gaap:AccretionExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">161000</us-gaap:AccretionExpense>
<us-gaap:AccretionExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">20000</us-gaap:AccretionExpense>
<aytu:RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="-5">24000000</aytu:RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember_RangeAxis_MinimumMember">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_RangeAxis_MaximumMember_BusinessAcquisitionAxis_NuelleIncMember">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:LiabilitiesAssumed1 contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">47000</us-gaap:LiabilitiesAssumed1>
<us-gaap:RevenueRecognitionMilestoneMethodDescription contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember">One-time, non-refundable payments to Acerus within 45 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $37.5 million)</us-gaap:RevenueRecognitionMilestoneMethodDescription>
<us-gaap:RevenueRecognitionMilestoneMethodDescription contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember">One-time payments to the Nuelle stockholders within 90 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $24.0 million).</us-gaap:RevenueRecognitionMilestoneMethodDescription>
<aytu:SubsidiariesPaymentDescription contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember">The first $1.0 million of earn-out payments will be paid in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock.</aytu:SubsidiariesPaymentDescription>
<aytu:SubsidiariesDescription contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember">In the event that we do not make all of the required earn-out payments to the Nuelle stockholders before May 3, 2022, and we also close a divestiture before May 3, 2022 of any of the products acquired in the transaction, we will pay the Nuelle stockholders a combination of (i) cash in an amount equal to 10% of the value of all cash, securities and other property paid to us in the divestiture (cash is to be 60% of the total consideration), and (ii) shares of our common stock equal to the Nuelle stockholders' portion of the divestiture payment divided by the average closing price of our common stock for the 10 trading days prior to the earlier of the closing date of the divestiture or the public disclosure of the divestiture (shares of common stock are to be 40% of the total consideration).</aytu:SubsidiariesDescription>
<aytu:PercentageOfNetRevenue contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="pure" decimals="2">0.25</aytu:PercentageOfNetRevenue>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember_RangeAxis_MinimumMember">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember_RangeAxis_MinimumMember">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="USD" decimals="0">405000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="USD" decimals="0">111000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="USD" decimals="0">287000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember" unitRef="USD" decimals="0">90000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="USD" decimals="0">405000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="USD" decimals="0">111000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="USD" decimals="0">287000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember" unitRef="USD" decimals="0">90000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">246000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">326000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:Depreciation contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">19000</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">80000</us-gaap:Depreciation>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">609000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">615000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedPatentsGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_ZertanePatentMember" unitRef="USD" decimals="0">500000</us-gaap:FiniteLivedPatentsGross>
<us-gaap:FiniteLivedPatentsGross contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LuoxisPatentMember" unitRef="USD" decimals="0">380000</us-gaap:FiniteLivedPatentsGross>
<us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_ZertanePatentMember">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
<us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LuoxisPatentMember">P15Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
<aytu:FiniteLivedIntangibleAssetsExpireDate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_ZertanePatentMember">2022-03-31</aytu:FiniteLivedIntangibleAssetsExpireDate>
<aytu:FiniteLivedIntangibleAssetsExpireDate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LuoxisPatentMember">2028-03-31</aytu:FiniteLivedIntangibleAssetsExpireDate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FinancialInstrumentAxis_WarrantMember" unitRef="pure" decimals="3">1.830</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FinancialInstrumentAxis_WarrantMember_SubsidiarySaleOfStockAxis_NoteWarrantMember" unitRef="pure" decimals="3">1.880</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FinancialInstrumentAxis_WarrantMember">P4Y10M17D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FinancialInstrumentAxis_WarrantMember_SubsidiarySaleOfStockAxis_NoteWarrantMember">P5Y0M0D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FinancialInstrumentAxis_WarrantMember" unitRef="pure" decimals="4">0.0190</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FinancialInstrumentAxis_WarrantMember_SubsidiarySaleOfStockAxis_NoteWarrantMember" unitRef="pure" decimals="4">0.0183</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FinancialInstrumentAxis_WarrantMember" unitRef="pure" decimals="4">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FinancialInstrumentAxis_WarrantMember_SubsidiarySaleOfStockAxis_NoteWarrantMember" unitRef="pure" decimals="4">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="0">3818000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
<aytu:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="0">4118000</aytu:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="0">-300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember" unitRef="USD" decimals="0">7648000</us-gaap:BusinessCombinationContingentConsiderationLiability>
<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember" unitRef="USD" decimals="0">7823000</us-gaap:BusinessCombinationContingentConsiderationLiability>
<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember" unitRef="USD" decimals="0">-12000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow>
<us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">755000</us-gaap:ContractualObligationDueInNextTwelveMonths>
<us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">108000</us-gaap:ContractualObligationDueInNextTwelveMonths>
<us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" decimals="0">647000</us-gaap:ContractualObligationDueInNextTwelveMonths>
<us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_ManufacturingAgreementMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInSecondYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">603000</us-gaap:ContractualObligationDueInSecondYear>
<us-gaap:ContractualObligationDueInSecondYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">30000</us-gaap:ContractualObligationDueInSecondYear>
<us-gaap:ContractualObligationDueInSecondYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInSecondYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" decimals="0">573000</us-gaap:ContractualObligationDueInSecondYear>
<us-gaap:ContractualObligationDueInSecondYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_ManufacturingAgreementMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInThirdYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">2500000</us-gaap:ContractualObligationDueInThirdYear>
<us-gaap:ContractualObligationDueInThirdYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInThirdYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" decimals="0">2500000</us-gaap:ContractualObligationDueInThirdYear>
<us-gaap:ContractualObligationDueInThirdYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInThirdYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_ManufacturingAgreementMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInFourthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">5000000</us-gaap:ContractualObligationDueInFourthYear>
<us-gaap:ContractualObligationDueInFourthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInFourthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" decimals="0">5000000</us-gaap:ContractualObligationDueInFourthYear>
<us-gaap:ContractualObligationDueInFourthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInFourthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_ManufacturingAgreementMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInFifthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInFifthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInFifthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInFifthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueInFifthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_ManufacturingAgreementMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueAfterFifthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">7500000</us-gaap:ContractualObligationDueAfterFifthYear>
<us-gaap:ContractualObligationDueAfterFifthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueAfterFifthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" decimals="0">7500000</us-gaap:ContractualObligationDueAfterFifthYear>
<us-gaap:ContractualObligationDueAfterFifthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligationDueAfterFifthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_ManufacturingAgreementMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ContractualObligation contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">16358000</us-gaap:ContractualObligation>
<us-gaap:ContractualObligation contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">138000</us-gaap:ContractualObligation>
<us-gaap:ContractualObligation contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" decimals="0">15000000</us-gaap:ContractualObligation>
<us-gaap:ContractualObligation contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" decimals="0">1220000</us-gaap:ContractualObligation>
<us-gaap:ContractualObligation contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_ManufacturingAgreementMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">35000</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">35000</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:PaymentsForRent contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">3000</us-gaap:PaymentsForRent>
<us-gaap:PaymentsForRent contextRef="Context_Custom_01_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">9000</us-gaap:PaymentsForRent>
<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember">P37M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="Context_Custom_01_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember">P37M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
<us-gaap:LeaseAndRentalExpense contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">112000</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_Custom_01_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">318000</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_24_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">9000</us-gaap:LeaseAndRentalExpense>
<us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_30_Apr_2016T00_00_00" unitRef="USD" decimals="-5">8000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
<us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_30_Apr_2016T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" decimals="-5">2000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
<us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" decimals="-5">1900000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
<us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" decimals="-5">2000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
<us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" decimals="-5">4000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
<aytu:FirstMilestonePayable contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" decimals="-5">2500000</aytu:FirstMilestonePayable>
<aytu:SecondMilestonePayable contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" decimals="-5">5000000</aytu:SecondMilestonePayable>
<aytu:ThirdMilestonePayable contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" decimals="-5">7500000</aytu:ThirdMilestonePayable>
<us-gaap:SaleOfStockDescriptionOfTransaction contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_ClassUnitsMember">Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares of common stock and were sold at a negotiated price of $3.00 per unit.</us-gaap:SaleOfStockDescriptionOfTransaction>
<us-gaap:SaleOfStockDescriptionOfTransaction contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_ClassBUnitsMember">Class B units consist of one (1) share of our newly created Series A Convertible Preferred Stock (the ''Series A Preferred Stock'') and warrants to purchase one and one-half (1.5) shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at a negotiated price of $1,000.00 per unit to those purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding common stock following the offering.</us-gaap:SaleOfStockDescriptionOfTransaction>
<aytu:PreferredStockConversionPricePerShare contextRef="Context_As_Of_11_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">3.00</aytu:PreferredStockConversionPricePerShare>
<aytu:IncrementalCommonSharesDueToConversionOfPreferredStock contextRef="Context_As_Of_11_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00" unitRef="shares" decimals="INF">750000</aytu:IncrementalCommonSharesDueToConversionOfPreferredStock>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="-3">3196665000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">2250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00" unitRef="shares" decimals="INF">83333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<aytu:SecuritiesPurchaseAgreementCashFeePercentage contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="pure" decimals="2">0.09</aytu:SecuritiesPurchaseAgreementCashFeePercentage>
<aytu:ClassOfWarrantOrRightPercentageOfSharesToBeIssued contextRef="Context_As_Of_11_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="pure" decimals="2">0.10</aytu:ClassOfWarrantOrRightPercentageOfSharesToBeIssued>
<aytu:WarrantsToPurchaseOfCommonStockShares contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">6314671</aytu:WarrantsToPurchaseOfCommonStockShares>
<aytu:WarrantsToPurchaseOfCommonStockShares contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_25_Aug_2017T00_00_00" unitRef="shares" decimals="0">6314671</aytu:WarrantsToPurchaseOfCommonStockShares>
<aytu:WarrantsIssuedToUnderwritersAsCompensationForTransaction contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">394669</aytu:WarrantsIssuedToUnderwritersAsCompensationForTransaction>
<us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">5704750</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
<us-gaap:OtherSellingGeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">4618404</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
<us-gaap:RestrictedInvestmentsAtFairValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">404000</us-gaap:RestrictedInvestmentsAtFairValue>
<us-gaap:InvestmentOwnedRestrictedAcquisitionDate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">2027-09-30</us-gaap:InvestmentOwnedRestrictedAcquisitionDate>
<aytu:DescriptionOfUnrecognizedExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">The unrecognized expense of $402,000 will be recognized over the next ten years.</aytu:DescriptionOfUnrecognizedExpense>
<aytu:DescriptionOfUnrecognizedExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_AwardTypeAxis_StockCompensationPlanMember">Aytu also has 43,000 shares of restricted stock outstanding and unvested which were not issued out of the 2015 Stock Option and Inventive Plan. These shares vest in July 2026 and the unrecognized expense of $2,435,000 will be recognized over the next ten years. During the quarter ended September 30, 2017, the expense related to these awards was $70,000.</aytu:DescriptionOfUnrecognizedExpense>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="0">38263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="0">38124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="0">139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="0">23385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="0">2761876</aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" decimals="2">16.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" decimals="2">16.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" decimals="2">16.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" decimals="2">16.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jul_2016T00_00_00_TO_30_Jun_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">P8Y1M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">P7Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">1119000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="0">1044000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_AwardTypeAxis_RestrictedStockMember_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="0">75000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">267000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="0">195000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_AwardTypeAxis_RestrictedStockMember_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="0">72000</us-gaap:AllocatedShareBasedCompensationExpense>
<aytu:ShareBasedCompensationShareWarrantsOutstanding contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" decimals="0">286049</aytu:ShareBasedCompensationShareWarrantsOutstanding>
<aytu:ShareBasedCompensationShareWarrantsOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="0">6600720</aytu:ShareBasedCompensationShareWarrantsOutstanding>
<aytu:ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="0">5920002</aytu:ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering>
<aytu:ShareBasedCompensationShareWarrantsIssuedOnUnderwriter contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="0">394669</aytu:ShareBasedCompensationShareWarrantsIssuedOnUnderwriter>
<aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD_per_Share" decimals="2">50.29</aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice>
<aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="2">5.62</aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice>
<aytu:ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="2">3.60</aytu:ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice>
<aytu:ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="2">3.60</aytu:ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice>
<aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm contextRef="Context_FYE_01_Jul_2016T00_00_00_TO_30_Jun_2017T00_00_00">P4Y2M23D</aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm>
<aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">P4Y10M10D</aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember" unitRef="shares" decimals="-5">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="-5">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<aytu:UnrecognizedShareBasedCompensationExpenses contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="-3">571000000</aytu:UnrecognizedShareBasedCompensationExpenses>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">P1Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_25_Aug_2017T00_00_00" unitRef="USD_per_Share" decimals="2">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<aytu:WarrantsExercisePriceTerm contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_25_Aug_2017T00_00_00">P5Y</aytu:WarrantsExercisePriceTerm>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Context_Custom_02_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00_AgreementAxis_SponsoredResearchAgreementMember" unitRef="USD" decimals="0">6000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_AgreementAxis_ServicesAgreementMember" unitRef="USD" decimals="0">12000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="Context_Custom_02_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00_AgreementAxis_SponsoredResearchAgreementMember">This agreement was terminated in March 2017.</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
<us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_AgreementAxis_ServicesAgreementMember">This agreement was terminated in June 2017.</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
<us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_AgreementAxis_SponsoredResearchAgreementMember" unitRef="USD" decimals="0">615000</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
<aytu:PrepaidExpensesAmortizationPeriod contextRef="Context_Custom_01_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00">P60M15D</aytu:PrepaidExpensesAmortizationPeriod>
<aytu:PrepaidExpensesAmortizationPeriod contextRef="Context_Custom_01_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_AgreementAxis_SponsoredResearchAgreementMember">P60Y0M18D</aytu:PrepaidExpensesAmortizationPeriod>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_Custom_05_Oct_2017T00_00_00_TO_25_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">116666</us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:SharesIssued contextRef="Context_As_Of_25_Oct_2017T00_00_00_TO_25_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_BusinessAcquisitionAxis_NuelleMember" unitRef="shares" decimals="INF">61000</us-gaap:SharesIssued>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_02_Nov_2017T00_00_00_TO_07_Nov_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">495000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>aytu-20170930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<schema targetNamespace="http://www.aytubio.com/20170930" elementFormDefault="qualified"
xmlns:aytu="http://www.aytubio.com/20170930"
 xmlns="http://www.w3.org/2001/XMLSchema"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:negated="http://www.xbrl.org/2009/role/negated"
 xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31"
 xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes"
 xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:us-types="http://fasb.org/us-types/2017-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:ref="http://www.xbrl.org/2006/ref"
 xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
>
<annotation><appinfo>
<link:roleType roleURI="http://www.aytubio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedBalanceSheetsUnaudited" id="ConsolidatedBalanceSheetsUnaudited">
<link:definition>002 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedBalanceSheetsParentheticalUnaudited" id="ConsolidatedBalanceSheetsParentheticalUnaudited">
<link:definition>003 - Statement - Consolidated Balance Sheets (Parenthetical) (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited" id="ConsolidatedStatementsOfOperationsUnaudited">
<link:definition>004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited" id="ConsolidatedStatementOfStockholdersEquityUnaudited">
<link:definition>005 - Statement - Consolidated Statement of Stockholders' Equity (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited" id="ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited">
<link:definition>006 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical) (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" id="ConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition>007 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger" id="BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger">
<link:definition>008 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/FixedAssets" id="FixedAssets">
<link:definition>009 - Disclosure - Fixed Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/Patents" id="Patents">
<link:definition>010 - Disclosure - Patents</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/RevenueRecognition" id="RevenueRecognition">
<link:definition>011 - Disclosure - Revenue Recognition</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/FairValueConsiderations" id="FairValueConsiderations">
<link:definition>012 - Disclosure - Fair Value Considerations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>013 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/CommonStock" id="CommonStock">
<link:definition>014 - Disclosure - Common Stock</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/EquityInstruments" id="EquityInstruments">
<link:definition>015 - Disclosure - Equity Instruments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>016 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/SegmentInformation" id="SegmentInformation">
<link:definition>017 - Disclosure - Segment Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>018 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerPolicies" id="BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerPolicies">
<link:definition>019 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" id="BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables">
<link:definition>020 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/FixedAssetsTables" id="FixedAssetsTables">
<link:definition>021 - Disclosure - Fixed Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/PatentsTables" id="PatentsTables">
<link:definition>022 - Disclosure - Patents (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/FairValueConsiderationsTables" id="FairValueConsiderationsTables">
<link:definition>023 - Disclosure - Fair Value Considerations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
<link:definition>024 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsTables" id="EquityInstrumentsTables">
<link:definition>025 - Disclosure - Equity Instruments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/SegmentInformationTables" id="SegmentInformationTables">
<link:definition>026 - Disclosure - Segment Information (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" id="BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails">
<link:definition>027 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/Businessbasisofpresentationbusinesscombinationsdivestitureslicensesupplyagreementandmergerdetailstextual" id="Businessbasisofpresentationbusinesscombinationsdivestitureslicensesupplyagreementandmergerdetailstextual">
<link:definition>028 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/FixedAssetsDetails" id="FixedAssetsDetails">
<link:definition>029 - Disclosure - Fixed Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/FixedAssetsDetails1" id="FixedAssetsDetails1">
<link:definition>030 - Disclosure - Fixed Assets (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/PatentsDetails" id="PatentsDetails">
<link:definition>031 - Disclosure - Patents (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/PatentsDetails1" id="PatentsDetails1">
<link:definition>032 - Disclosure - Patents (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/PatentsDetailsTextual" id="PatentsDetailsTextual">
<link:definition>033 - Disclosure - Patents (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/RevenueRecognitionDetails" id="RevenueRecognitionDetails">
<link:definition>034 - Disclosure - Revenue Recognition (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails" id="FairValueConsiderationsDetails">
<link:definition>035 - Disclosure - Fair Value Considerations (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails1" id="FairValueConsiderationsDetails1">
<link:definition>036 - Disclosure - Fair Value Considerations (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails2" id="FairValueConsiderationsDetails2">
<link:definition>037 - Disclosure - Fair Value Considerations (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails3" id="FairValueConsiderationsDetails3">
<link:definition>038 - Disclosure - Fair Value Considerations (Details 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
<link:definition>039 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
<link:definition>040 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
<link:definition>041 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/CommonStockDetails" id="CommonStockDetails">
<link:definition>042 - Disclosure - Common Stock (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails" id="EquityInstrumentsDetails">
<link:definition>043 - Disclosure - Equity Instruments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails1" id="EquityInstrumentsDetails1">
<link:definition>044 - Disclosure - Equity Instruments (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails2" id="EquityInstrumentsDetails2">
<link:definition>045 - Disclosure - Equity Instruments (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsDetailsTextual" id="EquityInstrumentsDetailsTextual">
<link:definition>046 - Disclosure - Equity Instruments (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>047 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/SegmentInformationDetails" id="SegmentInformationDetails">
<link:definition>048 - Disclosure - Segment Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.aytubio.com/role/SubsequentEventsDetails1" id="SubsequentEventsDetails1">
<link:definition>049 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="aytu-20170930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="aytu-20170930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="aytu-20170930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="aytu-20170930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="aytu_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CoreAndDevelopedTechnologyNet" id="aytu_CoreAndDevelopedTechnologyNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedCompensationCurrent" id="aytu_AccruedCompensationCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ResearchAndDevelopmentRelatedParty" id="aytu_ResearchAndDevelopmentRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmortizationAndImpairmentOfIntangibleAssets" id="aytu_AmortizationAndImpairmentOfIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfPreferredAndCommonStockNetCost" id="aytu_IssuanceOfPreferredAndCommonStockNetCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfPreferredAndCommonStockNetShare" id="aytu_IssuanceOfPreferredAndCommonStockNetShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdjustmentForRoundingOfValueDueToConversion" id="aytu_AdjustmentForRoundingOfValueDueToConversion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdjustmentForRoundingOfSharesDueToConversion" id="aytu_AdjustmentForRoundingOfSharesDueToConversion" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" id="aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInAccruedCompensation" id="aytu_IncreaseDecreaseInAccruedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" id="aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedToInvestorsAndUnderwriters" id="aytu_WarrantsIssuedToInvestorsAndUnderwriters" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="EarnOutPaymentToOtherShareholders" id="aytu_EarnOutPaymentToOtherShareholders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PrimsolBusinessPurchaseIncludedInPrimsolPayable" id="aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="FixedAssetsIncludedInAccountsPayable" id="aytu_FixedAssetsIncludedInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="RevenueRecognitionDisclosureTextBlock" id="aytu_RevenueRecognitionDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockTextBlock" id="aytu_CommonStockTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BusinessDescriptionAndBasisOfPresentationTable" id="aytu_BusinessDescriptionAndBasisOfPresentationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ProstascintBusinessMember" id="aytu_ProstascintBusinessMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PrimsolBusinessMember" id="aytu_PrimsolBusinessMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NatestoMember" id="aytu_NatestoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NuelleMember" id="aytu_NuelleMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BusinessDescriptionAndBasisOfPresentationLineItems" id="aytu_BusinessDescriptionAndBasisOfPresentationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesDisclosureTableTextBlock" id="aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" id="aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="JazzPharmaceuticalsIncMember" id="aytu_JazzPharmaceuticalsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NuelleIncMember" id="aytu_NuelleIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaidOnApril12016Member" id="aytu_PaidOnApril12016Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NoLaterThanJuly012016Member" id="aytu_NoLaterThanJuly012016Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NoLaterThanSeptember302016Member" id="aytu_NoLaterThanSeptember302016Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProstaScintMember" id="aytu_ProstaScintMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SecondUpfrontMember" id="aytu_SecondUpfrontMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ThirdUpfrontMember" id="aytu_ThirdUpfrontMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FirstMilestoneMember" id="aytu_FirstMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SecondMilestoneMember" id="aytu_SecondMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ThirdMilestoneMember" id="aytu_ThirdMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ForthMilestoneMember" id="aytu_ForthMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FifthMilestoneMember" id="aytu_FifthMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SixthMilestoneMember" id="aytu_SixthMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LicenseAndSupplyAgreementMember" id="aytu_LicenseAndSupplyAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BusinessAcquisitionTextualAbstract" id="aytu_BusinessAcquisitionTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationContingentConsiderationPercentage" id="aytu_BusinessCombinationContingentConsiderationPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationConsiderationTransferredInventory" id="aytu_BusinessCombinationConsiderationTransferredInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationConsiderationTransferredProductInventory" id="aytu_BusinessCombinationConsiderationTransferredProductInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationConsiderationTransferredWorkInProcessInventory" id="aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="OneTimeNonRefundablePayments" id="aytu_OneTimeNonRefundablePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SalesRevenueTarget" id="aytu_SalesRevenueTarget" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CostOfSaleForInvestment" id="aytu_CostOfSaleForInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales" id="aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SubsidiariesPaymentDescription" id="aytu_SubsidiariesPaymentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SubsidiariesDescription" id="aytu_SubsidiariesDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetRevenue" id="aytu_PercentageOfNetRevenue" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LabEquipmentMember" id="aytu_LabEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ZertanePatentMember" id="aytu_ZertanePatentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LuoxisPatentMember" id="aytu_LuoxisPatentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PatentsTextualAbstract" id="aytu_PatentsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FiniteLivedIntangibleAssetsExpireDate" id="aytu_FiniteLivedIntangibleAssetsExpireDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RevenueRecognitionTextualAbstract" id="aytu_RevenueRecognitionTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsAbstract" id="aytu_WarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" id="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ContingentConsiderationMember" id="aytu_ContingentConsiderationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ContingentConsiderationAbstract" id="aytu_ContingentConsiderationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PrescriptionDatabaseMember" id="aytu_PrescriptionDatabaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ManufacturingAgreementMember" id="aytu_ManufacturingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OfficeLeaseMember" id="aytu_OfficeLeaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesTextualAbstract" id="aytu_CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FirstMilestonePayable" id="aytu_FirstMilestonePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SecondMilestonePayable" id="aytu_SecondMilestonePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ThirdMilestonePayable" id="aytu_ThirdMilestonePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ClassUnitsMember" id="aytu_ClassUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ClassBUnitsMember" id="aytu_ClassBUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockTextualAbstract" id="aytu_CommonStockTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PreferredStockConversionPricePerShare" id="aytu_PreferredStockConversionPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncrementalCommonSharesDueToConversionOfPreferredStock" id="aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="SecuritiesPurchaseAgreementCashFeePercentage" id="aytu_SecuritiesPurchaseAgreementCashFeePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightPercentageOfSharesToBeIssued" id="aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsToPurchaseOfCommonStockShares" id="aytu_WarrantsToPurchaseOfCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedToUnderwritersAsCompensationForTransaction" id="aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfUnrecognizedExpense" id="aytu_DescriptionOfUnrecognizedExpense" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" id="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" id="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationShareWarrantsOutstanding" id="aytu_ShareBasedCompensationShareWarrantsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" id="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" id="aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoThousandFifteenStockOptionAndIncentivePlanMember" id="aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MayTwoThousandSixteenPublicOfferingMember" id="aytu_MayTwoThousandSixteenPublicOfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentWarrantsMember" id="aytu_PlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="InvestorsWarrantsMember" id="aytu_InvestorsWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BankersWarrantsMember" id="aytu_BankersWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MayTwoZeroOneSixWarrantsMember" id="aytu_MayTwoZeroOneSixWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OctoberTwoZeroOneSixWarrantsMember" id="aytu_OctoberTwoZeroOneSixWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConvertiblePromissoryNotesMay2016Member" id="aytu_ConvertiblePromissoryNotesMay2016Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OverAllotmentWarrantsAxis" id="aytu_OverAllotmentWarrantsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" />
<element name="OverAllotmentWarrantsDomain" id="aytu_OverAllotmentWarrantsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OverAllotmentWarrantsMember" id="aytu_OverAllotmentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EquityInstrumentsTextualAbstract" id="aytu_EquityInstrumentsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="UnrecognizedShareBasedCompensationExpenses" id="aytu_UnrecognizedShareBasedCompensationExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsExercisePriceTerm" id="aytu_WarrantsExercisePriceTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AgreementAxis" id="aytu_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" id="aytu_AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ServicesAgreementMember" id="aytu_ServicesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SponsoredResearchAgreementMember" id="aytu_SponsoredResearchAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionsTextualAbstract" id="aytu_RelatedPartyTransactionsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PrepaidExpensesAmortizationPeriod" id="aytu_PrepaidExpensesAmortizationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AytuBioscienceIncMember" id="aytu_AytuBioscienceIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AytuWomensHealthMember" id="aytu_AytuWomensHealthMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>aytu-20170930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.aytubio.com/role/ConsolidatedBalanceSheetsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="50" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CoreAndDevelopedTechnologyNet" xlink:label="loc_aytu_CoreAndDevelopedTechnologyNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_aytu_CoreAndDevelopedTechnologyNet" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="loc_us-gaap_IndefiniteLivedContractualRights" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_IndefiniteLivedContractualRights" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_IndefiniteLivedTradeNames" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_Goodwill" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent" order="80" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsNoncurrent" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AccruedCompensationCurrent" xlink:label="loc_aytu_AccruedCompensationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_aytu_AccruedCompensationCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRentCreditCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="50" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues" xlink:to="loc_us-gaap_SalesRevenueNet" order="10" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_CostOfRevenue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ResearchAndDevelopmentRelatedParty" xlink:label="loc_aytu_ResearchAndDevelopmentRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_aytu_ResearchAndDevelopmentRelatedParty" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AmortizationAndImpairmentOfIntangibleAssets" xlink:label="loc_aytu_AmortizationAndImpairmentOfIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_aytu_AmortizationAndImpairmentOfIntangibleAssets" order="60" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainLossOnInvestments" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RestrictedStockExpense" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" order="50" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="loc_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" order="70" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" order="90" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" order="100" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" order="110" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" order="120" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="130" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="140" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_aytu_IncreaseDecreaseInAccruedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_aytu_IncreaseDecreaseInAccruedCompensation" order="150" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidRent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidRent" order="160" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:label="loc_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" order="40" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#PatentsDetails" roleURI="http://www.aytubio.com/role/PatentsDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/PatentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="20" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear" order="60" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>aytu-20170930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" >
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#ConsolidatedStatementOfStockholdersEquityUnaudited" roleURI="http://www.aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#Businessbasisofpresentationbusinesscombinationsdivestitureslicensesupplyagreementandmergerdetailstextual" roleURI="http://www.aytubio.com/role/Businessbasisofpresentationbusinesscombinationsdivestitureslicensesupplyagreementandmergerdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FixedAssetsDetails" roleURI="http://www.aytubio.com/role/FixedAssetsDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#PatentsDetails" roleURI="http://www.aytubio.com/role/PatentsDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#PatentsDetails1" roleURI="http://www.aytubio.com/role/PatentsDetails1"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#PatentsDetailsTextual" roleURI="http://www.aytubio.com/role/PatentsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FairValueConsiderationsDetails" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FairValueConsiderationsDetails1" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails1"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FairValueConsiderationsDetails2" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails2"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FairValueConsiderationsDetails3" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails3"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#CommonStockDetails" roleURI="http://www.aytubio.com/role/CommonStockDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#EquityInstrumentsDetails" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#EquityInstrumentsDetails1" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails1"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#EquityInstrumentsDetailsTextual" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.aytubio.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#SegmentInformationDetails" roleURI="http://www.aytubio.com/role/SegmentInformationDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#SubsequentEventsDetails1" roleURI="http://www.aytubio.com/role/SubsequentEventsDetails1"/>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_PreferredStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_11" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_12" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_13" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_14" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_IssuanceOfPreferredAndCommonStockNetCost" xlink:label="loc_aytu_IssuanceOfPreferredAndCommonStockNetCost_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_aytu_IssuanceOfPreferredAndCommonStockNetCost_15" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_IssuanceOfPreferredAndCommonStockNetShare" xlink:label="loc_aytu_IssuanceOfPreferredAndCommonStockNetShare_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_aytu_IssuanceOfPreferredAndCommonStockNetShare_16" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:label="loc_aytu_AdjustmentForRoundingOfValueDueToConversion_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_aytu_AdjustmentForRoundingOfValueDueToConversion_17" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:label="loc_aytu_AdjustmentForRoundingOfSharesDueToConversion_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_aytu_AdjustmentForRoundingOfSharesDueToConversion_18" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_19" order="120" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables">
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:label="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_0" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessDescriptionAndBasisOfPresentationTable" xlink:label="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_0" xlink:to="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_ProstascintBusinessMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_PrimsolBusinessMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_NatestoMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NuelleMember" xlink:label="loc_aytu_NuelleMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_NuelleMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_8" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_ProstascintBusinessMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_PrimsolBusinessMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NuelleMember" xlink:label="loc_aytu_NuelleMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_NuelleMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="loc_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_Goodwill_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_10" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/Businessbasisofpresentationbusinesscombinationsdivestitureslicensesupplyagreementandmergerdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_ProstascintBusinessMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_JazzPharmaceuticalsIncMember" xlink:label="loc_aytu_JazzPharmaceuticalsIncMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_JazzPharmaceuticalsIncMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_PrimsolBusinessMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_NatestoMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NuelleIncMember" xlink:label="loc_aytu_NuelleIncMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_NuelleIncMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_9" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_10_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_9" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_10_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PaidOnApril12016Member" xlink:label="loc_aytu_PaidOnApril12016Member_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_10" xlink:to="loc_aytu_PaidOnApril12016Member_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NoLaterThanJuly012016Member" xlink:label="loc_aytu_NoLaterThanJuly012016Member_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_10" xlink:to="loc_aytu_NoLaterThanJuly012016Member_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NoLaterThanSeptember302016Member" xlink:label="loc_aytu_NoLaterThanSeptember302016Member_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_10" xlink:to="loc_aytu_NoLaterThanSeptember302016Member_13" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_ProductOrServiceAxis_14" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_14" xlink:to="loc_us-gaap_ProductsAndServicesDomain_15" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_15_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_14" xlink:to="loc_us-gaap_ProductsAndServicesDomain_15_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ProstaScintMember" xlink:label="loc_aytu_ProstaScintMember_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_15" xlink:to="loc_aytu_ProstaScintMember_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_19" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18" xlink:to="loc_us-gaap_TradeNamesMember_20" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="loc_us-gaap_CustomerContractsMember_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18" xlink:to="loc_us-gaap_CustomerContractsMember_21" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_RangeAxis_22" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_22" xlink:to="loc_us-gaap_RangeMember_23" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_23_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_22" xlink:to="loc_us-gaap_RangeMember_23_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_23" xlink:to="loc_us-gaap_MaximumMember_24" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_23" xlink:to="loc_us-gaap_MinimumMember_25" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_26" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_26" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_27" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_27_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_26" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_27_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SecondUpfrontMember" xlink:label="loc_aytu_SecondUpfrontMember_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_27" xlink:to="loc_aytu_SecondUpfrontMember_28" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ThirdUpfrontMember" xlink:label="loc_aytu_ThirdUpfrontMember_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_27" xlink:to="loc_aytu_ThirdUpfrontMember_29" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_30" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FirstMilestoneMember" xlink:label="loc_aytu_FirstMilestoneMember_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" xlink:to="loc_aytu_FirstMilestoneMember_32" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SecondMilestoneMember" xlink:label="loc_aytu_SecondMilestoneMember_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" xlink:to="loc_aytu_SecondMilestoneMember_33" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ThirdMilestoneMember" xlink:label="loc_aytu_ThirdMilestoneMember_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" xlink:to="loc_aytu_ThirdMilestoneMember_34" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ForthMilestoneMember" xlink:label="loc_aytu_ForthMilestoneMember_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" xlink:to="loc_aytu_ForthMilestoneMember_35" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FifthMilestoneMember" xlink:label="loc_aytu_FifthMilestoneMember_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" xlink:to="loc_aytu_FifthMilestoneMember_36" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SixthMilestoneMember" xlink:label="loc_aytu_SixthMilestoneMember_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" xlink:to="loc_aytu_SixthMilestoneMember_37" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_38" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_38" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_39" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_39_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_38" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_39_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_LicenseAndSupplyAgreementMember" xlink:label="loc_aytu_LicenseAndSupplyAgreementMember_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_39" xlink:to="loc_aytu_LicenseAndSupplyAgreementMember_40" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_41" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_43" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessAcquisitionTextualAbstract" xlink:label="loc_aytu_BusinessAcquisitionTextualAbstract_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_aytu_BusinessAcquisitionTextualAbstract_44" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_45" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_46" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_47" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_48" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_49" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_50" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationContingentConsiderationPercentage" xlink:label="loc_aytu_BusinessCombinationContingentConsiderationPercentage_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_aytu_BusinessCombinationContingentConsiderationPercentage_51" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_52" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_53" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_54" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationConsiderationTransferredInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredInventory_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_aytu_BusinessCombinationConsiderationTransferredInventory_55" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationConsiderationTransferredProductInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredProductInventory_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_aytu_BusinessCombinationConsiderationTransferredProductInventory_56" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory_57" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_58" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_59" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_60" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OneTimeNonRefundablePayments" xlink:label="loc_aytu_OneTimeNonRefundablePayments_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_aytu_OneTimeNonRefundablePayments_61" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SalesRevenueTarget" xlink:label="loc_aytu_SalesRevenueTarget_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_aytu_SalesRevenueTarget_62" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:label="loc_us-gaap_PaymentsForPurchaseOfOtherAssets1_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_PaymentsForPurchaseOfOtherAssets1_63" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_64" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CostOfSaleForInvestment" xlink:label="loc_aytu_CostOfSaleForInvestment_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_aytu_CostOfSaleForInvestment_65" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_66" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_67" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_AccretionExpense_68" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales" xlink:label="loc_aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales_69" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_70" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_70" order="250" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_71" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_71" order="260" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_LiabilitiesAssumed1_72" order="270" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_73" order="280" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodDescription" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodDescription_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodDescription_74" order="290" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SubsidiariesPaymentDescription" xlink:label="loc_aytu_SubsidiariesPaymentDescription_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_aytu_SubsidiariesPaymentDescription_75" order="300" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SubsidiariesDescription" xlink:label="loc_aytu_SubsidiariesDescription_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_aytu_SubsidiariesDescription_76" order="310" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PercentageOfNetRevenue" xlink:label="loc_aytu_PercentageOfNetRevenue_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_44" xlink:to="loc_aytu_PercentageOfNetRevenue_77" order="320" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FixedAssetsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaap_ManufacturingFacilityMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ManufacturingFacilityMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_LabEquipmentMember" xlink:label="loc_aytu_LabEquipmentMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_aytu_LabEquipmentMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_13" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_15" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/PatentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_PatentsMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/PatentsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_PatentsMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/PatentsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ZertanePatentMember" xlink:label="loc_aytu_ZertanePatentMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_aytu_ZertanePatentMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_LuoxisPatentMember" xlink:label="loc_aytu_LuoxisPatentMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_aytu_LuoxisPatentMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PatentsTextualAbstract" xlink:label="loc_aytu_PatentsTextualAbstract_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_aytu_PatentsTextualAbstract_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaap_FiniteLivedPatentsGross_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_PatentsTextualAbstract_6" xlink:to="loc_us-gaap_FiniteLivedPatentsGross_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_PatentsTextualAbstract_6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FiniteLivedIntangibleAssetsExpireDate" xlink:label="loc_aytu_FiniteLivedIntangibleAssetsExpireDate_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_PatentsTextualAbstract_6" xlink:to="loc_aytu_FiniteLivedIntangibleAssetsExpireDate_9" order="20" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_10" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_10" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_12" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoteWarrantMember" xlink:label="loc_us-gaap_NoteWarrantMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_NoteWarrantMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsAbstract" xlink:label="loc_aytu_WarrantsAbstract_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_0" xlink:to="loc_aytu_WarrantsAbstract_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_WarrantsAbstract_8" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_WarrantsAbstract_8" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_WarrantsAbstract_8" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_WarrantsAbstract_8" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:label="loc_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_2" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_2" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ContingentConsiderationMember" xlink:label="loc_aytu_ContingentConsiderationMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_3" xlink:to="loc_aytu_ContingentConsiderationMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ContingentConsiderationAbstract" xlink:label="loc_aytu_ContingentConsiderationAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0" xlink:to="loc_aytu_ContingentConsiderationAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_ContingentConsiderationAbstract_5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_ContingentConsiderationAbstract_5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_ContingentConsiderationAbstract_5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow_8" order="20" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_0" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytu_PrescriptionDatabaseMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_PrescriptionDatabaseMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_NatestoMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ManufacturingAgreementMember" xlink:label="loc_aytu_ManufacturingAgreementMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_ManufacturingAgreementMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytu_OfficeLeaseMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_OfficeLeaseMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_0" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_0" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_0" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_0" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_11" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_0" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_12" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_0" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_13" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_0" xlink:to="loc_us-gaap_ContractualObligation_14" order="70" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_0" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_NatestoMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytu_PrescriptionDatabaseMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_PrescriptionDatabaseMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytu_OfficeLeaseMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_OfficeLeaseMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_aytu_CommitmentsAndContingenciesTextualAbstract_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_0" xlink:to="loc_aytu_CommitmentsAndContingenciesTextualAbstract_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaap_PaymentsForRent_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_7" xlink:to="loc_us-gaap_PaymentsForRent_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_7" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_7" xlink:to="loc_us-gaap_LeaseAndRentalExpense_10" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_7" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_11" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FirstMilestonePayable" xlink:label="loc_aytu_FirstMilestonePayable_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_7" xlink:to="loc_aytu_FirstMilestonePayable_12" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SecondMilestonePayable" xlink:label="loc_aytu_SecondMilestonePayable_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_7" xlink:to="loc_aytu_SecondMilestonePayable_13" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ThirdMilestonePayable" xlink:label="loc_aytu_ThirdMilestonePayable_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_7" xlink:to="loc_aytu_ThirdMilestonePayable_14" order="60" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommonStockDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ClassUnitsMember" xlink:label="loc_aytu_ClassUnitsMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_aytu_ClassUnitsMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ClassBUnitsMember" xlink:label="loc_aytu_ClassBUnitsMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_aytu_ClassBUnitsMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7" xlink:to="loc_us-gaap_EquityComponentDomain_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7" xlink:to="loc_us-gaap_EquityComponentDomain_8_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8" xlink:to="loc_us-gaap_CommonStockMember_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_StockCompensationPlanMember_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CommonStockTextualAbstract" xlink:label="loc_aytu_CommonStockTextualAbstract_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_aytu_CommonStockTextualAbstract_13" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_15" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_16" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_17" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_PreferredStockSharesIssued_18" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_19" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_20" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_21" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_22" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PreferredStockConversionPricePerShare" xlink:label="loc_aytu_PreferredStockConversionPricePerShare_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_aytu_PreferredStockConversionPricePerShare_23" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:label="loc_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock_24" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:label="loc_aytu_SecuritiesPurchaseAgreementCashFeePercentage_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_aytu_SecuritiesPurchaseAgreementCashFeePercentage_26" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:label="loc_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued_27" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsToPurchaseOfCommonStockShares" xlink:label="loc_aytu_WarrantsToPurchaseOfCommonStockShares_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_aytu_WarrantsToPurchaseOfCommonStockShares_28" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" xlink:label="loc_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction_29" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_30" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_31" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherSellingGeneralAndAdministrativeExpense_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_OtherSellingGeneralAndAdministrativeExpense_32" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_RestrictedInvestmentsAtFairValue_33" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentOwnedRestrictedAcquisitionDate" xlink:label="loc_us-gaap_InvestmentOwnedRestrictedAcquisitionDate_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_us-gaap_InvestmentOwnedRestrictedAcquisitionDate_34" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_DescriptionOfUnrecognizedExpense" xlink:label="loc_aytu_DescriptionOfUnrecognizedExpense_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockTextualAbstract_13" xlink:to="loc_aytu_DescriptionOfUnrecognizedExpense_35" order="210" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaap_OffsettingAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_OffsettingAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OffsettingAssetsTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_us-gaap_StockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_10" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant_11" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_16" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_17" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_18" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_20" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_us-gaap_StockOptionMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_12" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:label="loc_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_MayTwoThousandSixteenPublicOfferingMember" xlink:label="loc_aytu_MayTwoThousandSixteenPublicOfferingMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_aytu_MayTwoThousandSixteenPublicOfferingMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9" xlink:to="loc_us-gaap_EquityComponentDomain_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_10_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9" xlink:to="loc_us-gaap_EquityComponentDomain_10_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_us-gaap_WarrantMember_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" xlink:to="loc_us-gaap_RelatedPartyDomain_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_13_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" xlink:to="loc_us-gaap_RelatedPartyDomain_13_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_14" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_15" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_15_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_15_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PlacementAgentWarrantsMember" xlink:label="loc_aytu_PlacementAgentWarrantsMember_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_15" xlink:to="loc_aytu_PlacementAgentWarrantsMember_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_InvestorsWarrantsMember" xlink:label="loc_aytu_InvestorsWarrantsMember_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_15" xlink:to="loc_aytu_InvestorsWarrantsMember_17" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BankersWarrantsMember" xlink:label="loc_aytu_BankersWarrantsMember_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_15" xlink:to="loc_aytu_BankersWarrantsMember_18" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_MayTwoZeroOneSixWarrantsMember" xlink:label="loc_aytu_MayTwoZeroOneSixWarrantsMember_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_15" xlink:to="loc_aytu_MayTwoZeroOneSixWarrantsMember_19" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OctoberTwoZeroOneSixWarrantsMember" xlink:label="loc_aytu_OctoberTwoZeroOneSixWarrantsMember_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_15" xlink:to="loc_aytu_OctoberTwoZeroOneSixWarrantsMember_20" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_21" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_22" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_22_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_22_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ConvertiblePromissoryNotesMay2016Member" xlink:label="loc_aytu_ConvertiblePromissoryNotesMay2016Member_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22" xlink:to="loc_aytu_ConvertiblePromissoryNotesMay2016Member_23" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_24" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_24" xlink:to="loc_us-gaap_RangeMember_25" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_25_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_24" xlink:to="loc_us-gaap_RangeMember_25_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_25" xlink:to="loc_us-gaap_MaximumMember_26" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_25" xlink:to="loc_us-gaap_MinimumMember_27" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_28" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_28" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_29" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_29_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_28" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_29_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_29" xlink:to="loc_us-gaap_OtherRestructuringMember_30" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_31" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_31" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_32" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_32_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_31" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_32_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_32" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_33" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OverAllotmentWarrantsAxis" xlink:label="loc_aytu_OverAllotmentWarrantsAxis_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_aytu_OverAllotmentWarrantsAxis_34" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OverAllotmentWarrantsDomain" xlink:label="loc_aytu_OverAllotmentWarrantsDomain_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_aytu_OverAllotmentWarrantsAxis_34" xlink:to="loc_aytu_OverAllotmentWarrantsDomain_35" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OverAllotmentWarrantsDomain" xlink:label="loc_aytu_OverAllotmentWarrantsDomain_35_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_aytu_OverAllotmentWarrantsAxis_34" xlink:to="loc_aytu_OverAllotmentWarrantsDomain_35_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OverAllotmentWarrantsMember" xlink:label="loc_aytu_OverAllotmentWarrantsMember_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_OverAllotmentWarrantsDomain_35" xlink:to="loc_aytu_OverAllotmentWarrantsMember_36" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_EquityInstrumentsTextualAbstract" xlink:label="loc_aytu_EquityInstrumentsTextualAbstract_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_aytu_EquityInstrumentsTextualAbstract_37" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_EquityInstrumentsTextualAbstract_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_38" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_UnrecognizedShareBasedCompensationExpenses" xlink:label="loc_aytu_UnrecognizedShareBasedCompensationExpenses_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_EquityInstrumentsTextualAbstract_37" xlink:to="loc_aytu_UnrecognizedShareBasedCompensationExpenses_39" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_EquityInstrumentsTextualAbstract_37" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_40" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsToPurchaseOfCommonStockShares" xlink:label="loc_aytu_WarrantsToPurchaseOfCommonStockShares_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_EquityInstrumentsTextualAbstract_37" xlink:to="loc_aytu_WarrantsToPurchaseOfCommonStockShares_41" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_EquityInstrumentsTextualAbstract_37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_42" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsExercisePriceTerm" xlink:label="loc_aytu_WarrantsExercisePriceTerm_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_EquityInstrumentsTextualAbstract_37" xlink:to="loc_aytu_WarrantsExercisePriceTerm_43" order="50" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AgreementAxis" xlink:label="loc_aytu_AgreementAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_aytu_AgreementAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AgreementDomain" xlink:label="loc_aytu_AgreementDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_aytu_AgreementAxis_2" xlink:to="loc_aytu_AgreementDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AgreementDomain" xlink:label="loc_aytu_AgreementDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_aytu_AgreementAxis_2" xlink:to="loc_aytu_AgreementDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ServicesAgreementMember" xlink:label="loc_aytu_ServicesAgreementMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_AgreementDomain_3" xlink:to="loc_aytu_ServicesAgreementMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SponsoredResearchAgreementMember" xlink:label="loc_aytu_SponsoredResearchAgreementMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_AgreementDomain_3" xlink:to="loc_aytu_SponsoredResearchAgreementMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_aytu_RelatedPartyTransactionsTextualAbstract_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_aytu_RelatedPartyTransactionsTextualAbstract_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_RelatedPartyTransactionsTextualAbstract_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_RelatedPartyTransactionsTextualAbstract_6" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_RelatedPartyTransactionsTextualAbstract_6" xlink:to="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_RelatedPartyTransactionsTextualAbstract_6" xlink:to="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrepaidExpensesAmortizationPeriod" xlink:label="loc_aytu_PrepaidExpensesAmortizationPeriod_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_RelatedPartyTransactionsTextualAbstract_6" xlink:to="loc_aytu_PrepaidExpensesAmortizationPeriod_11" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SegmentInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4" xlink:to="loc_us-gaap_SegmentDomain_5" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_5_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4" xlink:to="loc_us-gaap_SegmentDomain_5_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AytuBioscienceIncMember" xlink:label="loc_aytu_AytuBioscienceIncMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5" xlink:to="loc_aytu_AytuBioscienceIncMember_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AytuWomensHealthMember" xlink:label="loc_aytu_AytuWomensHealthMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5" xlink:to="loc_aytu_AytuWomensHealthMember_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RevenuesAbstract_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_8" xlink:to="loc_us-gaap_Revenues_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:label="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_10" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_10" xlink:to="loc_us-gaap_NetIncomeLoss_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12" xlink:to="loc_us-gaap_Assets_13" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SubsequentEventsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NuelleMember" xlink:label="loc_aytu_NuelleMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6" xlink:to="loc_aytu_NuelleMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_LeaseAndRentalExpense_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SharesIssued_11" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_12" order="50" use="optional"  />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>aytu-20170930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_DocumentAndEntityInformationAbstract" xlink:label="loc_9G8G5FJFF1I8_aytu_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_DocumentAndEntityInformationAbstract" xlink:to="lab_1I0I7HLHH3K0_aytu_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_FGKKG0GJKHFG9KI347I3_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_dei_EntityRegistrantName" xlink:to="lab_HIMMI2ILMJHI1MK569K5_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_9G8G5FJFF1I8_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_dei_EntityCentralIndexKey" xlink:to="lab_1I0I7HLHH3K0_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_FGKKG0GJKHFG9KI347I3_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_dei_TradingSymbol" xlink:to="lab_HIMMI2ILMJHI1MK569K5_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_9G8G5FJFF1I8_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_dei_AmendmentFlag" xlink:to="lab_1I0I7HLHH3K0_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_FGKKG0GJKHFG9KI347I3_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_dei_CurrentFiscalYearEndDate" xlink:to="lab_HIMMI2ILMJHI1MK569K5_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_9G8G5FJFF1I8_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_dei_DocumentType" xlink:to="lab_1I0I7HLHH3K0_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_FGKKG0GJKHFG9KI347I3_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_dei_DocumentPeriodEndDate" xlink:to="lab_HIMMI2ILMJHI1MK569K5_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_9G8G5FJFF1I8_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_dei_DocumentFiscalYearFocus" xlink:to="lab_1I0I7HLHH3K0_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_FGKKG0GJKHFG9KI347I3_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_dei_DocumentFiscalPeriodFocus" xlink:to="lab_HIMMI2ILMJHI1MK569K5_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_9G8G5FJFF1I8_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_dei_EntityFilerCategory" xlink:to="lab_1I0I7HLHH3K0_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_FGKKG0GJKHFG9KI347I3_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_HIMMI2ILMJHI1MK569K5_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AssetsAbstract" xml:lang="en-US">Total consolidated assets:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AssetsAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_AssetsCurrentAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_9G8G5FJFF1I8_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_1I0I7HLHH3K0_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AccountsReceivableNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_9G8G5FJFF1I8_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_InventoryNet" xml:lang="en-US">Inventory, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_InventoryNet" xml:lang="en-US">Inventory, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_InventoryNet" xlink:to="lab_1I0I7HLHH3K0_us-gaap_InventoryNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_9G8G5FJFF1I8_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_AssetsCurrent" xlink:to="lab_1I0I7HLHH3K0_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Fixed assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Fixed assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Fixed assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CoreAndDevelopedTechnologyNet" xlink:label="loc_9G8G5FJFF1I8_aytu_CoreAndDevelopedTechnologyNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_CoreAndDevelopedTechnologyNet" xml:lang="en-US">Core And Developed Technology Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_CoreAndDevelopedTechnologyNet" xml:lang="en-US">Developed technology, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_CoreAndDevelopedTechnologyNet" xml:lang="en-US">Amount of rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_CoreAndDevelopedTechnologyNet" xlink:to="lab_1I0I7HLHH3K0_aytu_CoreAndDevelopedTechnologyNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IndefiniteLivedContractualRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IndefiniteLivedContractualRights" xml:lang="en-US">Indefinite-Lived Contractual Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IndefiniteLivedContractualRights" xml:lang="en-US">Customer contracts, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IndefiniteLivedContractualRights" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IndefiniteLivedContractualRights"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="loc_9G8G5FJFF1I8_us-gaap_IndefiniteLivedTradeNames" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_IndefiniteLivedTradeNames" xml:lang="en-US">Indefinite-Lived Trade Names</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_IndefiniteLivedTradeNames" xml:lang="en-US">Trade names, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_IndefiniteLivedTradeNames" xlink:to="lab_1I0I7HLHH3K0_us-gaap_IndefiniteLivedTradeNames"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Natesto asset, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_OtherAssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_9G8G5FJFF1I8_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_1I0I7HLHH3K0_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_Goodwill" xlink:to="lab_1I0I7HLHH3K0_us-gaap_Goodwill"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Patents, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Patents, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Patents, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_9G8G5FJFF1I8_us-gaap_DepositsAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_DepositsAssetsNoncurrent" xml:lang="en-US">Deposits Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_DepositsAssetsNoncurrent" xml:lang="en-US">Deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_DepositsAssetsNoncurrent" xlink:to="lab_1I0I7HLHH3K0_us-gaap_DepositsAssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AssetsNoncurrent" xml:lang="en-US">Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AssetsNoncurrent" xml:lang="en-US">Total long-term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AssetsNoncurrent" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_9G8G5FJFF1I8_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_Assets" xml:lang="en-US">Total consolidated assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_Assets" xlink:to="lab_1I0I7HLHH3K0_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AccountsPayableCurrent" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_9G8G5FJFF1I8_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_1I0I7HLHH3K0_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AccruedCompensationCurrent" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_AccruedCompensationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AccruedCompensationCurrent" xml:lang="en-US">Accrued Compensation Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AccruedCompensationCurrent" xml:lang="en-US">Accrued compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AccruedCompensationCurrent" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable pertaining to costs that are statutory in nature of accrued compensation.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_AccruedCompensationCurrent" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_AccruedCompensationCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_9G8G5FJFF1I8_us-gaap_DeferredRentCreditCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_DeferredRentCreditCurrent" xml:lang="en-US">Deferred Rent Credit, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_DeferredRentCreditCurrent" xml:lang="en-US">Deferred rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_DeferredRentCreditCurrent" xlink:to="lab_1I0I7HLHH3K0_us-gaap_DeferredRentCreditCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xml:lang="en-US">Current contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_9G8G5FJFF1I8_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_LiabilitiesCurrent" xlink:to="lab_1I0I7HLHH3K0_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xml:lang="en-US">Contingent consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xml:lang="en-US">Long-term contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_9G8G5FJFF1I8_us-gaap_DeferredRentCreditNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_1I0I7HLHH3K0_us-gaap_DeferredRentCreditNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DerivativeLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Warrant derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_9G8G5FJFF1I8_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_Liabilities" xlink:to="lab_1I0I7HLHH3K0_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 6)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 7)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CommitmentsAndContingencies" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_StockholdersEquityAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, par value $.0001; 50,000,000 shares authorized; shares issued and outstanding 2,250 (unaudited) and 0, respectively as of September 30, 2017 and June 30, 2017</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PreferredStockValue" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_9G8G5FJFF1I8_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 4,224,840 (unaudited) and 824,831, respectively as of September 30, 2017 and June 30, 2017</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 824,831 in 2017 and 187,098 in 2016</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_CommonStockValue" xlink:to="lab_1I0I7HLHH3K0_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AdditionalPaidInCapital" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_9G8G5FJFF1I8_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_1I0I7HLHH3K0_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockholdersEquity" xml:lang="en-US">Balance (unaudited)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockholdersEquity" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_9G8G5FJFF1I8_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_1I0I7HLHH3K0_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_9G8G5FJFF1I8_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, authorized shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_1I0I7HLHH3K0_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, issued shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PreferredStockSharesIssued" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_9G8G5FJFF1I8_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_1I0I7HLHH3K0_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_9G8G5FJFF1I8_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, authorized shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, authorized shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, authorized shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_1I0I7HLHH3K0_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, issued shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CommonStockSharesIssued" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_9G8G5FJFF1I8_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, outstanding shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, outstanding shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_1I0I7HLHH3K0_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IncomeStatementAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SalesRevenueNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SalesRevenueNet" xml:lang="en-US">Product revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SalesRevenueNet" xml:lang="en-US">Product revenue recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SalesRevenueNet" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SalesRevenueNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_Revenues" xml:lang="en-US">Consolidated revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_Revenues" xml:lang="en-US">Total revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_Revenues" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_Revenues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_OperatingExpensesAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CostOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CostOfRevenue" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CostOfRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ResearchAndDevelopmentRelatedParty" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_ResearchAndDevelopmentRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ResearchAndDevelopmentRelatedParty" xml:lang="en-US">Research And Development Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ResearchAndDevelopmentRelatedParty" xml:lang="en-US">Research and development - related party (Note 9)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ResearchAndDevelopmentRelatedParty" xml:lang="en-US">Research and development - related party (Note 11)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ResearchAndDevelopmentRelatedParty" xml:lang="en-US">Amount of research and development related party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_ResearchAndDevelopmentRelatedParty" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_ResearchAndDevelopmentRelatedParty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Sales, general and administrative expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Sales, general and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SellingGeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CostsAndExpensesRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Costs and Expenses, Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Sales, general and administrative - related party (Note 9)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Sales, general and administrative - related party (Note 11)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CostsAndExpensesRelatedParty" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CostsAndExpensesRelatedParty"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AmortizationAndImpairmentOfIntangibleAssets" xlink:label="loc_9G8G5FJFF1I8_aytu_AmortizationAndImpairmentOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_AmortizationAndImpairmentOfIntangibleAssets" xml:lang="en-US">Amortization And Impairment Of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_AmortizationAndImpairmentOfIntangibleAssets" xml:lang="en-US">Amortization and impairment of intangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_AmortizationAndImpairmentOfIntangibleAssets" xml:lang="en-US">Amount of amortization and impairment of intangible assets.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_AmortizationAndImpairmentOfIntangibleAssets" xlink:to="lab_1I0I7HLHH3K0_aytu_AmortizationAndImpairmentOfIntangibleAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_OperatingExpenses" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_9G8G5FJFF1I8_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss), Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_OperatingIncomeLoss" xlink:to="lab_1I0I7HLHH3K0_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_9G8G5FJFF1I8_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_InterestExpense" xml:lang="en-US">Interest (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_InterestExpense" xlink:to="lab_1I0I7HLHH3K0_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DerivativeGainLossOnDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative income (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative (income) expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DerivativeGainLossOnDerivativeNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_9G8G5FJFF1I8_us-gaap_GainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_GainLossOnInvestments" xml:lang="en-US">Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_GainLossOnInvestments" xml:lang="en-US">Unrealized gain on investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_GainLossOnInvestments" xml:lang="en-US">(Loss) on investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_GainLossOnInvestments" xlink:to="lab_1I0I7HLHH3K0_us-gaap_GainLossOnInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense), Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other (expense) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_9G8G5FJFF1I8_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetIncomeLoss" xml:lang="en-US">Consolidated net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss (unaudited)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/measurementGuidance" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_NetIncomeLoss" xlink:to="lab_1I0I7HLHH3K0_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of Aytu common shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of Aytu common shares outstanding (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_9G8G5FJFF1I8_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted Aytu net loss per common share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted Aytu net loss per common share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_1I0I7HLHH3K0_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StatementOfStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_9G8G5FJFF1I8_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_StatementTable" xlink:to="lab_1I0I7HLHH3K0_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_EquityComponentDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PreferredStockMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_9G8G5FJFF1I8_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_CommonStockMember" xlink:to="lab_1I0I7HLHH3K0_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_9G8G5FJFF1I8_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_RetainedEarningsMember" xlink:to="lab_1I0I7HLHH3K0_us-gaap_RetainedEarningsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StatementLineItems" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (unaudited), shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SharesOutstanding" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation (unaudited)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_9G8G5FJFF1I8_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock (unaudited)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_1I0I7HLHH3K0_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock (unaudited), shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_9G8G5FJFF1I8_us-gaap_StockIssuedDuringPeriodValueOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Earn-out payment to Nuelle shareholders (unaudited)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock issued for first earn-out payment to nuelle shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_1I0I7HLHH3K0_us-gaap_StockIssuedDuringPeriodValueOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockIssuedDuringPeriodSharesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Earn-out payment to Nuelle shareholders (unaudited), shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Issued of common stock payment to Nuelle Shareholders for fiscal 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesOther"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_IssuanceOfPreferredAndCommonStockNetCost" xlink:label="loc_9G8G5FJFF1I8_aytu_IssuanceOfPreferredAndCommonStockNetCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_IssuanceOfPreferredAndCommonStockNetCost" xml:lang="en-US">Issuance Of Preferred And Common Stock Net Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_IssuanceOfPreferredAndCommonStockNetCost" xml:lang="en-US">Issuance of preferred and common stock, net of $1,402,831 in cash issuance costs (unaudited)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_IssuanceOfPreferredAndCommonStockNetCost" xml:lang="en-US">Issuance of preferred and common stock net cost.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_IssuanceOfPreferredAndCommonStockNetCost" xlink:to="lab_1I0I7HLHH3K0_aytu_IssuanceOfPreferredAndCommonStockNetCost"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_IssuanceOfPreferredAndCommonStockNetShare" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_IssuanceOfPreferredAndCommonStockNetShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_IssuanceOfPreferredAndCommonStockNetShare" xml:lang="en-US">Issuance Of Preferred And Common Stock Net Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_IssuanceOfPreferredAndCommonStockNetShare" xml:lang="en-US">Issuance of preferred and common stock, net of $1,402,831 in cash issuance costs (unaudited), shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_IssuanceOfPreferredAndCommonStockNetShare" xml:lang="en-US">Issuance of preferred and common stock net share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_IssuanceOfPreferredAndCommonStockNetShare" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_IssuanceOfPreferredAndCommonStockNetShare"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:label="loc_9G8G5FJFF1I8_aytu_AdjustmentForRoundingOfValueDueToConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_AdjustmentForRoundingOfValueDueToConversion" xml:lang="en-US">Adjustment For Rounding Of Value Due To Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_AdjustmentForRoundingOfValueDueToConversion" xml:lang="en-US">Adjustment for rounding of shares due to stock split (unaudited)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_AdjustmentForRoundingOfValueDueToConversion" xml:lang="en-US">Adjustment for rounding of shares due to stock split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_AdjustmentForRoundingOfValueDueToConversion" xml:lang="en-US">It refers to adjustment for rounding of values due to conversion.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:to="lab_1I0I7HLHH3K0_aytu_AdjustmentForRoundingOfValueDueToConversion"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_AdjustmentForRoundingOfSharesDueToConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AdjustmentForRoundingOfSharesDueToConversion" xml:lang="en-US">Adjustment For Rounding Of Shares Due To Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AdjustmentForRoundingOfSharesDueToConversion" xml:lang="en-US">Adjustment for rounding of shares due to stock split (unaudited), shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AdjustmentForRoundingOfSharesDueToConversion" xml:lang="en-US">Adjustment for rounding of shares due to stock split (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AdjustmentForRoundingOfSharesDueToConversion" xml:lang="en-US">It refers to adjustment for rounding of shares due to conversion.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_AdjustmentForRoundingOfSharesDueToConversion"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_9G8G5FJFF1I8_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xml:lang="en-US">Issuance of preferred and common stock net of cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_1I0I7HLHH3K0_us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to cash provided by (used in) operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensation" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RestrictedStockExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RestrictedStockExpense" xml:lang="en-US">Restricted Stock or Unit Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RestrictedStockExpense" xml:lang="en-US">Issuance of restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RestrictedStockExpense" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RestrictedStockExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_9G8G5FJFF1I8_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, amortization and accretion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_1I0I7HLHH3K0_us-gaap_DepreciationDepletionAndAmortization"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xml:lang="en-US">Amortization Of Prepaid Research And Development Due To Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xml:lang="en-US">Amortization of prepaid research and development - related party (Note 9)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xml:lang="en-US">Amortization of prepaid research and development due to related parties.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:label="loc_9G8G5FJFF1I8_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xml:lang="en-US">Unrealized (gain) on investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:to="lab_1I0I7HLHH3K0_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Compensation through issuance of stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_9G8G5FJFF1I8_us-gaap_AdjustmentOfWarrantsGrantedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Issuance of warrants to initial investors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="lab_1I0I7HLHH3K0_us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_9G8G5FJFF1I8_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">(Increase) in accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_1I0I7HLHH3K0_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Decrease (increase) in inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncreaseDecreaseInInventories"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_9G8G5FJFF1I8_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Decrease (increase) in prepaid expenses and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_1I0I7HLHH3K0_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">(Decrease) in accounts payable and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_9G8G5FJFF1I8_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (decrease) in accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_1I0I7HLHH3K0_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_IncreaseDecreaseInAccruedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_IncreaseDecreaseInAccruedCompensation" xml:lang="en-US">Increase Decrease In Accrued Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_IncreaseDecreaseInAccruedCompensation" xml:lang="en-US">Increase (decrease) in accrued compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_IncreaseDecreaseInAccruedCompensation" xml:lang="en-US">Increase decrease in accrued compensation.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_IncreaseDecreaseInAccruedCompensation" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_IncreaseDecreaseInAccruedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="loc_9G8G5FJFF1I8_us-gaap_IncreaseDecreaseInPrepaidRent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_IncreaseDecreaseInPrepaidRent" xml:lang="en-US">Increase (Decrease) in Prepaid Rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_IncreaseDecreaseInPrepaidRent" xml:lang="en-US">(Decrease) increase in deferred rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_IncreaseDecreaseInPrepaidRent" xlink:to="lab_1I0I7HLHH3K0_us-gaap_IncreaseDecreaseInPrepaidRent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_9G8G5FJFF1I8_us-gaap_PaymentsToAcquireOtherProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PaymentsToAcquireOtherProductiveAssets" xml:lang="en-US">Payments to Acquire Other Productive Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PaymentsToAcquireOtherProductiveAssets" xml:lang="en-US">Installment payment for Primsol asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_1I0I7HLHH3K0_us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Issuance of preferred, common stock and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Sale of stock subscription</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:label="loc_9G8G5FJFF1I8_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xml:lang="en-US">Payments Of Preferred Common Stock And Warrants Issuance Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xml:lang="en-US">Issuance costs related to preferred, common stock and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xml:lang="en-US">The cash outflow for cost incurred directly with the issuance of preferred, common stock and warrants.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xml:lang="en-US">Issuance costs related to preferred, common stock and warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:to="lab_1I0I7HLHH3K0_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Issuance of common stock to Lincoln Park Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_9G8G5FJFF1I8_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of stock issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Costs related to sale of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_1I0I7HLHH3K0_us-gaap_PaymentsOfStockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_9G8G5FJFF1I8_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net change in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_1I0I7HLHH3K0_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Non-cash transactions:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsIssuedToInvestorsAndUnderwriters" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_WarrantsIssuedToInvestorsAndUnderwriters" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_WarrantsIssuedToInvestorsAndUnderwriters" xml:lang="en-US">Warrants Issued To Investors And Underwriters</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_WarrantsIssuedToInvestorsAndUnderwriters" xml:lang="en-US">Warrants issued to investors and underwriters (see Note 5)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_WarrantsIssuedToInvestorsAndUnderwriters" xml:lang="en-US">Warrants issued to investors and underwriters.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_WarrantsIssuedToInvestorsAndUnderwriters" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_WarrantsIssuedToInvestorsAndUnderwriters"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_EarnOutPaymentToOtherShareholders" xlink:label="loc_9G8G5FJFF1I8_aytu_EarnOutPaymentToOtherShareholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_EarnOutPaymentToOtherShareholders" xml:lang="en-US">Earn Out Payment To Other Shareholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_EarnOutPaymentToOtherShareholders" xml:lang="en-US">Earn-out payment to Nuelle Shareholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_EarnOutPaymentToOtherShareholders" xml:lang="en-US">Earn-out payment to the shareholders of subsidiary company or on merger.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_EarnOutPaymentToOtherShareholders" xlink:to="lab_1I0I7HLHH3K0_aytu_EarnOutPaymentToOtherShareholders"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xml:lang="en-US">Primsol Business Purchase Included In Primsol Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xml:lang="en-US">Primsol accretion included in accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xml:lang="en-US">The amount of primsol business purchases included in primsol payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FixedAssetsIncludedInAccountsPayable" xlink:label="loc_9G8G5FJFF1I8_aytu_FixedAssetsIncludedInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_FixedAssetsIncludedInAccountsPayable" xml:lang="en-US">Fixed Assets Included In Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_FixedAssetsIncludedInAccountsPayable" xml:lang="en-US">Fixed assets included in accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_FixedAssetsIncludedInAccountsPayable" xml:lang="en-US">The fair value of fixed assets included in accounts payable in noncash investing or financing activities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_FixedAssetsIncludedInAccountsPayable" xlink:to="lab_1I0I7HLHH3K0_aytu_FixedAssetsIncludedInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Fixed Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Fixed Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Patents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Patents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DeferredRevenueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DeferredRevenueDisclosureAbstract" xml:lang="en-US">Revenue Recognition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DeferredRevenueDisclosureAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DeferredRevenueDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_RevenueRecognitionDisclosureTextBlock" xlink:label="loc_9G8G5FJFF1I8_aytu_RevenueRecognitionDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_RevenueRecognitionDisclosureTextBlock" xml:lang="en-US">Revenue Recognition Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_RevenueRecognitionDisclosureTextBlock" xml:lang="en-US">Revenue Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_RevenueRecognitionDisclosureTextBlock" xml:lang="en-US">The entire disclosure for revenue recognition at the end of the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_RevenueRecognitionDisclosureTextBlock" xlink:to="lab_1I0I7HLHH3K0_aytu_RevenueRecognitionDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Considerations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueDisclosuresAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Consideration [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Considerations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FairValueDisclosuresTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_EquityAbstract" xml:lang="en-US">Common Stock/Equity Instruments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_EquityAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_EquityAbstract"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CommonStockTextBlock" xlink:label="loc_9G8G5FJFF1I8_aytu_CommonStockTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_CommonStockTextBlock" xml:lang="en-US">Common Stock [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_CommonStockTextBlock" xml:lang="en-US">Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_CommonStockTextBlock" xml:lang="en-US">The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_CommonStockTextBlock" xlink:to="lab_1I0I7HLHH3K0_aytu_CommonStockTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SegmentReportingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SegmentReportingAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SegmentReportingAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SegmentReportingDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SegmentReportingDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SubsequentEventsAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Pronouncements, Not Adopted as of September 30, 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessDescriptionAndBasisOfPresentationTable" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_BusinessDescriptionAndBasisOfPresentationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessDescriptionAndBasisOfPresentationTable" xml:lang="en-US">Business Description And Basis Of Presentation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessDescriptionAndBasisOfPresentationTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_9G8G5FJFF1I8_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_1I0I7HLHH3K0_us-gaap_BusinessAcquisitionAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessAcquisitionAcquireeDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_9G8G5FJFF1I8_aytu_ProstascintBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ProstascintBusinessMember" xml:lang="en-US">Prostascint Business [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_ProstascintBusinessMember" xml:lang="en-US">ProstaScint [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ProstascintBusinessMember" xlink:to="lab_1I0I7HLHH3K0_aytu_ProstascintBusinessMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_PrimsolBusinessMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PrimsolBusinessMember" xml:lang="en-US">Primsol Business [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PrimsolBusinessMember" xml:lang="en-US">Primsol [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_PrimsolBusinessMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_PrimsolBusinessMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NatestoMember" xlink:label="loc_9G8G5FJFF1I8_aytu_NatestoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_NatestoMember" xml:lang="en-US">Natesto [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_NatestoMember" xml:lang="en-US">Natesto [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_NatestoMember" xlink:to="lab_1I0I7HLHH3K0_aytu_NatestoMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NuelleMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_NuelleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_NuelleMember" xml:lang="en-US">Nuelle [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_NuelleMember" xml:lang="en-US">Nuelle [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_NuelleMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_NuelleMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:label="loc_9G8G5FJFF1I8_aytu_BusinessDescriptionAndBasisOfPresentationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xml:lang="en-US">Business Description And Basis Of Presentation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="lab_1I0I7HLHH3K0_aytu_BusinessDescriptionAndBasisOfPresentationLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of allocation on consideration transferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of fixed assets and depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of patents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xml:lang="en-US">Schedule of amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Summary of fair value on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Summary of significant assumptions in valuing the warrant derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Summary of reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xml:lang="en-US">Summary of changes in the contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xml:lang="en-US">Commitments And Contingencies Disclosure [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xml:lang="en-US">Schedule of commitments and contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xml:lang="en-US">Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfRentExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfRentExpenseTableTextBlock" xml:lang="en-US">Schedule of Rent Expense [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfRentExpenseTableTextBlock" xml:lang="en-US">Schedule of rent expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfRentExpenseTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Common Stock/Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of stock option activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Summary of stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Summary of all warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US">Schedule of financial information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessAcquisitionLineItems"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="loc_9G8G5FJFF1I8_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Tangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xml:lang="en-US">Tangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed tangible assets.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="lab_1I0I7HLHH3K0_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible assets, trade names</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_9G8G5FJFF1I8_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Net identifiable asset acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Total assets acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Total assets acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_JazzPharmaceuticalsIncMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_JazzPharmaceuticalsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_JazzPharmaceuticalsIncMember" xml:lang="en-US">Jazz Pharmaceuticals Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_JazzPharmaceuticalsIncMember" xml:lang="en-US">Jazz Pharmaceuticals, Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_JazzPharmaceuticalsIncMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_JazzPharmaceuticalsIncMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NuelleIncMember" xlink:label="loc_9G8G5FJFF1I8_aytu_NuelleIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_NuelleIncMember" xml:lang="en-US">Nuelle, Inc. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_NuelleIncMember" xml:lang="en-US">Nuelle [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_NuelleIncMember" xlink:to="lab_1I0I7HLHH3K0_aytu_NuelleIncMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StatementScenarioAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StatementScenarioAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ScenarioUnspecifiedDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PaidOnApril12016Member" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_PaidOnApril12016Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PaidOnApril12016Member" xml:lang="en-US">Paid on April 1, 2016 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_PaidOnApril12016Member" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_PaidOnApril12016Member"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NoLaterThanJuly012016Member" xlink:label="loc_9G8G5FJFF1I8_aytu_NoLaterThanJuly012016Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_NoLaterThanJuly012016Member" xml:lang="en-US">No Later Than July 01, 2016 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_NoLaterThanJuly012016Member" xml:lang="en-US">Paid on July 1, 2016 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_NoLaterThanJuly012016Member" xlink:to="lab_1I0I7HLHH3K0_aytu_NoLaterThanJuly012016Member"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NoLaterThanSeptember302016Member" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_NoLaterThanSeptember302016Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_NoLaterThanSeptember302016Member" xml:lang="en-US">No Later Than September 30, 2016 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_NoLaterThanSeptember302016Member" xml:lang="en-US">Paid in November 2016 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_NoLaterThanSeptember302016Member" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_NoLaterThanSeptember302016Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ProductOrServiceAxis" xml:lang="en-US">Products and Services [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ProductOrServiceAxis" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ProductOrServiceAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ProductsAndServicesDomain" xml:lang="en-US">Products and Services [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ProductsAndServicesDomain" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ProductsAndServicesDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ProstaScintMember" xlink:label="loc_9G8G5FJFF1I8_aytu_ProstaScintMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ProstaScintMember" xml:lang="en-US">Prosta Scint [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_ProstaScintMember" xml:lang="en-US">Prosta Scint [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ProstaScintMember" xlink:to="lab_1I0I7HLHH3K0_aytu_ProstaScintMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DevelopedTechnologyRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DevelopedTechnologyRightsMember" xml:lang="en-US">Developed Technology Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DevelopedTechnologyRightsMember" xml:lang="en-US">Developed technology [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DevelopedTechnologyRightsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_9G8G5FJFF1I8_us-gaap_TradeNamesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_TradeNamesMember" xml:lang="en-US">Trade Names [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_TradeNamesMember" xml:lang="en-US">Trade names [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_TradeNamesMember" xlink:to="lab_1I0I7HLHH3K0_us-gaap_TradeNamesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CustomerContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CustomerContractsMember" xml:lang="en-US">Customer Contracts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CustomerContractsMember" xml:lang="en-US">Customer contracts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_CustomerContractsMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_CustomerContractsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_9G8G5FJFF1I8_us-gaap_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_RangeAxis" xlink:to="lab_1I0I7HLHH3K0_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RangeMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_9G8G5FJFF1I8_us-gaap_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_MaximumMember" xlink:to="lab_1I0I7HLHH3K0_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_MinimumMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_9G8G5FJFF1I8_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SecondUpfrontMember" xlink:label="loc_9G8G5FJFF1I8_aytu_SecondUpfrontMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_SecondUpfrontMember" xml:lang="en-US">Second Upfront [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_SecondUpfrontMember" xml:lang="en-US">Second Upfront [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_SecondUpfrontMember" xlink:to="lab_1I0I7HLHH3K0_aytu_SecondUpfrontMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ThirdUpfrontMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_ThirdUpfrontMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ThirdUpfrontMember" xml:lang="en-US">Third Upfront [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ThirdUpfrontMember" xml:lang="en-US">Third Upfront [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_ThirdUpfrontMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_ThirdUpfrontMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_9G8G5FJFF1I8_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_TypeOfArrangementAxis" xlink:to="lab_1I0I7HLHH3K0_us-gaap_TypeOfArrangementAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FirstMilestoneMember" xlink:label="loc_9G8G5FJFF1I8_aytu_FirstMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_FirstMilestoneMember" xml:lang="en-US">First Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_FirstMilestoneMember" xml:lang="en-US">First Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_FirstMilestoneMember" xlink:to="lab_1I0I7HLHH3K0_aytu_FirstMilestoneMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SecondMilestoneMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_SecondMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_SecondMilestoneMember" xml:lang="en-US">Second Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_SecondMilestoneMember" xml:lang="en-US">Second Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_SecondMilestoneMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_SecondMilestoneMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ThirdMilestoneMember" xlink:label="loc_9G8G5FJFF1I8_aytu_ThirdMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ThirdMilestoneMember" xml:lang="en-US">Third Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_ThirdMilestoneMember" xml:lang="en-US">Third Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ThirdMilestoneMember" xlink:to="lab_1I0I7HLHH3K0_aytu_ThirdMilestoneMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ForthMilestoneMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_ForthMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ForthMilestoneMember" xml:lang="en-US">Forth Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ForthMilestoneMember" xml:lang="en-US">Forth Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_ForthMilestoneMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_ForthMilestoneMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FifthMilestoneMember" xlink:label="loc_9G8G5FJFF1I8_aytu_FifthMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_FifthMilestoneMember" xml:lang="en-US">Fifth Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_FifthMilestoneMember" xml:lang="en-US">Fifth Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_FifthMilestoneMember" xlink:to="lab_1I0I7HLHH3K0_aytu_FifthMilestoneMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SixthMilestoneMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_SixthMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_SixthMilestoneMember" xml:lang="en-US">Sixth Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_SixthMilestoneMember" xml:lang="en-US">Sixth Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_SixthMilestoneMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_SixthMilestoneMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_9G8G5FJFF1I8_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_1I0I7HLHH3K0_us-gaap_RelatedPartyTransactionAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RelatedPartyTransactionDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_LicenseAndSupplyAgreementMember" xlink:label="loc_9G8G5FJFF1I8_aytu_LicenseAndSupplyAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_LicenseAndSupplyAgreementMember" xml:lang="en-US">License And Supply Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_LicenseAndSupplyAgreementMember" xml:lang="en-US">License and Supply Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_LicenseAndSupplyAgreementMember" xlink:to="lab_1I0I7HLHH3K0_aytu_LicenseAndSupplyAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_IncomeStatementLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_IncomeStatementLocationDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, general and administrative expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessAcquisitionTextualAbstract" xlink:label="loc_9G8G5FJFF1I8_aytu_BusinessAcquisitionTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_BusinessAcquisitionTextualAbstract" xml:lang="en-US">Business Acquisition Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_BusinessAcquisitionTextualAbstract" xml:lang="en-US">Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_BusinessAcquisitionTextualAbstract" xlink:to="lab_1I0I7HLHH3K0_aytu_BusinessAcquisitionTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockholdersEquityReverseStockSplit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' equity, reverse stock split, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockholdersEquityReverseStockSplit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_9G8G5FJFF1I8_us-gaap_PaymentsToAcquireBusinessesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Upfront fee amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Purchase of ProstaScint Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_1I0I7HLHH3K0_us-gaap_PaymentsToAcquireBusinessesGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xml:lang="en-US">Final upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_9G8G5FJFF1I8_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xml:lang="en-US">Increase due to accretion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xml:lang="en-US">Maximum aggregate payout for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:to="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationContingentConsiderationPercentage" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_BusinessCombinationContingentConsiderationPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessCombinationContingentConsiderationPercentage" xml:lang="en-US">Business Combination Contingent Consideration Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessCombinationContingentConsiderationPercentage" xml:lang="en-US">Percentage of net sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessCombinationContingentConsiderationPercentage" xml:lang="en-US">Business combination contingent consideration percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_BusinessCombinationContingentConsiderationPercentage" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessCombinationContingentConsiderationPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_9G8G5FJFF1I8_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xml:lang="en-US">Contingent consideration related to the ProstaScint purchase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xml:lang="en-US">Contingent consideration valued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Patents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_9G8G5FJFF1I8_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization expense of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_1I0I7HLHH3K0_us-gaap_AmortizationOfIntangibleAssets"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationConsiderationTransferredInventory" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_BusinessCombinationConsiderationTransferredInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessCombinationConsiderationTransferredInventory" xml:lang="en-US">Business Combination Consideration Transferred Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessCombinationConsiderationTransferredInventory" xml:lang="en-US">Intangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessCombinationConsiderationTransferredInventory" xml:lang="en-US">Represents the amount of business combination consideration transferred to inventory.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_BusinessCombinationConsiderationTransferredInventory" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessCombinationConsiderationTransferredInventory"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationConsiderationTransferredProductInventory" xlink:label="loc_9G8G5FJFF1I8_aytu_BusinessCombinationConsiderationTransferredProductInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_BusinessCombinationConsiderationTransferredProductInventory" xml:lang="en-US">Business Combination Consideration Transferred Product Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_BusinessCombinationConsiderationTransferredProductInventory" xml:lang="en-US">Transfer of related product inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_BusinessCombinationConsiderationTransferredProductInventory" xml:lang="en-US">Represents the amount of business combination consideration transferred to primsol related product inventory.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_BusinessCombinationConsiderationTransferredProductInventory" xlink:to="lab_1I0I7HLHH3K0_aytu_BusinessCombinationConsiderationTransferredProductInventory"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xml:lang="en-US">Business Combination Consideration Transferred Work In Process Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xml:lang="en-US">Work-in-process inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xml:lang="en-US">Represents the amount of business combination consideration transferred to work in process inventory.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_9G8G5FJFF1I8_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Stock issued aggregate shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_1I0I7HLHH3K0_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xml:lang="en-US">Purchase of common stock value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_9G8G5FJFF1I8_us-gaap_BusinessAcquisitionSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business Acquisition, Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Purchase price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_1I0I7HLHH3K0_us-gaap_BusinessAcquisitionSharePrice"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OneTimeNonRefundablePayments" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_OneTimeNonRefundablePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_OneTimeNonRefundablePayments" xml:lang="en-US">One Time Non Refundable Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_OneTimeNonRefundablePayments" xml:lang="en-US">One-time, non-refundable payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_OneTimeNonRefundablePayments" xml:lang="en-US">Amount represents the one time non-refundable payments based on sales revenue.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_OneTimeNonRefundablePayments" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_OneTimeNonRefundablePayments"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SalesRevenueTarget" xlink:label="loc_9G8G5FJFF1I8_aytu_SalesRevenueTarget" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_SalesRevenueTarget" xml:lang="en-US">Sales Revenue Target</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_SalesRevenueTarget" xml:lang="en-US">Sales revenue target</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_SalesRevenueTarget" xml:lang="en-US">The amount sales revenue target for non-refundable payment criteria.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_SalesRevenueTarget" xlink:to="lab_1I0I7HLHH3K0_aytu_SalesRevenueTarget"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PaymentsForPurchaseOfOtherAssets1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PaymentsForPurchaseOfOtherAssets1" xml:lang="en-US">Payments for Purchase of Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PaymentsForPurchaseOfOtherAssets1" xml:lang="en-US">Purchaser paid amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PaymentsForPurchaseOfOtherAssets1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_9G8G5FJFF1I8_us-gaap_GainLossOnSaleOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_GainLossOnSaleOfBusiness" xml:lang="en-US">Gain (Loss) on Disposition of Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_GainLossOnSaleOfBusiness" xml:lang="en-US">Recognized gain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_1I0I7HLHH3K0_us-gaap_GainLossOnSaleOfBusiness"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CostOfSaleForInvestment" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_CostOfSaleForInvestment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_CostOfSaleForInvestment" xml:lang="en-US">Cost Of Sale For Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_CostOfSaleForInvestment" xml:lang="en-US">Total of cost of sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_CostOfSaleForInvestment" xml:lang="en-US">The cost of sale of investments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_CostOfSaleForInvestment" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_CostOfSaleForInvestment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities, Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xml:lang="en-US">Gross proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xml:lang="en-US">Gross proceeds from the sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_UnrealizedGainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized gain/loss on investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_UnrealizedGainLossOnInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_9G8G5FJFF1I8_us-gaap_AccretionExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AccretionExpense" xml:lang="en-US">Accretion Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AccretionExpense" xml:lang="en-US">Natesto asset purchase included in Natesto payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AccretionExpense" xml:lang="en-US">Contingent consideration accretion expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_AccretionExpense" xlink:to="lab_1I0I7HLHH3K0_us-gaap_AccretionExpense"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales" xml:lang="en-US">Revenue Earn-Out Payments Equal to Designated Percentage of Net Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales" xml:lang="en-US">Milestone payments potential aggregate value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales" xml:lang="en-US">Amount represents the revenue earnout payments based on sales revenue.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Useful lives of patents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Intangible assets amortized period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_LiabilitiesAssumed1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Liabilities Assumed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Liabilities assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_LiabilitiesAssumed1" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_LiabilitiesAssumed1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodDescription" xlink:label="loc_9G8G5FJFF1I8_us-gaap_RevenueRecognitionMilestoneMethodDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RevenueRecognitionMilestoneMethodDescription" xml:lang="en-US">Revenue Recognition, Milestone Method, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RevenueRecognitionMilestoneMethodDescription" xml:lang="en-US">Maximum aggregate amount payable milestone payments, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_RevenueRecognitionMilestoneMethodDescription" xlink:to="lab_1I0I7HLHH3K0_us-gaap_RevenueRecognitionMilestoneMethodDescription"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SubsidiariesPaymentDescription" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_SubsidiariesPaymentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_SubsidiariesPaymentDescription" xml:lang="en-US">Subsidiaries Payment Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_SubsidiariesPaymentDescription" xml:lang="en-US">Subsidiaries payment, description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_SubsidiariesPaymentDescription" xml:lang="en-US">Subsidiaries payment description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_SubsidiariesPaymentDescription" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_SubsidiariesPaymentDescription"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SubsidiariesDescription" xlink:label="loc_9G8G5FJFF1I8_aytu_SubsidiariesDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_SubsidiariesDescription" xml:lang="en-US">Subsidiaries Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_SubsidiariesDescription" xml:lang="en-US">Merger subsidiaries, description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_SubsidiariesDescription" xml:lang="en-US">Subsidiaries payment description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_SubsidiariesDescription" xlink:to="lab_1I0I7HLHH3K0_aytu_SubsidiariesDescription"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PercentageOfNetRevenue" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_PercentageOfNetRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PercentageOfNetRevenue" xml:lang="en-US">Percentage Of Net Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PercentageOfNetRevenue" xml:lang="en-US">Percentage of net revenue (Aytu Women's Health)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PercentageOfNetRevenue" xml:lang="en-US">Percentage of net revenue.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_PercentageOfNetRevenue" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_PercentageOfNetRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ManufacturingFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ManufacturingFacilityMember" xml:lang="en-US">Manufacturing Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ManufacturingFacilityMember" xml:lang="en-US">Manufacturing equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ManufacturingFacilityMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ManufacturingFacilityMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_9G8G5FJFF1I8_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_1I0I7HLHH3K0_us-gaap_LeaseholdImprovementsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_OfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office equipment, furniture and other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_OfficeEquipmentMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_OfficeEquipmentMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_LabEquipmentMember" xlink:label="loc_9G8G5FJFF1I8_aytu_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_LabEquipmentMember" xml:lang="en-US">Lab Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_LabEquipmentMember" xml:lang="en-US">Lab equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_LabEquipmentMember" xml:lang="en-US">Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_LabEquipmentMember" xlink:to="lab_1I0I7HLHH3K0_aytu_LabEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_9G8G5FJFF1I8_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated Useful Lives in years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_1I0I7HLHH3K0_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Fixed assets, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PropertyPlantAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_9G8G5FJFF1I8_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less accumulated depreciation and amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_1I0I7HLHH3K0_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_Depreciation" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PatentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PatentsMember" xml:lang="en-US">Patents [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PatentsMember" xml:lang="en-US">Patents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PatentsMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PatentsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Less accumulated amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Less accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ZertanePatentMember" xlink:label="loc_9G8G5FJFF1I8_aytu_ZertanePatentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ZertanePatentMember" xml:lang="en-US">Zertane Patent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_ZertanePatentMember" xml:lang="en-US">Zertane Patents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ZertanePatentMember" xlink:to="lab_1I0I7HLHH3K0_aytu_ZertanePatentMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_LuoxisPatentMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_LuoxisPatentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_LuoxisPatentMember" xml:lang="en-US">Luoxis Patent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_LuoxisPatentMember" xml:lang="en-US">Luoxis Patents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_LuoxisPatentMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_LuoxisPatentMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PatentsTextualAbstract" xlink:label="loc_9G8G5FJFF1I8_aytu_PatentsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_PatentsTextualAbstract" xml:lang="en-US">Patents Textual [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_PatentsTextualAbstract" xlink:to="lab_1I0I7HLHH3K0_aytu_PatentsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FiniteLivedPatentsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedPatentsGross" xml:lang="en-US">Finite-Lived Patents, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedPatentsGross" xml:lang="en-US">Fair value of appraisal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FiniteLivedPatentsGross" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FiniteLivedPatentsGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xml:lang="en-US">Amortized over the lives term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FiniteLivedIntangibleAssetsExpireDate" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_FiniteLivedIntangibleAssetsExpireDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_FiniteLivedIntangibleAssetsExpireDate" xml:lang="en-US">Finite Lived Intangible Assets Expire Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_FiniteLivedIntangibleAssetsExpireDate" xml:lang="en-US">Finite lived intangible assets expire date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_FiniteLivedIntangibleAssetsExpireDate" xml:lang="en-US">It represent finite lived intangible assets expire date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_FiniteLivedIntangibleAssetsExpireDate" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_FiniteLivedIntangibleAssetsExpireDate"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_RevenueRecognitionTextualAbstract" xlink:label="loc_9G8G5FJFF1I8_aytu_RevenueRecognitionTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_RevenueRecognitionTextualAbstract" xml:lang="en-US">Revenue Recognition Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_RevenueRecognitionTextualAbstract" xml:lang="en-US">Revenue Recognition (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_RevenueRecognitionTextualAbstract" xlink:to="lab_1I0I7HLHH3K0_aytu_RevenueRecognitionTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueInputsLevel1Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FairValueInputsLevel2Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueInputsLevel3Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FairValueByMeasurementFrequencyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueMeasurementFrequencyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FairValueMeasurementsRecurringMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Financial Liabilities Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">LIABILITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FinancialInstrumentAxis" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FinancialInstrumentAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_9G8G5FJFF1I8_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_WarrantMember" xlink:to="lab_1I0I7HLHH3K0_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoteWarrantMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_NoteWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NoteWarrantMember" xml:lang="en-US">Note Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NoteWarrantMember" xml:lang="en-US">At Issuance [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_NoteWarrantMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_NoteWarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_WarrantsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_WarrantsAbstract" xml:lang="en-US">Warrants [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_WarrantsAbstract" xml:lang="en-US">Warrants:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_WarrantsAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_WarrantsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueAssumptionsExpectedTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Equivalent term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_9G8G5FJFF1I8_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_1I0I7HLHH3K0_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Balance as of June 30, 2017</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Balance as of September 30, 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:label="loc_9G8G5FJFF1I8_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Warrant issuances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xml:lang="en-US">Warrant issuances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xml:lang="en-US">Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:to="lab_1I0I7HLHH3K0_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Change in fair value included in earnings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ContingentConsiderationByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContingentConsiderationByTypeAxis" xml:lang="en-US">Contingent Consideration by Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContingentConsiderationByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ContingentConsiderationTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ContingentConsiderationTypeDomain" xml:lang="en-US">Contingent Consideration Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ContingentConsiderationTypeDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ContingentConsiderationMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_ContingentConsiderationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ContingentConsiderationMember" xml:lang="en-US">Contingent Consideration [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_ContingentConsiderationMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_ContingentConsiderationMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_9G8G5FJFF1I8_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_1I0I7HLHH3K0_us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ContingentConsiderationAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_ContingentConsiderationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ContingentConsiderationAbstract" xml:lang="en-US">Contingent Consideration [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ContingentConsiderationAbstract" xml:lang="en-US">Contingent Consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_ContingentConsiderationAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_ContingentConsiderationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_9G8G5FJFF1I8_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Balance as of June 30, 2017</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Balance as of September 30, 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_1I0I7HLHH3K0_us-gaap_BusinessCombinationContingentConsiderationLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, Low</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xml:lang="en-US">Decrease due to contractual payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="loc_9G8G5FJFF1I8_us-gaap_UnrecordedUnconditionalPurchaseObligationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:to="lab_1I0I7HLHH3K0_us-gaap_UnrecordedUnconditionalPurchaseObligationTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xml:lang="en-US">Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_PrescriptionDatabaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PrescriptionDatabaseMember" xml:lang="en-US">Prescription Database [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PrescriptionDatabaseMember" xml:lang="en-US">Prescription database [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_PrescriptionDatabaseMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_PrescriptionDatabaseMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ManufacturingAgreementMember" xlink:label="loc_9G8G5FJFF1I8_aytu_ManufacturingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ManufacturingAgreementMember" xml:lang="en-US">Manufacturing Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_ManufacturingAgreementMember" xml:lang="en-US">Manufacturing/commercial supply agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ManufacturingAgreementMember" xlink:to="lab_1I0I7HLHH3K0_aytu_ManufacturingAgreementMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OfficeLeaseMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_OfficeLeaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_OfficeLeaseMember" xml:lang="en-US">Office Lease [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_OfficeLeaseMember" xml:lang="en-US">Office Lease [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_OfficeLeaseMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_OfficeLeaseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_9G8G5FJFF1I8_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="lab_1I0I7HLHH3K0_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ContractualObligationDueInNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContractualObligationDueInNextTwelveMonths" xml:lang="en-US">Contractual Obligation, Due in Next Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContractualObligationDueInNextTwelveMonths" xml:lang="en-US">2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContractualObligationDueInNextTwelveMonths"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ContractualObligationDueInSecondYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ContractualObligationDueInSecondYear" xml:lang="en-US">Contractual Obligation, Due in Second Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ContractualObligationDueInSecondYear" xml:lang="en-US">2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ContractualObligationDueInSecondYear" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ContractualObligationDueInSecondYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ContractualObligationDueInThirdYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContractualObligationDueInThirdYear" xml:lang="en-US">Contractual Obligation, Due in Third Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContractualObligationDueInThirdYear" xml:lang="en-US">2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ContractualObligationDueInThirdYear" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContractualObligationDueInThirdYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ContractualObligationDueInFourthYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ContractualObligationDueInFourthYear" xml:lang="en-US">Contractual Obligation, Due in Fourth Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ContractualObligationDueInFourthYear" xml:lang="en-US">2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ContractualObligationDueInFourthYear" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ContractualObligationDueInFourthYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ContractualObligationDueInFifthYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContractualObligationDueInFifthYear" xml:lang="en-US">Contractual Obligation, Due in Fifth Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContractualObligationDueInFifthYear" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ContractualObligationDueInFifthYear" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContractualObligationDueInFifthYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ContractualObligationDueAfterFifthYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ContractualObligationDueAfterFifthYear" xml:lang="en-US">Contractual Obligation, Due after Fifth Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ContractualObligationDueAfterFifthYear" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ContractualObligationDueAfterFifthYear" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ContractualObligationDueAfterFifthYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ContractualObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContractualObligation" xml:lang="en-US">Contractual Obligation, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContractualObligation" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ContractualObligation" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ContractualObligation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_9G8G5FJFF1I8_us-gaap_OperatingLeasesRentExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Rent expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_1I0I7HLHH3K0_us-gaap_OperatingLeasesRentExpenseNet"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_CommitmentsAndContingenciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments And Contingencies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_CommitmentsAndContingenciesTextualAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_CommitmentsAndContingenciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_9G8G5FJFF1I8_us-gaap_PaymentsForRent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PaymentsForRent" xml:lang="en-US">Payments for Rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PaymentsForRent" xml:lang="en-US">Initial base rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_PaymentsForRent" xlink:to="lab_1I0I7HLHH3K0_us-gaap_PaymentsForRent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xml:lang="en-US">Operating leases, Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_9G8G5FJFF1I8_us-gaap_LeaseAndRentalExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Rent expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_LeaseAndRentalExpense" xlink:to="lab_1I0I7HLHH3K0_us-gaap_LeaseAndRentalExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US">Payment Of Contractual Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US">Installment payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FirstMilestonePayable" xlink:label="loc_9G8G5FJFF1I8_aytu_FirstMilestonePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_FirstMilestonePayable" xml:lang="en-US">First Milestone Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_FirstMilestonePayable" xml:lang="en-US">First milestone payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_FirstMilestonePayable" xml:lang="en-US">It represents the amount of first milestone payment which is require to make.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_FirstMilestonePayable" xlink:to="lab_1I0I7HLHH3K0_aytu_FirstMilestonePayable"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SecondMilestonePayable" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_SecondMilestonePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_SecondMilestonePayable" xml:lang="en-US">Second Milestone Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_SecondMilestonePayable" xml:lang="en-US">Second milestone payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_SecondMilestonePayable" xml:lang="en-US">It represents the amount of second milestone payment which is require to make.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_SecondMilestonePayable" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_SecondMilestonePayable"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ThirdMilestonePayable" xlink:label="loc_9G8G5FJFF1I8_aytu_ThirdMilestonePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ThirdMilestonePayable" xml:lang="en-US">Third Milestone Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_ThirdMilestonePayable" xml:lang="en-US">Third milestone payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_ThirdMilestonePayable" xml:lang="en-US">It represents the amount of third milestone payment which is require to make.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ThirdMilestonePayable" xlink:to="lab_1I0I7HLHH3K0_aytu_ThirdMilestonePayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xml:lang="en-US">Schedule of Subsidiary or Equity Method Investee [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_9G8G5FJFF1I8_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_StatementClassOfStockAxis" xlink:to="lab_1I0I7HLHH3K0_us-gaap_StatementClassOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ClassOfStockDomain" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ClassOfStockDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SeriesAPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SeriesAPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ClassUnitsMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_ClassUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ClassUnitsMember" xml:lang="en-US">Class A Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_ClassUnitsMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_ClassUnitsMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ClassBUnitsMember" xlink:label="loc_9G8G5FJFF1I8_aytu_ClassBUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ClassBUnitsMember" xml:lang="en-US">Class B Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ClassBUnitsMember" xlink:to="lab_1I0I7HLHH3K0_aytu_ClassBUnitsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_AwardTypeAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockCompensationPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockCompensationPlanMember" xml:lang="en-US">Stock Compensation Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockCompensationPlanMember" xml:lang="en-US">Stock Option and Inventive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockCompensationPlanMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockCompensationPlanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ShortTermDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShortTermDebtLineItems" xml:lang="en-US">Short-term Debt [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ShortTermDebtLineItems" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ShortTermDebtLineItems"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CommonStockTextualAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_CommonStockTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_CommonStockTextualAbstract" xml:lang="en-US">Common Stock Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_CommonStockTextualAbstract" xml:lang="en-US">Common Stock (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_CommonStockTextualAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_CommonStockTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SaleOfStockDescriptionOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of stock, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SaleOfStockDescriptionOfTransaction"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PreferredStockConversionPricePerShare" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_PreferredStockConversionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PreferredStockConversionPricePerShare" xml:lang="en-US">Preferred Stock Conversion Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PreferredStockConversionPricePerShare" xml:lang="en-US">Price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PreferredStockConversionPricePerShare" xml:lang="en-US">The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_PreferredStockConversionPricePerShare" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_PreferredStockConversionPricePerShare"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:label="loc_9G8G5FJFF1I8_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xml:lang="en-US">Incremental Common Shares Due To Conversion Of Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xml:lang="en-US">Increase common shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xml:lang="en-US">The number of shares by which the common shares outstanding will increase in case of conversion of preferred stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:to="lab_1I0I7HLHH3K0_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Lincoln park purchased an additional shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock subscription (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued in offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued in offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock purchases offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:label="loc_9G8G5FJFF1I8_aytu_SecuritiesPurchaseAgreementCashFeePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_SecuritiesPurchaseAgreementCashFeePercentage" xml:lang="en-US">Securities Purchase Agreement Cash Fee Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_SecuritiesPurchaseAgreementCashFeePercentage" xml:lang="en-US">Cash fee, percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_SecuritiesPurchaseAgreementCashFeePercentage" xml:lang="en-US">The percentage of cash fee to underwriters incurred in securities purchase agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:to="lab_1I0I7HLHH3K0_aytu_SecuritiesPurchaseAgreementCashFeePercentage"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xml:lang="en-US">Class Of Warrant Or Right, Percentage Of Shares To be Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xml:lang="en-US">Warrants purchase, percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xml:lang="en-US">The warrants to be issued as a percentage of shares issued in the transaction.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsToPurchaseOfCommonStockShares" xlink:label="loc_9G8G5FJFF1I8_aytu_WarrantsToPurchaseOfCommonStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_WarrantsToPurchaseOfCommonStockShares" xml:lang="en-US">Warrants To Purchase Of Common Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_WarrantsToPurchaseOfCommonStockShares" xml:lang="en-US">Warrants to purchase of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_WarrantsToPurchaseOfCommonStockShares" xml:lang="en-US">Warrants to purchase of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_WarrantsToPurchaseOfCommonStockShares" xml:lang="en-US">Number of warrants to purchase of common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_WarrantsToPurchaseOfCommonStockShares" xlink:to="lab_1I0I7HLHH3K0_aytu_WarrantsToPurchaseOfCommonStockShares"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" xml:lang="en-US">Warrants Issued To Underwriters As Compensation For Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" xml:lang="en-US">Warrants issued to underwriters as compensation for transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" xml:lang="en-US">Warrants issued to the underwriters as compensation for the transaction.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:label="loc_9G8G5FJFF1I8_us-gaap_OtherSellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_OtherSellingGeneralAndAdministrativeExpense" xml:lang="en-US">Other Selling, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_OtherSellingGeneralAndAdministrativeExpense" xml:lang="en-US">Sales, general and administrative expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="lab_1I0I7HLHH3K0_us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RestrictedInvestmentsAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RestrictedInvestmentsAtFairValue" xml:lang="en-US">Restricted Investments, at Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RestrictedInvestmentsAtFairValue" xml:lang="en-US">Fair value of restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RestrictedInvestmentsAtFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentOwnedRestrictedAcquisitionDate" xlink:label="loc_9G8G5FJFF1I8_us-gaap_InvestmentOwnedRestrictedAcquisitionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_InvestmentOwnedRestrictedAcquisitionDate" xml:lang="en-US">Investment Owned, Restricted, Acquisition Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_InvestmentOwnedRestrictedAcquisitionDate" xml:lang="en-US">Restricted vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_InvestmentOwnedRestrictedAcquisitionDate" xlink:to="lab_1I0I7HLHH3K0_us-gaap_InvestmentOwnedRestrictedAcquisitionDate"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_DescriptionOfUnrecognizedExpense" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_DescriptionOfUnrecognizedExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_DescriptionOfUnrecognizedExpense" xml:lang="en-US">Description Of Unrecognized Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_DescriptionOfUnrecognizedExpense" xml:lang="en-US">Description of unrecognized expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_DescriptionOfUnrecognizedExpense" xml:lang="en-US">Description of unrecognized expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_DescriptionOfUnrecognizedExpense" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_DescriptionOfUnrecognizedExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_9G8G5FJFF1I8_us-gaap_OffsettingAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_OffsettingAssetsTable" xml:lang="en-US">Offsetting Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_OffsettingAssetsTable" xlink:to="lab_1I0I7HLHH3K0_us-gaap_OffsettingAssetsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DerivativeInstrumentRiskAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_DerivativeContractTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockOptionMember" xml:lang="en-US">Equity Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockOptionMember" xml:lang="en-US">Stock option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockOptionMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of Warrants Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Purchase of additional common stock and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Options, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_9G8G5FJFF1I8_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of Options, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_1I0I7HLHH3K0_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of Options, Forfeited/Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Options Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xml:lang="en-US">Available for grant at September 30, 2017</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xml:lang="en-US">Available for grant at June 30, 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Warrants, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Forfeited/Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_9G8G5FJFF1I8_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Remaining Contractual Term [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Weighted Average Remaining Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life, Outstanding (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Life, Exercisable (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_9G8G5FJFF1I8_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_RestrictedStockMember" xlink:to="lab_1I0I7HLHH3K0_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_9G8G5FJFF1I8_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_1I0I7HLHH3K0_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_ShareBasedCompensationShareWarrantsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsOutstanding" xml:lang="en-US">Share Based Compensation Share Warrants Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsOutstanding" xml:lang="en-US">Number of Warrants Outstanding, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsOutstanding" xml:lang="en-US">Number of Warrants Outstanding, Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsOutstanding" xml:lang="en-US">Share Based Compensation Share Warrants Outstanding.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsOutstanding"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" xlink:label="loc_9G8G5FJFF1I8_aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Private Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" xml:lang="en-US">Warrants issued to investors in connection with the private offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" xml:lang="en-US">Number of warrants issued upon the private offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" xlink:to="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Underwriter</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" xml:lang="en-US">Warrants issued to underwritters for the private offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" xml:lang="en-US">Warrants issued to underwriter for the private offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" xml:lang="en-US">Number of warrants issued upon underwritters.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:label="loc_9G8G5FJFF1I8_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:to="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Investors In Connection With Private Offering Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" xml:lang="en-US">Warrants issued to investors in connection with the private offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of warrants issued upon investor private offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" xlink:label="loc_9G8G5FJFF1I8_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Underwriters For Private Offering Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" xml:lang="en-US">Warrants issued to underwritters for the private offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of warrants issued upon underwriter.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" xlink:to="lab_1I0I7HLHH3K0_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class Of Warrant Or Rights Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted Average Remaining Contractual Life, Warrants Outstanding (in years)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class of warrant or rights weighted average remaining contractual term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_9G8G5FJFF1I8_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_PlanNameAxis" xlink:to="lab_1I0I7HLHH3K0_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_PlanNameDomain" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:label="loc_9G8G5FJFF1I8_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xml:lang="en-US">Two Thousand Fifteen Stock Option And Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xml:lang="en-US">2015 Stock Option and Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:to="lab_1I0I7HLHH3K0_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_MayTwoThousandSixteenPublicOfferingMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_MayTwoThousandSixteenPublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_MayTwoThousandSixteenPublicOfferingMember" xml:lang="en-US">May Two Thousand Sixteen Public Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_MayTwoThousandSixteenPublicOfferingMember" xml:lang="en-US">May 2016 public offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_MayTwoThousandSixteenPublicOfferingMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_MayTwoThousandSixteenPublicOfferingMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_9G8G5FJFF1I8_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_EmployeeStockOptionMember" xlink:to="lab_1I0I7HLHH3K0_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_RelatedPartyDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ClassOfWarrantOrRightAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ClassOfWarrantOrRightDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PlacementAgentWarrantsMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_PlacementAgentWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PlacementAgentWarrantsMember" xml:lang="en-US">Placement Agent warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_PlacementAgentWarrantsMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_PlacementAgentWarrantsMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_InvestorsWarrantsMember" xlink:label="loc_9G8G5FJFF1I8_aytu_InvestorsWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_InvestorsWarrantsMember" xml:lang="en-US">Investors Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_InvestorsWarrantsMember" xlink:to="lab_1I0I7HLHH3K0_aytu_InvestorsWarrantsMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BankersWarrantsMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_BankersWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_BankersWarrantsMember" xml:lang="en-US">Bankers Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_BankersWarrantsMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_BankersWarrantsMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_MayTwoZeroOneSixWarrantsMember" xlink:label="loc_9G8G5FJFF1I8_aytu_MayTwoZeroOneSixWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_MayTwoZeroOneSixWarrantsMember" xml:lang="en-US">May Two Zero One Six Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_MayTwoZeroOneSixWarrantsMember" xml:lang="en-US">May 2016 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_MayTwoZeroOneSixWarrantsMember" xlink:to="lab_1I0I7HLHH3K0_aytu_MayTwoZeroOneSixWarrantsMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OctoberTwoZeroOneSixWarrantsMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_OctoberTwoZeroOneSixWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_OctoberTwoZeroOneSixWarrantsMember" xml:lang="en-US">October Two Zero One Six Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_OctoberTwoZeroOneSixWarrantsMember" xml:lang="en-US">October 2016 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_OctoberTwoZeroOneSixWarrantsMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_OctoberTwoZeroOneSixWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_9G8G5FJFF1I8_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_DebtInstrumentAxis" xlink:to="lab_1I0I7HLHH3K0_us-gaap_DebtInstrumentAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_DebtInstrumentNameDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ConvertiblePromissoryNotesMay2016Member" xlink:label="loc_9G8G5FJFF1I8_aytu_ConvertiblePromissoryNotesMay2016Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ConvertiblePromissoryNotesMay2016Member" xml:lang="en-US">Convertible Promissory Notes May 2016 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ConvertiblePromissoryNotesMay2016Member" xlink:to="lab_1I0I7HLHH3K0_aytu_ConvertiblePromissoryNotesMay2016Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RestructuringCostAndReserveAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RestructuringCostAndReserveAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_TypeOfRestructuringDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_TypeOfRestructuringDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_OtherRestructuringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_OtherRestructuringMember" xml:lang="en-US">Other Restructuring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_OtherRestructuringMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_OtherRestructuringMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OverAllotmentWarrantsAxis" xlink:label="loc_9G8G5FJFF1I8_aytu_OverAllotmentWarrantsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_OverAllotmentWarrantsAxis" xml:lang="en-US">Over Allotment Warrants [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_OverAllotmentWarrantsAxis" xlink:to="lab_1I0I7HLHH3K0_aytu_OverAllotmentWarrantsAxis"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OverAllotmentWarrantsDomain" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_OverAllotmentWarrantsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_OverAllotmentWarrantsDomain" xml:lang="en-US">Over Allotment Warrants [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_OverAllotmentWarrantsDomain" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_OverAllotmentWarrantsDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OverAllotmentWarrantsMember" xlink:label="loc_9G8G5FJFF1I8_aytu_OverAllotmentWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_OverAllotmentWarrantsMember" xml:lang="en-US">Over Allotment Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_OverAllotmentWarrantsMember" xlink:to="lab_1I0I7HLHH3K0_aytu_OverAllotmentWarrantsMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_EquityInstrumentsTextualAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_EquityInstrumentsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_EquityInstrumentsTextualAbstract" xml:lang="en-US">Equity Instruments Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_EquityInstrumentsTextualAbstract" xml:lang="en-US">Equity Instruments (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_EquityInstrumentsTextualAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_EquityInstrumentsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Aggregate shares of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_1I0I7HLHH3K0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_UnrecognizedShareBasedCompensationExpenses" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_UnrecognizedShareBasedCompensationExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_UnrecognizedShareBasedCompensationExpenses" xml:lang="en-US">Unrecognized Share Based Compensation Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_UnrecognizedShareBasedCompensationExpenses" xml:lang="en-US">Unrecognized expense share-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_UnrecognizedShareBasedCompensationExpenses" xml:lang="en-US">Unrecognized expense at June 30, 2017</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_UnrecognizedShareBasedCompensationExpenses" xml:lang="en-US">Unrecognized share based compensation expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_UnrecognizedShareBasedCompensationExpenses" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_UnrecognizedShareBasedCompensationExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted average remaining years to vest (in years)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted average remaining years to vest (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Warrants exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsExercisePriceTerm" xlink:label="loc_9G8G5FJFF1I8_aytu_WarrantsExercisePriceTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_WarrantsExercisePriceTerm" xml:lang="en-US">Warrants Exercise Price Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_WarrantsExercisePriceTerm" xml:lang="en-US">Warrants exercise price term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_1I0I7HLHH3K0_aytu_WarrantsExercisePriceTerm" xml:lang="en-US">Warrants exercise price term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_WarrantsExercisePriceTerm" xlink:to="lab_1I0I7HLHH3K0_aytu_WarrantsExercisePriceTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AgreementAxis" xlink:label="loc_9G8G5FJFF1I8_aytu_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_AgreementAxis" xlink:to="lab_1I0I7HLHH3K0_aytu_AgreementAxis"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AgreementDomain" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_AgreementDomain" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_AgreementDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ServicesAgreementMember" xlink:label="loc_9G8G5FJFF1I8_aytu_ServicesAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_ServicesAgreementMember" xml:lang="en-US">Services Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_ServicesAgreementMember" xlink:to="lab_1I0I7HLHH3K0_aytu_ServicesAgreementMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SponsoredResearchAgreementMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_SponsoredResearchAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_SponsoredResearchAgreementMember" xml:lang="en-US">Sponsored Research Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_SponsoredResearchAgreementMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_SponsoredResearchAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_9G8G5FJFF1I8_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_1I0I7HLHH3K0_us-gaap_RelatedPartyTransactionLineItems"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_RelatedPartyTransactionsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_RelatedPartyTransactionsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_9G8G5FJFF1I8_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Monthly payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_1I0I7HLHH3K0_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xml:lang="en-US">Related Party Transaction, Terms and Manner of Settlement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xml:lang="en-US">Agreement term, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_9G8G5FJFF1I8_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Due to Other Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Amount agreed to pay</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_1I0I7HLHH3K0_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrepaidExpensesAmortizationPeriod" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_PrepaidExpensesAmortizationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PrepaidExpensesAmortizationPeriod" xml:lang="en-US">Prepaid Expenses Amortization Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PrepaidExpensesAmortizationPeriod" xml:lang="en-US">Contractual term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_PrepaidExpensesAmortizationPeriod" xml:lang="en-US">Prepaid expenses amortization period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_PrepaidExpensesAmortizationPeriod" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_PrepaidExpensesAmortizationPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_9G8G5FJFF1I8_us-gaap_StatementBusinessSegmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_1I0I7HLHH3K0_us-gaap_StatementBusinessSegmentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SegmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SegmentDomain" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SegmentDomain"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AytuBioscienceIncMember" xlink:label="loc_9G8G5FJFF1I8_aytu_AytuBioscienceIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_aytu_AytuBioscienceIncMember" xml:lang="en-US">Aytu Bioscience Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_aytu_AytuBioscienceIncMember" xml:lang="en-US">Aytu [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_aytu_AytuBioscienceIncMember" xlink:to="lab_1I0I7HLHH3K0_aytu_AytuBioscienceIncMember"/>
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AytuWomensHealthMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_aytu_AytuWomensHealthMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AytuWomensHealthMember" xml:lang="en-US">Aytu Womens Health [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_aytu_AytuWomensHealthMember" xml:lang="en-US">Aytu Women's Health [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_aytu_AytuWomensHealthMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_aytu_AytuWomensHealthMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_9G8G5FJFF1I8_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RevenuesAbstract" xml:lang="en-US">Consolidated Revenue:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_RevenuesAbstract" xlink:to="lab_1I0I7HLHH3K0_us-gaap_RevenuesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xml:lang="en-US">Consolidated net loss:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SubsequentEventTable" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Events [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_SubsequentEventMember" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SubsequentEventLineItems" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ConversionOfStockSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Converted shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_ConversionOfStockSharesIssued1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_9G8G5FJFF1I8_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_1I0I7HLHH3K0_us-gaap_SharesIssued" xml:lang="en-US">Shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_9G8G5FJFF1I8_us-gaap_SharesIssued" xlink:to="lab_1I0I7HLHH3K0_us-gaap_SharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Restricted shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FGKKG0GJKHFG9KI347I3_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_HIMMI2ILMJHI1MK569K5_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>aytu-20170930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#DocumentAndEntityInformation" roleURI="http://www.aytubio.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.aytubio.com/role/ConsolidatedBalanceSheetsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#ConsolidatedBalanceSheetsParentheticalUnaudited" roleURI="http://www.aytubio.com/role/ConsolidatedBalanceSheetsParentheticalUnaudited"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#ConsolidatedStatementOfStockholdersEquityUnaudited" roleURI="http://www.aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited" roleURI="http://www.aytubio.com/role/ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FixedAssets" roleURI="http://www.aytubio.com/role/FixedAssets"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#Patents" roleURI="http://www.aytubio.com/role/Patents"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#RevenueRecognition" roleURI="http://www.aytubio.com/role/RevenueRecognition"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FairValueConsiderations" roleURI="http://www.aytubio.com/role/FairValueConsiderations"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#CommitmentsAndContingencies" roleURI="http://www.aytubio.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#CommonStock" roleURI="http://www.aytubio.com/role/CommonStock"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#EquityInstruments" roleURI="http://www.aytubio.com/role/EquityInstruments"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#RelatedPartyTransactions" roleURI="http://www.aytubio.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#SegmentInformation" roleURI="http://www.aytubio.com/role/SegmentInformation"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#SubsequentEvents" roleURI="http://www.aytubio.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerPolicies" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerPolicies"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FixedAssetsTables" roleURI="http://www.aytubio.com/role/FixedAssetsTables"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#PatentsTables" roleURI="http://www.aytubio.com/role/PatentsTables"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FairValueConsiderationsTables" roleURI="http://www.aytubio.com/role/FairValueConsiderationsTables"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesTables"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#EquityInstrumentsTables" roleURI="http://www.aytubio.com/role/EquityInstrumentsTables"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#SegmentInformationTables" roleURI="http://www.aytubio.com/role/SegmentInformationTables"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#Businessbasisofpresentationbusinesscombinationsdivestitureslicensesupplyagreementandmergerdetailstextual" roleURI="http://www.aytubio.com/role/Businessbasisofpresentationbusinesscombinationsdivestitureslicensesupplyagreementandmergerdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FixedAssetsDetails" roleURI="http://www.aytubio.com/role/FixedAssetsDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FixedAssetsDetails1" roleURI="http://www.aytubio.com/role/FixedAssetsDetails1"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#PatentsDetails" roleURI="http://www.aytubio.com/role/PatentsDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#PatentsDetails1" roleURI="http://www.aytubio.com/role/PatentsDetails1"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#PatentsDetailsTextual" roleURI="http://www.aytubio.com/role/PatentsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#RevenueRecognitionDetails" roleURI="http://www.aytubio.com/role/RevenueRecognitionDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FairValueConsiderationsDetails" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FairValueConsiderationsDetails1" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails1"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FairValueConsiderationsDetails2" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails2"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#FairValueConsiderationsDetails3" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails3"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#CommitmentsAndContingenciesDetails1" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#CommonStockDetails" roleURI="http://www.aytubio.com/role/CommonStockDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#EquityInstrumentsDetails" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#EquityInstrumentsDetails1" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails1"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#EquityInstrumentsDetails2" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails2"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#EquityInstrumentsDetailsTextual" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.aytubio.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#SegmentInformationDetails" roleURI="http://www.aytubio.com/role/SegmentInformationDetails"/>
<roleRef xlink:type="simple" xlink:href="aytu-20170930.xsd#SubsequentEventsDetails1" roleURI="http://www.aytubio.com/role/SubsequentEventsDetails1"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_DocumentAndEntityInformationAbstract" xlink:label="loc_aytu_DocumentAndEntityInformationAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_3" order="20" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_4" order="30" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="40" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_6" order="50" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_7" order="60" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_8" order="70" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" order="80" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_10" order="90" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_11" order="100" use="optional" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_InventoryNet_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CoreAndDevelopedTechnologyNet" xlink:label="loc_aytu_CoreAndDevelopedTechnologyNet_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_aytu_CoreAndDevelopedTechnologyNet_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="loc_us-gaap_IndefiniteLivedContractualRights_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_IndefiniteLivedContractualRights_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_IndefiniteLivedTradeNames_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Goodwill_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrent_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20" xlink:to="loc_us-gaap_AccountsPayableCurrent_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AccruedCompensationCurrent" xlink:label="loc_aytu_AccruedCompensationCurrent_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20" xlink:to="loc_aytu_AccruedCompensationCurrent_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_20" xlink:to="loc_us-gaap_LiabilitiesCurrent_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_Liabilities_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_CommitmentsAndContingencies_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_StockholdersEquityAbstract_32" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_PreferredStockValue_33" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_CommonStockValue_34" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_AdditionalPaidInCapital_35" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_36" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32" xlink:to="loc_us-gaap_StockholdersEquity_37" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_19" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_38" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheetsParentheticalUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_SalesRevenueNet_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_Revenues_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_CostOfRevenue_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ResearchAndDevelopmentRelatedParty" xlink:label="loc_aytu_ResearchAndDevelopmentRelatedParty_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_aytu_ResearchAndDevelopmentRelatedParty_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AmortizationAndImpairmentOfIntangibleAssets" xlink:label="loc_aytu_AmortizationAndImpairmentOfIntangibleAssets_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_aytu_AmortizationAndImpairmentOfIntangibleAssets_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_OperatingExpenses_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_OperatingIncomeLoss_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_us-gaap_InterestExpense_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_us-gaap_GainLossOnInvestments_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_PreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockholdersEquity_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SharesOutstanding_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_IssuanceOfPreferredAndCommonStockNetCost" xlink:label="loc_aytu_IssuanceOfPreferredAndCommonStockNetCost_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_aytu_IssuanceOfPreferredAndCommonStockNetCost_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_IssuanceOfPreferredAndCommonStockNetShare" xlink:label="loc_aytu_IssuanceOfPreferredAndCommonStockNetShare_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_aytu_IssuanceOfPreferredAndCommonStockNetShare_17" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:label="loc_aytu_AdjustmentForRoundingOfValueDueToConversion_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_aytu_AdjustmentForRoundingOfValueDueToConversion_18" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:label="loc_aytu_AdjustmentForRoundingOfSharesDueToConversion_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_aytu_AdjustmentForRoundingOfSharesDueToConversion_19" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_NetIncomeLoss_20" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockholdersEquity_21" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SharesOutstanding_22" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/measurementGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ShareBasedCompensation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_RestrictedStockExpense_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="loc_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_aytu_IncreaseDecreaseInAccruedCompensation_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_aytu_IncreaseDecreaseInAccruedCompensation_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidRent_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidRent_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_21" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_21" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_25" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:label="loc_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_25" xlink:to="loc_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_25" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_25" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_31" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_33" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_34" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsIssuedToInvestorsAndUnderwriters" xlink:label="loc_aytu_WarrantsIssuedToInvestorsAndUnderwriters_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_34" xlink:to="loc_aytu_WarrantsIssuedToInvestorsAndUnderwriters_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_EarnOutPaymentToOtherShareholders" xlink:label="loc_aytu_EarnOutPaymentToOtherShareholders_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_34" xlink:to="loc_aytu_EarnOutPaymentToOtherShareholders_36" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xlink:label="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_34" xlink:to="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable_37" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FixedAssetsIncludedInAccountsPayable" xlink:label="loc_aytu_FixedAssetsIncludedInAccountsPayable_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_34" xlink:to="loc_aytu_FixedAssetsIncludedInAccountsPayable_38" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FixedAssets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/Patents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/RevenueRecognition">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_RevenueRecognitionDisclosureTextBlock" xlink:label="loc_aytu_RevenueRecognitionDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_0" xlink:to="loc_aytu_RevenueRecognitionDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommonStock">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CommonStockTextBlock" xlink:label="loc_aytu_CommonStockTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_aytu_CommonStockTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstruments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SegmentInformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessDescriptionAndBasisOfPresentationTable" xlink:label="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_ProstascintBusinessMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_PrimsolBusinessMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_NatestoMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NuelleMember" xlink:label="loc_aytu_NuelleMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_NuelleMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:label="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1" xlink:to="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_8" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FixedAssetsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/PatentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:label="loc_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SegmentInformationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_ProstascintBusinessMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_PrimsolBusinessMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NuelleMember" xlink:label="loc_aytu_NuelleMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_NuelleMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="loc_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7" xlink:to="loc_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7" xlink:to="loc_us-gaap_Goodwill_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/Businessbasisofpresentationbusinesscombinationsdivestitureslicensesupplyagreementandmergerdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_ProstascintBusinessMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_JazzPharmaceuticalsIncMember" xlink:label="loc_aytu_JazzPharmaceuticalsIncMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_JazzPharmaceuticalsIncMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_PrimsolBusinessMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_NatestoMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NuelleIncMember" xlink:label="loc_aytu_NuelleIncMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3" xlink:to="loc_aytu_NuelleIncMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_9" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PaidOnApril12016Member" xlink:label="loc_aytu_PaidOnApril12016Member_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_10" xlink:to="loc_aytu_PaidOnApril12016Member_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NoLaterThanJuly012016Member" xlink:label="loc_aytu_NoLaterThanJuly012016Member_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_10" xlink:to="loc_aytu_NoLaterThanJuly012016Member_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NoLaterThanSeptember302016Member" xlink:label="loc_aytu_NoLaterThanSeptember302016Member_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_10" xlink:to="loc_aytu_NoLaterThanSeptember302016Member_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_ProductOrServiceAxis_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_14" xlink:to="loc_us-gaap_ProductsAndServicesDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ProstaScintMember" xlink:label="loc_aytu_ProstaScintMember_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_15" xlink:to="loc_aytu_ProstaScintMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18" xlink:to="loc_us-gaap_TradeNamesMember_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="loc_us-gaap_CustomerContractsMember_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_18" xlink:to="loc_us-gaap_CustomerContractsMember_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_RangeAxis_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_22" xlink:to="loc_us-gaap_RangeMember_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_23" xlink:to="loc_us-gaap_MaximumMember_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_23" xlink:to="loc_us-gaap_MinimumMember_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_26" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SecondUpfrontMember" xlink:label="loc_aytu_SecondUpfrontMember_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_27" xlink:to="loc_aytu_SecondUpfrontMember_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ThirdUpfrontMember" xlink:label="loc_aytu_ThirdUpfrontMember_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_27" xlink:to="loc_aytu_ThirdUpfrontMember_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_30" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FirstMilestoneMember" xlink:label="loc_aytu_FirstMilestoneMember_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" xlink:to="loc_aytu_FirstMilestoneMember_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SecondMilestoneMember" xlink:label="loc_aytu_SecondMilestoneMember_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" xlink:to="loc_aytu_SecondMilestoneMember_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ThirdMilestoneMember" xlink:label="loc_aytu_ThirdMilestoneMember_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" xlink:to="loc_aytu_ThirdMilestoneMember_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ForthMilestoneMember" xlink:label="loc_aytu_ForthMilestoneMember_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" xlink:to="loc_aytu_ForthMilestoneMember_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FifthMilestoneMember" xlink:label="loc_aytu_FifthMilestoneMember_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" xlink:to="loc_aytu_FifthMilestoneMember_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SixthMilestoneMember" xlink:label="loc_aytu_SixthMilestoneMember_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31" xlink:to="loc_aytu_SixthMilestoneMember_37" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_38" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_38" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_39" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_LicenseAndSupplyAgreementMember" xlink:label="loc_aytu_LicenseAndSupplyAgreementMember_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_39" xlink:to="loc_aytu_LicenseAndSupplyAgreementMember_40" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_41" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_43" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_44" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessAcquisitionTextualAbstract" xlink:label="loc_aytu_BusinessAcquisitionTextualAbstract_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_44" xlink:to="loc_aytu_BusinessAcquisitionTextualAbstract_45" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_46" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_47" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_48" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_49" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_50" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_51" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationContingentConsiderationPercentage" xlink:label="loc_aytu_BusinessCombinationContingentConsiderationPercentage_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_aytu_BusinessCombinationContingentConsiderationPercentage_52" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_53" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_54" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_55" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationConsiderationTransferredInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredInventory_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_aytu_BusinessCombinationConsiderationTransferredInventory_56" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationConsiderationTransferredProductInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredProductInventory_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_aytu_BusinessCombinationConsiderationTransferredProductInventory_57" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory_58" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_59" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_60" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_61" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OneTimeNonRefundablePayments" xlink:label="loc_aytu_OneTimeNonRefundablePayments_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_aytu_OneTimeNonRefundablePayments_62" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SalesRevenueTarget" xlink:label="loc_aytu_SalesRevenueTarget_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_aytu_SalesRevenueTarget_63" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:label="loc_us-gaap_PaymentsForPurchaseOfOtherAssets1_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_PaymentsForPurchaseOfOtherAssets1_64" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_65" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CostOfSaleForInvestment" xlink:label="loc_aytu_CostOfSaleForInvestment_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_aytu_CostOfSaleForInvestment_66" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_67" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_68" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_AccretionExpense_69" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales" xlink:label="loc_aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales_70" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales_70" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_71" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_LiabilitiesAssumed1_73" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_74" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodDescription" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodDescription_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodDescription_75" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SubsidiariesPaymentDescription" xlink:label="loc_aytu_SubsidiariesPaymentDescription_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_aytu_SubsidiariesPaymentDescription_76" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SubsidiariesDescription" xlink:label="loc_aytu_SubsidiariesDescription_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_aytu_SubsidiariesDescription_77" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PercentageOfNetRevenue" xlink:label="loc_aytu_PercentageOfNetRevenue_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessAcquisitionTextualAbstract_45" xlink:to="loc_aytu_PercentageOfNetRevenue_78" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FixedAssetsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaap_ManufacturingFacilityMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ManufacturingFacilityMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_LabEquipmentMember" xlink:label="loc_aytu_LabEquipmentMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_aytu_LabEquipmentMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FixedAssetsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_Depreciation_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/PatentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_PatentsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/PatentsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_PatentsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/PatentsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ZertanePatentMember" xlink:label="loc_aytu_ZertanePatentMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_aytu_ZertanePatentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_LuoxisPatentMember" xlink:label="loc_aytu_LuoxisPatentMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_aytu_LuoxisPatentMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PatentsTextualAbstract" xlink:label="loc_aytu_PatentsTextualAbstract_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6" xlink:to="loc_aytu_PatentsTextualAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaap_FiniteLivedPatentsGross_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_PatentsTextualAbstract_7" xlink:to="loc_us-gaap_FiniteLivedPatentsGross_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_PatentsTextualAbstract_7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FiniteLivedIntangibleAssetsExpireDate" xlink:label="loc_aytu_FiniteLivedIntangibleAssetsExpireDate_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_PatentsTextualAbstract_7" xlink:to="loc_aytu_FiniteLivedIntangibleAssetsExpireDate_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/RevenueRecognitionDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_RevenueRecognitionTextualAbstract" xlink:label="loc_aytu_RevenueRecognitionTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_0" xlink:to="loc_aytu_RevenueRecognitionTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RevenueRecognitionTextualAbstract_1" xlink:to="loc_us-gaap_SalesRevenueNet_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_11" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_11" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoteWarrantMember" xlink:label="loc_us-gaap_NoteWarrantMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_NoteWarrantMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsAbstract" xlink:label="loc_aytu_WarrantsAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8" xlink:to="loc_aytu_WarrantsAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_WarrantsAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_WarrantsAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_WarrantsAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_WarrantsAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:label="loc_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" xlink:to="loc_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_2" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ContingentConsiderationMember" xlink:label="loc_aytu_ContingentConsiderationMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_3" xlink:to="loc_aytu_ContingentConsiderationMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ContingentConsiderationAbstract" xlink:label="loc_aytu_ContingentConsiderationAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5" xlink:to="loc_aytu_ContingentConsiderationAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_ContingentConsiderationAbstract_6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_ContingentConsiderationAbstract_6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_ContingentConsiderationAbstract_6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_ContingentConsiderationAbstract_6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytu_PrescriptionDatabaseMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_PrescriptionDatabaseMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_NatestoMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ManufacturingAgreementMember" xlink:label="loc_aytu_ManufacturingAgreementMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_ManufacturingAgreementMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytu_OfficeLeaseMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_OfficeLeaseMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_8" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_8" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_8" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_8" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_8" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_8" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_8" xlink:to="loc_us-gaap_ContractualObligation_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_2" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_NatestoMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytu_PrescriptionDatabaseMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_PrescriptionDatabaseMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytu_OfficeLeaseMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_3" xlink:to="loc_aytu_OfficeLeaseMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_1" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_aytu_CommitmentsAndContingenciesTextualAbstract_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_7" xlink:to="loc_aytu_CommitmentsAndContingenciesTextualAbstract_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaap_PaymentsForRent_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_8" xlink:to="loc_us-gaap_PaymentsForRent_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_8" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_8" xlink:to="loc_us-gaap_LeaseAndRentalExpense_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_8" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_FirstMilestonePayable" xlink:label="loc_aytu_FirstMilestonePayable_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_8" xlink:to="loc_aytu_FirstMilestonePayable_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SecondMilestonePayable" xlink:label="loc_aytu_SecondMilestonePayable_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_8" xlink:to="loc_aytu_SecondMilestonePayable_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ThirdMilestonePayable" xlink:label="loc_aytu_ThirdMilestonePayable_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommitmentsAndContingenciesTextualAbstract_8" xlink:to="loc_aytu_ThirdMilestonePayable_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommonStockDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ClassUnitsMember" xlink:label="loc_aytu_ClassUnitsMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_aytu_ClassUnitsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ClassBUnitsMember" xlink:label="loc_aytu_ClassBUnitsMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_aytu_ClassBUnitsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7" xlink:to="loc_us-gaap_EquityComponentDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8" xlink:to="loc_us-gaap_CommonStockMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_StockCompensationPlanMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_CommonStockTextualAbstract" xlink:label="loc_aytu_CommonStockTextualAbstract_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_13" xlink:to="loc_aytu_CommonStockTextualAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_PreferredStockSharesIssued_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_23" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PreferredStockConversionPricePerShare" xlink:label="loc_aytu_PreferredStockConversionPricePerShare_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_aytu_PreferredStockConversionPricePerShare_24" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:label="loc_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock_25" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_26" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:label="loc_aytu_SecuritiesPurchaseAgreementCashFeePercentage_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_aytu_SecuritiesPurchaseAgreementCashFeePercentage_27" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:label="loc_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued_28" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsToPurchaseOfCommonStockShares" xlink:label="loc_aytu_WarrantsToPurchaseOfCommonStockShares_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_aytu_WarrantsToPurchaseOfCommonStockShares_29" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" xlink:label="loc_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction_30" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_31" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_32" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_OtherSellingGeneralAndAdministrativeExpense_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_OtherSellingGeneralAndAdministrativeExpense_33" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_RestrictedInvestmentsAtFairValue_34" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentOwnedRestrictedAcquisitionDate" xlink:label="loc_us-gaap_InvestmentOwnedRestrictedAcquisitionDate_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_us-gaap_InvestmentOwnedRestrictedAcquisitionDate_35" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_DescriptionOfUnrecognizedExpense" xlink:label="loc_aytu_DescriptionOfUnrecognizedExpense_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockTextualAbstract_14" xlink:to="loc_aytu_DescriptionOfUnrecognizedExpense_36" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaap_OffsettingAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_OffsettingAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3" xlink:to="loc_us-gaap_StockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OffsettingAssetsTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6" xlink:to="loc_us-gaap_StockOptionMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsOutstanding_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsOutstanding_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsOutstanding_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsOutstanding_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xlink:label="loc_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_11" xlink:to="loc_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:label="loc_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_MayTwoThousandSixteenPublicOfferingMember" xlink:label="loc_aytu_MayTwoThousandSixteenPublicOfferingMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_aytu_MayTwoThousandSixteenPublicOfferingMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9" xlink:to="loc_us-gaap_EquityComponentDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_us-gaap_WarrantMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_12" xlink:to="loc_us-gaap_RelatedPartyDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_14" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PlacementAgentWarrantsMember" xlink:label="loc_aytu_PlacementAgentWarrantsMember_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_15" xlink:to="loc_aytu_PlacementAgentWarrantsMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_InvestorsWarrantsMember" xlink:label="loc_aytu_InvestorsWarrantsMember_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_15" xlink:to="loc_aytu_InvestorsWarrantsMember_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_BankersWarrantsMember" xlink:label="loc_aytu_BankersWarrantsMember_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_15" xlink:to="loc_aytu_BankersWarrantsMember_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_MayTwoZeroOneSixWarrantsMember" xlink:label="loc_aytu_MayTwoZeroOneSixWarrantsMember_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_15" xlink:to="loc_aytu_MayTwoZeroOneSixWarrantsMember_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OctoberTwoZeroOneSixWarrantsMember" xlink:label="loc_aytu_OctoberTwoZeroOneSixWarrantsMember_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_15" xlink:to="loc_aytu_OctoberTwoZeroOneSixWarrantsMember_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ConvertiblePromissoryNotesMay2016Member" xlink:label="loc_aytu_ConvertiblePromissoryNotesMay2016Member_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22" xlink:to="loc_aytu_ConvertiblePromissoryNotesMay2016Member_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_24" xlink:to="loc_us-gaap_RangeMember_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_25" xlink:to="loc_us-gaap_MaximumMember_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_25" xlink:to="loc_us-gaap_MinimumMember_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_28" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_28" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_29" xlink:to="loc_us-gaap_OtherRestructuringMember_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_31" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_31" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_32" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_33" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OverAllotmentWarrantsAxis" xlink:label="loc_aytu_OverAllotmentWarrantsAxis_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_aytu_OverAllotmentWarrantsAxis_34" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OverAllotmentWarrantsDomain" xlink:label="loc_aytu_OverAllotmentWarrantsDomain_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_OverAllotmentWarrantsAxis_34" xlink:to="loc_aytu_OverAllotmentWarrantsDomain_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_OverAllotmentWarrantsMember" xlink:label="loc_aytu_OverAllotmentWarrantsMember_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_OverAllotmentWarrantsDomain_35" xlink:to="loc_aytu_OverAllotmentWarrantsMember_36" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_EquityInstrumentsTextualAbstract" xlink:label="loc_aytu_EquityInstrumentsTextualAbstract_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37" xlink:to="loc_aytu_EquityInstrumentsTextualAbstract_38" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_EquityInstrumentsTextualAbstract_38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_39" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_UnrecognizedShareBasedCompensationExpenses" xlink:label="loc_aytu_UnrecognizedShareBasedCompensationExpenses_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_EquityInstrumentsTextualAbstract_38" xlink:to="loc_aytu_UnrecognizedShareBasedCompensationExpenses_40" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_EquityInstrumentsTextualAbstract_38" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_41" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsToPurchaseOfCommonStockShares" xlink:label="loc_aytu_WarrantsToPurchaseOfCommonStockShares_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_EquityInstrumentsTextualAbstract_38" xlink:to="loc_aytu_WarrantsToPurchaseOfCommonStockShares_42" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_EquityInstrumentsTextualAbstract_38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_WarrantsExercisePriceTerm" xlink:label="loc_aytu_WarrantsExercisePriceTerm_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_EquityInstrumentsTextualAbstract_38" xlink:to="loc_aytu_WarrantsExercisePriceTerm_44" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AgreementAxis" xlink:label="loc_aytu_AgreementAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_aytu_AgreementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AgreementDomain" xlink:label="loc_aytu_AgreementDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_AgreementAxis_2" xlink:to="loc_aytu_AgreementDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_ServicesAgreementMember" xlink:label="loc_aytu_ServicesAgreementMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_AgreementDomain_3" xlink:to="loc_aytu_ServicesAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_SponsoredResearchAgreementMember" xlink:label="loc_aytu_SponsoredResearchAgreementMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_AgreementDomain_3" xlink:to="loc_aytu_SponsoredResearchAgreementMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_aytu_RelatedPartyTransactionsTextualAbstract_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6" xlink:to="loc_aytu_RelatedPartyTransactionsTextualAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RelatedPartyTransactionsTextualAbstract_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RelatedPartyTransactionsTextualAbstract_7" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RelatedPartyTransactionsTextualAbstract_7" xlink:to="loc_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RelatedPartyTransactionsTextualAbstract_7" xlink:to="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_PrepaidExpensesAmortizationPeriod" xlink:label="loc_aytu_PrepaidExpensesAmortizationPeriod_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RelatedPartyTransactionsTextualAbstract_7" xlink:to="loc_aytu_PrepaidExpensesAmortizationPeriod_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SegmentInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4" xlink:to="loc_us-gaap_SegmentDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AytuBioscienceIncMember" xlink:label="loc_aytu_AytuBioscienceIncMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5" xlink:to="loc_aytu_AytuBioscienceIncMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_AytuWomensHealthMember" xlink:label="loc_aytu_AytuWomensHealthMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5" xlink:to="loc_aytu_AytuWomensHealthMember_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_RevenuesAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9" xlink:to="loc_us-gaap_Revenues_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:label="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_11" xlink:to="loc_us-gaap_NetIncomeLoss_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_AssetsAbstract_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_Assets_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SubsequentEventsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="aytu-20170930.xsd#aytu_NuelleMember" xlink:label="loc_aytu_NuelleMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6" xlink:to="loc_aytu_NuelleMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_LeaseAndRentalExpense_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_SharesIssued_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825283792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Nov. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AYTU BIOSCIENCE, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001385818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AYTU<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,402,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825943248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,021,527<span></span>
</td>
<td class="nump">$ 802,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">75,371<span></span>
</td>
<td class="nump">75,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,211,845<span></span>
</td>
<td class="nump">528,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,171,260<span></span>
</td>
<td class="nump">1,312,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">262,057<span></span>
</td>
<td class="nump">310,760<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,742,060<span></span>
</td>
<td class="nump">3,028,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">566,913<span></span>
</td>
<td class="nump">647,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CoreAndDevelopedTechnologyNet', window );">Developed technology, net</a></td>
<td class="nump">1,294,306<span></span>
</td>
<td class="nump">1,337,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedContractualRights', window );">Customer contracts, net</a></td>
<td class="nump">76,667<span></span>
</td>
<td class="nump">77,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTradeNames', window );">Trade names, net</a></td>
<td class="nump">158,238<span></span>
</td>
<td class="nump">164,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Natesto asset, net</a></td>
<td class="nump">8,901,391<span></span>
</td>
<td class="nump">9,231,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">238,426<span></span>
</td>
<td class="nump">238,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">264,944<span></span>
</td>
<td class="nump">271,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">2,888<span></span>
</td>
<td class="nump">2,888<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
<td class="nump">11,503,773<span></span>
</td>
<td class="nump">11,969,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">21,245,833<span></span>
</td>
<td class="nump">14,998,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and other</a></td>
<td class="nump">1,660,764<span></span>
</td>
<td class="nump">2,220,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">903,386<span></span>
</td>
<td class="nump">782,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">680,545<span></span>
</td>
<td class="nump">339,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">6,455<span></span>
</td>
<td class="nump">6,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current contingent consideration</a></td>
<td class="nump">257,036<span></span>
</td>
<td class="nump">261,155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,508,186<span></span>
</td>
<td class="nump">3,610,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Long-term contingent consideration</a></td>
<td class="nump">7,566,443<span></span>
</td>
<td class="nump">7,386,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">3,818,263<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,892,892<span></span>
</td>
<td class="nump">10,998,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, par value $.0001; 50,000,000 shares authorized; shares issued and outstanding 2,250 (unaudited) and 0, respectively as of September 30, 2017 and June 30, 2017</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 4,224,840 (unaudited) and 824,831, respectively as of September 30, 2017 and June 30, 2017</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">79,667,289<span></span>
</td>
<td class="nump">73,069,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(73,314,771)<span></span>
</td>
<td class="num">(69,069,729)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">6,352,941<span></span>
</td>
<td class="nump">3,999,816<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 21,245,833<span></span>
</td>
<td class="nump">$ 14,998,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable pertaining to costs that are statutory in nature of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CoreAndDevelopedTechnologyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CoreAndDevelopedTechnologyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedContractualRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date of rights with an indefinite period of benefit that arose from a contractual arrangement with a third party (not including franchise rights and license agreements).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedContractualRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTradeNames">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trade name to gain or protect exclusive use thereof for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTradeNames</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825585712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, authorized shares</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="nump">4,224,840<span></span>
</td>
<td class="nump">824,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, outstanding shares</a></td>
<td class="nump">4,224,840<span></span>
</td>
<td class="nump">824,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826844368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Product revenue</a></td>
<td class="nump">$ 1,076,368<span></span>
</td>
<td class="nump">$ 697,980<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,076,368<span></span>
</td>
<td class="nump">697,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">287,201<span></span>
</td>
<td class="nump">191,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">140,954<span></span>
</td>
<td class="nump">232,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ResearchAndDevelopmentRelatedParty', window );">Research and development - related party (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">47,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative</a></td>
<td class="nump">4,618,403<span></span>
</td>
<td class="nump">5,704,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Sales, general and administrative - related party (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AmortizationAndImpairmentOfIntangibleAssets', window );">Amortization and impairment of intangible assets</a></td>
<td class="nump">385,841<span></span>
</td>
<td class="nump">437,014<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,432,399<span></span>
</td>
<td class="nump">6,664,480<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,356,031)<span></span>
</td>
<td class="num">(5,966,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest (expense)</a></td>
<td class="num">(188,745)<span></span>
</td>
<td class="num">(415,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative income (expense)</a></td>
<td class="nump">299,734<span></span>
</td>
<td class="num">(70,609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Unrealized gain on investment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">728,100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="nump">110,989<span></span>
</td>
<td class="nump">242,110<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,245,042)<span></span>
</td>
<td class="num">$ (5,724,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of Aytu common shares outstanding</a></td>
<td class="nump">2,415,402<span></span>
</td>
<td class="nump">244,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted Aytu net loss per common share</a></td>
<td class="num">$ (1.76)<span></span>
</td>
<td class="num">$ (23.37)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AmortizationAndImpairmentOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization and impairment of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AmortizationAndImpairmentOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ResearchAndDevelopmentRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ResearchAndDevelopmentRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting and losses recognized for other than temporary impairments (OTTI) of the subject investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (c)-(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27405-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825907904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Equity (Unaudited) - 3 months ended Sep. 30, 2017 - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2017</a></td>
<td class="nump">$ 3,999,816<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 73,069,463<span></span>
</td>
<td class="num">$ (69,069,729)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">824,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation (unaudited)</a></td>
<td class="nump">195,105<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">195,105<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock (unaudited)</a></td>
<td class="nump">72,306<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">72,286<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock (unaudited), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Earn-out payment to Nuelle shareholders (unaudited)</a></td>
<td class="nump">11,589<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,589<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Earn-out payment to Nuelle shareholders (unaudited), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IssuanceOfPreferredAndCommonStockNetCost', window );">Issuance of preferred and common stock, net of $1,402,831 in cash issuance costs (unaudited)</a></td>
<td class="nump">6,319,167<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">6,318,846<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IssuanceOfPreferredAndCommonStockNetShare', window );">Issuance of preferred and common stock, net of $1,402,831 in cash issuance costs (unaudited), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">3,196,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentForRoundingOfValueDueToConversion', window );">Adjustment for rounding of shares due to stock split (unaudited)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentForRoundingOfSharesDueToConversion', window );">Adjustment for rounding of shares due to stock split (unaudited), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (unaudited)</a></td>
<td class="num">(4,245,042)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,245,042)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance (unaudited) at Sep. 30, 2017</a></td>
<td class="nump">$ 6,352,941<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 79,667,289<span></span>
</td>
<td class="num">$ (73,314,771)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (unaudited), shares at Sep. 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">4,224,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentForRoundingOfSharesDueToConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to adjustment for rounding of shares due to conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentForRoundingOfSharesDueToConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentForRoundingOfValueDueToConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to adjustment for rounding of values due to conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentForRoundingOfValueDueToConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IssuanceOfPreferredAndCommonStockNetCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of preferred and common stock net cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IssuanceOfPreferredAndCommonStockNetCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IssuanceOfPreferredAndCommonStockNetShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of preferred and common stock net share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IssuanceOfPreferredAndCommonStockNetShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816583824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Equity (Parenthetical) (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Issuance of preferred and common stock net of cost</a></td>
<td class="nump">$ 1,402,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825804320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,245,042)<span></span>
</td>
<td class="num">$ (5,724,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash provided by (used in) operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">195,105<span></span>
</td>
<td class="nump">1,043,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Issuance of restricted stock</a></td>
<td class="nump">72,306<span></span>
</td>
<td class="nump">75,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and accretion</a></td>
<td class="nump">653,313<span></span>
</td>
<td class="nump">822,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative (income) expense</a></td>
<td class="num">(299,734)<span></span>
</td>
<td class="nump">70,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties', window );">Amortization of prepaid research and development - related party (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1', window );">Unrealized (gain) on investment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(728,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Compensation through issuance of stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">509,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Issuance of warrants to initial investors</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">589,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) in accounts receivable</a></td>
<td class="num">(683,806)<span></span>
</td>
<td class="num">(347,013)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventory</a></td>
<td class="nump">140,961<span></span>
</td>
<td class="num">(60,650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Decrease (increase) in prepaid expenses and other</a></td>
<td class="nump">48,703<span></span>
</td>
<td class="num">(337,525)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">(Decrease) in accounts payable and other</a></td>
<td class="num">(559,636)<span></span>
</td>
<td class="num">(109,365)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Increase (decrease) in accrued liabilities</a></td>
<td class="nump">120,850<span></span>
</td>
<td class="num">(498,516)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncreaseDecreaseInAccruedCompensation', window );">Increase (decrease) in accrued compensation</a></td>
<td class="nump">340,841<span></span>
</td>
<td class="num">(668,792)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidRent', window );">(Decrease) increase in deferred rent</a></td>
<td class="num">(1,669)<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(4,217,808)<span></span>
</td>
<td class="num">(5,332,459)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows used in investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Installment payment for Primsol asset</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(504,721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Issuance of preferred, common stock and warrants</a></td>
<td class="nump">11,839,995<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost', window );">Issuance costs related to preferred, common stock and warrants</a></td>
<td class="num">(1,402,831)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock to Lincoln Park Capital</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">631,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs related to sale of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(24,247)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,437,164<span></span>
</td>
<td class="nump">607,234<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">6,219,356<span></span>
</td>
<td class="num">(5,229,946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">877,542<span></span>
</td>
<td class="nump">8,054,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">7,096,898<span></span>
</td>
<td class="nump">2,824,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsIssuedToInvestorsAndUnderwriters', window );">Warrants issued to investors and underwriters (see Note 5)</a></td>
<td class="nump">4,117,997<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EarnOutPaymentToOtherShareholders', window );">Earn-out payment to Nuelle Shareholders</a></td>
<td class="nump">11,589<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable', window );">Primsol accretion included in accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">49,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FixedAssetsIncludedInAccountsPayable', window );">Fixed assets included in accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 95,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of prepaid research and development due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EarnOutPaymentToOtherShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earn-out payment to the shareholders of subsidiary company or on merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EarnOutPaymentToOtherShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedAssetsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of fixed assets included in accounts payable in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedAssetsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncreaseDecreaseInAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncreaseDecreaseInAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of preferred, common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of primsol business purchases included in primsol payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsIssuedToInvestorsAndUnderwriters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued to investors and underwriters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsIssuedToInvestorsAndUnderwriters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investments in debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816448304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Note 1 - Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Business</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Aytu BioScience, Inc. (&#8220;Aytu&#8221;, the &#8220;Company&#8221; or &#8220;we&#8221;) was incorporated as Rosewind Corporation on August&#160;9, 2002 in the State of Colorado. Aytu was re-incorporated in the state of Delaware on June&#160;8, 2015. Aytu is a commercial-stage specialty life sciences company concentrating on developing and commercializing products with an initial focus on urological diseases and conditions. Aytu is currently focused on addressing significant medical needs in the areas of hypogonadism, urological cancers, male infertility, and sexual wellness and vitality.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">These unaudited consolidated financial statements represent the financial statements of Aytu and its subsidiary, Aytu Women&#8217;s Health. These unaudited consolidated financial statements should be read in conjunction with Aytu&#8217;s Annual Report on Form 10-K for the year ended June 30, 2017, which included all disclosures required by generally accepted accounting principles (&#8220;GAAP&#8221;). In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position of Aytu for the balance sheet, the results of operations and cash flows for the interim periods presented. The results of operations for the period ended September 30, 2017 are not necessarily indicative of expected operating results for the full year. The information presented throughout this report as of and for the period ended September 30, 2017 and 2016 is unaudited.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Through a multi-step reverse triangular merger, on April 16, 2015, Vyrix Pharmaceuticals, Inc. (&#8217;&#8216;Vyrix&#8217;&#8217;) and Luoxis Diagnostics, Inc. (&#8217;&#8216;Luoxis&#8217;&#8217;) merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue the specialty healthcare market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS and Zertane products. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares held. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares held. On August 25, 2017, Aytu effected a third reverse stock split in which each common stockholder received one share of common stock for every 20
 shares held
 (herein referred to collectively as the &#8220;Reverse Stock Splits&#8221;). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Business Combination&#8212;ProstaScint</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (&#8220;Jazz Pharmaceuticals&#8221;). Pursuant to the agreement, Aytu purchased assets related to the Jazz Pharmaceuticals&#8217; product known as ProstaScint<sup>&#174;</sup>&#160;(capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &#8217;&#8216;ProstaScint Business&#8217;&#8217;), and assumed certain of Jazz Pharmaceuticals&#8217; liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consisted of an upfront payment of $1.0 million. We also agreed to pay an additional $500,000, which was paid after the transfer of the ProstaScint-related product inventory, and $227,000 which was paid September 30, 2015 (which represents a portion of certain FDA fees). We will also pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was initially valued at $664,000 and was revalued as of June 30, 2017 at $54,000 using a discounted cash flow. The total fair value consideration for the purchase was $2.4 million.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s allocation of consideration transferred for ProstaScint as of the purchase date of May&#160;20, 2015 is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Tangible assets</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">727,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Intangible assets</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">1,590,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Goodwill</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px;
 font-size: 10pt; border-bottom-color: black;
 border-bottom-width: 1.5pt; border-bottom-style: solid;">74,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Total assets acquired</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,391,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Included in the intangible assets is developed technology of $790,000, customer contracts of $720,000 and trade names of $80,000, each of which will be amortized over a ten-year period. At June 30, 2017, the ProstaScint asset was impaired based upon sales projections that we intend to only sell this product through mid-fiscal 2019, when this product expires. The value for the intangible assets were adjusted to $54,000 for developed technology, $7,000 for trade names and $0 for customer contracts. The amortization expense was $12,000 and $40,000 for the three months ended September 30, 2017 and 2016, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of September 30, 2017, the contingent consideration increased by $6,000 due to accretion.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Business Combination&#8212;Primsol</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (&#8220;FSC&#8221;). Pursuant to the agreement, Aytu purchased assets related to FSC&#8217;s product known as Primsol&#174; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the &#8220;Primsol Business&#8221;), and assumed certain of FSC&#8217;s liabilities, including those related to the sale and marketing of Primsol arising after the closing.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Aytu paid $500,000 at closing for the purchase of the Primsol Business, and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 which was paid on April 1, 2016, (b) $500,000 which was paid on July 1, 2016, and (c) $250,000 which was paid in November 2016 (together, the &#8220;Installment Payments&#8221;).</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial;
 text-decoration-color: initial;">The Company&#8217;s allocation on
 consideration transferred for Primsol as of the purchase date of October 5, 2015 was as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Tangible assets</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">182,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Intangible assets</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">1,470,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Goodwill</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">147,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Total assets acquired</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,799,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Included in tangible assets was $102,000 of inventory and $80,000 of work-in-process inventory. Included in the intangible assets was developed technology of $520,000, customer contracts of $810,000 and trade names of $140,000, each of which was being amortized over a six-year period. Amortization expense of $0 and $61,000 was recognized in the three months ended September 30, 2017 and 2016, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Divestiture &#8211; Primsol</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On March 31,
 2017, we entered into and closed on an Asset Purchase Agreement with Allegis Holdings, LLC (the
 &#8220;Purchaser&#8221;). Pursuant to the agreement, we sold to the Purchaser all of our assets related to our product known as Primsol, including certain intellectual property and contracts, inventory, work in process and all marketing assets and materials related solely to Primsol (together, the &#8220;Primsol Asset&#8221;). We retain any liability associated with the Primsol Asset that occurred prior to the closing. The Purchaser paid us $1,750,000 at the closing for the Primsol Asset. We recognized a gain of approximately $428,000 on the sale which is included in sales, general and administrative expense on our statement of operations.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We have evaluated this transaction and concluded that it is not significant to our business and therefore the results are included in continuing operations, as the criteria to be presented as discontinued operations was not satisfied.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>License and Supply Agreement&#8212;Natesto</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In April 2016, Aytu entered into and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto&#174; (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we acquired effective upon the expiration of the former licensee&#8217;s rights, which occurred on June 30, 2016. The license&#8217;s term runs for the greater of eight years or until the expiry of the latest to expire patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic product.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Aytu paid Acerus an upfront fee of $2.0 million upon execution of the agreement. In October 2016, we paid an additional $2.0 million, and in January 2017, Aytu paid the final upfront payment of $4.0 million. Aytu also purchased, on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2.5 million (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately US $0.16 per share. These shares were a held for sale trading security and were valued at fair market value. Aytu could not dispose of these shares until after August 29, 2016. During the second half of fiscal 2017, Aytu sold all of these shares. The gross proceeds from the sales totaled $1.1 million, the cost of the sales totaled $92,000, and we recognized a loss on investment of $1.0 million. In the quarter ended September 30, 2016, we had an unrealized gain on this investment of $728,000.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In addition to the upfront payments, we must make the following one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $37.5 million):</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align:
 top;"><td style="width: 63px; font-size: 10pt;">&#160;</td><td style="width: 63px; font-size: 10pt;"><font
 style="font-size: 10pt;">&#9679;</font></td><td style="width: 1441px; font-size: 10pt;"><font style="font-size: 10pt;">$2.5 million if net sales during any four consecutive calendar quarter period equal or exceed $25.0 million (the &#8220;First Milestone&#8221;); the First Milestone payment is required to be paid even if the threshold is not met in the event that the agreement is terminated for any reason other than material breach by Acerus, bankruptcy of either party, or termination by Acerus because it believes the amounts payable to Aytu for agreed upon trial work would no longer make the agreement economically viable for Acerus;</font></td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="font-size: 10pt;"><font style="font-size: 10pt;">$5.0 million if net sales during any four consecutive calendar quarter period equal or exceed $50.0 million;</font></td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="font-size: 10pt;"><font style="font-size: 10pt;">$7.5 million if net sales during any four consecutive calendar quarter period equal or exceed $75.0 million;</font></td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="font-size: 10pt;"><font style="font-size: 10pt;">$10.0 million if net sales during any four consecutive calendar quarter period equal or exceed $100.0 million; and</font></td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="font-size: 10pt;"><font style="font-size: 10pt;">$12.5 million if net sales during any four consecutive calendar quarter period equal or exceed $125.0 million.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of the net identifiable asset acquired totaled $10.5 million which is being amortized over eight years. The amortization expense for each of the three months ended September 30, 2017 and 2016 were $330,000.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The contingent consideration was valued at $3.2 million using a Monte Carlo simulation, as of June 30, 2016. As of June 30, 2017, the contingent consideration was revalued and increased to $5.7 million based on increased future estimated sales performance of Natesto using a Monte Carlo simulation. The contingent consideration accretion expenses for the three months ended September 30, 2017 was $161,000, resulting in the contingent consideration value of $5.8 million. The contingent consideration accretion expense for the three months ended September 30, 2016 was $46,000.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Merger/Subsidiary</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2017, Aytu Women&#8217;s Health, LLC., a wholly-owned subsidiary of Aytu, acquired Nuelle, Inc., or Nuelle, a women&#8217;s sexual health company. This transaction expanded our product portfolio with the addition of the Fiera<sup>&#174;</sup>&#160;personal care device for women.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;
 text-decoration-style: initial; text-decoration-color: initial;">In the Merger, (i) each share of Nuelle common stock and each option or warrant to purchase Nuelle stock was cancelled, and (ii) each share of Nuelle preferred stock was converted into the right to receive shares of our common stock. We issued to the Nuelle preferred stockholders an aggregate of 125,000 shares of our common stock.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In addition, Nuelle preferred stockholders will be entitled to revenue earn-out payments equal to a designated percentage of net sales on tiers of net sales up to $100.0 million, with an average rate for all tiers in the mid-single digit range and a maximum aggregate payout of $6.9 million.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Nuelle stockholders additionally will be entitled to milestone earn-out payments of up to a potential aggregate of $24.0 million, upon the attainment by us of designated net sales thresholds over any sequential four calendar quarter period.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The first $1.0 million of earn-out payments will be paid in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock. The stock portion of any earn-out will be calculated by dividing each Nuelle stockholder&#8217;s portion of the earn-out by the average closing price of our common stock for the 10 trading days prior to the earlier of the date we deliver notice to the Nuelle stockholders of the earn-out or any public disclosure by us of the earn-out being due and payable.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the event that we do not make all of the required earn-out payments to the Nuelle stockholders before May 3, 2022, and we also close a divestiture before May 3, 2022 of any of the products acquired in the transaction, we will pay the Nuelle stockholders a combination of (i) cash in an amount equal to 10% of the value of all cash, securities and other property paid to us in the divestiture (cash is to be 60% of the total consideration), and (ii) shares of our common stock equal to the Nuelle stockholders&#8217; portion of the divestiture payment divided by the average closing price of our common stock for the 10 trading days prior to the earlier of the closing date of the divestiture or the public disclosure of the divestiture (shares of common stock are to be 40% of the total consideration).</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In addition to the upfront issuance of common stock, we must make the following one-time payments to the Nuelle stockholders within 90 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $24.0 million):</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 63px; text-indent: 0px; font-size:
 10pt;">&#160;</td><td style="padding: 0px; width: 63px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td
 style="padding: 0px; width: 1441px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">Upon achieving the first occurrence of Net Sales of $10.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.0 million;</font></td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="padding: 0px; text-align: justify; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">Upon achieving the first occurrence of Net Sales of $17.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.8 million;</font></td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-align: justify; text-indent: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="padding: 0px; text-align: justify; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">Upon achieving the first occurrence of Net Sales of $25.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $2.5 million;</font></td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">Upon achieving the first occurrence of Net Sales of $37.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $3.8 million;</font></td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">Upon achieving the first occurrence of Net Sales of $50.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $5.0 million; and</font></td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px;"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; font-stretch: normal;">&#9679;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; font-stretch: normal;">&#160;</p></td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">Upon achieving the first occurrence of Net Sales of $100.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $10.0 million.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;The Company&#8217;s allocation on consideration transferred for Nuelle as of the purchase date May&#160;5, 2017 is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Tangible assets</td><td
 style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px;
 text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">2,061,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Intangible assets</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">1,540,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Goodwill</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">238,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Total assets acquired</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,839,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Included in the intangible assets is developed technology of $1.3 million, customer contracts of $80,000 and trade names of $160,000, each of which will be amortized over a nine to twelve-year period. Amortization expense of $38,000 and $0 was recognized for the three months ended September 30, 2017 and September 30, 2016, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The contingent consideration was valued at $1.9 million using a Monte Carlo simulation, as of May 2017. The contingent consideration accretion expense for the three months ended September 30, 2017 and September 30, 2016 was $20,000, and $0 respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the quarter ended September 30, 2017, we paid the first earn-out payment to Nuelle shareholders of $12,000 issued in Aytu common stock, which was 25% of the Aytu Women&#8217;s Health net revenue for fiscal 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Additionally, upon the closing of the merger, we assumed liabilities of $47,000.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Recently Issued Accounting Pronouncements, Not Adopted as of September 30, 2017</b></p><p style="font: 10pt/normal
 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;
 text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2017, the FASB issued ASU No. 2017-09,&#160;&#8220;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&#160;(ASU 2017-09).&#8221; ASU 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of its adoption of this standard on its consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2017, the FASB issued ASU 2017-04, &#8220;Intangibles - Goodwill and Other (Topic 350).&#8221; The amendment simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe that adoption of this amendment will have a material impact on its consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2017, the FASB issued ASU 2017-01, &#8220;Business Combinations (Topic 805) Clarifying the Definition of a Business.&#8221; The amendment clarifies the definition of a business, which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively for public business entities for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect an immediate impact from this codification however, if Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business combination or an asset purchase.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="background-color: white;">In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses&#8221; to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. This ASU is effective for private companies and emerging growth companies beginning after December 15, 2020; the ASU allows for early adoption as of the beginning of an interim or annual reporting period beginning after December 15, 2018. The Company is currently assessing the impact that ASU 2016-13 will have on its consolidated financial statements but does not anticipate there to be a material impact.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform:
 none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases (Topic 842).&#8221; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its adoption of this standard on its consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2016, the FASB issued ASU 2016-01, &#8220;Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,&#8221; which requires that all equity investments be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2014, the FASB issued ASU 2014-09, Topic 606, Revenue from Contracts with Customers (the &#8220;New Revenue Standard&#8221;). The amendments in this ASU provide a single model for use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14 which deferred the effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12 to clarify, among other things, the implementation guidance related to principal versus agent considerations, identifying performance obligations, and accounting for licenses of intellectual property. The New Revenue Standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is not permitted. The amendments in this update are to be applied on a retrospective basis, either to each prior reporting period presented or by presenting the cumulative effect of applying the update recognized at the date of initial application. The New Revenue Standard will be effective for the Company in fiscal 2019. The Company is evaluating the adoption methodology and the impact of this ASU on its consolidated financial statements.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6641123728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Note 2 &#8211; Fixed Assets</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over the estimated useful lives. Fixed assets consist of the following:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 24.5pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;">Estimated<br />Useful Lives in</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">As of<br />September 30,</td><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">As of<br />June 30,</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">years</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; width: 1019px; text-align: left; text-indent: 0px; font-size: 10pt;">Manufacturing equipment</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: center; font-size: 10pt;"><font style="font-size: 10pt;">2 - 5</font></td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">405,000</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">405,000</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-align: left; text-indent: 0px; font-size: 10pt;">Leasehold improvements</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;">3</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">111,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">111,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-align: left; text-indent: 0px; font-size: 10pt;">Office equipment, furniture and other</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;"><font style="font-size: 10pt;">2 - 5</font></td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">287,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">287,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-align: left; text-indent: 0px; font-size: 10pt;">Lab equipment</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;"><font style="font-size: 10pt;">3 - 5</font></td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align:
 left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">90,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">90,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 1.5pt; text-align: left; text-indent: 0px; font-size: 10pt;">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(326,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(246,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px; font-size: 10pt;">Fixed assets, net</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: center; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">567,000</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">647,000</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The depreciation expense was as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><font style="font-style: normal; font-weight: normal;">Three Months Ended<br />September 30,</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-style: normal; font-weight: normal;">2017</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-style: normal; font-weight: normal;">2016</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px;
 font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Depreciation expense</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">80,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">19,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816460704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patents<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Patents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Patents</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Note 3 &#8211; Patents</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third-party appraisal, was $500,000. The Zertane patents were acquired in connection with the 2011 acquisition of DMI BioSciences by Ampio, the former parent company of Aytu, and were being amortized over the remaining U.S. patent lives of approximately 11 years, which were to expire in March 2022. In fiscal 2016, we redirected our resources towards our commercial-stage products and the Company determined that this asset had no further value as the Company did not have the resources to complete the necessary clinical trials and bring it to market before the patents expired. The remaining fair value of the Zertane patents were expensed as of June 30, 2016.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The cost of the Luoxis patents were $380,000 when they were acquired in connection with the 2013 formation of Luoxis and are being amortized over the remaining U.S. patent lives of approximately 15 years, which expires in March 2028. Patents consist of the following:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">As of<br />September 30,</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">As of&#160;<br />June 30,</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Patents</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">880,000</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">880,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Less accumulated amortization</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(615,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px;
 font-size: 10pt;">)</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(609,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Patents, net</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">265,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">271,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The amortization expense was as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><font style="font-style: normal; font-weight: normal;">Three Months Ended<br />September 30,</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-style: normal; font-weight: normal;">2017</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-style: normal; font-weight: normal;">2016</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;Amortization expense</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">6,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">7,000</td><td style="text-align: left;
 text-indent: 0px; padding-left: 0px; font-size: 10pt;"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793134880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RevenueRecognitionDisclosureTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Note 4 &#8211; Revenue Recognition</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The $1,076,000 and $698,000 of product revenue recognized during the three months ended September 30, 2017 and 2016, respectively, represent sales of the Company&#8217;s products, Natesto, ProstaScint, and Primsol, and the MiOXSYS and RedoxSYS Systems, as well as products in the Fiera line.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RevenueRecognitionDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue recognition at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RevenueRecognitionDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816463312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Considerations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Considerations</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Note 5 &#8211; Fair Value Considerations</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Aytu&#8217;s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities, and warrant derivative liability. The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential future events. The valuation policies are determined by the Chief Financial Officer and approved by the Company&#8217;s Board of Directors.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu&#8217;s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr><td style="width: 126px; font-size: 10pt; vertical-align: top;"><font style="font-size: 10pt;">Level&#160;1:</font></td><td style="width: 1441px; font-size: 10pt; vertical-align: bottom;"><font style="font-size: 10pt;">Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;</font></td></tr><tr><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr><td style="font-size: 10pt; vertical-align: top;"><font style="font-size: 10pt;">Level&#160;2:</font></td><td style="font-size: 10pt; vertical-align: bottom;"><font style="font-size: 10pt;">Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and</font></td></tr><tr><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr><td style="font-size: 10pt; vertical-align: top;"><font style="font-size: 10pt;">Level&#160;3:</font></td><td style="font-size: 10pt; vertical-align: bottom;"><font style="font-size: 10pt;">Unobservable inputs that are supported by little or no market activity.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Aytu&#8217;s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Aytu&#8217;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif;
 margin: 0pt 0px; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following table presents Aytu&#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of September 30, 2017, by level within the fair value hierarchy.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">Fair Value Measurements Using</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 1</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 2</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 3</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"><u>September 30, 2017</u></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">LIABILITIES</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Warrant derivative liability</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px;
 text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align:
 left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">3,818,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">3,818,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Contingent consideration</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">7,823,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">7,823,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt; text-decoration: underline;">June 30, 2017</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">LIABILITIES</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size:
 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td
 style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Warrant derivative liability</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Contingent consideration</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">7,648,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">7,648,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The warrant derivative liability was valued using the lattice valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. The warrants related to the warrant derivative liability are not actively traded and therefore classified as Level 3. Significant assumptions in valuing the warrant derivative liability, based on estimates of the value of Aytu common stock and various factors regarding the warrants, were as follows as of issuance and as of September 30, 2017:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 24.5pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 24.5pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: right;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2017</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">At Issuance</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Warrants:</td><td>&#160;</td><td
 style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1177.67px; text-align: left;
 padding-left: 10pt;">Volatility</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">183.0</td><td style="width: 16px; text-align: left;">%</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">188.0</td><td style="width: 15px; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt;">Equivalent term (years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4.88</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.00</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt;">Risk-free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.90</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.83</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt;">Dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.00</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.00</td><td style="text-align: left;">%</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 24.5pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following table sets forth a reconciliation of changes in the fair value of the derivative financial liabilities classified as Level 3 in the fair value hierarchy:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Derivative Instruments</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">Balance as of June 30, 2017</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1365.67px; text-align: left; text-indent: 0px; padding-left: 10pt; font-size: 10pt;">Warrant issuances</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">4,118,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;">Change in fair value included in earnings</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(300,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Balance as of September 30, 2017</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width:
 4pt; border-bottom-style: double;">3,818,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We classify our contingent consideration liability in connection with the acquisition of ProstaScint, Natesto and Fiera within Level 3 as factors used to develop the estimated fair value are unobservable inputs that are not supported by market activity. We estimate the fair value of our contingent consideration liability based on projected payment dates, discount rates, probabilities of payment, and projected revenues. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. There was no change in the fair value of the contingent consideration during the period ended September 30, 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;">The following table sets forth a summary of changes in the contingent consideration for the period ended September 30, 2017:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: right;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Contingent Consideration</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: right;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px;">Balance as of June 30, 2017</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">7,648,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt;">Increase due to accretion</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">187,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;">Decrease due to contractual payment</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(12,000</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">Balance as of September 30, 2017</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">7,823,000</td><td style="text-align: left; padding-bottom: 4pt;"></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6658899184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Note 6 &#8211; Commitments and Contingencies</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Commitments and contingencies are described below and summarized by the following table for the designated fiscal years ending June 30, as of September 30, 2017:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">Remaining</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2019</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2020</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2021</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2022</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Thereafter</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 251px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Prescription Database</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">1,220,000</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px;
 text-indent:
 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">647,000</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">573,000</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">Natesto</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">15,000,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">2,500,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">5,000,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">7,500,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt; font-size: 10pt;">Manufacturing/commercial supply agreement</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size:
 10pt;">-</td><td
 style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Office Lease</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">138,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">108,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">30,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">16,358,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">755,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">603,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size:
 10pt;">&#160;</td><td
 style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,500,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">5,000,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">7,500,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Prescription Database</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2016, Aytu entered into an agreement with a company that will provide Aytu with prescription database information. Aytu agreed to pay approximately $1.9 million over three years for access to the database of prescriptions written for Natesto. The payments have been broken down into quarterly payments, the first of which was made in November 2016, the second payment was made in January 2017, the third payment was made in April 2017, and the fourth payment was made in August 2017</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Natesto</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In April 2016, the Company entered into an agreement with Acerus whereby Aytu agreed to pay $8.0 million for the exclusive U.S. rights to Natesto (see Note 1). The first payment totaling $2.0 million was paid in April 2016, the second installment payment was paid in October 2016. The final payment totaling $4.0 million was paid in January 2017. Additionally, Aytu is required to make the first milestone payment of $2.5 million even if the milestone is not reached, and anticipates making the second milestone payment of $5.0 million along with the third milestone payment of $7.5 million.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Manufacturing/Commercial Supply Agreements</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif;
 margin: 0pt 0px; color:
 #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In October 2015, Aytu entered into a Master Services Agreement with Biovest International, Inc. (&#8220;Biovest&#8221;). The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. Aytu expects to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of its products for the ProstaScint product. In September 2016, Aytu entered into a Commercial Supply Agreement with Grand River Aseptic Manufacturing, Inc. (&#8220;GRAM&#8221;). The agreement provides that Aytu may engage GRAM from time to time to provide services in accordance with mutually agreed upon work orders. As of September, 30, 2017, both contracts were still on hold as the Company evaluates its strategic options for the ProstaScint product. If the contracts are not restarted, Aytu does not anticipate any future liability related to either contract.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Office Lease</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In June 2015, Aytu entered into a 37-month operating lease for a space in Raleigh, North Carolina. This lease has initial base rent of $3,000 a month, with total base rent over the term of the lease of approximately $112,000. In September 2015, the Company entered into a 37-month operating lease in Englewood, Colorado. This lease has an initial base rent of $9,000 a month with a total base rent over the term of the lease of approximately $318,000. The Company recognizes rental expense of the facilities on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Three Months Ended<br />September 30,</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;Rent expense</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">35,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td
 style="text-align: right; text-indent:
 0px; padding-left: 0px; font-size: 10pt;">35,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816463312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock/Equity Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextBlock', window );">Common Stock</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Note 7 &#8211; Common Stock</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Capital Stock / Restricted Stock</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At September 30, 2017 and June 30, 2017, Aytu had 4,224,840 and 824,831 common shares outstanding, respectively, and 2,250 and 0 preferred shares outstanding, respectively. The Company has 100.0&#160;million shares of common stock authorized with a par value of $0.0001&#160;per share and 50.0&#160;million shares of preferred stock authorized with a par value of $0.0001 per share, of which 10,000 were designated Series A Convertible Preferred Stock. Included in the common stock outstanding are 243,000 shares of restricted stock issued to employees and directors.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On August 11, 2017, we entered into a Securities Purchase Agreement with various investors pursuant to which we agreed to sell Class A and Class B equity units for gross proceeds of approximately $11.8 million. Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares of common stock and were sold at a negotiated price of $3.00 per unit. Class B units consist of one (1) share of our newly created Series A Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;) and warrants to purchase one and one-half (1.5) shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at a negotiated price of $1,000.00 per unit to those purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding common stock following the offering. These Series A Preferred stock converts into common shares at $3.00 per common share, which when fully exercised will increase the common shares outstanding by 750,000 shares. The offering closed on August 15, 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the offering, we issued an aggregate of 3,196,665 shares of our common stock, 2,250 shares of Series A Preferred Stock and warrants to purchase up to an aggregate of 6,314,671 shares of our common stock, which included 394,669 warrants issued to the underwriters as compensation for the transaction.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We incurred certain expenses related to this transaction to attorneys and underwriters inclusive of a 9% cash fee and warrants to purchase 10% of the aggregate number of shares issued in the transaction.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In connection with the closing of the financing, we terminated the Purchase Agreement, dated as of July 27, 2016, by and between us and Lincoln Park Capital Fund, LLC. The
 termination was
 effective on August 16, 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In September 2017, Aytu issued 200,000 shares of restricted stock to employees, which vest in September 2027. This expense is included in sales, general and administrative. For the three months ended September 30, 2017, the expense was $2,000. The fair value of the restricted stock was $404,000. The unrecognized expense of $402,000 will be recognized over the next ten years.</p><p style="font: 10pt/normal times-roman, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal times-roman, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Aytu also has 43,000 shares of restricted stock outstanding and unvested which were not issued out of the 2015 Stock Option and Inventive Plan. These shares vest in July 2026 and the unrecognized expense of $2,435,000 will be recognized over the next ten years. During the quarter ended September 30, 2017, the expense related to these awards was $70,000.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In September 2017, Aytu issued 3,018 shares of common stocks as the earn-out payment to Nuelle Shareholders for fiscal 2017. (See Note 1).</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799956240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock/Equity Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity Instruments</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>Note 8 &#8211; Equity Instruments</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Options</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On June&#160;1, 2015, Aytu&#8217;s stockholders approved the 2015 Stock Option and Incentive Plan (the &#8220;2015 Plan&#8221;), which, as amended in July 2017, provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 3.0 million shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Pursuant to the 2015 Stock Plan, 3.0 million shares of the Company&#8217;s common stock, are reserved for issuance. The fair value of options granted was calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Stock option activity is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Options</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Exercise Price</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Remaining Contractual Life in Years</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Outstanding June 30, 2017</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">38,263</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">16.31</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size:
 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">8.40</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-left: 10pt; font-size: 10pt;">Granted</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 10pt; font-size: 10pt;">Exercised</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;">Forfeited/Cancelled</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(139</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">)</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">16.40</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Outstanding September 30, 2017</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">38,124</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">16.31</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">8.13</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Exercisable at September 30, 2017</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">23,385</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt;
 padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">16.40</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">7.85</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Available for grant at September 30, 2017</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,761,876</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and selling, general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period<font style="font-family: 'times new roman', times, serif;">.&#160;</font>The following table summarizes stock-based compensation expense for the stock option issuances for the three months ended September 30, 2017 and 2016:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Three Months Ended<br />September 30,</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Selling, general and administrative:</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1177.67px; text-align: left; text-indent: 0px; padding-left: 10pt; font-size: 10pt;">Stock options</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">195,000</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px;
 text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">1,044,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;">Restricted Stock</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">72,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">75,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Total share-based compensation expense</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">267,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,119,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;">As of&#160;September 30, 2017, there was&#160;$571,000 of total unrecognized share-based compensation expense related to non-vested stock options. The Company expects to recognize this expense over a weighted-average period of 1.60&#160;years.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Warrants</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">A summary of all warrants is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Warrants</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td
 style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Exercise Price</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Remaining Contractual Life in Years</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Outstanding June 30, 2017</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">286,049</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">50.29</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">4.23</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Warrants issued to investors in connection with the private offering</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">5,920,002</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">3.60</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Warrants issued to underwritters for the private offering</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">394,669</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">3.60</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Outstanding September 30, 2017</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style:
 double;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">6,600,720</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">5.62</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">4.86</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">In connection with our August 2017 private offering,&#160;</font>we issued to investors and underwriters warrants to purchase an aggregate of 6, 314,671 shares of common stock&#160;<font style="font-family: 'times new roman', times, serif;">at an exercise price of $3.60 with a term of five years from August 25, 2017. These warrants are accounted for under derivative liability treatment.&#160;</font>(see Note 5).</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">All warrants issued in fiscal 2018 were valued using the lattice option pricing model. In order to calculate the fair value of the warrants, certain assumptions were made regarding components of the model, including the selling price or fair market value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and contractual life. Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Significant assumptions in valuing the warrants issued during the September 30, 2017 quarter are included in Note 5.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807980080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Note 9 &#8211; Related Party Transactions</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Executive Stock Purchases</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">When Aytu completed the August 2017 offering, our executive officers Joshua Disbrow and Jarrett Disbrow participated in this offering, purchasing 83,333, units each.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Services Agreement</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In July 2015, Aytu entered into an agreement with Ampio, whereby Aytu agreed to pay Ampio a set amount per month for shared overhead, which includes costs related to the shared corporate staff and other miscellaneous overhead expenses. This agreement as amended in November 2015, April 2016, July 2016, and again in January 2017 required a monthly payment of $12,000. This agreement was terminated in June 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Sponsored Research Agreement</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&#8217;s director and Chief Scientific Officer, Dr.&#160;Bar-Or. The agreement was amended in January 2015 and provided for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration for services related to research and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $615,000 which was being amortized over the contractual term of 60.5 months and was divided between current and long-term on the balance sheet; as of September 2014, this amount had been paid in full. This agreement was terminated in March 2017.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800653440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Note 10 &#8211; Segment Information</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Aytu manages our Company and aggregates our operational and financial information in accordance with two reportable segments: Aytu and Aytu Women&#8217;s Health. The Aytu segment consists of our core male urology products. The Aytu Women&#8217;s Health segment contains our women&#8217;s health products. Select financial information for these segments is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">Three months ended<br />September 30,</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2017</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2016</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">Consolidated Revenue:</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1177.67px; text-indent: 0px; padding-left: 10pt; font-stretch: normal;">Aytu</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 18px; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;">972,000</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;">698,000</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;
 background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">Aytu Women&#8217;s Health</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">104,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">Consolidated revenue</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">1,076,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">698,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">Consolidated net loss:</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 10pt; font-stretch: normal;">Aytu</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;">(3,725,000</td><td
 style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;">(5,724,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">Aytu Women&#8217;s Health</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(520,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">Consolidated net loss</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(4,245,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(5,724,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">Total consolidated assets:</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px;
 font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 10pt; font-stretch: normal;">Aytu</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;">18,115,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;">14,999,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">Aytu Women&#8217;s Health</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">3,131,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">Total consolidated assets</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">21,246,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">14,999,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6658899184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Note 11 &#8211; Subsequent Events</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">October 20, 2017, the Company was approved for listing and began trading on The NASDAQ Capital Market under the company&#8217;s current ticker symbol, AYTU.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On October 24, 2017, Aytu entered into a 24-month extension of our operating lease for the Englewood, Colorado office space. The base rent will remain at $9,000 per month.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On October 25, 350 of our preferred shares outstanding converted into 116,666 shares of our common stock.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On October 25, Aytu issued 61,000 shares to Nuelle shareholders as a prepayment for the fiscal 2018 earn-out payment that will be due to them.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On November 7, 2017, Aytu issued 495,000 restricted shares to executives, directors and consultants.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816421568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">These unaudited consolidated financial statements represent the financial statements of Aytu and its subsidiary, Aytu Women&#8217;s Health. These unaudited consolidated financial statements should be read in conjunction with Aytu&#8217;s Annual Report on Form 10-K for the year ended June 30, 2017, which included all disclosures required by generally accepted accounting principles (&#8220;GAAP&#8221;). In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position of Aytu for the balance sheet, the results of operations and cash flows for the interim periods presented. The results of operations for the period ended September 30, 2017 are not necessarily indicative of expected operating results for the full year. The information presented throughout this report as of and for the period ended September 30, 2017 and 2016 is unaudited.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Through a multi-step reverse triangular merger, on April 16, 2015, Vyrix Pharmaceuticals, Inc. (&#8217;&#8216;Vyrix&#8217;&#8217;) and Luoxis Diagnostics, Inc. (&#8217;&#8216;Luoxis&#8217;&#8217;) merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue the specialty healthcare market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS and Zertane products. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares held. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares held. On August 25, 2017, Aytu effected a third reverse stock split in which each common stockholder received one share of common stock for every 20 shares held (herein referred to collectively as the &#8220;Reverse Stock Splits&#8221;). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combination</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Business Combination&#8212;ProstaScint</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (&#8220;Jazz Pharmaceuticals&#8221;). Pursuant to the agreement, Aytu purchased assets related to the Jazz Pharmaceuticals&#8217; product known as ProstaScint<sup>&#174;</sup>&#160;(capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &#8217;&#8216;ProstaScint Business&#8217;&#8217;), and assumed certain of Jazz Pharmaceuticals&#8217; liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consisted of an upfront payment of $1.0 million. We also agreed to pay an additional $500,000, which was paid after the transfer of the ProstaScint-related product inventory, and $227,000 which was paid September 30, 2015 (which represents a portion of certain FDA fees). We will also pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was initially valued at $664,000 and was revalued as of June 30, 2017 at $54,000 using a discounted cash flow. The total fair value consideration for the purchase was $2.4 million.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s allocation of consideration transferred for ProstaScint as of the purchase date of May&#160;20, 2015 is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Tangible assets</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">727,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Intangible assets</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">1,590,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Goodwill</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">74,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Total assets acquired</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align:
 left; text-indent: 0px; padding-left: 0px;
 font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,391,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Included in the intangible assets is developed technology of $790,000, customer contracts of $720,000 and trade names of $80,000, each of which will be amortized over a ten-year period. At June 30, 2017, the ProstaScint asset was impaired based upon sales projections that we intend to only sell this product through mid-fiscal 2019, when this product expires. The value for the intangible assets were adjusted to $54,000 for developed technology, $7,000 for trade names and $0 for customer contracts. The amortization expense was $12,000 and $40,000 for the three months ended September 30, 2017 and 2016, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of September 30, 2017, the contingent consideration increased by $6,000 due to accretion.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Business Combination&#8212;Primsol</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (&#8220;FSC&#8221;). Pursuant to the agreement, Aytu purchased assets related to FSC&#8217;s product known as Primsol&#174; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the &#8220;Primsol Business&#8221;), and assumed certain of FSC&#8217;s liabilities, including those related to the sale and marketing of Primsol arising after the closing.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Aytu paid $500,000 at closing for the purchase of the Primsol Business, and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 which was paid on April 1, 2016, (b) $500,000 which was paid on July 1, 2016, and (c) $250,000 which was paid in November 2016 (together, the &#8220;Installment Payments&#8221;).</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 was as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px;
 text-transform: none; text-indent: 0px; letter-spacing: normal;
 font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Tangible assets</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">182,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Intangible assets</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">1,470,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Goodwill</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">147,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Total assets acquired</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,799,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Included in tangible assets was $102,000 of inventory and $80,000 of work-in-process inventory. Included in the intangible assets was developed technology of $520,000, customer contracts of $810,000 and trade names of $140,000, each of which was being amortized over a six-year period. Amortization expense of $0 and $61,000 was recognized in the three months ended September 30, 2017 and 2016, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Divestiture &#8211; Primsol</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On March 31, 2017, we entered into and closed on an Asset Purchase Agreement with Allegis Holdings, LLC (the &#8220;Purchaser&#8221;). Pursuant to the agreement, we sold to the Purchaser all of our assets related to our product known as Primsol, including certain intellectual property and contracts, inventory, work in process and all marketing assets and materials related solely to Primsol (together, the &#8220;Primsol Asset&#8221;). We retain any liability associated with the Primsol Asset that occurred prior to the closing. The Purchaser paid us
 $1,750,000 at the closing for the Primsol Asset. We recognized a gain of approximately $428,000 on the sale which is
 included in sales, general and administrative expense on our statement of operations.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We have evaluated this transaction and concluded that it is not significant to our business and therefore the results are included in continuing operations, as the criteria to be presented as discontinued operations was not satisfied.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>License and Supply Agreement&#8212;Natesto</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In April 2016, Aytu entered into and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto&#174; (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we acquired effective upon the expiration of the former licensee&#8217;s rights, which occurred on June 30, 2016. The license&#8217;s term runs for the greater of eight years or until the expiry of the latest to expire patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic product.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Aytu paid Acerus an upfront fee of $2.0 million upon execution of the agreement. In October 2016, we paid an additional $2.0 million, and in January 2017, Aytu paid the final upfront payment of $4.0 million. Aytu also purchased, on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2.5 million (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately US $0.16 per share. These shares were a held for sale trading security and were valued at fair market value. Aytu could not dispose of these shares until after August 29, 2016. During the second half of fiscal 2017, Aytu sold all of these shares. The gross proceeds from the sales totaled $1.1 million, the cost of the sales totaled $92,000, and we recognized a loss on investment of $1.0 million. In the quarter ended September 30, 2016, we had an unrealized gain on this investment of $728,000.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In addition to the upfront payments, we must make the following one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $37.5 million):</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 63px; font-size: 10pt;">&#160;</td><td style="width: 63px; font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="width: 1441px; font-size: 10pt;"><font style="font-size: 10pt;">$2.5 million if net sales during any four consecutive calendar quarter period equal or exceed $25.0 million (the &#8220;First Milestone&#8221;); the First Milestone payment is required to be paid even if the threshold is not met in the event that the agreement is terminated for any reason other than material
 breach by Acerus, bankruptcy of either party, or termination by Acerus because it believes the amounts payable to Aytu for agreed upon
 trial work would no longer make the agreement economically viable for Acerus;</font></td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="font-size: 10pt;"><font style="font-size: 10pt;">$5.0 million if net sales during any four consecutive calendar quarter period equal or exceed $50.0 million;</font></td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="font-size: 10pt;"><font style="font-size: 10pt;">$7.5 million if net sales during any four consecutive calendar quarter period equal or exceed $75.0 million;</font></td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="font-size: 10pt;"><font style="font-size: 10pt;">$10.0 million if net sales during any four consecutive calendar quarter period equal or exceed $100.0 million; and</font></td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="vertical-align: top;"><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="font-size: 10pt;"><font style="font-size: 10pt;">$12.5 million if net sales during any four consecutive calendar quarter period equal or exceed $125.0 million.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of the net identifiable asset acquired totaled $10.5 million which is being amortized over eight years. The amortization expense for each of the three months ended September 30, 2017 and 2016 were $330,000.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The contingent consideration was valued at $3.2 million using a Monte Carlo simulation, as of June 30, 2016. As of June 30, 2017, the contingent consideration was revalued and increased to $5.7 million based on increased future estimated sales performance of Natesto using a Monte Carlo simulation. The contingent consideration accretion expenses for the three months ended September 30, 2017 was $161,000, resulting in the contingent consideration value of $5.8 million. The contingent consideration accretion expense for the three months ended September 30, 2016 was $46,000.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Merger/Subsidiary</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2017, Aytu Women&#8217;s Health, LLC., a wholly-owned subsidiary of Aytu, acquired Nuelle, Inc., or Nuelle, a women&#8217;s sexual health company. This transaction expanded our product portfolio with the addition of the Fiera<sup>&#174;</sup>&#160;personal care device for women.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the Merger, (i) each share of Nuelle common stock and each option or warrant to purchase Nuelle stock was cancelled, and (ii) each share of Nuelle preferred stock was converted into the right to receive shares of our common stock. We issued to the Nuelle preferred stockholders an aggregate of 125,000 shares of our common
 stock.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px;
 white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In addition, Nuelle preferred stockholders will be entitled to revenue earn-out payments equal to a designated percentage of net sales on tiers of net sales up to $100.0 million, with an average rate for all tiers in the mid-single digit range and a maximum aggregate payout of $6.9 million.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Nuelle stockholders additionally will be entitled to milestone earn-out payments of up to a potential aggregate of $24.0 million, upon the attainment by us of designated net sales thresholds over any sequential four calendar quarter period.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The first $1.0 million of earn-out payments will be paid in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock. The stock portion of any earn-out will be calculated by dividing each Nuelle stockholder&#8217;s portion of the earn-out by the average closing price of our common stock for the 10 trading days prior to the earlier of the date we deliver notice to the Nuelle stockholders of the earn-out or any public disclosure by us of the earn-out being due and payable.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the event that we do not make all of the required earn-out payments to the Nuelle stockholders before May 3, 2022, and we also close a divestiture before May 3, 2022 of any of the products acquired in the transaction, we will pay the Nuelle stockholders a combination of (i) cash in an amount equal to 10% of the value of all cash, securities and other property paid to us in the divestiture (cash is to be 60% of the total consideration), and (ii) shares of our common stock equal to the Nuelle stockholders&#8217; portion of the divestiture payment divided by the average closing price of our common stock for the 10 trading days prior to the earlier of the closing date of the divestiture or the public disclosure of the divestiture (shares of common stock are to be 40% of the total consideration).</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In addition to the upfront issuance of common stock, we must make the following one-time payments to the Nuelle stockholders within 90 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $24.0 million):</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding: 0px; width: 63px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; width: 63px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="padding: 0px; width: 1441px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">Upon achieving the first occurrence of Net Sales of $10.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.0 million;</font></td></tr><tr style="vertical-align: top;"><td
 style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size:
 10pt;">&#160;</td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="padding: 0px; text-align: justify; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">Upon achieving the first occurrence of Net Sales of $17.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.8 million;</font></td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-align: justify; text-indent: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="padding: 0px; text-align: justify; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">Upon achieving the first occurrence of Net Sales of $25.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $2.5 million;</font></td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">Upon achieving the first occurrence of Net Sales of $37.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $3.8 million;</font></td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">&#9679;</font></td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">Upon achieving the first occurrence of Net Sales of $50.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $5.0 million; and</font></td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: top;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding: 0px; text-indent: 0px;"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; font-stretch: normal;">&#9679;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; font-stretch: normal;">&#160;</p></td><td style="padding: 0px; text-indent: 0px; font-size: 10pt;"><font style="font-size: 10pt;">Upon achieving the first occurrence of Net Sales of $100.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $10.0 million.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s allocation on consideration transferred for Nuelle as of the purchase date May&#160;5, 2017 is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Tangible assets</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">2,061,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px;
 padding-left: 0px; font-size: 10pt;">Intangible assets</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent:
 0px; padding-left: 0px; font-size: 10pt;">1,540,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Goodwill</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">238,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Total assets acquired</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,839,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Included in the intangible assets is developed technology of $1.3 million, customer contracts of $80,000 and trade names of $160,000, each of which will be amortized over a nine to twelve-year period. Amortization expense of $38,000 and $0 was recognized for the three months ended September 30, 2017 and September 30, 2016, respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The contingent consideration was valued at $1.9 million using a Monte Carlo simulation, as of May 2017. The contingent consideration accretion expense for the three months ended September 30, 2017 and September 30, 2016 was $20,000, and $0 respectively.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the quarter ended September 30, 2017, we paid the first earn-out payment to Nuelle shareholders of $12,000 issued in Aytu common stock, which was 25% of the Aytu Women&#8217;s Health net revenue for fiscal 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Additionally, upon the closing of the merger, we assumed liabilities of $47,000.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements, Not Adopted as of September 30, 2017</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>Recently Issued Accounting Pronouncements, Not Adopted as of September 30, 2017</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2017, the FASB issued ASU No. 2017-09,&#160;&#8220;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&#160;(ASU 2017-09).&#8221; ASU 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of its adoption of this standard on its consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2017, the FASB issued ASU 2017-04, &#8220;Intangibles - Goodwill and Other (Topic 350).&#8221; The amendment simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe that adoption of this amendment will have a material impact on its consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2017, the FASB issued ASU 2017-01, &#8220;Business Combinations (Topic 805) Clarifying the Definition of a Business.&#8221; The amendment clarifies the definition of a business, which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively for public business entities for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect an immediate impact from this codification however, if Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business combination or an asset purchase.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="background-color: white;">In June 2016, the FASB issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses&#8221; to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. This ASU is effective for private companies and emerging growth
 companies
 beginning after December 15, 2020; the ASU allows for early adoption as of the beginning of an interim or annual reporting period beginning after December 15, 2018. The Company is currently assessing the impact that ASU 2016-13 will have on its consolidated financial statements but does not anticipate there to be a material impact.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases (Topic 842).&#8221; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its adoption of this standard on its consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2016, the FASB issued ASU 2016-01, &#8220;Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,&#8221; which requires that all equity investments be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May 2014, the FASB issued ASU 2014-09, Topic 606, Revenue from Contracts with Customers (the &#8220;New Revenue Standard&#8221;). The amendments in this ASU provide a single model for use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14 which deferred the effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12 to clarify, among other things, the implementation guidance related to principal versus agent considerations, identifying performance obligations, and accounting for licenses of intellectual property. The New Revenue Standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is not permitted. The amendments in this update are to be applied on a retrospective basis, either to each prior reporting period presented or by presenting the cumulative effect of applying the update recognized at the date of initial application. The New Revenue Standard will be effective for the Company in fiscal 2019. The Company is evaluating the adoption methodology and the impact of this ASU on its consolidated financial statements.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825630352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">ProstaScint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of allocation on consideration transferred</a></td>
<td class="text"><div><table style="width: 1422.73px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1252.73px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Tangible assets</td><td style="width: 14.54px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 14.54px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 127.27px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">727,000</td><td style="width: 13.63px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Intangible assets</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">1,590,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Goodwill</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">74,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Total assets acquired</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,391,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of allocation on consideration transferred</a></td>
<td class="text"><div><table style="width: 1422.73px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1252.73px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Tangible assets</td><td style="width: 14.54px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 14.54px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 127.27px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">182,000</td><td style="width: 13.63px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Intangible assets</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">1,470,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Goodwill</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">147,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Total assets acquired</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,799,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleMember', window );">Nuelle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of allocation on consideration transferred</a></td>
<td class="text"><div><table style="width: 1422.73px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Fair Value</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1252.73px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Tangible assets</td><td style="width: 14.54px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 14.54px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 127.27px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">2,061,000</td><td style="width: 13.63px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Intangible assets</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">1,540,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Goodwill</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">238,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Total assets acquired</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,839,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessDescriptionAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NuelleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6606203904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets and depreciation expense</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;">Estimated<br />Useful Lives in</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">As of<br />September 30,</td><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">As of<br />June 30,</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">years</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="padding: 0px; text-indent: 0px; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; width: 1019px; text-align: left; text-indent: 0px; font-size: 10pt;">Manufacturing equipment</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: center; font-size: 10pt;"><font style="font-size: 10pt;">2 - 5</font></td><td style="width: 16px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 16px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">405,000</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 15px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; font-size: 10pt;">405,000</td><td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-align: left; text-indent: 0px; font-size: 10pt;">Leasehold improvements</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;">3</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">111,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">111,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-align: left; text-indent: 0px; font-size: 10pt;">Office equipment, furniture and other</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;"><font style="font-size: 10pt;">2 - 5</font></td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">287,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">287,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px; text-align: left; text-indent: 0px; font-size: 10pt;">Lab equipment</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;"><font style="font-size: 10pt;">3 - 5</font></td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">90,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">90,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 1.5pt; text-align: left; text-indent: 0px; font-size: 10pt;">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(326,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(246,000</td><td style="text-align:
 left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px 0px 0px 10pt; text-align: left; text-indent: 0px; font-size: 10pt;">Fixed assets, net</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: center; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">567,000</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">647,000</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr></table></div><div>&#160;</div><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><font style="font-style: normal; font-weight: normal;">Three Months Ended<br />September 30,</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-style: normal; font-weight: normal;">2017</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-style: normal; font-weight: normal;">2016</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Depreciation expense</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">80,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">19,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803601008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patents (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Patents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of patents</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">As of<br />September 30,</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">As of&#160;<br />June 30,</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Patents</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">880,000</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">880,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Less accumulated amortization</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(615,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">)</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(609,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Patents, net</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">265,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">271,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of amortization expense</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><font style="font-style: normal; font-weight: normal;">Three Months Ended<br />September 30,</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-style: normal; font-weight: normal;">2017</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;"><font style="font-style: normal; font-weight: normal;">&#160;</font></td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-style: normal; font-weight: normal;">2016</font></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;Amortization expense</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">6,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">7,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820091376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Considerations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary of fair value on a recurring basis</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">Fair Value Measurements Using</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 1</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 2</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level 3</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;"><u>September 30, 2017</u></td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">LIABILITIES</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Warrant derivative liability</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">3,818,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td
 style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">3,818,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Contingent consideration</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">7,823,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">7,823,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt; text-decoration: underline;">June 30, 2017</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">LIABILITIES</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Warrant derivative liability</td><td style="text-indent: 0px; padding-left: 0px; font-size:
 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Contingent consideration</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">7,648,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">7,648,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of significant assumptions in valuing the warrant derivative liability</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: right;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September 30, 2017</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">At Issuance</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Warrants:</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1177.67px; text-align: left; padding-left: 10pt;">Volatility</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">183.0</td><td style="width: 16px; text-align: left;">%</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">188.0</td><td style="width: 15px; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt;">Equivalent term (years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4.88</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.00</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt;">Risk-free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.90</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.83</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt;">Dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.00</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.00</td><td style="text-align: left;">%</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Derivative Instruments</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">Balance as of June 30, 2017</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1365.67px; text-align: left; text-indent: 0px; padding-left: 10pt; font-size: 10pt;">Warrant issuances</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">4,118,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;">Change in fair value included in earnings</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(300,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Balance as of September 30, 2017</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,818,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Summary of changes in the contingent consideration</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: right;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Contingent Consideration</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: right;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px;">Balance as of June 30, 2017</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">7,648,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt;">Increase due to accretion</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">187,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;">Decrease due to contractual payment</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(12,000</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">Balance as of September 30, 2017</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">7,823,000</td><td style="text-align: left; padding-bottom: 4pt;"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807798032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock', window );">Schedule of commitments and contingencies</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">Remaining</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2018</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2019</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2020</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2021</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2022</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Thereafter</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 251px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Prescription Database</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">1,220,000</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">647,000</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">573,000</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td
 style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">Natesto</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">15,000,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">2,500,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">5,000,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">7,500,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt; font-size: 10pt;">Manufacturing/commercial supply agreement</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Office Lease</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black;
 border-bottom-width: 1.5pt; border-bottom-style: solid;">138,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">108,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">30,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">16,358,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">755,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">603,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,500,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">5,000,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;
 border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">7,500,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRentExpenseTableTextBlock', window );">Schedule of rent expense</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Three Months Ended<br />September 30,</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1191px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;Rent expense</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">35,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">35,000</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommitmentsAndContingenciesDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals.  Rental payments under leases with terms of a month or less that were not renewed need not be included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6606056880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Options</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Exercise Price</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Remaining Contractual Life in Years</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Outstanding June 30, 2017</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">38,263</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">16.31</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">8.40</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-left: 10pt; font-size: 10pt;">Granted</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 10pt; font-size: 10pt;">Exercised</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">-</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;">Forfeited/Cancelled</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(139</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">)</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">16.40</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px;
 padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Outstanding September 30, 2017</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">38,124</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">16.31</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">8.13</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Exercisable at September 30, 2017</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">23,385</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">16.40</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">7.85</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Available for grant at September 30, 2017</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,761,876</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of stock-based compensation expense</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Three Months Ended<br />September 30,</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Selling, general and administrative:</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;" colspan="2">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1177.67px; text-align: left; text-indent: 0px; padding-left: 10pt; font-size: 10pt;">Stock options</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">195,000</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">1,044,000</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-size: 10pt;">Restricted Stock</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">72,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">75,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Total share-based compensation expense</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">267,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,119,000</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of all warrants</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Warrants</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Exercise Price</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: center; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Remaining Contractual Life in Years</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Outstanding June 30, 2017</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">286,049</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">50.29</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">4.23</td><td style="width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">Warrants issued to investors in connection with the private offering</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">5,920,002</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">3.60</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">Warrants issued to underwritters for the private offering</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">394,669</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">3.60</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left;
 text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">Outstanding September 30, 2017</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">6,600,720</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">$</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">5.62</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">4.86</td><td style="text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-size: 10pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6645482288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of financial information</a></td>
<td class="text"><div><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">Three months ended<br />September 30,</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2017</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2016</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">Consolidated Revenue:</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1177.67px; text-indent: 0px; padding-left: 10pt; font-stretch: normal;">Aytu</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 18px; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;">972,000</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;">698,000</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">Aytu Women&#8217;s Health</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">104,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent:
 0px;
 padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">Consolidated revenue</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">1,076,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">698,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">Consolidated net loss:</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 10pt; font-stretch: normal;">Aytu</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;">(3,725,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;">(5,724,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">Aytu Women&#8217;s Health</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(520,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td
 style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">Consolidated net loss</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(4,245,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(5,724,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">Total consolidated assets:</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 10pt; font-stretch: normal;">Aytu</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;">18,115,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; font-stretch: normal;">14,999,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">Aytu Women&#8217;s Health</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times
 new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">3,131,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: right; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td><td style="text-align: left; text-indent: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">Total consolidated assets</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">21,246,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; text-indent: 0px; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">14,999,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 4pt; padding-left: 0px; font-stretch: normal;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8813-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826594144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>May 05, 2017</div></th>
<th class="th"><div>Oct. 05, 2015</div></th>
<th class="th"><div>May 20, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 238,426<span></span>
</td>
<td class="nump">$ 238,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">ProstaScint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 727,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,590,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,391,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,799,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleMember', window );">Nuelle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,061,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed tangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NuelleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6937931552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Details Textual)<br> CAD / shares in Units, $ / shares in Units, CAD in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 11, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 05, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 05, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2016 </div>
<div>CAD </div>
<div>CAD / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 20, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares held. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares held. On August 25, 2017, Aytu effected a third reverse stock split in which each common stockholder received one share of common stock for every 20 shares held (herein referred to collectively as the "Reverse Stock Splits"). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,566,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,386,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Gross proceeds from the sales</a></td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock issued for first earn-out payment to nuelle shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_ThirdUpfrontMember', window );">Third Upfront [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Final upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">ProstaScint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Net identifiable asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,391,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Maximum aggregate payout for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationPercentage', window );">Percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Contingent consideration valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationConsiderationTransferredProductInventory', window );">Transfer of related product inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,590,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">ProstaScint [Member] | Developed technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">ProstaScint [Member] | Trade names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">ProstaScint [Member] | Customer contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember', window );">Jazz Pharmaceuticals, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Net identifiable asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember', window );">Jazz Pharmaceuticals, Inc [Member] | Prosta Scint [Member] | Developed technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember', window );">Jazz Pharmaceuticals, Inc [Member] | Prosta Scint [Member] | Trade names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember', window );">Jazz Pharmaceuticals, Inc [Member] | Prosta Scint [Member] | Customer contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Net identifiable asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,799,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Final upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationConsiderationTransferredInventory', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationConsiderationTransferredProductInventory', window );">Transfer of related product inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory', window );">Work-in-process inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForPurchaseOfOtherAssets1', window );">Purchaser paid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol [Member] | Selling, general and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Recognized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol [Member] | Developed technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol [Member] | Customer contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol [Member] | Paid on April 1, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Final upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol [Member] | Paid on July 1, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Final upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol [Member] | Paid in November 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Final upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Net identifiable asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Contingent consideration valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,000<span></span>
</td>
<td class="nump">330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Stock issued aggregate shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,245,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Purchase of common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Purchase price per share | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 0.207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Contingent consideration accretion expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,000<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodDescription', window );">Maximum aggregate amount payable milestone payments, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">One-time, non-refundable payments to Acerus within 45 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $37.5 million)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | License and Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CostOfSaleForInvestment', window );">Total of cost of sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Gross proceeds from the sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain/loss on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | First Milestone [Member] | License and Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | Second Milestone [Member] | License and Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | Third Milestone [Member] | License and Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | Forth Milestone [Member] | License and Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | Fifth Milestone [Member] | License and Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | Second Upfront [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Net identifiable asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Maximum aggregate payout for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Contingent consideration valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Stock issued aggregate shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Contingent consideration accretion expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales', window );">Milestone payments potential aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock issued for first earn-out payment to nuelle shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodDescription', window );">Maximum aggregate amount payable milestone payments, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">One-time payments to the Nuelle stockholders within 90 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $24.0 million).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SubsidiariesPaymentDescription', window );">Subsidiaries payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The first $1.0 million of earn-out payments will be paid in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SubsidiariesDescription', window );">Merger subsidiaries, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In the event that we do not make all of the required earn-out payments to the Nuelle stockholders before May 3, 2022, and we also close a divestiture before May 3, 2022 of any of the products acquired in the transaction, we will pay the Nuelle stockholders a combination of (i) cash in an amount equal to 10% of the value of all cash, securities and other property paid to us in the divestiture (cash is to be 60% of the total consideration), and (ii) shares of our common stock equal to the Nuelle stockholders' portion of the divestiture payment divided by the average closing price of our common stock for the 10 trading days prior to the earlier of the closing date of the divestiture or the public disclosure of the divestiture (shares of common stock are to be 40% of the total consideration).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PercentageOfNetRevenue', window );">Percentage of net revenue (Aytu Women's Health)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle [Member] | First Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle [Member] | Second Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle [Member] | Third Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle [Member] | Forth Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle [Member] | Fifth Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle [Member] | Sixth Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets amortized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets amortized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle [Member] | Developed technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle [Member] | Trade names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle [Member] | Customer contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessAcquisitionTextualAbstract', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessAcquisitionTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessAcquisitionTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationConsiderationTransferredInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of business combination consideration transferred to inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationConsiderationTransferredInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationConsiderationTransferredProductInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of business combination consideration transferred to primsol related product inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationConsiderationTransferredProductInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of business combination consideration transferred to work in process inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CostOfSaleForInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cost of sale of investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CostOfSaleForInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OneTimeNonRefundablePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the one time non-refundable payments based on sales revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OneTimeNonRefundablePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PercentageOfNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PercentageOfNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the revenue earnout payments based on sales revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RevenueEarnOutPaymentsEqualToDesignatedPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SalesRevenueTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount sales revenue target for non-refundable payment criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SalesRevenueTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SubsidiariesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiaries payment description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SubsidiariesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SubsidiariesPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiaries payment description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SubsidiariesPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from sale or disposal of an organization or integrated set of activities (for example, but not limited to, a partnership or corporation) engaged in providing a product or service in a commercial, industrial, or professional environment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPurchaseOfOtherAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid to purchase other assets as part of operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPurchaseOfOtherAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the overall arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_ThirdUpfrontMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_ThirdUpfrontMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=aytu_ProstaScintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=aytu_ProstaScintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=aytu_PaidOnApril12016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=aytu_PaidOnApril12016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=aytu_NoLaterThanJuly012016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=aytu_NoLaterThanJuly012016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=aytu_NoLaterThanSeptember302016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=aytu_NoLaterThanSeptember302016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=aytu_LicenseAndSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=aytu_LicenseAndSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_FirstMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_FirstMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_SecondMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_SecondMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_ThirdMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_ThirdMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_ForthMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_ForthMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_FifthMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_FifthMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_SecondUpfrontMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_SecondUpfrontMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_SixthMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_SixthMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841783712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">$ (326,000)<span></span>
</td>
<td class="num">$ (246,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">566,913<span></span>
</td>
<td class="nump">647,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 405,000<span></span>
</td>
<td class="nump">405,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 111,000<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment, furniture and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 287,000<span></span>
</td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment, furniture and other [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment, furniture and other [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember', window );">Lab equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember', window );">Lab equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649341376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826619568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Patents (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patents</a></td>
<td class="nump">$ 380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">264,944<span></span>
</td>
<td class="nump">$ 271,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patents</a></td>
<td class="nump">880,000<span></span>
</td>
<td class="nump">880,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(615,000)<span></span>
</td>
<td class="num">(609,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="nump">$ 271,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825310448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patents (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6938074752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patents (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ZertanePatentMember', window );">Zertane Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PatentsTextualAbstract', window );"><strong>Patents Textual [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Fair value of appraisal</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortized over the lives term</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FiniteLivedIntangibleAssetsExpireDate', window );">Finite lived intangible assets expire date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_LuoxisPatentMember', window );">Luoxis Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PatentsTextualAbstract', window );"><strong>Patents Textual [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Fair value of appraisal</a></td>
<td class="nump">$ 380,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortized over the lives term</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FiniteLivedIntangibleAssetsExpireDate', window );">Finite lived intangible assets expire date</a></td>
<td class="text">Mar. 31,  2028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FiniteLivedIntangibleAssetsExpireDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent finite lived intangible assets expire date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FiniteLivedIntangibleAssetsExpireDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PatentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PatentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ZertanePatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ZertanePatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_LuoxisPatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_LuoxisPatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816583824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RevenueRecognitionTextualAbstract', window );"><strong>Revenue Recognition (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Product revenue recognized</a></td>
<td class="nump">$ 1,076,368<span></span>
</td>
<td class="nump">$ 697,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RevenueRecognitionTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RevenueRecognitionTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826696320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Considerations (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">$ 3,818,263<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">7,566,443<span></span>
</td>
<td class="nump">7,386,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">3,818,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">7,823,000<span></span>
</td>
<td class="nump">7,648,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member | Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">3,818,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 7,823,000<span></span>
</td>
<td class="nump">$ 7,648,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815173488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Details 1) - Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">183.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Equivalent term (years)</a></td>
<td class="text">4 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">At Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">188.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Equivalent term (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.83%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758204432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Details 2) - Level 1 [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of June 30, 2017</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances', window );">Warrant issuances</a></td>
<td class="nump">4,118,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value included in earnings</a></td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of September 30, 2017</a></td>
<td class="nump">$ 3,818,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6660170240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Details 3) - Contingent Consideration [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ContingentConsiderationAbstract', window );"><strong>Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance as of June 30, 2017</a></td>
<td class="nump">$ 7,648,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Increase due to accretion</a></td>
<td class="nump">187,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow', window );">Decrease due to contractual payment</a></td>
<td class="num">(12,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance as of September 30, 2017</a></td>
<td class="nump">$ 7,823,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentConsiderationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentConsiderationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the low-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=aytu_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=aytu_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6836407840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2018</a></td>
<td class="nump">$ 755,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2019</a></td>
<td class="nump">603,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2020</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2021</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2022</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">16,358,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember', window );">Prescription database [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2018</a></td>
<td class="nump">647,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2019</a></td>
<td class="nump">573,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2020</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2021</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2022</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">1,220,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2018</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2019</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2020</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2021</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2022</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_ManufacturingAgreementMember', window );">Manufacturing/commercial supply agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2018</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2019</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2020</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2021</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2022</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember', window );">Office Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2018</a></td>
<td class="nump">108,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2019</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2020</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2021</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2022</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">$ 138,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_ManufacturingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_ManufacturingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761920576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814268416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Installment payments</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FirstMilestonePayable', window );">First milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SecondMilestonePayable', window );">Second milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ThirdMilestonePayable', window );">Third milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember', window );">Prescription Database [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember', window );">Office Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Initial base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Operating leases, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">37 months<span></span>
</td>
<td class="text">37 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FirstMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of first milestone payment which is require to make.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FirstMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SecondMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of second milestone payment which is require to make.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SecondMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ThirdMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of third milestone payment which is require to make.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ThirdMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829137568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Aug. 25, 2017</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,224,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">824,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Gross proceeds</a></td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock', window );">Increase common shares outstanding</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,314,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,618,404<span></span>
</td>
<td class="nump">$ 5,704,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Fair value of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedRestrictedAcquisitionDate', window );">Restricted vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_DescriptionOfUnrecognizedExpense', window );">Description of unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The unrecognized expense of $402,000 will be recognized over the next ten years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock Option and Inventive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_DescriptionOfUnrecognizedExpense', window );">Description of unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aytu also has 43,000 shares of restricted stock outstanding and unvested which were not issued out of the 2015 Stock Option and Inventive Plan. These shares vest in July 2026 and the unrecognized expense of $2,435,000 will be recognized over the next ten years. During the quarter ended September 30, 2017, the expense related to these awards was $70,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued in offering</a></td>
<td class="nump">3,196,665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issued of common stock payment to Nuelle Shareholders for fiscal 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PreferredStockConversionPricePerShare', window );">Price per share</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued in offering</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SecuritiesPurchaseAgreementCashFeePercentage', window );">Cash fee, percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued', window );">Warrants purchase, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="nump">6,314,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction', window );">Warrants issued to underwriters as compensation for transaction</a></td>
<td class="nump">394,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aytu_ClassUnitsMember', window );">Class A Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of stock, description</a></td>
<td class="text">Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares of common stock and were sold at a negotiated price of $3.00 per unit.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aytu_ClassBUnitsMember', window );">Class B Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of stock, description</a></td>
<td class="text">Class B units consist of one (1) share of our newly created Series A Convertible Preferred Stock (the ''Series A Preferred Stock'') and warrants to purchase one and one-half (1.5) shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at a negotiated price of $1,000.00 per unit to those purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding common stock following the offering.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The warrants to be issued as a percentage of shares issued in the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DescriptionOfUnrecognizedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of unrecognized expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DescriptionOfUnrecognizedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares by which the common shares outstanding will increase in case of conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncrementalCommonSharesDueToConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SecuritiesPurchaseAgreementCashFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of cash fee to underwriters incurred in securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SecuritiesPurchaseAgreementCashFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued to the underwriters as compensation for the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsToPurchaseOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants to purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsToPurchaseOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedRestrictedAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date of acquisition for owned restricted investments, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedRestrictedAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of all restricted investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-12C.9(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611225-123010<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.6(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4582445-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569655-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_ClassUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_ClassUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_ClassBUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_ClassBUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815450928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details) - Stock option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning Balance</a></td>
<td class="nump">38,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited/Cancelled</a></td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Ending Balance</a></td>
<td class="nump">38,124<span></span>
</td>
<td class="nump">38,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable</a></td>
<td class="nump">23,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant', window );">Available for grant at September 30, 2017</a></td>
<td class="nump">2,761,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 16.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="nump">16.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">16.31<span></span>
</td>
<td class="nump">$ 16.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 16.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding (in years)</a></td>
<td class="text">8 years 1 month 16 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Exercisable (in years)</a></td>
<td class="text">7 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799273936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 267,000<span></span>
</td>
<td class="nump">$ 1,119,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock option [Member] | Selling, general and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">195,000<span></span>
</td>
<td class="nump">1,044,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Selling, general and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815495552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Warrants Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsOutstanding', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">286,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering', window );">Warrants issued to investors in connection with the private offering</a></td>
<td class="nump">5,920,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter', window );">Warrants issued to underwritters for the private offering</a></td>
<td class="nump">394,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsOutstanding', window );">Number of Warrants Outstanding, Ending Balance</a></td>
<td class="nump">6,600,720<span></span>
</td>
<td class="nump">286,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning Balance</a></td>
<td class="nump">$ 50.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice', window );">Warrants issued to investors in connection with the private offering</a></td>
<td class="nump">3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice', window );">Warrants issued to underwritters for the private offering</a></td>
<td class="nump">3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending Balance</a></td>
<td class="nump">$ 5.62<span></span>
</td>
<td class="nump">$ 50.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life, Warrants Outstanding (in years)</a></td>
<td class="text">4 years 10 months 10 days<span></span>
</td>
<td class="text">4 years 2 months 23 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon investor private offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon the private offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon underwritters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon underwriter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Share Warrants Outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815729360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 25, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_UnrecognizedShareBasedCompensationExpenses', window );">Unrecognized expense share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 571,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining years to vest (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="nump">6,314,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Warrants exercise price</a></td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsExercisePriceTerm', window );">Warrants exercise price term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember', window );">2015 Stock Option and Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EquityInstrumentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EquityInstrumentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_UnrecognizedShareBasedCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized share based compensation expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_UnrecognizedShareBasedCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsExercisePriceTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise price term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsExercisePriceTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsToPurchaseOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants to purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsToPurchaseOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6835666976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock purchases offering</a></td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PrepaidExpensesAmortizationPeriod', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months 15 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AgreementAxis=aytu_ServicesAgreementMember', window );">Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Monthly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Agreement term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">This agreement was terminated in June 2017.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AgreementAxis=aytu_SponsoredResearchAgreementMember', window );">Sponsored Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Monthly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Agreement term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">This agreement was terminated in March 2017.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Amount agreed to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PrepaidExpensesAmortizationPeriod', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 years 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PrepaidExpensesAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PrepaidExpensesAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RelatedPartyTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RelatedPartyTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms and manner of settlement of the related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AgreementAxis=aytu_ServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AgreementAxis=aytu_ServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AgreementAxis=aytu_SponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AgreementAxis=aytu_SponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812502752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Consolidated Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Consolidated revenue</a></td>
<td class="nump">$ 1,076,368<span></span>
</td>
<td class="nump">$ 697,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract', window );"><strong>Consolidated net loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(4,245,042)<span></span>
</td>
<td class="num">(5,724,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Total consolidated assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total consolidated assets</a></td>
<td class="nump">21,245,833<span></span>
</td>
<td class="nump">14,999,000<span></span>
</td>
<td class="nump">$ 14,998,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember', window );">Aytu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Consolidated Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Consolidated revenue</a></td>
<td class="nump">972,000<span></span>
</td>
<td class="nump">698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract', window );"><strong>Consolidated net loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(3,725,000)<span></span>
</td>
<td class="num">(5,724,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Total consolidated assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total consolidated assets</a></td>
<td class="nump">18,115,000<span></span>
</td>
<td class="nump">14,999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuWomensHealthMember', window );">Aytu Women's Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Consolidated Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Consolidated revenue</a></td>
<td class="nump">104,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract', window );"><strong>Consolidated net loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(520,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Total consolidated assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total consolidated assets</a></td>
<td class="nump">$ 3,131,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuWomensHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_AytuWomensHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6836337120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 07, 2017</div></th>
<th class="th"><div>Oct. 25, 2017</div></th>
<th class="th"><div>Oct. 24, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Converted shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted shares issued</a></td>
<td class="nump">495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events [Member] | Nuelle [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NuelleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MZP^_F[#UVNS-/S:^"K8-_+J+]@M02P,$%     @ #(%I2YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MF_OXRIBDRI_H27E2J1$];QIZE7JY46L^SJEQ(UD_S6 P_Q$H_@!02P,$%
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MR%ZLZ,5R+X%XL:P7#5J7QA(W7&>A5!AD.TZTXY@=5,2.XW:TU^"(;B/H4 .
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MKKFZ$1"T1.$T4'%'"]Z2"=*3B6M. >RX#XPR[C)JJA[1OD=@EB,PJS&J^D.
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MH4ER2P0;)*Z*X#OKJE"3Y8.$LT9F$H+IOR?@:BYQBE\=3T/76^\@53&R#GZ
M_3F>M;/(RM(, J09E$0:VA(_I,=3[O$!\&N V6S.R%=R4>K9&U^;$B=>$'"H
MK6=@;KO"(W#NB9R,/PLG7E/ZP.WYE?USJ-W5<F$&'A7_/32V+_$]1@VT;.+V
M2<U?8*GG@-%2_#>X G=PK\3EJ!4W847U9*P2"XN3(MA+W <9]CG>W!V6L/T
MN@30-8#&6F*BH/P3LZPJM)J1CKT?F7_B]$A=;VKO#*T(=TZ\<=YKE:990:Z>
M:,&<(H9N,2N"./8U!=U+<:+_AZ?Y/D&VJS$+!-D[@L,^0;Y+D >"_!W![8<B
M(^8N8&3$Y F]SSZ62C:=%:"[,%,&U6J289XWWG5L'VAXF3=XG/GO3'>#-.BB
MK'O?\ JM4A:<G.3&#5+OOMEJ<&BM/[JQ0#H.6S2L&I=_1-;/7/T#4$L#!!0
M   (  R!:4LI.T/(Y@0  $D7   8    >&PO=V]R:W-H965T<R]S:&5E=#<N
M>&ULC9C=;N,V$(5?Q?"]UR2'/U+@&(A=%"W0 HLMMKU68B8VUK9<28FW;U]*
M5KS.S&'17,26?#@\0TH?AUR<Z^9;NXVQFWP_[(_M_73;=:>[^;Q]VL9#U7ZJ
M3_&8?GFNFT/5I<OF9=Z>FEAMAD:'_=PHY>>':G><+A?#O<_-<E&_=OO=,7YN
M)NWKX5 U_ZSBOC[?3_7T_<:7W<NVZV_,EXM3]1+_B-W7T^<F7<VO43:[0SRV
MN_HX:>+S_?1!WZVMZAL,BC]W\=S>?)_TJ3S6];?^XM?-_53UCN(^/G5]B"I]
MO,5UW._[2,G'WV/0Z;7/ON'M]_?H/P_)IV0>JS:NZ_U?NTVWO9\6T\DF/E>O
M^^Y+??XEC@FYZ63,_K?X%O=)WCM)?3S5^W;X/WEZ;;OZ,$9)5@[5]\OG[CA\
MGL?X[\UP S,V,-<&J>__:D!C _K1P [)7YP-J?Y4==5RT=3G27.9K5/5/Q3Z
MCM)@/O4WA[$;?DO9MNGNVU+KL)B_]8%&S>JB,;>:JV*>HE^[,*B+E1'-S<<.
MUE(1"/= , D:VM.') H<P,( =@A@;P*4F@W"11(&R7&0S*RQ3EF>#!"Z8"R5
M"CMRT)$#*94X@(<!O$A)&\5RNFC<C55=.JT<RPC(E*6@#?83H)\ _/ Q#J*C
M8$AY9@>HG/4>FRF@F0*88?.X*D0WWA%I8FZDK#!&^\P;4D([);##^EF5HI^9
M*<M EOF1NJ"\RCPZ6F$H*&#(<BI(D6,3NAXUMVY(V3(S5SJ#* W<..Y&BJ0;
M+<<PF$*KS)NI(<\>M %^//<C1=*/$7Z<*LOL\&#X:0)V!,*E2-HA::<H*82,
M'8Q2;26Y3 ;&&K-/.Y!1R3-R<C)]087 !1*2#4IGEAB->:H!4(D#50-46E5Z
M,=12-_/*N]R#B)&J 5.),U5+7-HB*(XQ()L1!7?SHGVTA,&J 5F)DU5+9LZ<
M*SV)J0-"K4KR.5,8KQKPE3A?M01G6C +I[@G &);%DYGWEJ#$6L 8CG+5P;@
MTZK"\L<)Z&;>%Z',K- &@]8 T!('K0$0U=Z7W)*4A<RL&8Q9 S#+GY"5D0A-
M99D.A2JX(:!,ZWDJX3)KH\&X-:#8I PB#4:DD>6FIH)G)D6"V*/F8_;!Y*IS
M3%L#:$N<MD DW0#0.M7_9?Q@T!H 6LM!"T32#X!LJM?SXX,I:X*<<)L+@:EH
M !7YOF%E).S2+H92/<#K<1#.Y0QA(AI 1,N): #ITDR8@J\Q:Q N9X@P#@G@
MT'(< I&8=)(H]*1MD;.#24B A):3$(BD'4!+D_:-&6 01B$!%%J.0I* NVS3
M/-\B *57::=E,Z8RFVY0=UI>=Y*L*;W1)3F^U /AS)FTP[&9=94P6PFPU7*V
MDN1F$=(FDF_ED4XYJW-;><*$)4!8RPE+DIXA58Y%R1<R(#1%_TSEI@]CEKS$
M6J[^)$Q& O4G?P-6!.I/K4/:NO*\9+0L1#!F"6#6<<P2PFS:YW W_Y^QA!E+
M@+&.,Q:()$,DAVUYN^/\>,"% 6L!8!T'+! )-Z/F]GRK=(4X?IG?'$ >8O,R
MG-6VDZ?Z]=CU1WTW=Z_GP0^F/\!D]U?Z;GTYU?T1YG+(_'O5O.R.[>2Q[KKZ
M,!QB/M=U%Y-+]2F-UC96F^O%/CYW_=>0OC>7P]W+15>?QH/K^?7T?/DO4$L#
M!!0    (  R!:4O_*["NL0$  -(#   8    >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL?5/;;MLP#/T501]0)4K2#H%MH.DP;, &!!VV/2LV;0O5Q9/DN/O[
M4;+C>9VQ%XND>0X/*2H;K'OQ+4 @KUH9G],VA.[(F"];T,+?V0X,_JFMTR*@
MZQKF.P>B2B"M&-]L[ID6TM B2[&S*S+;!R4-G!WQO=;"_3J!LD-.M_06>)9-
M&V* %5DG&O@*X5MW=NBQF:62&HR7UA '=4X?M\?3/N:GA.\2!K^P2>SD8NU+
M=#Y5.=U$0:"@#)%!X'&%)U J$J&,GQ,GG4M&X-*^L7](O6,O%^'AR:H?L@IM
M3M]14D$M>A6>[? 1IGX.E$S-?X8K*$R/2K!&:95/7U+V/E@]L: 4+5['4YIT
M#A/_#;8.X!. OP&PL5!2_EX$463.#L2-L^]$O.+MD>-LRAA,HTC_4+S'Z+78
M'@X9NT:B*><TYO!ESIS!D'TNP==*G/@_<+X.WZTJW"7X[B^%]^L$^U6"?2+8
M_[?%M9R'-T788J8:7).VR9/2]B9M\B(Z+^PC3W?R)WW<]B_"-=)X<K$!;S;-
MO[8V $K9W.$*M?C 9D=!':+Y@+8;UVQT@NVF%\3F9US\!E!+ P04    "  ,
M@6E+>1HU-K4!  #2 P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;'U3
M86_<( S]*X@?4')<VMU.2:1>IVF3-NG4:=MG+G$25(@S()?NWP](FF5MM"^
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M^P^V&!):%XZO_=G,8S8;#H?T@]CRC:N?4$L#!!0    (  R!:4L:#=>[M $
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M"8T/QP]XMM.8388W_?R#V/*-R]]02P,$%     @ #(%I2TBC4Y^T 0  T@,
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M#^%LQS$;#8_=](/8_(V+7U!+ P04    "  ,@6E+)#)OC;(!  #2 P  &0
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M."YX;6Q]4V%OVR 0_2N('U 2XG999%MJ.DV;M$E1I[6?B7VV4<&X@./NW^_
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MO?AT]LX$J,I/&!WD\MSZ\3;S3E/L,?;O])]\&('?F:J:5@<G:>QK]V^RE-*
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M7^!^=T?C/3*S5%R"LEPK9*#.\5VZ/^P"/@)>. QV8:/0R4GKU^#\J'*<A()
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M9XL66U@JJ:%STG3$0IW3N_WQE(;X&/!#PNA69Q(JN1CS'(S/54YW(2%04/K
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MGC%)%:G_H#(_JLMN.RGH7NIAHL:\N?$U$\EJ>YOUVBOUXB]02P,$%     @
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MHW;0A\Y,(9FD2T(:!I!&+"CRO=&D45M20SC#:,XPL2@EKCNC7O0^5YRQ0L
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M&B:L:$8\=96&*28:!#$]W2!7UA4:#5-.-"A=ZND&^;).T](P_40#T"M4NL1
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M'ECV4E9"Y>+>J)J/:H;M+E*QK^K34)T7S2#77%3RU ZI3C<IK_\"4$L#!!0
M   (  R!:4M@>@)5W@$  &8$   9    >&PO=V]R:W-H965T<R]S:&5E=#,P
M+GAM;'U4ZVZ;,!1^%>0'J $G2QL!4I.JVJ1-BCIM^^W X:+ZPFP3NK>?+Y2R
M!"T_8OOX^[YS\3EDHU2ON@4PT1MG0N>H-:;?8ZS+%CC5=[('86]JJ3@U]J@:
MK'L%M/(DSG :QY\PIYU 1>9M)U5D<C"L$W!2D1XXI^K/ 9@<<Y2@=\-+U[3&
M&7"1];2![V!^]"=E3WA6J3H.0G=21 KJ'#TF^^/&X3W@9P>C7NPCE\E9RE=W
M^%+E*'8! 8/2. 5JEPL<@3$G9,/X/6FBV:4C+O?OZL\^=YO+F6HX2O:KJTR;
MHWL455#3@9D7.7Z&*9\MBJ;DO\(%F(6[2*R/4C+M_Z-RT$;R2<6&PNE;6#OA
MUS'<D.U$6R>D$R&="<G_"60BD ^"KR8.D?E4GZBA1:;D&*GP6#UU/9'LB2UF
MZ8R^=O[.9JNM]5*0;9KABQ.:,(> 21>89$9@JSZ[2-=<'-(;^I6#XRUB1]8]
MD-4DB.>398#;AW6!S:K Q@ML_JD"N:I"P.P\1GC,?6Q_5ZG<HI*')2H$@Q?/
MPT$UOI-U5,I!&%>(A74>EL?4/>^5_6"'*/3\ATR8P&]4-9W0T5D:VSS^B6LI
M#=@@XSO;UJT=^OG H#9NN[-[%5H_'(SLIZG&\Z>E^ M02P,$%     @ #(%I
M2_ZW1I\< @  ;08  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULC95K
M;YLP%(;_"N+[:NZ7B""U5-,F;5+4:=MG)SD$5(.9[83NW\\7BDAPU^9#\.4]
M[WG.B7&*D;)GW@ (YZ4C/=^ZC1##!B%^:*##_(X.T,N=FK(."SEE)\0'!OBH
M@SJ" L]+4(?;WBT+O;9C94'/@K0][)C#SUV'V=\'('3<NK[[NO#4GAJA%E!9
M#/@$/T#\''9,SM#L<FP[Z'E+>X=!O77O_4V5*[T6_&IAY(NQHRK94_JL)E^/
M6]=30$#@()0#EH\+5$"(,I(8?R9/=TZI I?C5_?/NG99RQYSJ"CYW1Y%LW4S
MUSE"C<]$/-'Q"TSUQ*XS%?\-+D"D7)'(' =*N/YV#F<N:#>Y2)0.OYAGV^OG
M:':B: JS!P130# '^/\/"*> \"8 &3)=ZB,6N"P8'1UF?JP!JS/A;T+9S(-:
MU+W3>[):+E<O91A'!;HHHTGS8#3!0A-<*RJ+(IXE2 +,%(&5(M#QX17%&P:A
MU2#4!M'"P$_\FS*,)M6:WB3)//FQYXFL>:)5GC"_26,D\2)-D$1Y=-/4*EK1
M!*D?I)F=)K;2Q&N:.+$;)%:#Y.-]3ZT&Z0?ZGJX:DEWWW33D7=D53F;%R2P-
M26]PLE6>3XD?KWEL.B]_$RBW N7OGY=\?1 2"XY%EOIK&K1X\=5%_!VS4]MS
M9T^%O$/TFUY3*D!:>G>RN$;>_?.$0"W4,)5C9FY ,Q%TF"YW-/_#E/\ 4$L#
M!!0    (  R!:4LT/954Y@$  *4$   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;'U4V8Z;,!3]%8L/&!.69!H!TB15U4JM%$W5Z;,#ET7CA=HF3/^^
M7AB&)*@OV/?ZG',7?)V-0KZJ%D"C-T:YRH-6ZWZ/L2I;8$0]B!ZX.:F%9$0;
M4S98]1)(Y4B,XB@,MYB1C@=%YGPG661BT+3C<))(#8P1^?< 5(QYL G>'<]=
MTVKKP$76DP9^@O[5GZ2Q\*Q2=0RXZ@1'$NH\>-KLCZG%.\!+!Z-:[)&MY"S$
MJS6^57D0VH2 0JFM C'+!8Y J14R:?R9-(,YI"4N]^_J7USMII8S47 4]'=7
MZ38/'@-404T&JI_%^!6F>M( 3<5_APM0 [>9F!BEH,I]43DH+=BD8E)AY,VO
M'7?KZ$^29**M$Z*)$,V$3?I?0CP1X@^"BX!]9J[4ST23(I-B1-+_K)[8.['9
MQZ:9I76ZWKDS4ZTRWDL1IX\9OEBA"7/PF&B!V<P(;-3G$-%:B$-T1X^N QSO
M$;MX/4*\6D3L^,E5$=MU@615('$"\95 NBZ0K@JD*QE\NFFCQ^P<ACO,-@S#
MFU;<@W9+D$\%+_XN ]FX05"H% /7MH\+[SQK3Y&]'3?^@YE!/S(?,GZ ?Q#9
M=%RAL]#F[KD;4@NAP>08/I@D6_-FS :%6MOMSNREGQQO:-%/CP*>7Z;B'U!+
M P04    "  ,@6E+_J.V\!X"  "@!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6R-56%OFS 0_2N('U"#(2&)"%+2J=JD38HZK?OLD$M M3&UG=#]
M^]F&,II=I.1#;)_?O7?GP^>\D^I55P F>!>\T>NP,J9=$:++"@33#[*%QNX<
MI1+,V*4Z$=TJ8 ?O)#BA430G@M5-6.3>ME-%+L^&UPWL5*#/0C#U9PM<=NLP
M#C\,S_6I,LY BKQE)_@)YE>[4W9%1I9#+:#1M6P"!<=UN(E7VY@Z!X]XJ:'3
MDWG@4ME+^>H6WP[K,'(1 8?2. IFAPL\ N>.R<;Q-I"&HZ9SG,X_V)]\\C:9
M/=/P*/GO^F"J=;@(@P,<V9F;9]E]A2&A61@,V7^'"W +=Y%8C5)R[?^#\JR-
M% .+#46P]WZL&S]V_4Z:#&ZX QT<Z.A ^UQZ(1_Y%V98D2O9!:H__):Y&L<K
M:L^F=$9_%'[/!J^M]5(D\R@G%T<T8+8]ADXP\8@@EGV4H)C$EO[O'J<X08+&
MF'B"]%.,-R)(48+4$R2?""A.,$,)9D@$R=4I]9C,8QJ/F47NA^O,49TYHI->
MZ6"8&2Z2H2(90C"_$L$P&2ZR0$46",$")UBB!,O[:Q9'^*<=W5&U 30M6[*X
M7;;XQBV*[R@<"EK>T$&OTB:F=]0. V77^9!)@Q"@3KXUZJ"4Y\;WY8EU;+\;
MWWW)/WC?NW\P=:H;'>REL6W*-Y.CE 9L+-&#O165?2[&!8>C<=/,SE7?,_N%
MD>WP'I#Q42K^ E!+ P04    "  ,@6E+U@SKA>$!  !I!   &0   'AL+W=O
M<FMS:&5E=',O<VAE970S-"YX;6Q]5-N.FS 0_17+'[ F0$,V J1-JJJ56BG:
MJMMG!X:+UL;4=L+V[^L+(21!?<'V^)PS%\^0#D*^JP9 HP_..I7A1NM^2X@J
M&N!4/8D>.G-3"<FI-D=9$]5+H*4C<4;"(%@33ML.YZFS'62>BI-F;0<'B=2)
M<RK_[H")(<,K?#&\MG6CK8'D:4]K^ GZ5W^0YD0FE;+ET*E6=$A"E>&7U78?
M6[P#O+4PJ-D>V4R.0KS;P[<RPX$-"!@4VBI0LYQA#XQ9(1/&GU$33RXM<;Z_
MJ']QN9M<CE3!7K#?;:F;#&\P*J&B)Z9?Q? 5QGP^830F_QW.P S<1F)\%((I
M]T7%26G!1Q43"J<??FT[MP[^)K[0E@GA2 @G@O']/T(T$J(KP563^,A<JI^I
MIGDJQ8"D?ZR>VIY8;2-3S,(:7>W<G<E6&>LYCY)52LY6:,3L/":<8:X(8M0G
M%^&2BUWX0 ]O'>P?$4FT["%:3")R_.@FB7!9(%X4B)U ?",0W57!8Q*'Z7P5
M@F0=K3=WR3SBUL_)\R:XBX?,7HB#K%TS*U2(4Z=M+6;6:5Y>0OO"=_:=F2/?
M]E<9/X0_J*S;3J&CT*9_W"M70F@P409/IK,;,_?3@4&E[38Q>^F[WQ^TZ,?!
M)M/?)?\'4$L#!!0    (  R!:4OV(.'*G0(  . *   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,U+GAM;)56[8[:,!!\E2@/<(GM) XG0"I452NU$KJJ[6\#
M!J)+XM0V<'W[VDXN(GB!W!_\D=GQK >O=GH6\E4=.-?!6U76:A8>M&Z>HTAM
M#KQBZDDTO#9?=D)63)NEW$>JD9QM75!51CB.LZAB11W.IVYO)>=3<=1E4?.5
M#-2QJIC\M^"E.,]"%+YOO!3[@[8;T7S:L#W_R?6O9B7-*NI9MD7%:U6(.I!\
M-PL_H><ECFV 0_PN^%E=S .;REJ(5[OXMIV%L57$2[[1EH*9X<27O"PMD]'Q
MMR,-^S-MX.7\G?V+2]XDLV:*+T7YI]CJPRS,PV#+=^Q8ZA=Q_LJ[A-(PZ++_
MSD^\-'"KQ)RQ$:5RO\'FJ+2H.A8CI6)O[5C4;CRW7[*D"X,#<!> ^P!T/X!T
M >0J(&J5N50_,\WF4RG.@6S=:IC]4Z!G8BYS8S?=W;EO)EME=D]S0I-I=+)$
M'6;18O %!@\12P"1]I#(".A58% %=O%DH.(& 0$)B"-(+@C2*XV+%D(=I&[/
MR%&.,W*5"T"%8"D)*"7QXKTS%BTFO=!"TRQ+DFLM ([D&<TQ+"@%!:6>($(S
MF" #";+Q[E"0@#YVAWJ96G?B.+ZZ$8#JACLY*"4?X4[NWWJ.B:\%P&7)0/-
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M7X?Q0*"0>INH/>]'9'^0K!W&/QJ_0=D_4$L#!!0    (  R!:4M&"[.8@@(
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M4.8UT>^R;53;@1*U:\*#VW\"Z_]02P,$%     @ #(%I2]13T*Q+ @  W <
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M=Z)CT+42@%-G8J' ##HW9HR\BGN@E=?P2Y[AQ<'[< ^GO//H6CGG!N"2E%?
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M6..R(>R0G$9SGK<'XGTUWI"_'_&Z$):V/M:0OCN35PF+T3!+.$VKOT[4BHW
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MA=&T\06 @S? ,]:"Y;,6R++>E7=L93;"R#YA(/MNGS"@/II604 IT51D =S
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MI:#(>S(^-8BKL';< B+WK'_ND=L"A3MKI]>"B-)T,E["K9\-S,!; ^TP1PL
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M5H\UIA--8&(P\\';%9'$0>."WUW1NT+@=:[4S$51I1*%YKD4V01<  C<"J9
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M'(XF9L[A6&?A5+9&P^%HW!N?3=T<\S[\<1%0,+ZDEK=[\]FP=S:?\;U(WX)
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M>EJJN8N=G\>8#/SXA\:(M]0TKZ565ZZNO<RS)*&0OB&6\VJQH7ZC\NFH'A5
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MTN(W](?LX*5?4:ZX0UZ30&L&[8EMO%)WT2]-/3,KMS0;CV8J =K$7Z='&=_
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M:$:-AL"Z[?)!7 FT+I//B-42;RTQIQ)E;Q5SV'],N[06'G2:@X"1YJ:SB@I
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M]7XUQ=3J)H<-\9PIH5)L?6WRNR2XUC;A(:\[!1,V%#A"D\[J@3II)QA5X))
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M ).2K[_<MLKW/I0*^Q\<,.TCP;SV_B..L.'M=TV=ZG[. +9YW:/?K_6R:QM
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M:V)O;VLN>&ULQ9E;;]L@%(#_"O)3)TUS,#2]J*FTWJ1*TQHU7=^)31)4&Z>
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ML(L \@2 /,&%O&JLTM+:KW[66-7!C8VT_J7M)>@4@#S%A;Q3[[X+OUOKIW-
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M5:'(JE!D52BR*A19%8JLZHJR=L>TUF7S5Y)/8Q;[^:S[WW?R#5!+ 0(4 Q0
M   (  R!:4L?(\\#P    !,"   +              "  0    !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    (  R!:4MF\PM@@@   +$    0              "
M >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ #(%I2[RZZX?O
M*P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ #(%I2YE<G",0!@  G"<  !,              ( !MP(  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  ,@6E+V^H_.&4"   4"   &
M            @ 'X"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ #(%I2VVU]?N\!   ?Q8  !@              ( !DPL  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  R!:4MZY]*Z/0(  +@'
M   8              "  840  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "  ,@6E+MITE<WP#  #Z#0  &               @ 'X$@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ #(%I2V(['8%S
M P  - \  !@              ( !JA8  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    (  R!:4N3\/?&O@$  -@#   8              "
M 5,:  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  ,@6E+
M*3M#R.8$  !)%P  &               @ %''   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ #(%I2_\KL*ZQ 0  T@,  !@
M     ( !8R$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M  R!:4MY&C4VM0$  -(#   8              "  4HC  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "  ,@6E+SCBSN[(!  #2 P  &0
M            @ $U)0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    (  R!:4L:#=>[M $  -(#   9              "  1XG  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ #(%I2TBC4Y^T 0
MT@,  !D              ( !"2D  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "  ,@6E+)#)OC;(!  #2 P  &0              @ 'T
M*@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  R!:4MZ
MLL#0M@$  - #   9              "  =TL  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ #(%I2]S!AUNT 0  T@,  !D
M     ( !RBX  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  R!:4N&2V52]P$  .<%   9              "
M 7HX  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ #(%I
M2XT@''RV 0  T@,  !D              ( !J#H  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "  ,@6E+? KSSL8!   W!   &0
M        @ &5/   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   (  R!:4L%3S9-W $   $%   9              "  9(^  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ #(%I2UXL0H;% 0  -P0
M !D              ( !I4   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "  ,@6E+(;;X_M0!  "<!   &0              @ &A0@
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  R!:4L%E4L[
MMP$  -(#   9              "  :Q$  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ #(%I2R83-J?, @  7@L  !D
M ( !FD8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  ,
M@6E+0C]!N4<*   A1@  &0              @ &=20  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  R!:4NP4:$X,@,  #4/   9
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M970S,RYX;6Q02P$"% ,4    "  ,@6E+U@SKA>$!  !I!   &0
M    @ %>8   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M  R!:4OV(.'*G0(  . *   9              "  79B  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ #(%I2]/9-) F @  ) <  !D
M             ( !2F4  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    "  ,@6E+(199K^\!   .!0  &0              @ &G9P  >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  R!:4MJ(:0(]P$
M !$%   9              "  <UI  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ #(%I2R 8COB, P  ;!,  !D              ( !
M^VL  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  ,@6E+
M=@HOA=P!  !F!   &0              @ &^;P  >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    (  R!:4LN48G_W@(  (\+   9
M      "  =%Q  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ #(%I2T:-[/XB!   (A4  !D              ( !YG0  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  ,@6E+LD,G?<\"  #S"@
M&0              @ $_>0  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    (  R!:4OKQI>@+ (  (\&   9              "  45\  !X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ #(%I2T8+LYB"
M @  B0@  !D              ( !J'X  'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    "  ,@6E+H%/"@E@"  "7!P  &0
M@ %A@0  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  R!
M:4N$57?5@0(  ,T(   9              "  ?"#  !X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ #(%I2_097D<% P  %0P  !D
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M='EL97,N>&UL4$L! A0#%     @ #(%I2[ZZ4QI] P  Y1\   \
M     ( ![.X  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  R!:4N<X3!X
MU $   @>   :              "  9;R  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    (  R!:4MBCXVUQ $  /\=   3
M  "  :+T  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Z #H R \  )?V
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>168</ContextCount>
  <ElementCount>246</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets (Parenthetical) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedBalanceSheetsParentheticalUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statement of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited</Role>
      <ShortName>Consolidated Statement of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited</Role>
      <ShortName>Consolidated Statement of Stockholders' Equity (Parenthetical) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger</Role>
      <ShortName>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Patents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/Patents</Role>
      <ShortName>Patents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Fair Value Considerations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FairValueConsiderations</Role>
      <ShortName>Fair Value Considerations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Equity Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstruments</Role>
      <ShortName>Equity Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerPolicies</Role>
      <ShortName>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables</Role>
      <ShortName>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FixedAssets</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Patents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/PatentsTables</Role>
      <ShortName>Patents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/Patents</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Fair Value Considerations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FairValueConsiderationsTables</Role>
      <ShortName>Fair Value Considerations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FairValueConsiderations</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Equity Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsTables</Role>
      <ShortName>Equity Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SegmentInformation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails</Role>
      <ShortName>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/Businessbasisofpresentationbusinesscombinationsdivestitureslicensesupplyagreementandmergerdetailstextual</Role>
      <ShortName>Business, Basis of Presentation, Business Combinations, Divestitures, License/supply agreement and Merger (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Fixed Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FixedAssetsDetails</Role>
      <ShortName>Fixed Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FixedAssetsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Fixed Assets (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FixedAssetsDetails1</Role>
      <ShortName>Fixed Assets (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FixedAssetsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Patents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/PatentsDetails</Role>
      <ShortName>Patents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/PatentsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Patents (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/PatentsDetails1</Role>
      <ShortName>Patents (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/PatentsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Patents (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/PatentsDetailsTextual</Role>
      <ShortName>Patents (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/PatentsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/RevenueRecognitionDetails</Role>
      <ShortName>Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/RevenueRecognition</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Fair Value Considerations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FairValueConsiderationsDetails</Role>
      <ShortName>Fair Value Considerations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Fair Value Considerations (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FairValueConsiderationsDetails1</Role>
      <ShortName>Fair Value Considerations (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Fair Value Considerations (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FairValueConsiderationsDetails2</Role>
      <ShortName>Fair Value Considerations (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - Fair Value Considerations (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FairValueConsiderationsDetails3</Role>
      <ShortName>Fair Value Considerations (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/CommonStock</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - Equity Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsDetails</Role>
      <ShortName>Equity Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - Equity Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsDetails1</Role>
      <ShortName>Equity Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>045 - Disclosure - Equity Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsDetails2</Role>
      <ShortName>Equity Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>046 - Disclosure - Equity Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsDetailsTextual</Role>
      <ShortName>Equity Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>047 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>048 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SegmentInformationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="aytu-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>049 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SubsequentEventsDetails1</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SubsequentEvents</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aytu-20170930.xml</File>
    <File>aytu-20170930.xsd</File>
    <File>aytu-20170930_cal.xml</File>
    <File>aytu-20170930_def.xml</File>
    <File>aytu-20170930_lab.xml</File>
    <File>aytu-20170930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001213900-17-011671-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-17-011671-xbrl.zip
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METM0T]*RG[3\Z2,W_LHL-QJ?EK L8O:H9&6^C.J1W8;,W\154W9T>R)I!7P
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MC#I/?VV>8W7B9:?+93"6C=6.W#D85J*TZ44<C?T @XS+Y]&2BJO=YGPP\FK
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M./357T0?T%HX&!95F@.U6$;+LL:;YF##;6Y3\3LPTKMO5!29BO!;GLTN1\E
M5$PVH21LOABN7/UFU6N;0[/7EQ&SF\+U,(B4>DAMXRGU^)'>?0\ S@\&G=XI
M$&'GW:!VF.Q2[:PZ_BVO6U&#/<0<]GJ][A;H)T4NZH?_/C=D.^*?NIWAC'?E
MQW2I=CDB ^AMS+[Z@.H="T+0+8=-CCDP7!4<$NJ(Q[[Q6'7$:3^U7S-D=CP+
MK$)%V,0U6S3+U'E+62+;(%-;"NSOR/IBS42JVGON@68'=%0Q3:7K*9_Q($G0
MK5S,SX:0+02>O)Z_OSQ XGZST^Z;K;DPD@5 2@&UY B0]9#..6T/EC'2[W9Z
MF8NJ8C!* ;3<2]OU@+YETP &($K#OUTF,T>SB:35TW?0:IF]7,O+]5!5@,6^
MCH5NNVVVM\=B(7.73-HI&"W%Q0E(N6=2N9?UX2F51>UF9]@KR#+>'M;#H5QJ
MPMK%G<5=Z\9E(S\(+9==8^LL*OG\6^"'X1]>P"P7"]NI]#KS\*E_V\-8.8:E
M\B ]\XE+.\_YTPH""TP0L(%D2%!X&;QQ+3XYP)KH-H?#84;=;@5>E7B5*_B)
MH7DY4F#]AO^7.1GH#D#MP;#=[Q>%[:V"JQ),RA5JSX:%%;*W3/SW@W=AVV#/
M4W<^QN]P11Y OW?ZS>SFM0E4%6"Q[Q8\: ^R!M#^6&"*M!?YP4$VV5ZSEXT
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M/4?O&^*(F W^'=>O!TL7"1P"=1TF\;BT(Y^F,Y4A/94QAO&4#HCP\@\^B2=
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MEE9<ZMS'* B.D^2>QE-R(.3N@%2<-, -R@('PCP,$5.!_1]I%'D>Q[Z/Z"\
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M8%2F8K]#N:0RB_*DX>>.&)M'9RZ29M?;QSVNX-</5JZ4M#:4DFK%0AVK\[*
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M@E[<_,_U<M?*]<2H74SCE& 5$&N[^Y>L>=0^;[=3DTF@FQOUGJ$]61I?*N:
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MWGVQ5/?"FR*PD>(9(QC48[<^D!PUS33 2"T*40&M2#H1X3Q/L%\/M1\'*.J
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MY03\29;ZVU#_Y XE"+D%IPDG%$JF3TI66Q?UU!&:VE59%Z!$S,&2"XU0U:F
MA>>=H7I("XX9GV/FNLRXQB^QI@63-3Y'/+0M4?+RW'A^G:F8EN=V&LRX-"01
MXQ55I"/](N=Y1U=G.&Q!D*..8UPJFPNYK'O592"V#G*QAX(QL$_ MW%:S^I4
M(ZW*I>><6M1$VXAH*OA/F"F/MGZ:KO]1!84N19V/E% B>$36_$@T7_^G4&R8
M:A^DP(T[Z4A;9DO;&5MZ(6R!/L)?LG$*\FC?P&W9F@BC-[6X<6=/2F*I.R@R
M<<D)+DX$8I4T5! 'P,EL+EQOHMYI8_$800$0%"X@8U:DW8QS%%^YM3/E.HM-
M"W&87Q)'01<"[DP<6Y+IJ,H7QE7 O"/&J:Z5C16[7/P7EAB5Y4M5R==IP)$*
M/AU-R,N)%W0A5<]0-=9P?+2$J/*7(E,#CPP\H*II%,B!R-_S,.<C?2Y(0B$/
M-VE P0L!?<IY8J\ZWV!-.8>2M]1-XK+PFCN+NU0% JF<0%@P]BD>6;1Z.PB%
MOF1"U^8T%4I68\DZSA0"RJG _(4Z+ASX@ 6H![-"7.3\4X7N;O%R#Y<GWJE;
MKAV+$WL<JA/_:TPZ/[NV0=,B,$*?8@P4OC#Q'>92[2+*.T>TDD%D&9]YCV.B
M$-45I@503B0TB )5YD?-%J@8IBFP%&\@Y0@T:;9\(QV80.%,"/3%*3/:+4^Q
M@(??ST;H5N44EQA&!A8";!AW/F! I?D:LN(DPW!=U/2@FF><85R8YZ2_2;JX
M? 34?@,:ZI8E71>R"-H4RV5;6+L2HY+YB-LH#Z*^C2@[A/J3JA.F32 4=F'B
M7J%9J;80EF6B""B:ZXZIDI/XI]3#XD7E'5*E!6-T!68J)TG."&E90AKT7^<F
MI,+=7S&4*PYFDC)X+TT72A@@1JYKK ,I9R&!$[NE^BI,HT!Q0^"P "PLVXEU
M*J-9E>HVFUU8N[I'6@570:'KC%EF8#C"'1I8NM*6KJBE*VH]U)Q'4S+G<Q+B
ME/5^U(J6FG\K^/<GEOY$R^E"VDGOY"'2^()1_?6CK.;F-MR\8A,X4:#!^R9C
MXWX$HQQMTK_C;68-R%U=V1E%RF:SG6RS.U7*N,S<8^>26-=6[]$5L':M4S-H
MM'KM6F-]Q+Q=7FRHPJ)79N^\;:Z=N)QZ5T]T0;.#\G9PWEE>M.CH2IDM+:*X
M#E2QV1?"^IOP+.ZPX=:L%-:6T^TM6F>UPNH8.'2@4G*:,75?.G5!K^+*DKLI
M9'76U2I9KWRMDA\K8[1*/I2%O-)OM$)/OU?1-B_?4+"-NY/&/HR3< ]V5>(B
M/+"$5X;#<[,]+(4!.XK!BZ.5N!VA*&F_VG%VL[?*G7  ](_@/N*!,:]8 FI.
MC(<XT"@<.MM@D+VY6$Q/VT.XMX*BSKMH9^G^X_CQC<N.8!/=#(7VH&&V.J4N
MITJ$H+9BMQ,,)6^D6\V]^L)%,_Q!L:Z4\_]_>V_:W#:2+(I^=\3]#WC]/#%R
M!$43W-5]IB/DK4?];,O74D^_OE\<$%@D,0T";"R2V;_^9F9582'!!21  E2=
MF#-C@4!5Y5I96;D,F_KZN]/3H>!TA\Y<ZQ>>08K8,[*J6=>4G]6^N0\([4ZC
M,^Q54)KRLMV+6NG1$V^<!9\_U<99CXUST*RDJ%>C-=M>,%VG$@EYNHO:5)_]
MIMH8]/7&<+"EXVH5]$UE.:^^6K9.B'B>4#]?\J]M?JCRWFAJE6EY2*;E)<\6
M3I5KSRX/MY2XG2J?0>GIUE);)C^ KV<R,]R=,UZ3BS(Y,0_>\,PI[[/$'IGM
MSJF.5E0P&W_ 5C$6EJE87W\S\8$/[U/F<C"-:EJ3G?< HS^)3.T1XQ4K1"F2
M!$Q&E, ^$D4[N&V8)]4^2CJG%2U-  N&Y2SB.GXR^QLP8[D40X#$3/+GSDF4
M1-#F$L_C"/B<J@O$W45XXF<X VX&'20*M6SB UDZ)4GRJ'A!7%EEIP*HO#E:
M2^^7F<1;:[%4";LJ8;<@0Z7**8+]'[AJ0IWQB>N,]Z@S$)H'3WM-.U12?50
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MG791=*W %[ )@H4IG/+ =F#J<;.)SKUB;3P$BS!H.>B%=SW^#3#;G[AKPL^
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MQYHOW;>)FVFZ59K-#1YF3C?$X1P#G^C::^ZY_V4FCXSF&84\K-JA*T#7L1?
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M8.K.,6D1?@L1/_N'1R;BYU8"("E<$>SV.&@0GW";7WJ=**80,R@QW%"")A*
M $(!P+I82D"H?&,Y>!*QNS9B<AEQNT9(;HJ%Y,LP/(L'O$71B,@_\$39$DJ!
MGAFVN7["\%@9E(N!GX+?5^,VHVC<M,!R(>4AO.FH5;W;YNZ)R#/Q4F_Q<_$3
MXQHS'8(M3\J!^V1X(W_-=-$Y>B5,F-Y<'R*\6X#RA?$JQL=2&'&<!"K3WRX>
M-K[]:PAZ,'H98;PPX8-V+_,#*U&CAG*PUZO-&\</0#?3WO6%QPVG@_V5 "EU
M=5[8WB6HUMD:5"NV^?4!M=*F[(E06JK;6]E8VK.D]!Z1M"\.Q=8+%4M;BP!(
M%4NK8FE5+&VUP\94+&UM8VGU85O%TJI8VE/$TG8'*I96Q=*J6-JM,.C=S?D.
M*ICVO(-ICRM8YQY*JS<&6UKVJ5!:Y8M2/M[CA](N1W927*6X0'+'RW='/!:6
M[II<[T_ T^7<<['L;O(":'NH+LZR-E:WU]X<JSO4U\?JZMWL8%V8[X'1E?-R
MN*YO?5\*U\T*-\6Q1:"I:!3"R[N8[L2AT02H*NRTXKRO-,U) NG>85>/P I"
MCZ5:EZH(.M4^\?D1X!8K%WJP+\6%RY[804%UU[;-)I:O_=NUT1@&(GS\^%:[
M6 X#$U][.T?7P;) /*.PKF@ "ED3/>-60^YX\>KL,+N"@^C,-3%T14?.$?K3
M:/L=H]YXQP5G$47'8:%AWS4MFHEHDPRPX52D_!W7I#:R&$)C8;"-FPJ$H\R7
M&-T4N1+Z+\#":0QZ41A1XHLH8B<UE5AE9*88VD1$]U']PN\68@=P\;+;'G++
MSHGC]T1+#)C52EAT%)K8D$TP..Y',^!O$!;><2$RFASBA*A%1;J_@S)WE+ES
M9M@&6:,2X%3UD2M#3+$C5!B\<XU0:D*<2!%@972?.ICX%HCIV#*%+D;AB2KU
MBRJC'@.<LE0'%BQ(GA10GLT34LQM)&T-6?_<]"S2ASC! TLT-\$C&9:?I(_C
M7BF8;XAG'5H?_.V/+=6J1,GN^6%;&L4?+9-V+Q2XNW ^A]TQ,K82N3^?0;[]
MP%6&LQ*)<\7VC0S$3C8A67-(,<  CN7&YW(3EUBGA%&Z[N%M,+[#=N6CK?A;
M\Z[);RQXTUTA5<E<''S@PZR ]E>:8X#]"<:GS=N[7,,1(O27ZWHGF[TT *_B
M-5D-6TR7[&O#^W+@@BCEGJ]Q;GE1&5GJ$0:X!UM< ,I2\;%\3#E#9-N[2ZU<
MN%TO1D@-  #.-"],]#T#Y.'1A1J8X>C4GLQ'<+#KAQTO<B$7:!/V>"M5S.:'
M8T. V$^<N&P#3@? XH_ _/"WP#<1+3$J'+H6\BC #U5T9 B QPT_H/8LUV\N
M>0\?.@A8ICSP*=- Z<$SPW:<PB/43:),_YCQRX%V7**?JQ#1S#C6'I$RI 9;
MB:3*/KE9LG)[$H,V1&LQ[5?#"0UJ?Q0U7Z)/92='.[.#0#?908!W\:3Z^C)O
M,M%ZK3V,,VD2=?-A%+W=:'=[C:ZNR\Y+V">2HV2E2=/;$<R4K*FO7:1=#K_=
MI0!\U1 =U)8;),1=E]A?Z!\";<7';C7;K0&JP]5Q6TV]'W\H^X^*1?/B);QK
M%*Z4?!UXD80*T0>J>9;P/M&;<7E_JKXOU"$]%:@TJ54I'I#@ #5WHRRN>$JN
M6GFZHVR@=25WA'>A9XF^;#"["_-.#7N,8\0E6R2IR1DG?&_)&?B^,O%<W^=>
M,3;R^0XIO3D^;R$ D+S4FWK,5KS^@R][4BV_>R6RRT2#NI0KR<;9J$H$.O>S
MNU6(7G) .0^!7W,EQD5@:I $A YL?#;-P9U5HE+-TC0#[K%2^XW:;\X,VS?Q
M+B#=PDLZW2=YF:$>F1E_,F&=8NX4>7T<=HFX;B#*+CTV#IT1)?7(KZD!(M?;
MJ'-!QKH];60LHGPM8;]BR]_(]I6CLT<:X@+;WUC2B=40IN)RMQ7>*"]NRT+-
M'/W0Q))4-EJ>3F)5LJ36R\X@WC9>J62P:B:#'8RL?*E@*Y%JSR0W+'#G&[(_
M^IT"LBHV#0+OXP])H5LSTU5_<,6GPI?BB+I-J14\MV+_F5/VI35.=(D:<:,*
M;^;&Z$?'C%4RR.&(#]@%.\3P(JM$MNLF^Q(;C'Y' PHSR!-6_?)EZ@?+ _7[
M2:JQY-W@3Z0-EUZ(['$KT4U>..'1@$>]BC#(,"(?FZ+*FX$9"V2($>E??G.0
M.E;@J^A$P#)%(A$7H<?Z77@(H8ZQ\)4378B^T!X\"I-Z6$0.D@?#^=,+YX&Y
MX&X'^FH.6%J0'T6.C_B(O@((3",$4]0*X)^V!0OD5PVR2ZK4_K+M+BV-%P?
MH](+Z@1M\UO=)V%+@W'I8./C:'N+X40;V9VAC&#S+8N&'D=.GHTLN%/@]!J)
MRRMDA_Q\S'5N_JX4^3] X),26;S ]UKQ\(J1SIJ1!J7N'(.>8J1GPDAZJU25
MI+>2.@G],(J=SIJ=RC5I]:1-V]R1E4I,BU$G<.5B.U&9HT0S7>'D0EFS$&QK
MS(\5O#![=$L<>]!;"2&589+9&2:)J]L-Y<SQ_")35O+GD?"+BI>=3DMYQ)6X
MGB&VMW;C3O3@[C3;\4VLZ*O]";YEVEO#LUW-MV:A+4)#5MMR]YO:]6JO[BUE
MTM.MONF>5M9-I]X(S4&T(M[7(55:?1Q26@SFQ\QX?#IO^, \I+(AG/ R4F,S
M2%L:ET=%VZ7BB:--=M,X/#V0I\ U1 0JKD?XIM9.'*E90,9PQR[K*XO-M=8^
M7VNWKU2B2BMZ9@3XQ+P)\U[?A0\@3I;A+10=E" \(P+<8'Y=*D3J=W?&XLX-
M&&_Y;V;8P93RY)I@" !DKFTO+MTG!W?@2'(HQ E&:,2G@,\A)JOQLO5T*R(?
MP" KT_CL.Y[ IS0;1DEA957<^);R0F"+,V@C2^;.S>&D,'9AJXP3R:+  '%0
M^&#!=HF<Y(?S!,L-NIS1TD^!$<&J\"FXS,2(JA%[Q! KW%=IZ6J?5$>',\.V
M"$#C6V)#N[!>\8,V#RE$PYJD-QW B#8\/X[/N;"!?!B>)_*RH@!%\2G_!LU-
M$ZUU>#029<BM=;/-/28*)B<^=AWT@,K@>DKQ(N<!_.$QDZ&?+XZ[Y![ >,V4
MZ6GY?A@W8<B>"Z^500ED1'?V* ,T:XH78HY:,^R+FG"LT@\G"K9K;)$8&9^&
M#L+ YG+F83@&'&V9X3F7;AA'Z,71R@9LLYC9R?LE, ^K/QD3DKG8N8^A?A9.
MDGH:SLF!D+H#DG'2L&Y0%S@0YF'PH KL_TBCB/,X]GU$?P' -+(F5@"OPDF;
MYVQG1.O!VA$$/*;WFU?I6P+%ADKHSP;;R8T[V@^CQ M[D2GJ<<3JJK"#R'!9
M-<!HQYPK#&A*;:\OV]VD#$=I9D: )20HL.EAH84T5$)?Q+H@B@GS1>DJ!SN^
M_A6*R?B58/8UH))@)<%GAFVZP*, RV2^"04MK@BG%&;9_F>]$1U5DN'ADNN'
MPH.\9Y$K?ZSU6_\ R?.G]'47_MADI>/"^5QXNA=K1EF.)HOF,&PSY!5K0#.,
MK$>+,I3H/+&JP-(][N*A*614#@WCD,X1AH,L'<,3K;+P(3WN>BO*D*(\@53-
M&AC>MN(64=3CY0F="[:%BLIQ QP^?2A)J=[E98K0U7GX8%LF5:6 A>(=2:0A
MTU#1O2OVI>5-LBC:5.D\I?/.#-LW*P'@*&4N#Q#'..DX,3".,%_581L$\8%7
MET'G:0=OT=KM*/./\D4IV1\/-(ER?JO?2(TFFS]Q;V9<\#DJEAG[/RF?B10?
M]HI;MSP#E9/LPXO#HS>'-"\5X9+91M')2P==+!8174 BCO"3ADSUM$07>J[R
MH^IC/*D6[UOE<I- 7_!9?1' WX\GHAB1]$WFJX0W:,/>$RU[#?@)#;^LX)-+
MDVD&M&'PO:-\G2]'E?V]EA<5M3E<UN@9[U[$.$KOS1X3Z.YN1K=2_4KUGQFV
M-Z2$HL]7!HDDY66G%-&==@61(WK5JE*.:/(XK7)$58ZHRA%=B4(78T@F2R9[
MKE)@WZCZ B8I)00_<UTRX[3(E?TVIUBUJ<4>91D/[IA(*\C/+-#NN*M_K*63
M1O*Z\T1, ZE";O>OZ/-E=2ZKFB1.W!GV<M*54GC6THMLRI3%B:<8]T5AS7MV
MDNA3H^X(<DM+$3CY+]@RUGA1!>E-)@]627J'I><<5HL#]QIW7W92 GVV ITJ
M]% =@4ZD BJ!+F7<\\'<L63WE&+:J>:^VU'[KA)3)::1F/:J>;CM':F.0K48
M3HGJUG&CE13J-\YTU&;*=SE^ZVWSKSIRZZ!;4J&P%5(N28>>*JM1G4L+#+=Z
MR[.N4A%2AFV[IH@C<)82CSF>> #X.,KO$LGB_!I;)(#0=?<G8Q%+5$\D2EL^
MOL]OQ'QU/:6NI\;/YC9*-)[/V-]7$5MT[_:-[<+U9J_$?O&RJ?=>0.;ONRZ
MR>R\[KNV-4)2NDA)YU\_M F@#UCPYC\8"%4!).YD)U:.E4XV^#(M3P-%'J)I
M#\"\$P_LI)'DY__7-!D;C[/H*;FZ,[A:=A/C:O<4*VX"I)N/K\677$(_V] M
MD 569RH(U)=;ITS<?XLY*<?TD$G;C18O"+-U\E[1\);%J&3QK%4[FQ?_8N?5
MWSC!CJQ9OD(JFR#9TV7PWHM\$^J-7K>UD?GJP&\;%&/A._(OKCO" W %;(#"
MB52*&54,7Y\>AG9G6)B@G-(:+%A?K\#4S0/1/<6?RW;C(L'A -'*-7F5!:N[
MEB5';@A;WC:#Y73BM-O*.XUAYZIP>2J&_,K'>"K/DTJ*.&I21-ST'-VRUK(]
MC5[8$7MDMCO'' 1F3AT89K(0;>HZ<3J^&?H@?XR*:@,J39[2_W)(IB7OO>X9
M(Z8YQDQ>1/1;O BF+-O+RP#+_(2E*L"&YE@.SX%]8O8CN\2"P#([7[O.*@E,
M 0_#:/Z7+5%F-&K EZ]R)[6SSNB[YS%_SEO?V@N5.*42I\X,VWDJ!^MQS9L=
M*P?+*H.E5K)=)[N\P&V[%3?H!!VAQ%F)\QEC.]$K=TM+V4'<53F.+%A.AJ>6
M\^*B'Y..$Y?\+W7J?"M+ZH&)(7K]IC(L^9X/<MCN12G)&PN.4D$?630,M4"B
MQZ^25R6O9X;MZT11K431*UDN0$C,3!3G?"+#/9R!O-F6\6#9O#H#-3 ?9-1Q
M?SVR'O'?__,Z]"\GAC'_\0WNV\SWW\9U(OPOKFV9BY__UXO_D6]]9D_7IHD1
M/+"(+Y[KP#]-:BXH7N;_?0\ OK&Q] #N[/#'5S;^UP]O^;^_=3Z]_];2O_T:
MVM]0>.];K6_\/_>WWSJM;Z"0TL]_^!F7+%:L.*[TXMM?&=[(VPOMAFOPF.):
MFN0-[;,;:-<C=XZEEKAAM[J=$+^I"MY*2Y\AME/UTJFJ^/7=&VGY7-_]!@+2
MI%\O6U>-96\7-</%$#LXV/ I[JA<2_*1=G'OSBU3&^C#5]J=Z<[)O?')'5EC
M2T3AQ>(93W"!<XMY7S43'7:UQ ^PF1A 7]PHN#EF3K'(:531 GO6^EB !I0X
MWXQX$">W^"YY0Q9I#QI/AC>2Q9,PT),*0"ZHLN-\#LIDEERS$:L4L \C$&61
M-P,C4*F%+QN/^:&,3#X+ X6L&2\VYS@80NHQJNB#=7G()X2EF(!9'3J$CM',
M?0?JC!22WHOL6ZP#BX5X%IHQ$I6JY]BA%]ASQ!<A0A]Q#3RF%A4B=:HQ FE(
M6_"*255?+;S#D"/1W@S?17!@TYJ RE33I1+O,@R;K&-BV"V\%G!]JLQ8I2#/
M#-N@('\U0%"]34J2ZZ-N(]DD/ [Q\+5+35Z]D^3?4KTQH1@[O59:P?%.<7"V
M);7D@XS:7,?AS-B>@@>\@^EL8!TM>@LD=B)G>,#.WS,WBJSWL6LV7DVQ>50Z
MZ\F]I+]1 5@>/P\S/V@N32ZTH9]6AZ(]%=<9I,2H%X;4;=%"E@;'A5$7C.@<
MGV[#9R1480@DX$J.]([A>0N+-]@#I=O4KIWDX*#UX1 !2IT:B#^P+$^YB-J'
M)?"=@HXBZ6%%HTQ?%-%++B5UFH]7_9,V=9_@0.]QKH"33<I++Q:$-?I$#\ZX
M;)F8,DDW$9<NB_@;P=(B"&Q!!3_ +Z8&7ZQ0VPG2""\)G*(,VGOP4L3W"5M4
M+7P9U?#IB/$6[TQVHH?O<3(^P#(ML3D];$N^#X*QS#4Q(7#CM'C3,P/KZTD'
M)?9"L_QF4G96]TKA'J'^B5OWQ*L&ME6SPQ'?D3DGR@U55+$*IEC",#EL4WN?
MWD,M/]Y&4QLVU26E_7H=>T=MVSB\^,@29?%\L6BI2/1&PG4L]^F1BQK:Q9JF
M@+-'QEE@94^.T?S$60"IJV'W. _W8KFCJPV[.EN(VK KNF'KJ0U;.I"TI =)
M[M+#5N^5]I:.&PNY?;UC8YI9%'+6Y  ;=O/XP$*E+Y<&>! #2.\RB/LX! L<
M/T79%L5(A:*.2J$^31D9%(FBJGY2"?.CBE!HAHA5\L5YZ *>C2Q_[OJ&[;^B
M=? +='@NU\-\T;8J/34\ '4#VP@VQYF VHZ+I2)S3I*')#@\,=O70E\L@Z[.
M@P4_#286SG7B) 2=A4F ,,6$.<RCROQX@V8&LOD&]I]$E(S9TS+LM/-Q.@&X
M$HID!5E_><]*[3Z)G<I>T')%]=)H*-J&+=%#4VP,.8YO.VY5XN'&76K-)L)Q
MA7:;-8,=R<)L-;$WC$&C\+W$3)YH(U/&XFW/0-.P/_U4TZ.X3T(49<%)+OJ8
M6GC[B5S'=R5'SD@&!6QFT4"XCZUP92:A^,8KNC'+[]6NI7:M<\-V"3A6^$WC
M-YF6OC&0&$T([ '-PZ36V _]2[V3LA\^1/;UC0-0A+QJ;71T!%O@K0>:.- ^
MNKBE)HT$VM"XXY%?BJ5.]M&^9_+O;?I>G)'DG%9BSBFS*:PE?9"EC.6H"37H
M_\#U,,::QO<L3+IO2%=ATF.*'@OL5PUZ'^/KL.2[:<!YA^\\,P/V /?AOV+K
ME,<41!*OD2X* 6<=/] <$$6&P4"@II0F&"9 0OAA'")0U >;>UP?\/:>"I!G
MXP/>R49'7.(=K_"M(*IZ#'P#^[\<AK#VL$@=CL5QVPBXP9)&IC"*!*CIP^O<
MLQX1W[SMIRPTSV;",@+6>PJF+^*?7VPS&]HHO1AB +,9E%HN[*B491 GJL?#
M\;(%JP?99<?S5L-EN,&QS!T,2WYEVO03XI(XLNYZ0 6C((BM&G1(F-8<$8OT
ME$7A5\Z_&648U/ZEK(6SP39L4!_8@R</N9LVJ58[M4E]!$7.XE-MM[WJ>T:"
M1#<_S,<L LN?H@;CV1B7[ACULW;Q]?:W5_Q@)]V5TEL,& =]P$3[4L R/(*W
MA1G/>Q#:N)(HV&.AB?B0!\.FDQ_,R(*HM:'-E\U[(=.MGNTZ$SSW 6$TO2WB
M*)O:1_FB:*1DPY1XX*;;?6;1+L#U#'6FP(X?=!TFKM3D^_*6C^MTH=5 [\#<
MCMR2,9A3>'OYJ4R&HH-29[$*:ZXB]3!7YW!/5^>UN,%DN)T'"6<L21"'P9C#
M=FUPUT/41P97* B _S2-N44N;-Q6)?[D"^R[Q?V>6/0?]R=<G^QK2_ T5K>G
MN*N('X@K NYU%AO3')B*.4$<[I^U4T@*,@^[ZL$WZ V0YLW(XI; HV'9U")*
M79&>LWY4N]'I/*X;-R,]YXGI]I%\?]K%7?@0\"VKW;O46Z]^U+XF5"^JHD_I
M0U,\]K7(T(1WXH<?XR##1G(#Y([7:"?C=S"P 'P FY3E8+,B89E&!S4Z;"4N
M,[DB$K$H4F7%/R>N"(,IG$$G/#18;!P7_*A"&QM7XVE7&6^20BJ3KVG&X#7J
M1ICPM]*U)WXL=F;I+8WU4Z*'%(>*L5=+7E&Q> N[$=/ID3J!98;("!4-PD+*
M&_VF>"Z4IR[X>0H;)MTD<C!I0TVWLA(-G0AO&6@C%WEL+W"8$%9R:!I+'\8'
MP$O<Z'!/EP<]S_+_1*>YZ*G&8<"[5&9'_F5!67ZO&\V9)K/%PX \[JKFMLG2
MDOEFL?:DWM12/:B#C<AGMD6N=Y;L\B9#V45?+9:!M.Q#<9)UXXPUT_6YT14Y
MN+D$ ";P_+76#4YI<EM6Q?GTPG]%;V.;6S*T,/0*(W_GW-M -P1X-@<S8B:!
M30!$ZTE:)_P(*&<:;7"+; !YK?&Y#N*-]P?I)20.LT(?YC;Y!EE7 $200V*^
ME %3V2U5&3"G"8+MKC5>NA@ *P(]^RTP<K[*3![<?=Y&N<.T#;P5.<5PT,;A
M$B;/9R"/_/).B%["_EB_ ^,RI"O5T-#39C-Q^":KP(_V(V$!X%.9;63 EA?M
ME&9ZK6:T5E++(:@44*,LTB#1(,FSKKR@31]%1S"4MXCW6_FE?%OF2F*K2@\^
MM.9VU$$.^58ZC;G)PK_-C.JB<"6@!/<'RZ*=.!2@:$;-F3%,ARZQ@?L?+9,'
M!<>PIKJ&B@G'N/WSF_FEJJ!N(FI,V O<"2V[@#+9+-["1$]AB8PC(XPOAO K
M5M/4D!/B;IA^PK\->SP\:8C5D1C3U@"?8^8"G6\#RF2/Z(M>;&Q+.B;'\([D
M]M(&W8BLD>MP@HT#@>-[:V4!+/"NP,B(B6JIA)IH!TPV \UB>9IJVV%AV$@X
MCUO)/W2>]!H_:!-U>7@&(0Y-8&%' R;\AMSZ;-K$C!03 P)L&7<G^!+T*9P\
M_!"PM)K4"Z-9J Y%B($(^^(N); 6)O(E\G.E!1)L"?0;D9<>73<VLAP%#XCF
MLUQ$LE!VH-=H]ZB#S  Y#.0SC0VFQX9#0^RG3X8#IGU0%!#8D!XZM/_0"\7[
MSJY<5,3^( Q26<B_I85CACQ9^U%R)!T=,(9?OB%6EM HXK9,\JW8'I)P;Z",
M]#:FR1,D#3(GD>UYM6*L+9EHD97'369>N$*:V$OV&\K GJ;;:@Y=WNRX9&;=
MG3EEH]!FM^.O$5ION)@ S?DA_%I42;IV1HD#^#5/_+M'QURQB7??9$C6=1SR
M=/W=\K\!;( 6'RR50+[RB<1E)54OLX9PM]UN#N)&AZJ,L"HCK,H(JS+"E1[\
MN901;O=2NOE$E82[S5XW6D/9Q813DQVMGG![T&P/EJ<]N*3PH#W8J:!PI]DO
MG,B5KE&I2@J762M25A2^4A6%545A55%X*PR#KBHH7'115U50^)D6%&XW.E>;
MVRB4SGOY"PJO>H\*]@#5V+EDS4!5*L>2<BQ5PPA2CB7E6%*.)>58>M:.)7W8
M5HXEY5@ZD6.I.U".)>584HZEK3#HW<W^?^594IXEY5G:=>5Z8W!5NU95RK.T
MSK/$&Q8HAY)R*"F'DG(H*8>2<B@IA]+)'$J[-S]7+B7E4BHA5DEU/U<N)>52
M4MW/E4NI2H)U[BZE6G8_/ZI+Z8O(Y?QB&TX W[Z'4>:81%>LEV@W!U"O'UN^
MROMS+.^/&":YTA2:]]5J13IO,L=Z+\JND"I_\+37^/ W7HWUH_5(]8P*7UVI
M4"U[$ZXQ^3H)7:KAW^$8+)(:1\,!E3O>!/Y1'5YE2<\:(ZY,U)=FU%)Z_K$@
M/1?$+<M!U-U3X;#".*RH-JF"]C_Y=WOXZL]_S>4YQ=*\+(6VI5_MZE[.!.23
MX81CPPQ"ZLS'Y'%EJU^[7\B50'MY[9N%PDXW<LAVS6N76H]FQI]CLFR#916#
MAT)7"(KRK&W[;4A77W,5DCE>M]7;Z8ZC5P[^>D7@+\_::HV_LKR)&5OH/GJ&
MBK-/77N$18P\]Y%7%CK=!MO)X<(ZI95PV IVY51=SYN#J'!R8H'=V5+86V1O
MQV/+9+%-T-#&H>=8U.XMZJMS0A.Y8&O@.?)X>Y@WXEKAY-PW:N-AAV- -:2[
MHZ1[$R?G+FBC4%*+/9W^7[C3#C#(?>K$R@NFLA%65?:8:1E15PU1)Y\>K,78
M$5R;)4[!,58?;V\V3U8L NAHR[OHM/LYQ3D/;5XI"I^<PNWNSA1^40")CV&;
MQ1J\=9 "_V!]I]9V&*W2P"Y".[-KMVP-7=@$V10]:/B2UUK)(+)C+:K7SWMT
M4J2M"6G[N7.S"Z#&UI@^_+?\9WJ0C!=L%297H3"Y$R6?Y0_BY@^>&,H; F3O
M9SH=EC>YNH:2 SSZ&[PP_),4W\NEB8<\3'SJ,:9]<K$[K_8>($X%%JZ&WNWF
MPRF;JH= O,02:P Z74IH^;"=';'.0IC;AV,K"O5ZIH0_.X">,R?W*T3X8U\3
M2:SK5W$L2]FIW_T3S'2\W-[UT6P'9_K6!/+>T>B[)E3J./1=%_QU9I"7G-==
MT/+?):^KL".GX^]3[Z4ZZ:;Y?3_[3S.L0/D 19VU]1V*R[$]1CKM]IS7[*)K
M']#/Q#"S<!07!>'9MR445CN;E%GI_].W^O_.T7]7I6IF9>:7U@0#%4%Y:@4[
M)[:>V':JCE"IRH$[Y#.>#'V*9-4G63WE_IF7>:STX-5 4?F5, _V0WXQ@HVI
M9&?@A-PA,;%XW^-PBY- .1[+IFGQ_L9=:5H;9V.A1?!R&@,K$?0[!<R?VJ13
ME29+"E7NZYNSO8_ D>LCUA77G2O7M8HOR'@@UU7C_FA#=<G$A?P:8W)S//U>
MD]93E,Z]HFF[7[S2+H7XBMW.@MT&I^[UO?<MWQ[W=LEKOPT?72?,YO?\(E_=
M_ZG[OXK&[U<R+%)%ZZMH?17CK&*<5;3^F0+TG#E91>NK:'T5K:\NS7+25T7K
M5RA:/UY^\K2OXO9S3I.WW%$%XUK.ESAY"V0<=C3<SXMWB!LNY<XS+(]:+">:
M8WUBAA]Z;'3K?&5FZ&%!^3>&;_G*CZ=J>E3,)WANL;!ZER"*.Y]K0ABIRKKV
MFP_+JP!BZQDEJ]BK+>*='IFMZ=7#H*+:5JJUJX=!1;6M5-O2I$)1K6)4H\;(
M%<!?:?OLO@N%X<.5:T0MNJ4(C^;8K5'.QAD*LD*H0F@-YZPM0DM-KMCK(/;Q
MYOK-S<>;^YOW=_7W*QXQ@+S*X)T3+(I4M8%%D:HVL)P;J4K/BAX6?X'\N^%Y
MAA-H<)BU'HW >F2:+>YN%FNQ>08A(2?)G;X\/IS/(\!'4?.<PGE.D@/?:0SU
M8<6RX(])U1>*K,<B:Q6*&VQ;/,9AP'OP(89G^!;8!_L6,*B8^7:DL)_UNX,Z
M-BC"*,)D!<H-VQT5R:@(=+)CMN*FY^R^4:2J*WCG!(LB56U@.3=25>I>>#EB
M_4<-IF*>;3EB#EG'6]NSUF]=J'+F3*=(55?PS@D61:K:P')NI*KB<5;%8YT!
M8RE2U16\<X)%D:HVL)P;J>IPS[I7_%7.Z5Z<_<V$NM-3A%&$4811A*GX:51%
M)RDN4X11A*D?80:-?G=S(*DBD")0:@/=6G5MGVIIF>761*DV9[1Y)'CAL^MX
MJ8'Q>]H[[YDY=:R_0G;\-NN(88[<U[S$V@Y%U8JMZ%9(C;:(42Z-T7]#/Y#+
MX,\#CP7F-)ZR]A7=4H*[JV*1\I7.:=]'+<FZ+\>HX+*F0$GQ -83/=>!=N/[
MH>&8ZVNV[@/9G@5K$GXU_\>5!>V/RSQ5'0[[^1B+.$(/W\&@F5#/J9TWO<_&
M^^I_7!O4V<[9IWGSI[(S\O*.LBZ9D,;1AYWFONUQ:8!_;/VXMP?DV>E-N2%?
MDZ$E(!_N /F&A2Q#?CP'_CIV?/]7:#T:-CH:0/AFVL6"&9Z_VE!S7[-Z__L9
M^K+;' Z+F^Q$0/2:>6SVZKBOUO',5\O_\W*,;9,LU-C,#S0PT59WQA.A6V]>
MY47WJD8ZV=J'6XH?UD"GO+,>+3B2C+2%Q>Q155#;RB^%E6&+ M:^S[&]S%/W
MOE75?W/<!S@B/^)@-\X\A&,[G-]-^$I,IXJNJZ+K)?H>5<U7?BI[%\=SW#C
M.B&57*\ 0NM9;/UD@Q=:R+&JM[)[+?:-8:/#1S-\S1UK9Y:-\SQN^\IN3]?I
M]]8Z@+:!PU7UQI@Y2_@<UZO5,RAM58!SYH#9NPW]W,KG%!2BLG%?WL"\;\'0
MG*!K0!MC6Y9':LMB.:8=CM@('S/#<V"D*M@*A:NC4DROO<^.%8/AHM-J%79_
MO2<K+'LVCY\2+!?>S;/LM"V2X[:NX'5469*Z:WEPY(9P;#^6X5/6RK=7>MM'
M?HHA?TE!(;LZ>Y+.I#MSRD:AS6[';T+?<ICO7YM_A99OX1?^FT7BKSC*\FTR
MR%)%AJC($!49(OP!B4CDMSM%(A\Q#F)_FNR/]!J%)W0&5_(>?1]?1DEA"/M7
M2=TQ"O*0@(#37Y[=.*8'NR'31G!L"ES-,.'O3($[T5V4/LS9\+<ZA]W=C[;"
MQ9TF!5H#GF$&(>S2<V.!#N\C*'N^]&J=*TL[(>KMG ;N!CP?ZZB795$?=FA;
M.^)Q6*>$@U1):]BG8.=ZY.Y]I"GPR($G&6,1A#^^=6<S*Z!+M6MG%'UFPFGI
MG>6;MHL'IJ,'LM?HREN>3O2MYXUSO*9^YO>))[B1.^C*?@5M7]G,L-!-?JY8
M4XRE4*105,7!%8IJ@J)Z1CJI +IJ-4VOP)RUH1F<E+:DHRB258]D5]5#GR+9
M1I*UMSAT%,FJ1S*]>NA3)-M,LG;UT*=(MLEDG#*/&6-890606/K]=;NW<@]\
M:,CM%X_YIF?-T>6NO3,"X\'PUU=T.(/@ZI/T#=8;[?;F0,\J!),KJN:;M-_=
M?.^O:%H_FO8&FV]/%4W+IFGQ&2W;N[:?9W_OTJ%<I>9*2W%%SCJ34U%34;.V
MU*Q4;T,:Y[,1,#]P3WBO=^1:M86=GWIHE)V^TJLB5=7SVQ6%%(5J3Z%VHZ>T
M72THI?:ENE!*:;VJ4VA0#:UWLEHCE_S:+"/W*AN"3X83CC'Y"I/#7YON;,8\
MTS)LS0_G<WNA&1./L8TI68H5E;)0%%(44A12%#HY5(I"BD**0HI"9T:A*G2D
MWC/0[78\MDRF?62;0L(*G[7*!=7J59KPQ4% Z)WB2ZN=7XBL8K]R8-!;BOL4
M]YT*AL[)J[(JYGNVS%>,P:KX3O&=XCO%=XKO%-\IOJL/WYVB[T^R\-]Q)4>5
MVC^YM.RV<KW?Z/2J6FM?<=P9<MR@UU/LIMCM6"OOM_*6S57L=G*BU9?=B@WQ
M5@RG&&[+RHN-5%<,=S8,MWQ+7-C2BSU?*TZK/:>5U_.@NGOI#CT3]FUND-WB
M[2L,\?[[G#F^ZH50YUX(Y^O/KG)5N3X!=#_U&-,^P=137WL/*QPA- ^>]AI_
M3;6MJ0"65='K>O):5(WWD%ZU2CV<A&3]"J"OK,ABB1C]*JX/4Y9^.(.29CGF
M+J%>74T@KW$=I3ST+;Z@4B4A/UF*])[+QS.1QOBA: _%79VS_Y$.ZCP&MKCK
MM^>4WO2,J+-7/\BU_HEL=\;=U/#8&\-GH[?N#+^BYI!W 7QP2T6K_6LSL!ZM
M8*&\'<K;H8XS>QQG/H?DS'#'FI"HZN%2T6\#_7YGN)FPD78-DFA,F/;^.Q:"
M\9GVQ;/,"F9N*FKFH6;4]U3#;4QV6_]HC9EF.=H?S/"J(+"E][[06ZW.88?(
MVS#P \/!=[5?0X=M[SJNO!.'6JG#1KO?J334-:;M22H\Z_UF9WUCJRIX892O
M:<_9A\WN]L87M?$R[5V_F^_UF6O]!8YW ;\-K+>7XID58:DAA8[D1U*$J;KH
M5 6\4R2F;57(\JBK5+*2?*62GRMAE$H^EH6\T6VT04]_<+TQ@]E&K]\:#MXH
M[*6Q5;Y]G?/M+_3.EK[SY:;<OZHMQ^VYBH+VJSUGU_N;W E' +\&UQ$GAGP+
M![PX<VS4IM1&\N8B%7V^^?JBX%54>1O=+5&HTKOH;B!TA@V]W2U4G)Y79MU>
M:RAX)\TU]^8+%T7PDT)=*N6'37W]W>GI4'"Z4V>N]0O7($7L&8':-Y_WOMGN
M-#K#7@6EJ2YL5\=]L^#SIR)X/?;-0;.2DEZ-K)F]8+I^-"R;=M*QZVD3C()0
M>ZK:4QN#OMX8#K8DPU9!WU26\^JK9>N$B.<)]?,E_UZ9:?NFFF4GKB7'>.OZ
MP0?7BR?X8BRPU,^U!SOIA/&J/S:,16^O6PF.XK]9?+$-1^6ZJ5RW"EYG53F[
M1E7V.7RA=R >\%Y#FS"'>8:M&<Y(,T8SR[% ND!)/;(?*X"V^C&G*@547Y+5
MK130'@&X)3'1R09?IF(]H7@&*"H_JU0?#)H)FS:7OVA#O".=&C1W2S[]\\A!
M+#ZM5+_:7/VD"GFE-<Y"/$U>::/5[>Y$U?//0*SX9J*B]A6IG@>IJG5EES?I
MXBN#4[EE8C$1LD<J<%"IP/7<,\JX&+15&VO%?*=BON+;MU4D\'^S75?FA=>]
M&QBVYN/UT.4#W@_!,3V^(#J@Q&D5K@!/$,%0WYXG[?Z@HAU/%+N=(;OI#5V_
MJBC#[779?\3K^36%;=$BG[HVX-U__U=H!8O/;L!^-W#.P+_UOB(7^.J.OYYW
M_&=@%U?_\BTN7"O%IGK(5 14E6N?*S55Y5I5N?8H<Y=PQ=@>]ANM[OIZ)54
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M<(77WRW_VQ?/]0/#-RTGD*]\HMY(/VBA8_%I?[M[]X,V8J8%./>Q0=?/@_8
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M=292'AQ\@:W<V0WR$TE9CG"?+0%FE5]_!2D'!I<76'^3=74[7GY]TQFJK4L
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M3%.@A6%G6?BDH?G1*9Y@Y-P&BYTS.!%R/H4Q0E\N-PGT!9^5D F<V(\G"MS
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M3438K^*G<CZ[NUY7<I?TEB[[/T$J_<EOZ_"O&A<?(L3NT3<;>O0I=):&SA/
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MBWTR(&T>;@L<Y3Z9H-J(VP)[L4\&G!/*IR6-R%KLE0%H7&J M=@G P;HKLP
M>[%/!F27X(DI^*!X\Z-ARUI*G\S*,Q&58C"UM)B]"&8Y7%2%V*-LUI)E+9)2
M7KB[H@]I*#/SB6W]KAY[YESAV7GZU*M4MJ"V>@4MW5F3NTE8'E!<:_\Z]IU8
M?Z]AFIB:1DG(-P3(E/)OP^DSH5_D/A0)!?V&:+ED[01F/0R': 8_R26=<8(C
M*2[?R];@*"?;A0W^ 1##=;8S-01T4CBN:2O<"??)4P2]L51?S K33?99\8BF
MDV(7G):YI+BE+G_@&L1#<@H9FF!UR&8QHO7&\OP9B M'=S:2L@LPR5=:480
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MD&.?1&0VO\:(T$\6LVW]IY-T>1\EQ:_(:?2$2!9E.2UW$0648D3RQ\?X9?J
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MG%<.YY7#>>5P7CF<5X:Z9SV<5WY>[@_G%6/G%<'EM?]!F(J"RKV3_/8:I^C
M3R(R6";&G^C"8)[2CJ*C\MV28(\0+33.1V7$22G*?50>#;;R!8FTSB\]1->A
M @Y,OW E;PNG?K.&&V^@0M'*!6$;P2!6_QO$=!(E#QLA[T4"1UGFT8XM6KJD
M:YG8M@AMSH(2L;[^>(PP.J4X19.B5F5;-W<-<M0.C"IZPGIZ.#_"13+4C1<C
MG07^U])442<;B; OD4]RC,(92Z*=8Y;@A!:X2A-<__/8)Y&>%<SD=UR8RTP
M4%G3C'W#B;'--,."B=BDCH9NM*MU<?RR^O%?$9U1<+!XN4!/*%;9Z[0:@&"J
M,TJ[HF<IE0%H*U<+6JF@?+%M1WJU&:=-.^X->-I,*9C61?O3$P[&:K=?Y@&&
M%ZR$/4\>\XP4F$?*8 -)+<<&O[9#4<$K'Q_ \=L0=-R)OC$(ZZ$]^L:&[8CV
M^)MTXF\"(36?1?X:^"!=6%@O( W(9QC]G:,D>-'?+XMJ6S)6 MXLRS0!<>3R
MY.VT7]JJ;<N:V65;+.-$?V?$ 0AP);7')\!=KR5B(6]TFTO3:LK27W(EU=W8
MMEN.N!8'&0X\0.,U2OPDB/RXL1:M4)Q&A)G2*!"))[=C2XYS,>[++MI!*8!6
MYU.$HR<_BYY00WZJ!Z8%>0HS14W'22&[T,(G6 <GG-'.>8CU)$TRVJ&IK!N>
MKQK-BQ;;O=IUG'[27%_HKP77D?UR+^C^[R0;F*19_0+%'0H62437\;UY1F6?
M'JJSE(-I'_Y3T6>'ZE)5=0U[7E:9)H?N>*UG\O.$SM4YDTQ],X)7X[6X5F5<
M*_:KNPJ!LXNYPWY"Y@@SI=PB_!0%%'!Q6V1;=L+>UR#\/RF-$28_X]XY*R:6
MWQ-,HS]TGUX*!&/T<MN/ %K$_O0QA:A^ FJCG%OWKNFQS6=^!S"<*6#U-O3+
MK<\N&MYF:?"78J\@K&/)USN W8)4)8#,6 WIV)V9V;P8 /0P3P52SN/JRK:<
MQ=J+NY0' 75:J "-6-L40EE@+7$)<.&\2C.DNWCNE'6;BU!O]/#9XD*Q> FR
M^A917<;;+N?F&I [(XM0"8 6LJ96\F4A![M'@X(,A7^D,07+C,HW_-M%[1MQ
M>,N(1X3:**:& V=%D\E]A_"R(X.LJB/?JD'B5BB #[Z;B/QUAA$Z3S*$$<DZ
M##U>$X[<HP8(%**!&&W(Z7BGT5,4HB3L,8<VFW#DVS0X$G?0N,Z3+/=1CH?H
MH]R70Q*2]Y$C<B'C]R2])P@_,<M#$;=,_YPF 05:;N7:.1O[?&6HOL7VCL2^
M6AJZW_"GO;#9EWA%[SI<V3Q<V3Q<V3Q<V03IMSM<V93R.I@KFPV\?T;98F?I
M(IMK%[G9VBQ5D9A%6RW'>>_O ;DFNJ?-IFG-64WAU%%H@<S56?R<GJ_])$"\
MS>0^/@OD6JN=_K8O!4*T9)E!^XVR>)$2<IX$<1ZRE%U??<QRJ&D=?FS+X/CY
M,=B392=MPC;E3?9MRJOO;TR#O_.(1-+[&VJ#78?6W#XXP!&8'+^HQ==_C:#7
M%UR8XSIR* C3,*>'@1O<!/".7UBTH<+6IJP+P<QFD&I^7]+2 IS#F@@D_:[2
MP**LZ]R*ID5&*QXWP?TT/$(QCMDE=!^O#0C$D"?!EU9R:]W2&B><XZ 2DL7
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MW6%VR&%SQ&1@.=?H/_X_4$L#!!0    (  R!:4L^=_?H#FP  )2,!@ 5
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M P[UKO/&>Q*/W4:^Z&QC@59O2NJ4#QW+D3C?JMB3<RQ&(GZ>HF= JS>;+10
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M] 9@+R1L:\J/5+C&MI*N'P>T@%-0-M#^C_Q4C,246^U&"3K!K&,UAXZN)0+
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MW)E)->$@=8JS5]U0E;EHJ8S"Q7T5$!%IQ7YFM=2(+23P1[!2T3?>D]#/(KG
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M!C.TL6"U"WW'>]5SM@672Q0O,XZ#-)!,?JB/DIGN,B_)G/3_:/I[CS3Q,O)
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M8CS8%G8CS H!S<W>]H,_%JE Z2:YE9U3QUB9MA,@,"ZM]T1K4S:P_8Z43II
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M1+&P:H.5+J36I]8@@@Z]Z&@T9#E '\QUURVB&6HLXWVR)$XS[\YG469A1/=
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M9=Y=&34AAXX;H]T#, WHPO=:36B%<'PV;?Z0LH!Y"9<=I;6O/ZAJ_V0(%6@
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MJ6,6X3!&^#Q" ZH[R>PEL,AQU3[33Q&G%9I^;</$PD%TRU>CS[1WZP-EP<^
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MO=0/<1RDFZ0H=TV+\&Q" [M[T*EF@U-@$^U6]T@.G,/5V2F4Z$F<D&H"4LV
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MV<6$1H:7(280B\N42N69Y4*I;J.[)6<Y#7?S>.B61M9H$ODQ/5D4,M!87]K
MMZ]_5M39VY*NY'TZA9>_&!"*Q#RT$CEJN] ,S60"LA"X]_'GAF6^3IM9EY=Q
MHD^P4>L4]TE S<,1>Z,\J&4 F O<)C:R3L]3ESG"65-UG'/CYMB3TC1J^X7<
MEO*;>R+*>V<S[HF[33GOI@A[<7AC4!N58Z7,L&WI/,/B;6CXETKN:,@1[S[0
MB"9>N(Z"=7!@D<@9\40XV+(DL15*L!8U5G1WRA<+:%*"KTB)0";3G*- 5-%X
M',4B\R]=D5V#4N^<4G0-;NPY6]_NQ@+?TJ?XEHK\+C^C92&=HO5'=NFQY%]>
MF%L7<AK&!WWQ;4!QMU1W!4(:,"N1<2? B(1#$ ,;0:*DXU'\47@C24UPK^L%
M?I-FRK9&=VB#R)8^E/4R-E\B&M3K6_N_Y"R5*0<77F:L5\WQ02E5"XJ[R6H5
M*)&PHB% !;TB#7@B$*!H S>"VH8H$CC0Z$Q;EM4J3&-DHZ,&9V\1/D<)]>-=
MQ'ZE@=IR53L'P\A HP &M+:YK?GF9K,E32 8^W0VZKC2RYO4*6Q20-]\'@*1
M^=>FYW'8CQ[$M+B_O-VF-!.=:]8I_R%5U4GM=TGZ@<%\8 4M'6_W-(X4 R&+
MF-ILK(E7UPNY?+^;A#U*#[)N\''+4E4-TH'.(SI<T'[; *5=V5<-)_5XK.64
M3+ZB8:<7#2(XWJQZ"HFZ,W9%D_0XH.3? &4:7JS&XZME9/*UM )1BP#D<4=1
M:V9$1:%S!- 2L(\F1;VLLLK.;#6#1C]+&""CR-B(]52 BVTEDYFG;I]!HZN&
MIRHB=FU?,&C\3&@KW9GL4K<0$8=X^2 ?$IU=F#?PBD>(S7%5D[ZR&-XURM)%
M4W'4N/)WP],\F[-62(AT4[\ZO8W#\#).Q!^MM=I,JP!7C7/M[N3G=E7J9M%G
MNO&0^"<Q+2GG157C;ZF=K7/D3JDCFQD?G(^R8);?DQ(2GPDTJU@SLZ/F6<(S
M5A %V\QNFZDG?G:FFF8/%]( *U+,N")OZ8Y%D5 *;ST^LS_])<2Q>".:>4EF
M=6^YQ/9V1-YR&_(^"I[#=KPO+ ;%7CP_TW](?LWC"2AG?6YR_T.1+AH5#[\_
M)'%J7[-DCB4\=Y>@?U_GU 8?RH3IZ%1/1<[Z&W(&S/;TIO$NIE%AY:P\G4@C
MK=[2_*9\ [,MZE$+$K#[%/?9>P@:^;:(>] W/ZI258TX<OK^*TU\EO8^=U>T
M2+3'#->8TF$7YA38U3P-F8TBOW"2C>JS/*OA>(Q.YX,QT/K3&NUS,QLOXV1+
M699S@BK9MK39V+N$YVXV]N_KG%*H,>,<<NB'8C,CNO.X>0%B$YGM:8_ *@%I
M\-T[X2N'X6_0/M(<Y$7LH[[YGYLP+,6XR.!;-G;:,_%SC9WV[>$"QI>8KXJ=
MXC"^%MC'CJAK[@8>XVRN4SEK1+ [Z_CBB2.7M'[T6"@6Q&6M=$=-+;6Y9@=]
MQS+';O8**O)6+ZC>EH*J''>>GE,=S--LLA2&G ]!0&^QC:S)%\4==K*PG)>1
M.RY+9,X;>?-J1<2)0?32YMDS6.=1S_C-9*D?QBDW\CZ(!A^1WWFY KZC"D[[
M1QY1)9/!/G::32T,OXZ:?NKG9O(W+OY^I*)^'PW6W-SS=K2*Z<AF+2(C9*O,
MM9O[(M1X9<_5:7#Z"HME9%1+(N6:3@'0LD'6C#T?'5K08?@45>K>X-[])ERU
M:;;,;J.>K3?G+G"72@ Q7=9O5-4!YI+KE_7<KP3,]Q^+9D.2A(CTJZ#9/$W"
MXG/=.OCD1APR#R;_7;LF=&HOM<K<L51];C;0E$M"Z]--NN\N*B]USZA<VBV9
MP8^;=?OG;I4\BYLVZXX,JBS Q$MX(36%AS;A>IZ=CCJE$#JJJ7'6RL2K0^^H
M3?TU9E5>/=FEZ,)JN#_'L+<!F="*ZNA.Z6],N[1G)])[$N)0^![6ZWJV#HC]
M%YA5D/<FZ*(3Y5@_Q: 01Y+DB^30+F&0VRX*G0@W3P'$=&%BO"ST=OAD^[]8
M@C&JN!'2S4>FT'X;NX3?$YE6F"YRY6&Z)OC,[RB0SPW7QV-"?2:A9;?9M+7N
M6RK*K+)H5]5>S;WPGB:'*D-IR,O MEJ0]K.(Z)\S83@*RHZXS746O;[3KJ([
MK94T%DO$:N?,?[/N/(OYVQGNZ37;PJ=[H=M,M3^#;*D@7L[#,.4/UO?^*E*_
M=_)XEEXB"N]G\>\"ESJF5A#X+'[PSV*A"LX+Q+Y@$7FB7I)^B]-#@!%$YM["
MPNM[;LI [1&I:'QM=7&Q]-) [RX6_PYP83 \PA_QY[ 2^HTI@84^GM-L>JFQ
M\+H6%_+^G@9Y2#=;]RL<5=LYO8:?;F)PZWS"/>R(W1*W*,PQ_@89LE?>4MQ@
M8\5--BM<CW49:5#VH^J5MPI@*/M&18NF3W$1:X1LXF2SL0:JIA\2@*NX9>#O
MUU%P01]I&!\%FY?=3=UZGAFAA!;@9G3W\*.$DH6#&W!5&^/Y6J6YW^0N3"FX
M7K'@:".-88)OZ5.[#B5R&O0K,77;\5X99HH-2EL84]LIYE(!JNVHN?J/N[B9
M '2"Z4T[#M8J4D-4,]W"R]]6!2L:,3Y3K>F$&F'E-,T^&%]"%W^HD,S:N,OU
MW?@T.Z#O4H;WZ?<RU.M?;X\F?>J2;O-R?J<*&\9J8T-"T+64F!+O$L*\J-R^
MB6YD0VJZV6YITB_835,?S- C2EHRW ]7-B\PDDU$2IRD0@KX@GKZ[3C1RPIZ
MLYBPZ)&[_W$BGW+PPQA17V[0%Y;M2;:GY%AN2#S7A@Q)P9GWI-8!7UJ[DQ_Y
M/O1M 8@DG/9HNZ4A&>%>4B)^C@*:?$E89AX<&C4%=G.W?U_&2\4&/@0!I6EW
MHT<HYA6 6)NLO[J()'1)!UIN+[B07&PG9K6,S;9B0"^<L<CS,XTU G02$[D/
M_\)QCS&/E">?#JLI/;*6GYT'N?BK,]O&P//OVN#KW^9V(0B^8-X>X.C,;^^\
MH75C',L,SOJ%EG1SKBHG_2IZ=W+1?^0>>LOWFN)U-\S:GHMC-=&7&.^1G1;"
M?R+U4HA82R>(]0R>>R/Y$,\R0H9Z0RO.\TK.HQ7G'65I1I5_5>TZCN ;(DDY
M@Y,VR<* PGZB>,LX+3@JL#IF)5A]PDEV>=*88RI[08%KM8D><<^_V7A"FK->
M[DR[9XZ*JA$??7[W0N,%Z2172".6,5KMO N]--ULRR5M$JO'\E9.U<B90%VD
ML;O4/FT2'Y?DE> GF\2A8@>>&YBI]\?JB5UO[$?]U@[0'YF'C6K13+A>2PHV
M^M*6Y\EI!_W&#G*1<T#F4DPBD88=A''3+)UH?L._^R?O0-=?66J:3GX. Y4T
MWEIYIT,!_Q<1?R<_B1%X'A3U[;@V_?D, (H_+F+!L*9Z604-_2BH0XV&:XHQ
M^)Z_]'\1HY<N+=#1-M[]E_A^'^<I5XV7;)M1&LF7;L53Z7447'$JHXP]4C&Q
MV7M&=[P@;K_;#K2YCF,A%1I2XBG?0Q:89#&V$RXBN13F)=I<6\"9ZX_G)'OF
M),/X@R.X7^W=N2 =?8X_>D^->>_85S'O3?X0,K]R%NU>BMIB!?7!;*AOLRV'
M)6>GMP0G!7P=4T/T;G02HCD3_8D<"R+C(2)A[7YK[AZV\<U1+FVOO3\<P_B)
MTH;4L"LDH$$ 9>GK:&KS9C7V7)?,=OI<7H':D-.D(L6C_XRY3>O8J*&7+Y(0
MBO>E-UZ2/=USMSWUY%U=^O:I^1>%CSSP6-T<,[1W9+4+W7H"<@B18P!][LF^
MAH5?98$6DK.5/KRB\$D7$JZ<3 \5 QP(Z+\;[Z>!D.P!6YJ'>B.:+L)0@PA:
M]NEH5$;'?ZRCXW(\5K$W^ &-I)P:"PJ&M)-N6A108DY/EP4;8I-]!A],*P1U
M\*.C'S>AY\MZ<.L=_Y_JTL\AX*%'!!KC&*"Q)PQ>#"=R?)VA@=/#-_F"PTZ]
M%LMH+CLE PXR6#?2J(0%B7FK*6FS49U,_2,&!K+8V*$PK0IP-)N\]:*?J0&3
MJ ^# @.H^%%1U6:8<AP.=K'>8E-!TP\^413_?],DWD3TCGUU$#1#*$#DS2!=
MJJ"\ "$<1@3EAUEJT5B@.V$R\(Y+BIHQGEJ8#L"//A@;/XLY(KO#H3[])NA
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MJ[=.JO=GSIJEKP '#4W? ?0&Q&W>T;!4M8_?OJ.!J:Z'_/8=#4QO"LAZZ<B
MJ7MT$/=B_ :J-SQ^>\/&3<TYP6VN-2Q6^$,0Q\5/A&A)F:'!#Q]I\,/D?3[P
M\J]OW"?$4<1Z),7'O;Z*1J__XZ<^1GB'8ASYG\)F0SUHW>N8'U(R&UJ,NM:^
MIW$_1JD;-!IQK65/8[U%S62[;=>73%&<H&8RW;4T.-;T>)S:@MQ)D*Q2=?O-
M#1G&W@#)'H5"G\8A%']+.V@1%)6'K47>WD\$-% LBF4K-?T;1]3YV1/98<FV
M57444(QY]XYR6^?-JY]>*P^R%$,NX@1YORRCY]<^PD34D[?T#Q3 VY_?3,J
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ML)6K$?,<'&,(O6B@U$IVL5;].E-@(YJ!:UM[ 4 ?"[LZ82B:R?G-G"FPZ<Z
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M;/7&X"D_K7C6Q&DJ"7=HLW]KW [U[JVU=N"Y0=V>*+806YO#!G&<:!='U%F
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M6I%;(,IS5EO?'+8]0;VG;N1,V0*SJ542Z+#YX*V0G]&"K&4L^]_(O_8)4KS
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M^=_%_CP\V\0XF)!_?2\YD#"_!C? BB7..HOP<0R,G]OHABA?[C'ZKRQX>:-
MDJ"),P&WJ6@R)0-C:J%LNBW*:7M FS0?[^R-%G?,=LX$V"C2AD ^HC'$$]W%
MD9]YZ3Q^0/$S]I#D9,/ZW)D VU#,G6RX\$Q1#72R*7'1Z@8ELD1ZLN&V<2;
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MA4[4#,(ALQ5J&9*[]];7%^32-<2?TW?"LI@65"4?W$9A7/WGN9M@J;_&V&]
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M5(!(6-!9TA+\%8 FE+*50P7I*)2!X<NXB,*43"0"<\_#5@GB14E56O4+_HB
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M2M(D/V$]U7(F$H6:.^TZ!GD;:K%(4$JK.YTEY ^)K!(/\WOH>COMQ<XY:O'
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M5XODV3HB(/[.F2@V8]YA5=H0]MW&QO1J@.O,4]2'V^$!+>D"=ATNHGA=9&S
M.!S*@=RC#15RN%1P-/":@#@8JL07J>=@[T-HEX!(A+S#^N'X+0\NK_"4]=**
M9UH5'X\X; /N+3@B1T(B"X#=?-81J=8.KGT,_02@D!DVF6P0=K.X%<-YEN 0
M)4FY4"D_Z\)J!_TRH/;LY(&PW/I=PI$_ 5;_#OKQ/RDI'"X/,0S,SW1&_N<<
M1XF'4>BAZ] 3NY<XGX,['0ZES'+#\H<^Q/0 .MP_(H(J^2=R@W0EY^7X:V@7
M@2HM[)&/P0JWRX=7244\^AC\F3K='6MOY)8_(7:/GE&8(;60M_U/P1^08_+!
M,W8>CWT$GK<*E@)KX,^\L2@0DV7R,3?8V/XO.(SB/!B8: M*TNOP%J5%,9&;
MB-YK+F@T2(!]:L?[%*:8&E<5IF2K?L'?C-.9P.V1CF&GW<,LT(N][\#?BFO/
M'5LGCE&.8$D_2Q*4JLS]_0_!WW_3F<R,H8_!KUC DE(&_H0;0_PBGNJOKG6P
M#??B ,J>$O171GK\]$S-&:7[9]*[_^=@'"K^'TX3$/_/_EBD7B#&Y^"^(($X
M.=<^#@K+;<\'J,COR:S.[!;@WB ./6IDUD",CD^YZ9G7!MP_Q&=)F=;1.(GV
MH<D+:K*^!W<*B?A1HM1X#@NL0:#RKYQY?V68QNE*2R=S6H![C+267P$(R]U]
M+&3TCS&2K\/2MM">)P%MZCP?(1J8D_ V0T' ?Z[GZ!MHOY.2C!F^J$,,(["9
M'"Q"2FXH3A-P9U2;X^R8'%,WR$U0_HH&(2$HHU,%A#*_!W=1"?AA,\J%,8)I
M>E>-M%; J5;,2T"NI"6X;TN?9Q5$IHY$L$?=XC7'A(R\#-\KP!:I<*(*?.*&
M\-XK;<X5 (W!#%Y')=J!:Y^!NZCTR3P:/FS*2P^9O/E#1IC682SB=6E5LL^Q
MV!'9K$-X9Y:^.C0'VF]JS6LZ?%IQD_S'_P=02P$"% ,4    "  ,@6E+L<D"
MZ9;-  #4Q L $0              @ $     87ET=2TR,#$W,#DS,"YX;6Q0
M2P$"% ,4    "  ,@6E+5\UP;" 1  #QP   $0              @ '%S0
M87ET=2TR,#$W,#DS,"YX<V102P$"% ,4    "  ,@6E+.K7;>FH*   SHP
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E,#$W,#DS,%]P<F4N>&UL4$L%!@     &  8 B@$  #;$ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
